https://simplecast.com MPR Weekly Dose Each week the MPR team brings you the top stories from the world of medicine and pharma in a matter of minutes. With 35 years of publishing drug information behind us, you can rely on MPR to provide accurate and up-to-date news. All rights reserved en Fri, 16 Oct 2026 19:08:46 +0000 Fri, 16 Oct 2026 19:08:58 +0000 https://www.empr.com MPR Weekly Dose https://image.simplecastcdn.com/images/9b4488bd-df00-482b-bf98-d5f4ee9671eb/e601dd29-c9f7-4de2-b8ec-b32eba0adf19/3000x3000/mpr-podcast-logo-final-square.jpg?aid=rss_feed https://www.empr.com episodic Each week the MPR team brings you the top stories from the world of medicine and pharma in a matter of minutes. With 35 years of publishing drug information behind us, you can rely on MPR to provide accurate and up-to-date news. MPR Weekly Dose false https://feeds.simplecast.com/wBWgoS5Q MPR Weekly Dose editor@empr.com 75c56ccc-ff8e-42cc-ab2e-90f3fb8fa09d MPR Weekly Dose Podcast #290 — Weltruza, Hovilpri Approved, Atezolizuman Regimens for Stage III dMMR Colon CA; Subcutaneous Tx for TED; Vanda’s Anxiety Tx Falls Fri, 16 Oct 2026 19:08:46 +0000 editor@empr.com (Steve Duffy) https://www.empr.com MPR Weekly Dose Podcast #290 — Weltruza, Hovilpri Approved, Atezolizuman Regimens for Stage III dMMR Colon CA; Subcutaneous Tx for TED; Vanda’s Anxiety Tx Falls Steve Duffy 00:13:52 Recent regulatory and clinical developments include the approval of Weltruza — the first once-monthly subcutaneous long-acting formulation of olanzapine for schizophrenia — as well as the first subcutaneous therapy for thyroid eye disease and Hovilpri for refractory mucocutaneous HSV. In addition, the FDA expanded Tecentriq’s reach with newly approved regimens, while Vanda Pharmaceuticals reported disappointing trial results for its social anxiety disorder candidate. Recent regulatory and clinical developments include the approval of Weltruza — the first once-monthly subcutaneous long-acting formulation of olanzapine for schizophrenia — as well as the first subcutaneous therapy for thyroid eye disease and Hovilpri for refractory mucocutaneous HSV. In addition, the FDA expanded Tecentriq’s reach with newly approved regimens, while Vanda Pharmaceuticals reported disappointing trial results for its social anxiety disorder candidate. herpes simpex virus, schizophrenia, pharmaceuticals, hovilpri, social anxiety disorder, olanzapine, vanda pharmaceuticals, weltruza, medicine, tecentriq, mpr false full 291 3830735d-33e9-4639-8d4e-1b0a7ae863e0 MPR Weekly Dose Podcast #289 — Juvmo for Parkinson Disease; Camzyos Approval Expanded; MS Treatment Gains Priority Review; Sudden BLA Withdrawal for a Key Lung Cancer Candidate Fri, 2 Oct 2026 16:20:06 +0000 editor@empr.com (Steve Duffy) https://www.empr.com MPR Weekly Dose Podcast #289 — Juvmo for Parkinson Disease; Camzyos Approval Expanded; MS Treatment Gains Priority Review; Sudden BLA Withdrawal for a Key Lung Cancer Candidate Steve Duffy 00:12:01 New FDA approvals for Juvmo in Parkinson disease and Camzyos in pediatric obstructive hypertrophic cardiomyopathy, a Priority Review green light for fenebrutinib in MS, and the sudden BLA withdrawal for a key lung cancer candidate. New FDA approvals for Juvmo in Parkinson disease and Camzyos in pediatric obstructive hypertrophic cardiomyopathy, a Priority Review green light for fenebrutinib in MS, and the sudden BLA withdrawal for a key lung cancer candidate. merck, camzyos, ohcm, fenebrutinib, multiple sclerosis, juvmo, parkinson disease, genetech, daiichi sankyo, lung cancer false full 289 235f7d14-182e-425b-b350-7809b1af618b MPR Weekly Dose Podcast #288 — CagriSema Weight Loss Results; ALS Treatment Shows Promise; Primary IgA Nephropathy Tx; Gene Therapy Approved for Sanfilippo Syndrome; Lyrfigtu Approved Results for weight loss treatment combo cagrilintide and semaglutide; positive results for treatment of rare form of ALS, and for sefaxersen in adults with primary IgA nephropathy; gene therapy approved for Sanfilippo syndrome; and Lyrfigtu gains approval for FGFR2+ advanced cholangiocarcinoma.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 25 Sep 2026 18:30:48 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com Results for weight loss treatment combo cagrilintide and semaglutide; positive results for treatment of rare form of ALS, and for sefaxersen in adults with primary IgA nephropathy; gene therapy approved for Sanfilippo syndrome; and Lyrfigtu gains approval for FGFR2+ advanced cholangiocarcinoma.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose Podcast #288 — CagriSema Weight Loss Results; ALS Treatment Shows Promise; Primary IgA Nephropathy Tx; Gene Therapy Approved for Sanfilippo Syndrome; Lyrfigtu Approved MPR Weekly Dose 00:12:06 Results for weight loss treatment combo cagrilintide and semaglutide; positive results for treatment of rare form of ALS, and for sefaxersen in adults with primary IgA nephropathy; gene therapy approved for Sanfilippo syndrome; and Lyrfigtu gains approval for FGFR2+ advanced cholangiocarcinoma. Results for weight loss treatment combo cagrilintide and semaglutide; positive results for treatment of rare form of ALS, and for sefaxersen in adults with primary IgA nephropathy; gene therapy approved for Sanfilippo syndrome; and Lyrfigtu gains approval for FGFR2+ advanced cholangiocarcinoma. false full 287 6bc9a21c-d2fa-404c-a674-1d910dffea00 MPR Weekly Dose Podcast #287 — Approvals for SMA and CKD; Joenja Approval Expanded; LSD Breakthrough in Depressive Disorder; Zasocitinib in Plaque Psoriasis Approvals for spinal muscular atrophy and chronic kidney disease; Joenja gains expanded approval in APDS; LSD derivative earns Breakthrough status to treat major depressive disorder; and zasocitinib is granted Priority Review for psoriasis.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 18 Sep 2026 16:09:40 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com Approvals for spinal muscular atrophy and chronic kidney disease; Joenja gains expanded approval in APDS; LSD derivative earns Breakthrough status to treat major depressive disorder; and zasocitinib is granted Priority Review for psoriasis.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose Podcast #287 — Approvals for SMA and CKD; Joenja Approval Expanded; LSD Breakthrough in Depressive Disorder; Zasocitinib in Plaque Psoriasis MPR Weekly Dose 00:13:06 Approvals for spinal muscular atrophy and chronic kidney disease; Joenja gains expanded approval in APDS; LSD derivative earns Breakthrough status to treat major depressive disorder; and zasocitinib is granted Priority Review for psoriasis. Approvals for spinal muscular atrophy and chronic kidney disease; Joenja gains expanded approval in APDS; LSD derivative earns Breakthrough status to treat major depressive disorder; and zasocitinib is granted Priority Review for psoriasis. false full 286 74f0a8ed-e818-4b7d-ba68-054d9e20e0cb MPR Weekly Dose Podcast #286 — Alexander Disease Tx; Hyrnuo and Etcamah Approved; Pelacarsen Misses Endpoint; Atogepant Shows Promise in Menstrual Migraines First treatment approved for Alexander disease; Hyrnuo and Etcamah are approved for lung cancer and breast cancer, respectively; Pelacarsen misses endpoint in the phase 3 HORIZON trial, and atogepant shows promise from relieving menstrual migraines.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 11 Sep 2026 15:35:34 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com First treatment approved for Alexander disease; Hyrnuo and Etcamah are approved for lung cancer and breast cancer, respectively; Pelacarsen misses endpoint in the phase 3 HORIZON trial, and atogepant shows promise from relieving menstrual migraines.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose Podcast #286 — Alexander Disease Tx; Hyrnuo and Etcamah Approved; Pelacarsen Misses Endpoint; Atogepant Shows Promise in Menstrual Migraines MPR Weekly Dose 00:13:07 First treatment approved for Alexander disease; Hyrnuo and Etcamah are approved for lung cancer and breast cancer, respectively; Pelacarsen misses endpoint in the phase 3 HORIZON trial, and atogepant shows promise from relieving menstrual migraines.    First treatment approved for Alexander disease; Hyrnuo and Etcamah are approved for lung cancer and breast cancer, respectively; Pelacarsen misses endpoint in the phase 3 HORIZON trial, and atogepant shows promise from relieving menstrual migraines.    false full 285 4be64669-bc1f-412b-8aff-e0b578d9b58b MPR Weekly Dose Podcast #285 — Mounjaro Approval Expanded; Updated RSV Pediatric Recs; Remibrutinib Shows Promise for Relapsing MS; Boxed Warning Added to Injectafer PI Mounjaro approval expanded to reduce the risk of major cardiovascular events; The American Academy of Pediatrics has issued updated recommendations for RSV immunization; BTK inhibitor shows promise in relapsing MS; and The FDA adds a boxed warning to Injectafer.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 4 Sep 2026 15:22:43 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com Mounjaro approval expanded to reduce the risk of major cardiovascular events; The American Academy of Pediatrics has issued updated recommendations for RSV immunization; BTK inhibitor shows promise in relapsing MS; and The FDA adds a boxed warning to Injectafer.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose Podcast #285 — Mounjaro Approval Expanded; Updated RSV Pediatric Recs; Remibrutinib Shows Promise for Relapsing MS; Boxed Warning Added to Injectafer PI MPR Weekly Dose 00:11:13 Mounjaro approval expanded to reduce the risk of major cardiovascular events; The American Academy of Pediatrics has issued updated recommendations for RSV immunization; BTK inhibitor shows promise in relapsing MS; and The FDA adds a boxed warning to Injectafer. Mounjaro approval expanded to reduce the risk of major cardiovascular events; The American Academy of Pediatrics has issued updated recommendations for RSV immunization; BTK inhibitor shows promise in relapsing MS; and The FDA adds a boxed warning to Injectafer. false full 284 c3b5ec52-efd0-4e2d-a7a3-65083fcd8121 MPR Weekly Dose Podcast #285 — Mounjaro Approval Expanded; Updated RSV Pediatric Recs; Remibrutinib Shows Promise for Relapsing MS; Boxed Warning Added to Injectafer PI Mounjaro approval expanded to reduce the risk of major cardiovascular events; The American Academy of Pediatrics has issued updated recommendations for RSV immunization; BTK inhibitor shows promise in relapsing MS; and The FDA adds a boxed warning to Injectafer.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 4 Sep 2026 15:22:36 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com Mounjaro approval expanded to reduce the risk of major cardiovascular events; The American Academy of Pediatrics has issued updated recommendations for RSV immunization; BTK inhibitor shows promise in relapsing MS; and The FDA adds a boxed warning to Injectafer.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose Podcast #285 — Mounjaro Approval Expanded; Updated RSV Pediatric Recs; Remibrutinib Shows Promise for Relapsing MS; Boxed Warning Added to Injectafer PI MPR Weekly Dose 00:11:13 Mounjaro approval expanded to reduce the risk of major cardiovascular events; The American Academy of Pediatrics has issued updated recommendations for RSV immunization; BTK inhibitor shows promise in relapsing MS; and The FDA adds a boxed warning to Injectafer. Mounjaro approval expanded to reduce the risk of major cardiovascular events; The American Academy of Pediatrics has issued updated recommendations for RSV immunization; BTK inhibitor shows promise in relapsing MS; and The FDA adds a boxed warning to Injectafer. false full 283 8daeeb7e-0552-439f-9c72-5440fec18067 Navigating the New mRNA Flu Shot: A Discussion With Dr William Schaffner In a special episode of the MPR Weekly Dose podcast, Dr William Schaffner — professor of preventive medicine and infectious diseases at Vanderbilt University School of Medicine and former CDC Epidemic Intelligence Service officer — discusses the clinical rollout of mFlusiva, the newly-approved mRNA-based influenza vaccine. Dr Schaffner breaks down how this modern platform differs from traditional egg- and cell-based manufacturing, detailing its mechanism of action as a genetic "blueprint" and analyzing the trial data behind its approval for adults aged 50 and older.

Beyond the science, Dr Schaffner offers actionable guidance for health care providers navigating the realities of modern clinical practice. He addresses practical logistics like coadministering mFlusiva alongside routine fall immunizations, including COVID-19, RSV, and pneumococcal vaccines. He also offers empathetic strategies for overcoming vaccine hesitancy, urging clinicians to look beyond technical lectures and focus on patient reassurance and emotional comfort.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Mon, 17 Aug 2026 16:56:03 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com In a special episode of the MPR Weekly Dose podcast, Dr William Schaffner — professor of preventive medicine and infectious diseases at Vanderbilt University School of Medicine and former CDC Epidemic Intelligence Service officer — discusses the clinical rollout of mFlusiva, the newly-approved mRNA-based influenza vaccine. Dr Schaffner breaks down how this modern platform differs from traditional egg- and cell-based manufacturing, detailing its mechanism of action as a genetic "blueprint" and analyzing the trial data behind its approval for adults aged 50 and older.

Beyond the science, Dr Schaffner offers actionable guidance for health care providers navigating the realities of modern clinical practice. He addresses practical logistics like coadministering mFlusiva alongside routine fall immunizations, including COVID-19, RSV, and pneumococcal vaccines. He also offers empathetic strategies for overcoming vaccine hesitancy, urging clinicians to look beyond technical lectures and focus on patient reassurance and emotional comfort.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Navigating the New mRNA Flu Shot: A Discussion With Dr William Schaffner MPR Weekly Dose 00:14:40 In a special episode of the MPR Weekly Dose podcast, Dr William Schaffner — professor of preventive medicine and infectious diseases at Vanderbilt University School of Medicine and former CDC Epidemic Intelligence Service officer — discusses the clinical rollout of mFlusiva, the newly-approved mRNA-based influenza vaccine. Dr Schaffner breaks down how this modern platform differs from traditional egg- and cell-based manufacturing, detailing its mechanism of action as a genetic "blueprint" and analyzing the trial data behind its approval for adults aged 50 and older.  Beyond the science, Dr Schaffner offers actionable guidance for health care providers navigating the realities of modern clinical practice. He addresses practical logistics like coadministering mFlusiva alongside routine fall immunizations, including COVID-19, RSV, and pneumococcal vaccines. He also offers empathetic strategies for overcoming vaccine hesitancy, urging clinicians to look beyond technical lectures and focus on patient reassurance and emotional comfort. In a special episode of the MPR Weekly Dose podcast, Dr William Schaffner — professor of preventive medicine and infectious diseases at Vanderbilt University School of Medicine and former CDC Epidemic Intelligence Service officer — discusses the clinical rollout of mFlusiva, the newly-approved mRNA-based influenza vaccine. Dr Schaffner breaks down how this modern platform differs from traditional egg- and cell-based manufacturing, detailing its mechanism of action as a genetic "blueprint" and analyzing the trial data behind its approval for adults aged 50 and older.  Beyond the science, Dr Schaffner offers actionable guidance for health care providers navigating the realities of modern clinical practice. He addresses practical logistics like coadministering mFlusiva alongside routine fall immunizations, including COVID-19, RSV, and pneumococcal vaccines. He also offers empathetic strategies for overcoming vaccine hesitancy, urging clinicians to look beyond technical lectures and focus on patient reassurance and emotional comfort. false full 282 6b84f1ab-896d-4782-b71b-fdd440f87280 MPR Weekly Dose Podcast #283 — mRNA Influenza Vaccine; Pluvicto for PSMA+ mHSPC; Mucinex 12HR Approved; Narcolepsy Tx Approved; Peanut Allergy Treatment Fast Tracked Moderna's mRNA influenza vaccine gains FDA approval; approvals for prostate cancer, narcolepsy type 1 and Mucinex 12HR; and peanut allergy treatment gains Fast Track status.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 7 Aug 2026 14:50:46 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com Moderna's mRNA influenza vaccine gains FDA approval; approvals for prostate cancer, narcolepsy type 1 and Mucinex 12HR; and peanut allergy treatment gains Fast Track status.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose Podcast #283 — mRNA Influenza Vaccine; Pluvicto for PSMA+ mHSPC; Mucinex 12HR Approved; Narcolepsy Tx Approved; Peanut Allergy Treatment Fast Tracked MPR Weekly Dose 00:12:12 Moderna's mRNA influenza vaccine gains FDA approval; approvals for prostate cancer, narcolepsy type 1 and Mucinex 12HR; and peanut allergy treatment gains Fast Track status. Moderna's mRNA influenza vaccine gains FDA approval; approvals for prostate cancer, narcolepsy type 1 and Mucinex 12HR; and peanut allergy treatment gains Fast Track status. false full 281 153a7057-ae98-4ef9-99eb-61f6f9eb1237 MPR Weekly Dose Podcast #282 — OTC Acetaminophen/Naproxen; Novel ADHD Tx; COVID-19 PEP; Contraceptive Patch; Furosemide Autoinjector for Edema An over-the-counter acetaminophen/naproxen sodium fixed-dose tablet gains approval; Simtriyo approved for ADHD; Xocova approved for COVID-19 postexposure prophylaxis; A new contraceptive patch is approved; and Furoscix ReadyFlow approval is expanded to treat edema in CHF, CKD.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 31 Jul 2026 15:01:47 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com An over-the-counter acetaminophen/naproxen sodium fixed-dose tablet gains approval; Simtriyo approved for ADHD; Xocova approved for COVID-19 postexposure prophylaxis; A new contraceptive patch is approved; and Furoscix ReadyFlow approval is expanded to treat edema in CHF, CKD.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose Podcast #282 — OTC Acetaminophen/Naproxen; Novel ADHD Tx; COVID-19 PEP; Contraceptive Patch; Furosemide Autoinjector for Edema MPR Weekly Dose 00:14:49 An over-the-counter acetaminophen/naproxen sodium fixed-dose tablet gains approval; Simtriyo approved for ADHD; Xocova approved for COVID-19 postexposure prophylaxis; A new contraceptive patch is approved; and Furoscix ReadyFlow approval is expanded to treat edema in CHF, CKD. An over-the-counter acetaminophen/naproxen sodium fixed-dose tablet gains approval; Simtriyo approved for ADHD; Xocova approved for COVID-19 postexposure prophylaxis; A new contraceptive patch is approved; and Furoscix ReadyFlow approval is expanded to treat edema in CHF, CKD. false full 280 735a6b5c-e5d7-4774-a2bc-a666939c960f MPR Weekly Dose Podcast #281 — Kalshi Start Clinical Trial Predictions; Positive Results for Retatrutide; Jideytro Approved; Smart Toilet Launches; Daraxonrasib NDA Accepted Kalshi start clinical trials, FDA approvals prediction market; positive results shared for triple hormone therapy retatrutide; Jideytro gains approval in advanced or metastatic ROS1-positive NSCLC; a smart toilet seat hits the market to measure your vitals; and the FDA accepts an application for pretreated metastatic pancreatic cancer treatment, daraxonrasib.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 24 Jul 2026 15:12:55 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com Kalshi start clinical trials, FDA approvals prediction market; positive results shared for triple hormone therapy retatrutide; Jideytro gains approval in advanced or metastatic ROS1-positive NSCLC; a smart toilet seat hits the market to measure your vitals; and the FDA accepts an application for pretreated metastatic pancreatic cancer treatment, daraxonrasib.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose Podcast #281 — Kalshi Start Clinical Trial Predictions; Positive Results for Retatrutide; Jideytro Approved; Smart Toilet Launches; Daraxonrasib NDA Accepted MPR Weekly Dose 00:15:02 Kalshi start clinical trials, FDA approvals prediction market; positive results shared for triple hormone therapy retatrutide; Jideytro gains approval in advanced or metastatic ROS1-positive NSCLC; a smart toilet seat hits the market to measure your vitals; and the FDA accepts an application for pretreated metastatic pancreatic cancer treatment, daraxonrasib.   Kalshi start clinical trials, FDA approvals prediction market; positive results shared for triple hormone therapy retatrutide; Jideytro gains approval in advanced or metastatic ROS1-positive NSCLC; a smart toilet seat hits the market to measure your vitals; and the FDA accepts an application for pretreated metastatic pancreatic cancer treatment, daraxonrasib.   false full 279 a29d784a-59e5-4481-9689-5eb5a2102dc7 MPR Weekly Dose Podcast #280 — Cyclospora Outbreak Latest; Hypercholesterolemia Tx Approved; New Lecanemab SC Regimen; Oral Sleep Apnea Tx; Revtorpyk Approved for Breast Cancer The latest on the multistate cyclospora outbreak; Lipfendra approved to reduce low-density lipoprotein cholesterol in adults with hypercholesterolemia; subcutaneous starting dose regimen approved for Leqembi; NDA accepted for oral sleep apnea treatment; and Revtorpyk combination approved for advanced breast cancer.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 17 Jul 2026 15:01:47 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com The latest on the multistate cyclospora outbreak; Lipfendra approved to reduce low-density lipoprotein cholesterol in adults with hypercholesterolemia; subcutaneous starting dose regimen approved for Leqembi; NDA accepted for oral sleep apnea treatment; and Revtorpyk combination approved for advanced breast cancer.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose Podcast #280 — Cyclospora Outbreak Latest; Hypercholesterolemia Tx Approved; New Lecanemab SC Regimen; Oral Sleep Apnea Tx; Revtorpyk Approved for Breast Cancer MPR Weekly Dose 00:14:35 The latest on the multistate cyclospora outbreak; Lipfendra approved to reduce low-density lipoprotein cholesterol in adults with hypercholesterolemia; subcutaneous starting dose regimen approved for Leqembi; NDA accepted for oral sleep apnea treatment; and Revtorpyk combination approved for advanced breast cancer.   The latest on the multistate cyclospora outbreak; Lipfendra approved to reduce low-density lipoprotein cholesterol in adults with hypercholesterolemia; subcutaneous starting dose regimen approved for Leqembi; NDA accepted for oral sleep apnea treatment; and Revtorpyk combination approved for advanced breast cancer.   false full 278 b5eacd0a-e542-4658-841b-dd844e3c1dab MPR Weekly Dose Podcast #279 — Trutakna Approved; Xtoro and Amerithroid Now Available; Casgevy Approval Expanded; Lupus Tx Granted Breakthrough Designation A new treatment is approved to reduce proteinuria in adults with primary immunoglobulin A nephropahty; a swimmer's ear treatment and the thyroid hormone replacement therapy Amerithroid are now available; Casgevy approval expanded include pediatrics; and a lupus treatment is granted breakthrough status.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 10 Jul 2026 15:19:01 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com A new treatment is approved to reduce proteinuria in adults with primary immunoglobulin A nephropahty; a swimmer's ear treatment and the thyroid hormone replacement therapy Amerithroid are now available; Casgevy approval expanded include pediatrics; and a lupus treatment is granted breakthrough status.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose Podcast #279 — Trutakna Approved; Xtoro and Amerithroid Now Available; Casgevy Approval Expanded; Lupus Tx Granted Breakthrough Designation MPR Weekly Dose 00:13:34 A new treatment is approved to reduce proteinuria in adults with primary immunoglobulin A nephropahty; a swimmer's ear treatment and the thyroid hormone replacement therapy Amerithroid are now available; Casgevy approval expanded include pediatrics; and a lupus treatment is granted breakthrough status.   A new treatment is approved to reduce proteinuria in adults with primary immunoglobulin A nephropahty; a swimmer's ear treatment and the thyroid hormone replacement therapy Amerithroid are now available; Casgevy approval expanded include pediatrics; and a lupus treatment is granted breakthrough status.   false full 277 7f840bb0-ae10-4a9b-9a5d-e62c5129e531 MPR Weekly Dose Podcast #278 — Once-Weekly HIV Tx; Hympavzi Approval Expanded; Orforglipron Assessed in Menopause; Warning Label for Weight Loss Tx A single, once-weekly tablet could change HIV treatment landscape; weight loss drug orforglipron efficacy assessed at all stages of menopause; hemophilia treatment Hympavzi gains expanded indication; and the FDA adds a warning label for kidney injury to an over-the-counter weight loss aid.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 12 Jun 2026 16:04:03 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com A single, once-weekly tablet could change HIV treatment landscape; weight loss drug orforglipron efficacy assessed at all stages of menopause; hemophilia treatment Hympavzi gains expanded indication; and the FDA adds a warning label for kidney injury to an over-the-counter weight loss aid.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose Podcast #278 — Once-Weekly HIV Tx; Hympavzi Approval Expanded; Orforglipron Assessed in Menopause; Warning Label for Weight Loss Tx MPR Weekly Dose 00:13:12 A single, once-weekly tablet could change HIV treatment landscape; weight loss drug orforglipron efficacy assessed at all stages of menopause; hemophilia treatment Hympavzi gains expanded indication; and the FDA adds a warning label for kidney injury to an over-the-counter weight loss aid. A single, once-weekly tablet could change HIV treatment landscape; weight loss drug orforglipron efficacy assessed at all stages of menopause; hemophilia treatment Hympavzi gains expanded indication; and the FDA adds a warning label for kidney injury to an over-the-counter weight loss aid. false full 276 a7260dad-1289-47fe-8677-4ec1459e9b08 MPR Weekly Dose Podcast #277 — Treatment Approved for cUTI; COVID-19 Postexposure Prophylaxis; Eye Drops Fail to Meet Endpoint; Afrezza Indication Expanded; Obefazimod UC Trial Results New treatment approved for adults with complicated urinary tract infections; Xocova approved for COVID-19 postexposure prophylaxis; investigational diabetic macular edema eye drop fails to meet trial endpoint; Afrezza expanded for pediatric use; obefazimod looks promising for ulcerative colitis.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 5 Jun 2026 15:21:03 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com New treatment approved for adults with complicated urinary tract infections; Xocova approved for COVID-19 postexposure prophylaxis; investigational diabetic macular edema eye drop fails to meet trial endpoint; Afrezza expanded for pediatric use; obefazimod looks promising for ulcerative colitis.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose Podcast #277 — Treatment Approved for cUTI; COVID-19 Postexposure Prophylaxis; Eye Drops Fail to Meet Endpoint; Afrezza Indication Expanded; Obefazimod UC Trial Results MPR Weekly Dose 00:11:44 New treatment approved for adults with complicated urinary tract infections; Xocova approved for COVID-19 postexposure prophylaxis; investigational diabetic macular edema eye drop fails to meet trial endpoint; Afrezza expanded for pediatric use; obefazimod looks promising for ulcerative colitis. New treatment approved for adults with complicated urinary tract infections; Xocova approved for COVID-19 postexposure prophylaxis; investigational diabetic macular edema eye drop fails to meet trial endpoint; Afrezza expanded for pediatric use; obefazimod looks promising for ulcerative colitis. false full 275 9b87826e-8b02-40dd-905b-10ef14065089 MPR Daily Dose Podcast #276 — Retatrutide Shows Significant Weight Loss; Hepcludex Approved; Acne Gel for OTC Use; Linzess Indication Expanded; Camizestrant Review Extended New triple hormone receptor agonist shows significant weight loss; hepatitis delta virus treatment gains accelerated approval; acne gel gains OTC designation; constipation treatment expanded to include younger patients; and the FDA extends review for camizestrant in advanced breast cancer.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 29 May 2026 15:47:08 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com New triple hormone receptor agonist shows significant weight loss; hepatitis delta virus treatment gains accelerated approval; acne gel gains OTC designation; constipation treatment expanded to include younger patients; and the FDA extends review for camizestrant in advanced breast cancer.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Daily Dose Podcast #276 — Retatrutide Shows Significant Weight Loss; Hepcludex Approved; Acne Gel for OTC Use; Linzess Indication Expanded; Camizestrant Review Extended MPR Weekly Dose 00:14:16 New triple hormone receptor agonist shows significant weight loss; hepatitis delta virus treatment gains accelerated approval; acne gel gains OTC designation; constipation treatment expanded to include younger patients; and the FDA extends review for camizestrant in advanced breast cancer. New triple hormone receptor agonist shows significant weight loss; hepatitis delta virus treatment gains accelerated approval; acne gel gains OTC designation; constipation treatment expanded to include younger patients; and the FDA extends review for camizestrant in advanced breast cancer. false full 274 a2c5bd19-ee55-4dfc-b24c-214865ceab3f MPR Daily Dose #275 — Top OTC Meds and Products; FDA Assess Safety in Pregnancy; Efgartigimod gMG Indication Broadened; R/R Mantle Cell Lymphoma Approval; ALS Treatment Fast Tracked US News and World Report releases their annual best over-the-counter products list; new guidance for drug safety evaluation during pregnancy; gMG indication broadened for efgartigimod; Beqalzi gains accelerated approval for MCL; and a novel treatment fast tracked for ALS.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 15 May 2026 16:06:24 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com US News and World Report releases their annual best over-the-counter products list; new guidance for drug safety evaluation during pregnancy; gMG indication broadened for efgartigimod; Beqalzi gains accelerated approval for MCL; and a novel treatment fast tracked for ALS.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Daily Dose #275 — Top OTC Meds and Products; FDA Assess Safety in Pregnancy; Efgartigimod gMG Indication Broadened; R/R Mantle Cell Lymphoma Approval; ALS Treatment Fast Tracked MPR Weekly Dose 00:11:56 US News and World Report releases their annual best over-the-counter products list; new guidance for drug safety evaluation during pregnancy; gMG indication broadened for efgartigimod; Beqalzi gains accelerated approval for MCL; and a novel treatment fast tracked for ALS.   US News and World Report releases their annual best over-the-counter products list; new guidance for drug safety evaluation during pregnancy; gMG indication broadened for efgartigimod; Beqalzi gains accelerated approval for MCL; and a novel treatment fast tracked for ALS.   false full 273 61694e38-9f3d-48f6-9b45-f98b84721d33 MPR Weekly Dose Podcast #274 — Ozempic Tablets; ALS Tx Fast Tracked; Phase 3 results for aficamten in HCM; Motion Sickness Drug Approved; Lantus Alternative Ozempic tablets are now available; investigational ALS treatment gains FDA Fast Track status; positive results for aficamten in non-obstructive hypertrophic cardiomyopathy; motion sickness drug Nereus now available; Lantus alternative Langlara gains approval.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 8 May 2026 17:27:54 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com Ozempic tablets are now available; investigational ALS treatment gains FDA Fast Track status; positive results for aficamten in non-obstructive hypertrophic cardiomyopathy; motion sickness drug Nereus now available; Lantus alternative Langlara gains approval.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose Podcast #274 — Ozempic Tablets; ALS Tx Fast Tracked; Phase 3 results for aficamten in HCM; Motion Sickness Drug Approved; Lantus Alternative MPR Weekly Dose 00:09:50 Ozempic tablets are now available; investigational ALS treatment gains FDA Fast Track status; positive results for aficamten in non-obstructive hypertrophic cardiomyopathy; motion sickness drug Nereus now available; Lantus alternative Langlara gains approval. Ozempic tablets are now available; investigational ALS treatment gains FDA Fast Track status; positive results for aficamten in non-obstructive hypertrophic cardiomyopathy; motion sickness drug Nereus now available; Lantus alternative Langlara gains approval. false full 272 73ad6f90-0eee-43ef-bbbc-3296e187f8a4 MPR Weekly Dose Podcast #273 — Gene Therapy Approved for Rare Hearing Loss; Pattern Hair Loss Tx Shows Growth; Brestri for Asthma; CRISPR gene for HAE; Novel Obesity Tx Gene therapy approved to restore hereditary hearing loss; investigational treatment shows hair coverage improvements in male pattern loss; Breztri approved as a maintenance treatment for asthma; gene editing candidate meets endpoints in hereditary angioedema trial; novel dual glucagon/GLP-1 receptor agonist demonstrates significant weight loss.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 1 May 2026 16:44:41 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com Gene therapy approved to restore hereditary hearing loss; investigational treatment shows hair coverage improvements in male pattern loss; Breztri approved as a maintenance treatment for asthma; gene editing candidate meets endpoints in hereditary angioedema trial; novel dual glucagon/GLP-1 receptor agonist demonstrates significant weight loss.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose Podcast #273 — Gene Therapy Approved for Rare Hearing Loss; Pattern Hair Loss Tx Shows Growth; Brestri for Asthma; CRISPR gene for HAE; Novel Obesity Tx MPR Weekly Dose 00:13:48 Gene therapy approved to restore hereditary hearing loss; investigational treatment shows hair coverage improvements in male pattern loss; Breztri approved as a maintenance treatment for asthma; gene editing candidate meets endpoints in hereditary angioedema trial; novel dual glucagon/GLP-1 receptor agonist demonstrates significant weight loss. Gene therapy approved to restore hereditary hearing loss; investigational treatment shows hair coverage improvements in male pattern loss; Breztri approved as a maintenance treatment for asthma; gene editing candidate meets endpoints in hereditary angioedema trial; novel dual glucagon/GLP-1 receptor agonist demonstrates significant weight loss. false full 271 d3761104-3b9c-4444-84f6-00571459275f MPR Weekly Dose Podcast #272 — Idvynso Approved for HIV; Expanded Indication for Dupixent; Novel Tx Shows Promise for Pancreatic CA; Oral Semaglutide for Adolescents; GLP-1 Potential Knee OA Tx Two-drug, single-tablet approved to replace current antiretroviral regimen; Dupixent approved for pediatric CSU; novel treatment significantly improves survival in metastatic pancreatic cancer; oral semaglutide for adolescents; GLP-1 Fast Tracked for knee osteoarthritis.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 24 Apr 2026 16:08:29 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com Two-drug, single-tablet approved to replace current antiretroviral regimen; Dupixent approved for pediatric CSU; novel treatment significantly improves survival in metastatic pancreatic cancer; oral semaglutide for adolescents; GLP-1 Fast Tracked for knee osteoarthritis.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose Podcast #272 — Idvynso Approved for HIV; Expanded Indication for Dupixent; Novel Tx Shows Promise for Pancreatic CA; Oral Semaglutide for Adolescents; GLP-1 Potential Knee OA Tx MPR Weekly Dose 00:11:30 Two-drug, single-tablet approved to replace current antiretroviral regimen; Dupixent approved for pediatric CSU; novel treatment significantly improves survival in metastatic pancreatic cancer; oral semaglutide for adolescents; GLP-1 Fast Tracked for knee osteoarthritis. Two-drug, single-tablet approved to replace current antiretroviral regimen; Dupixent approved for pediatric CSU; novel treatment significantly improves survival in metastatic pancreatic cancer; oral semaglutide for adolescents; GLP-1 Fast Tracked for knee osteoarthritis. false full 270 b5ab4263-2cf2-460c-b946-39f5b6361c9e MPR Weekly Dose Podcast #271 — Foundayo Now Available, Meets Safety Endpoints; Filspari, Sdamlo Approved; FDA Encourages TRT Makers to Purse Label Expansion Foundayo, an oral GLP-1, now available for weight loss; results from the ACHIEVE-4 trial; Filspari gains approval for FSGS; a new formulation of amlodipine, and the FDA signals support for broader use of testosterone replacement therapy.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 17 Apr 2026 16:08:33 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com Foundayo, an oral GLP-1, now available for weight loss; results from the ACHIEVE-4 trial; Filspari gains approval for FSGS; a new formulation of amlodipine, and the FDA signals support for broader use of testosterone replacement therapy.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose Podcast #271 — Foundayo Now Available, Meets Safety Endpoints; Filspari, Sdamlo Approved; FDA Encourages TRT Makers to Purse Label Expansion MPR Weekly Dose 00:14:44 Foundayo, an oral GLP-1, now available for weight loss; results from the ACHIEVE-4 trial; Filspari gains approval for FSGS; a new formulation of amlodipine, and the FDA signals support for broader use of testosterone replacement therapy. Foundayo, an oral GLP-1, now available for weight loss; results from the ACHIEVE-4 trial; Filspari gains approval for FSGS; a new formulation of amlodipine, and the FDA signals support for broader use of testosterone replacement therapy. false full 269 6ed05922-d8ca-4f41-b10f-87efa2acd34f MPR Weekly Dose Podcast #270 — High Dose Wegovy; Durvalumab Combo for Unresectable HCC; Generic Dapagliflozin; Yuviwel Now Available for Achondroplasia High-dose Wegovy now available for additional weight reduction when clinically indicated; trial results for durvalumab combo treatment in patients with unresectable hepatocellular; generic dapagliflozin gets green light, paving the way for generic manufacturers; achondroplasia treatment Yuviwel now available.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 10 Apr 2026 14:57:57 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com High-dose Wegovy now available for additional weight reduction when clinically indicated; trial results for durvalumab combo treatment in patients with unresectable hepatocellular; generic dapagliflozin gets green light, paving the way for generic manufacturers; achondroplasia treatment Yuviwel now available.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose Podcast #270 — High Dose Wegovy; Durvalumab Combo for Unresectable HCC; Generic Dapagliflozin; Yuviwel Now Available for Achondroplasia MPR Weekly Dose 00:10:13 High-dose Wegovy now available for additional weight reduction when clinically indicated; trial results for durvalumab combo treatment in patients with unresectable hepatocellular; generic dapagliflozin gets green light, paving the way for generic manufacturers; achondroplasia treatment Yuviwel now available. High-dose Wegovy now available for additional weight reduction when clinically indicated; trial results for durvalumab combo treatment in patients with unresectable hepatocellular; generic dapagliflozin gets green light, paving the way for generic manufacturers; achondroplasia treatment Yuviwel now available. false full 268 87563df0-f450-4d9d-8a6a-f383b29cae98 MPR Weekly Dose Podcast #269 — Lifyorli, Avlayah Approved; Lyme Disease Vaccine Trial Results; Once-Weekly Basal Insulin Approved for T2DM Lifyorli combo approved for ovarian cancer; mixed results from Lyme disease vaccine trial; treatment approved for rare Hunter syndrome and Awiqli gets approval as once-weekly basal insulin for type 2 diabetes.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 27 Mar 2026 17:24:38 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com Lifyorli combo approved for ovarian cancer; mixed results from Lyme disease vaccine trial; treatment approved for rare Hunter syndrome and Awiqli gets approval as once-weekly basal insulin for type 2 diabetes.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose Podcast #269 — Lifyorli, Avlayah Approved; Lyme Disease Vaccine Trial Results; Once-Weekly Basal Insulin Approved for T2DM MPR Weekly Dose 00:10:55 Lifyorli combo approved for ovarian cancer; mixed results from Lyme disease vaccine trial; treatment approved for rare Hunter syndrome and Awiqli gets approval as once-weekly basal insulin for type 2 diabetes. Lifyorli combo approved for ovarian cancer; mixed results from Lyme disease vaccine trial; treatment approved for rare Hunter syndrome and Awiqli gets approval as once-weekly basal insulin for type 2 diabetes. false full 267 3376ab09-fed4-4e9e-a6ed-18668bc9d8ef MPR Weekly Dose Podcast #268 — Childhood Immunization Schedule Changes Blocked; High Dose Wegovy Gets Green Light; Hidradenitis Suppurativa Tx Indication Expanded; Triple Therapy Show Significant Weight Loss A federal court blocks changes to the childhood immunization schedule by the recently appointed vaccine advisory committee; higher dose Wegovy injection gets green light; Cosentyx expanded to include pediatric hidradenitis suppurativa; investigative triple hormone therapy shows significant weight reduction in diabetes.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 20 Mar 2026 15:57:16 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com A federal court blocks changes to the childhood immunization schedule by the recently appointed vaccine advisory committee; higher dose Wegovy injection gets green light; Cosentyx expanded to include pediatric hidradenitis suppurativa; investigative triple hormone therapy shows significant weight reduction in diabetes.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose Podcast #268 — Childhood Immunization Schedule Changes Blocked; High Dose Wegovy Gets Green Light; Hidradenitis Suppurativa Tx Indication Expanded; Triple Therapy Show Significant Weight Loss MPR Weekly Dose 00:11:03 A federal court blocks changes to the childhood immunization schedule by the recently appointed vaccine advisory committee; higher dose Wegovy injection gets green light; Cosentyx expanded to include pediatric hidradenitis suppurativa; investigative triple hormone therapy shows significant weight reduction in diabetes. A federal court blocks changes to the childhood immunization schedule by the recently appointed vaccine advisory committee; higher dose Wegovy injection gets green light; Cosentyx expanded to include pediatric hidradenitis suppurativa; investigative triple hormone therapy shows significant weight reduction in diabetes. false full 266 fc724007-a3d7-4839-ae64-0ca6ed98eb7b MPR Weekly Dose Podcast #267 — Sotyktu, Leucovorin Gain Approval; Follicular Lymphoma Treatment Withdrawn; FDA to Review Potential Hypertension Drug Sotyktu's approval expanded to encompass active psoriatic arthritis; the FDA approves leucovorin for rare disorder, not autism; safety concerns prompt Tazverik withdrawal; FDA to review potential new hypertension treatment.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Thu, 12 Mar 2026 20:18:08 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com Sotyktu's approval expanded to encompass active psoriatic arthritis; the FDA approves leucovorin for rare disorder, not autism; safety concerns prompt Tazverik withdrawal; FDA to review potential new hypertension treatment.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose Podcast #267 — Sotyktu, Leucovorin Gain Approval; Follicular Lymphoma Treatment Withdrawn; FDA to Review Potential Hypertension Drug MPR Weekly Dose 00:12:01 Sotyktu's approval expanded to encompass active psoriatic arthritis; the FDA approves leucovorin for rare disorder, not autism; safety concerns prompt Tazverik withdrawal; FDA to review potential new hypertension treatment. Sotyktu's approval expanded to encompass active psoriatic arthritis; the FDA approves leucovorin for rare disorder, not autism; safety concerns prompt Tazverik withdrawal; FDA to review potential new hypertension treatment. false full 265 6be8c9ee-291c-4ce7-b1f2-5774b22a5860 MPR Weekly Dose Podcast #266 — Generic Flovent HFA; Achondroplasia Tx Gains Approval; Dupixent Approved for Allergic Fungal Rhinosinusitis; Swallowable Gastric Balloon Glenmark to launch the first generic version of Flovent HFA, expanding affordable access; achondroplasia treatment granted accelerated approval; Dupixent approved for allergic fungal rhinosinusitis; and a swallowable balloon offers a unique outpatient alternative for weight management.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 6 Mar 2026 15:44:48 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com Glenmark to launch the first generic version of Flovent HFA, expanding affordable access; achondroplasia treatment granted accelerated approval; Dupixent approved for allergic fungal rhinosinusitis; and a swallowable balloon offers a unique outpatient alternative for weight management.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose Podcast #266 — Generic Flovent HFA; Achondroplasia Tx Gains Approval; Dupixent Approved for Allergic Fungal Rhinosinusitis; Swallowable Gastric Balloon MPR Weekly Dose 00:11:22 Glenmark to launch the first generic version of Flovent HFA, expanding affordable access; achondroplasia treatment granted accelerated approval; Dupixent approved for allergic fungal rhinosinusitis; and a swallowable balloon offers a unique outpatient alternative for weight management. Glenmark to launch the first generic version of Flovent HFA, expanding affordable access; achondroplasia treatment granted accelerated approval; Dupixent approved for allergic fungal rhinosinusitis; and a swallowable balloon offers a unique outpatient alternative for weight management. false full 264 b5390430-c3cc-4640-a048-dafac1be1bb2 MPR Weekly Dose Podcast #265 — Wakix Approval Expanded; Psoriasis, Weight-Loss Combo Tx; Psilocybin Shows Promise in TRD; Remibrutinib for Chronic Inducible Urticaria; Injectable Regimen Benefits HIV Treatment Adherence We explore the FDA's expansion of Wakix as the first non-scheduled treatment for pediatric cataplexy; a Taltz and Zepbound combo shows promise in skin clearance for patients with psoriasis and obesity; we also look at the frontier of mental health with synthetic psilocybin; there's phase 3 results from a potential new treatment for chronic inducible hives; and a long-acting HIV injection could be a game-changer for patients who struggle with the daily pill grind.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 20 Feb 2026 17:09:37 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com We explore the FDA's expansion of Wakix as the first non-scheduled treatment for pediatric cataplexy; a Taltz and Zepbound combo shows promise in skin clearance for patients with psoriasis and obesity; we also look at the frontier of mental health with synthetic psilocybin; there's phase 3 results from a potential new treatment for chronic inducible hives; and a long-acting HIV injection could be a game-changer for patients who struggle with the daily pill grind.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose Podcast #265 — Wakix Approval Expanded; Psoriasis, Weight-Loss Combo Tx; Psilocybin Shows Promise in TRD; Remibrutinib for Chronic Inducible Urticaria; Injectable Regimen Benefits HIV Treatment Adherence MPR Weekly Dose 00:12:18 We explore the FDA's expansion of Wakix as the first non-scheduled treatment for pediatric cataplexy; a Taltz and Zepbound combo shows promise in skin clearance for patients with psoriasis and obesity; we also look at the frontier of mental health with synthetic psilocybin; there's phase 3 results from a potential new treatment for chronic inducible hives; and a long-acting HIV injection could be a game-changer for patients who struggle with the daily pill grind.   We explore the FDA's expansion of Wakix as the first non-scheduled treatment for pediatric cataplexy; a Taltz and Zepbound combo shows promise in skin clearance for patients with psoriasis and obesity; we also look at the frontier of mental health with synthetic psilocybin; there's phase 3 results from a potential new treatment for chronic inducible hives; and a long-acting HIV injection could be a game-changer for patients who struggle with the daily pill grind.   false full 263 34074d2d-309c-4d93-b68b-6a4ea92e214c MPR Weekly Dose Podcast #264 — Hep B Birth Dose Study; FDA Approves Treatments for Pancreatic, Ovarian Cancer; Priority Review for Narcolepsy Treatment Recent medical updates highlight the long-term health benefits of the universal hepatitis B birth dose, alongside FDA milestones including the approval of Optune Pax for pancreatic cancer and a pembrolizumab-based regimen for platinum-resistant ovarian cancer, and the granting of priority review to oveporexton for narcolepsy type 1.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 13 Feb 2026 16:53:55 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com Recent medical updates highlight the long-term health benefits of the universal hepatitis B birth dose, alongside FDA milestones including the approval of Optune Pax for pancreatic cancer and a pembrolizumab-based regimen for platinum-resistant ovarian cancer, and the granting of priority review to oveporexton for narcolepsy type 1.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose Podcast #264 — Hep B Birth Dose Study; FDA Approves Treatments for Pancreatic, Ovarian Cancer; Priority Review for Narcolepsy Treatment MPR Weekly Dose 00:13:15 Recent medical updates highlight the long-term health benefits of the universal hepatitis B birth dose, alongside FDA milestones including the approval of Optune Pax for pancreatic cancer and a pembrolizumab-based regimen for platinum-resistant ovarian cancer, and the granting of priority review to oveporexton for narcolepsy type 1. Recent medical updates highlight the long-term health benefits of the universal hepatitis B birth dose, alongside FDA milestones including the approval of Optune Pax for pancreatic cancer and a pembrolizumab-based regimen for platinum-resistant ovarian cancer, and the granting of priority review to oveporexton for narcolepsy type 1. false full 262 8817d78c-19a9-47c4-879e-79e85c6b5c3a MPR Weekly Dose Podcast #263 — Combo Tx Shows Superior Weight Loss; Amgen Refuse to Withdraw Drug; Legal Action Threatened Against Hims & Hers; Film Approved for ED; NDA for mCRC accepted for review Combo treatment aims to be latest to enter the weight loss space; Amgen refuses to remove drug from market despite FDA request; Novo Nordisk threatens legal action against Hims & Hers; an oral film formulation of sildenafil is approved; and the FDA accepts the NDA for zanzalintinib plus atezolizumab for metastatic colorectal cancer.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 6 Feb 2026 17:40:45 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com Combo treatment aims to be latest to enter the weight loss space; Amgen refuses to remove drug from market despite FDA request; Novo Nordisk threatens legal action against Hims & Hers; an oral film formulation of sildenafil is approved; and the FDA accepts the NDA for zanzalintinib plus atezolizumab for metastatic colorectal cancer.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose Podcast #263 — Combo Tx Shows Superior Weight Loss; Amgen Refuse to Withdraw Drug; Legal Action Threatened Against Hims & Hers; Film Approved for ED; NDA for mCRC accepted for review MPR Weekly Dose 00:15:04 Combo treatment aims to be latest to enter the weight loss space; Amgen refuses to remove drug from market despite FDA request; Novo Nordisk threatens legal action against Hims & Hers; an oral film formulation of sildenafil is approved; and the FDA accepts the NDA for zanzalintinib plus atezolizumab for metastatic colorectal cancer. Combo treatment aims to be latest to enter the weight loss space; Amgen refuses to remove drug from market despite FDA request; Novo Nordisk threatens legal action against Hims & Hers; an oral film formulation of sildenafil is approved; and the FDA accepts the NDA for zanzalintinib plus atezolizumab for metastatic colorectal cancer. false full 261 732710b9-82af-4141-b5b5-1f1353d1ac71 MPR Weekly Dose Podcast #262 — Docs Turn to AAP's Vaccine Schedule; Safety Alert for Burn, Wound Products; SC Lecanemab to Be Reviewed; Cardamyst Nasal Spray Available; Gene Therapies Placed on Hold AAP maintains routine vaccine recs despite CDC changes; FDA warns of serious injury with wound and burn products; subcutaneous Alzheimer disease treatment under review; Cardamyst nasal spray available; and the FDA places clinical hold on 2 gene therapies.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 30 Jan 2026 16:01:48 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com AAP maintains routine vaccine recs despite CDC changes; FDA warns of serious injury with wound and burn products; subcutaneous Alzheimer disease treatment under review; Cardamyst nasal spray available; and the FDA places clinical hold on 2 gene therapies.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose Podcast #262 — Docs Turn to AAP's Vaccine Schedule; Safety Alert for Burn, Wound Products; SC Lecanemab to Be Reviewed; Cardamyst Nasal Spray Available; Gene Therapies Placed on Hold MPR Weekly Dose 00:14:06 AAP maintains routine vaccine recs despite CDC changes; FDA warns of serious injury with wound and burn products; subcutaneous Alzheimer disease treatment under review; Cardamyst nasal spray available; and the FDA places clinical hold on 2 gene therapies. AAP maintains routine vaccine recs despite CDC changes; FDA warns of serious injury with wound and burn products; subcutaneous Alzheimer disease treatment under review; Cardamyst nasal spray available; and the FDA places clinical hold on 2 gene therapies. false full 260 ff7d41af-d3aa-4937-8cc8-ab8d11e0354f MPR Weekly Dose Podcast #261 — New Research on Prenatal Acetaminophen Use; Chikungunya Vaccine Withdrawn; Nexplanon Use Extended; GLP-1 RAs and Suicidal Behavior; At-Home Device for Depression New research on acetaminophen use during pregnancy; the chikungunya vaccine Ixchiq is withdrawn; FDA approves Nexplanon for up to 5 years of use; suicidal ideation warning removed from GLP-1s; at-home neuromodulation therapy cleared for adults with major depressive disorder.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 23 Jan 2026 16:53:28 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com New research on acetaminophen use during pregnancy; the chikungunya vaccine Ixchiq is withdrawn; FDA approves Nexplanon for up to 5 years of use; suicidal ideation warning removed from GLP-1s; at-home neuromodulation therapy cleared for adults with major depressive disorder.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose Podcast #261 — New Research on Prenatal Acetaminophen Use; Chikungunya Vaccine Withdrawn; Nexplanon Use Extended; GLP-1 RAs and Suicidal Behavior; At-Home Device for Depression MPR Weekly Dose 00:13:54 New research on acetaminophen use during pregnancy; the chikungunya vaccine Ixchiq is withdrawn; FDA approves Nexplanon for up to 5 years of use; suicidal ideation warning removed from GLP-1s; at-home neuromodulation therapy cleared for adults with major depressive disorder. New research on acetaminophen use during pregnancy; the chikungunya vaccine Ixchiq is withdrawn; FDA approves Nexplanon for up to 5 years of use; suicidal ideation warning removed from GLP-1s; at-home neuromodulation therapy cleared for adults with major depressive disorder. false full 259 a8a08138-106d-4740-bfed-d149f72fbb29 MPR Weekly Dose Podcast #260 — Top 2026 Health Trends With US News' Annika Urban Fifty-eight health experts have weighed in on the future of wellness. In this episode, we sit down with Annika Urban, health editor for US News and World Report, to analyze the implications of these findings. Annika shares her perspective on the major shifts happening across the health spectrum.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 16 Jan 2026 14:11:26 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com Fifty-eight health experts have weighed in on the future of wellness. In this episode, we sit down with Annika Urban, health editor for US News and World Report, to analyze the implications of these findings. Annika shares her perspective on the major shifts happening across the health spectrum.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose Podcast #260 — Top 2026 Health Trends With US News' Annika Urban MPR Weekly Dose 00:12:05 Fifty-eight health experts have weighed in on the future of wellness. In this episode, we sit down with Annika Urban, health editor for US News and World Report, to analyze the implications of these findings. Annika shares her perspective on the major shifts happening across the health spectrum. Fifty-eight health experts have weighed in on the future of wellness. In this episode, we sit down with Annika Urban, health editor for US News and World Report, to analyze the implications of these findings. Annika shares her perspective on the major shifts happening across the health spectrum. false full 258 4d3c2e5a-1aa3-4f9f-a1a4-1e37afd639b1 MPR Weekly Dose Podcast #259 — ACIP Hep B Recommendation; Retatrutide Shows Promise; Omisirge Approved; Counterfeit Ozempic Seized; Gene Tx Approved for Wiskott-Aldrich Syndrome ACIP votes to change hep B vaccination for infants; positive results for retatrutide; Omisirge approved; counterfeit Ozempic seized by FDA; gene therapy approved for Wiskott-Aldrich syndrome.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 12 Dec 2025 16:37:36 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com ACIP votes to change hep B vaccination for infants; positive results for retatrutide; Omisirge approved; counterfeit Ozempic seized by FDA; gene therapy approved for Wiskott-Aldrich syndrome.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose Podcast #259 — ACIP Hep B Recommendation; Retatrutide Shows Promise; Omisirge Approved; Counterfeit Ozempic Seized; Gene Tx Approved for Wiskott-Aldrich Syndrome MPR Weekly Dose 00:14:27 ACIP votes to change hep B vaccination for infants; positive results for retatrutide; Omisirge approved; counterfeit Ozempic seized by FDA; gene therapy approved for Wiskott-Aldrich syndrome. ACIP votes to change hep B vaccination for infants; positive results for retatrutide; Omisirge approved; counterfeit Ozempic seized by FDA; gene therapy approved for Wiskott-Aldrich syndrome. false full 257 35f91c8f-05e2-4385-b974-bf048c4f82b7 MPR Weekly Dose Podcast #258 — Jaypirca Gains Expanded Approval; Allograft to Restore Nerve Function; Baxdrostat Gets Priority Review; Stargardt Tx Shows Promise; Edema Autoinjector Accepted for Review Jaypirca gains expanded approval; allograft approved to restore peripheral nerve function; baxdrostat to be reviewed as an add-on treatment for hypertension; treatment for a genetic eye disorder that causes vision loss shows promise; and an autoinjector to treat edema is accepted for Priority Review.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 5 Dec 2025 18:12:56 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com Jaypirca gains expanded approval; allograft approved to restore peripheral nerve function; baxdrostat to be reviewed as an add-on treatment for hypertension; treatment for a genetic eye disorder that causes vision loss shows promise; and an autoinjector to treat edema is accepted for Priority Review.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose Podcast #258 — Jaypirca Gains Expanded Approval; Allograft to Restore Nerve Function; Baxdrostat Gets Priority Review; Stargardt Tx Shows Promise; Edema Autoinjector Accepted for Review MPR Weekly Dose 00:11:01 Jaypirca gains expanded approval; allograft approved to restore peripheral nerve function; baxdrostat to be reviewed as an add-on treatment for hypertension; treatment for a genetic eye disorder that causes vision loss shows promise; and an autoinjector to treat edema is accepted for Priority Review. Jaypirca gains expanded approval; allograft approved to restore peripheral nerve function; baxdrostat to be reviewed as an add-on treatment for hypertension; treatment for a genetic eye disorder that causes vision loss shows promise; and an autoinjector to treat edema is accepted for Priority Review. false full 256 6a3c0919-c871-41ed-94b6-04cbcf9f9324 MPR Weekly Dose Podcast #257 — Tonmya Available; Elevidys Safety Warning; Mitapivat SCD Trial Results; Redemplo Approved for FCS; Hyrnuo Granted Accelerated Approval Tonmya now available for fibromyalgia; safety warnings for DMD treatment; mitapivat shows mixed results in sickle cell disease trial; Redemplo approved for familial chylomicronemia syndrome; Hyrnuo approved for HER2-mutant NSCLC.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 21 Nov 2025 16:14:55 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com Tonmya now available for fibromyalgia; safety warnings for DMD treatment; mitapivat shows mixed results in sickle cell disease trial; Redemplo approved for familial chylomicronemia syndrome; Hyrnuo approved for HER2-mutant NSCLC.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose Podcast #257 — Tonmya Available; Elevidys Safety Warning; Mitapivat SCD Trial Results; Redemplo Approved for FCS; Hyrnuo Granted Accelerated Approval MPR Weekly Dose 00:14:49 Tonmya now available for fibromyalgia; safety warnings for DMD treatment; mitapivat shows mixed results in sickle cell disease trial; Redemplo approved for familial chylomicronemia syndrome; Hyrnuo approved for HER2-mutant NSCLC. Tonmya now available for fibromyalgia; safety warnings for DMD treatment; mitapivat shows mixed results in sickle cell disease trial; Redemplo approved for familial chylomicronemia syndrome; Hyrnuo approved for HER2-mutant NSCLC. false full 255 ad5b92a4-efa6-4a03-b348-1e7b800b4070 MPR Weekly Dose Podcast #256 — HRT Label Changes; Calypta Approved for MDD; Darzalex Faspro Indication Expanded; MS Tx Potential; Simplified HIV Regimen The FDA requests boxed warnings be removed from HRT product labels; Caplyta approved for MDD; Darzalex Faspro gains new indication; investigational MS treatment looks promising; trial investigates simplified HIV regimen.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 14 Nov 2025 15:29:21 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com The FDA requests boxed warnings be removed from HRT product labels; Caplyta approved for MDD; Darzalex Faspro gains new indication; investigational MS treatment looks promising; trial investigates simplified HIV regimen.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose Podcast #256 — HRT Label Changes; Calypta Approved for MDD; Darzalex Faspro Indication Expanded; MS Tx Potential; Simplified HIV Regimen MPR Weekly Dose 00:13:43 The FDA requests boxed warnings be removed from HRT product labels; Caplyta approved for MDD; Darzalex Faspro gains new indication; investigational MS treatment looks promising; trial investigates simplified HIV regimen. The FDA requests boxed warnings be removed from HRT product labels; Caplyta approved for MDD; Darzalex Faspro gains new indication; investigational MS treatment looks promising; trial investigates simplified HIV regimen. false full 254 6d186c70-0ecc-4de1-8d07-40e0708f9a93 MPR News Weekly Dose #255 — Fluoride Supplements Restricted; AAP Leucovorin Statement; At-Home Ultrasound; Kygevvi Approved; Gazyva Lupus Trial Results FDA restrict the sale of unapproved fluoride products; the AAP statement on leucovorin in ASD; at-home prenatal ultrasound; Kygevvi approved; Gazyva reduces SLE disease activity.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 7 Nov 2025 15:45:58 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com FDA restrict the sale of unapproved fluoride products; the AAP statement on leucovorin in ASD; at-home prenatal ultrasound; Kygevvi approved; Gazyva reduces SLE disease activity.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR News Weekly Dose #255 — Fluoride Supplements Restricted; AAP Leucovorin Statement; At-Home Ultrasound; Kygevvi Approved; Gazyva Lupus Trial Results MPR Weekly Dose 00:13:53 FDA restrict the sale of unapproved fluoride products; the AAP statement on leucovorin in ASD; at-home prenatal ultrasound; Kygevvi approved; Gazyva reduces SLE disease activity. FDA restrict the sale of unapproved fluoride products; the AAP statement on leucovorin in ASD; at-home prenatal ultrasound; Kygevvi approved; Gazyva reduces SLE disease activity. false full 253 da491ae5-65e1-4b18-809f-15fdef7f2907 MPR Weekly Dose #254 — Tranexamic Acid Label Change; New Tezspire Approval; Psychedelic Gains Breakthrough; Oral Semaglutide for MACE Reduction; Gazyva Approved for Lupus Label changes for tranexamic acid; new approval for Tezspire; psychedelic gains Breakthrough Tx for depression; oral semaglutide approved to reduce MACE risk in T2DM; Gazyva approved for lupus.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 24 Oct 2025 12:31:40 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com Label changes for tranexamic acid; new approval for Tezspire; psychedelic gains Breakthrough Tx for depression; oral semaglutide approved to reduce MACE risk in T2DM; Gazyva approved for lupus.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose #254 — Tranexamic Acid Label Change; New Tezspire Approval; Psychedelic Gains Breakthrough; Oral Semaglutide for MACE Reduction; Gazyva Approved for Lupus MPR Weekly Dose 00:15:09 Label changes for tranexamic acid; new approval for Tezspire; psychedelic gains Breakthrough Tx for depression; oral semaglutide approved to reduce MACE risk in T2DM; Gazyva approved for lupus. Label changes for tranexamic acid; new approval for Tezspire; psychedelic gains Breakthrough Tx for depression; oral semaglutide approved to reduce MACE risk in T2DM; Gazyva approved for lupus. false full 252 bba7f978-0768-449f-b472-5d32238dd9cf MPR Weekly Dose Podcast #253 — Bipolar I Treatment; Blood-Based Test for Alzheimer Disease; UC Tx Approved for Pediatrics; Rinvoq Expanded; Oral Glucagon-Like Peptide-1 New treatment approved for Bipolar I disorder; IBD treatments gain expanded approval; blood-based test for early detection of Alzheimer disease; and an oral glucagon-like peptide-1 treatment continues to show promise.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 17 Oct 2025 15:38:28 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com New treatment approved for Bipolar I disorder; IBD treatments gain expanded approval; blood-based test for early detection of Alzheimer disease; and an oral glucagon-like peptide-1 treatment continues to show promise.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose Podcast #253 — Bipolar I Treatment; Blood-Based Test for Alzheimer Disease; UC Tx Approved for Pediatrics; Rinvoq Expanded; Oral Glucagon-Like Peptide-1 MPR Weekly Dose 00:11:47 New treatment approved for Bipolar I disorder; IBD treatments gain expanded approval; blood-based test for early detection of Alzheimer disease; and an oral glucagon-like peptide-1 treatment continues to show promise.   New treatment approved for Bipolar I disorder; IBD treatments gain expanded approval; blood-based test for early detection of Alzheimer disease; and an oral glucagon-like peptide-1 treatment continues to show promise.   false full 251 219eef52-2058-49e9-bec9-d52ea9d476c3 MPR Weekly Dose Podcast #252 — CDC Approves New Immunization Sched; Novel Furosemide Delivery Device; New IPF Treatment Approved; Libtayo approved for CSCC; Breakthrough Therapy for influenza CDC approves new immunization schedule; new treatments approved for edema, idiopathic pulmonary fibrosis, and high risk cutaneous squamous cell carcinoma; and the FDA grants Breakthrough therapy designation to a novel influenza therapy.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 10 Oct 2025 15:12:22 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com CDC approves new immunization schedule; new treatments approved for edema, idiopathic pulmonary fibrosis, and high risk cutaneous squamous cell carcinoma; and the FDA grants Breakthrough therapy designation to a novel influenza therapy.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose Podcast #252 — CDC Approves New Immunization Sched; Novel Furosemide Delivery Device; New IPF Treatment Approved; Libtayo approved for CSCC; Breakthrough Therapy for influenza MPR Weekly Dose 00:13:22 CDC approves new immunization schedule; new treatments approved for edema, idiopathic pulmonary fibrosis, and high risk cutaneous squamous cell carcinoma; and the FDA grants Breakthrough therapy designation to a novel influenza therapy. CDC approves new immunization schedule; new treatments approved for edema, idiopathic pulmonary fibrosis, and high risk cutaneous squamous cell carcinoma; and the FDA grants Breakthrough therapy designation to a novel influenza therapy. false full 250 f81135b4-6941-4dc8-96b2-9d48a36101f3 MPR Weekly Dose Podcast #251 — Qivigy for Primary Humoral Immunodeficiency; Near Vision Eyedrops; Tremfya Expanded; Meth Intoxication Tx; Alzheimer Disease Tx Fast Tracked New treatment approved for primary humoral immunodeficiency; eyedrops now available to improve near vision; Tremfya approval expanded to include pediatric plaque psoriasis, psoriatic arthritis; FDA fast tracks treatments for methamphetamine intoxication, Alzheimer disease.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 3 Oct 2025 15:03:27 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com New treatment approved for primary humoral immunodeficiency; eyedrops now available to improve near vision; Tremfya approval expanded to include pediatric plaque psoriasis, psoriatic arthritis; FDA fast tracks treatments for methamphetamine intoxication, Alzheimer disease.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose Podcast #251 — Qivigy for Primary Humoral Immunodeficiency; Near Vision Eyedrops; Tremfya Expanded; Meth Intoxication Tx; Alzheimer Disease Tx Fast Tracked MPR Weekly Dose 00:11:20 New treatment approved for primary humoral immunodeficiency; eyedrops now available to improve near vision; Tremfya approval expanded to include pediatric plaque psoriasis, psoriatic arthritis; FDA fast tracks treatments for methamphetamine intoxication, Alzheimer disease. New treatment approved for primary humoral immunodeficiency; eyedrops now available to improve near vision; Tremfya approval expanded to include pediatric plaque psoriasis, psoriatic arthritis; FDA fast tracks treatments for methamphetamine intoxication, Alzheimer disease. false full 249 79ce65b3-d9a9-4327-b668-3b1e623ae738 MPR Weekly Dose Podcast #250 — Changes to MMRV Recs; Trump Admin Links Acetaminophen to Autism; Forzinity Accelerated Approval; Huntington Disease Breakthrough; SC Formulation of Keytruda The CDC recommends changes to MMRV vaccine use; Trump administration claims acetaminophen linked to autism; first Barth syndrome treatment gets green light; gene therapy looks promising for Huntington disease; and a new SC formulation of Keytruda gains approval.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 26 Sep 2025 15:46:44 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com The CDC recommends changes to MMRV vaccine use; Trump administration claims acetaminophen linked to autism; first Barth syndrome treatment gets green light; gene therapy looks promising for Huntington disease; and a new SC formulation of Keytruda gains approval.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose Podcast #250 — Changes to MMRV Recs; Trump Admin Links Acetaminophen to Autism; Forzinity Accelerated Approval; Huntington Disease Breakthrough; SC Formulation of Keytruda MPR Weekly Dose 00:16:14 The CDC recommends changes to MMRV vaccine use; Trump administration claims acetaminophen linked to autism; first Barth syndrome treatment gets green light; gene therapy looks promising for Huntington disease; and a new SC formulation of Keytruda gains approval. The CDC recommends changes to MMRV vaccine use; Trump administration claims acetaminophen linked to autism; first Barth syndrome treatment gets green light; gene therapy looks promising for Huntington disease; and a new SC formulation of Keytruda gains approval. false full 248 e79b9c3b-47ed-4d4c-89a0-7aa370f77b2c MPR Weekly Dose Podcast #249 — Device for Asherman Syndrome; Novel Oral GLP-1 Trial Results; Nasal Spray for Edema; Capvaxive in Adolescents; Ocaliva Withdrawn New device approved to prevent intrauterine adhesions; oral GLP-1 receptor agonists assessed in head to head trial; nasal spray formulation of bumetanide gains approval; Capvaxive elicits immune response in children aged 2 to 17 years; and a primary biliary cholangitis treatment is withdrawn from the market.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 19 Sep 2025 15:02:22 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com New device approved to prevent intrauterine adhesions; oral GLP-1 receptor agonists assessed in head to head trial; nasal spray formulation of bumetanide gains approval; Capvaxive elicits immune response in children aged 2 to 17 years; and a primary biliary cholangitis treatment is withdrawn from the market.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose Podcast #249 — Device for Asherman Syndrome; Novel Oral GLP-1 Trial Results; Nasal Spray for Edema; Capvaxive in Adolescents; Ocaliva Withdrawn MPR Weekly Dose 00:12:08 New device approved to prevent intrauterine adhesions; oral GLP-1 receptor agonists assessed in head to head trial; nasal spray formulation of bumetanide gains approval; Capvaxive elicits immune response in children aged 2 to 17 years; and a primary biliary cholangitis treatment is withdrawn from the market. New device approved to prevent intrauterine adhesions; oral GLP-1 receptor agonists assessed in head to head trial; nasal spray formulation of bumetanide gains approval; Capvaxive elicits immune response in children aged 2 to 17 years; and a primary biliary cholangitis treatment is withdrawn from the market. false full 247 d80d79ea-a67d-41c9-b7a0-6d28947a4a33 MPR Weekly Dose Podcast #248 — COVID-19 Vaccines Approved for Upcoming Season; CDC Leadership in Turmoil; Pill Reduces Body Weight; Ixchiq Use Suspended; Filspari REMS Updated COVID-19 vaccine approvals; CDC leadership in turmoil; orforglipron weight loss trial results; Ixchiq license suspended by FDA; REMS updated for Filspari


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 29 Aug 2025 15:14:55 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com COVID-19 vaccine approvals; CDC leadership in turmoil; orforglipron weight loss trial results; Ixchiq license suspended by FDA; REMS updated for Filspari


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose Podcast #248 — COVID-19 Vaccines Approved for Upcoming Season; CDC Leadership in Turmoil; Pill Reduces Body Weight; Ixchiq Use Suspended; Filspari REMS Updated MPR Weekly Dose 00:14:18 COVID-19 vaccine approvals; CDC leadership in turmoil; orforglipron weight loss trial results; Ixchiq license suspended by FDA; REMS updated for Filspari COVID-19 vaccine approvals; CDC leadership in turmoil; orforglipron weight loss trial results; Ixchiq license suspended by FDA; REMS updated for Filspari false full 246 dfb1bca3-0af9-4d96-98e5-ab80ada082e6 MPR Weekly Dose Podcast #248 — COVID-19 Vaccines Approved for Upcoming Season; CDC Leadership in Turmoil; Pill Reduces Body Weight; Ixchiq Use Suspended; Filspari REMS Updated COVID-19 vaccine approvals; CDC leadership in turmoil; orforglipron weight loss trial results; Ixchiq license suspended by FDA; REMS updated for Filspari


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 29 Aug 2025 15:14:50 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com COVID-19 vaccine approvals; CDC leadership in turmoil; orforglipron weight loss trial results; Ixchiq license suspended by FDA; REMS updated for Filspari


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose Podcast #248 — COVID-19 Vaccines Approved for Upcoming Season; CDC Leadership in Turmoil; Pill Reduces Body Weight; Ixchiq Use Suspended; Filspari REMS Updated MPR Weekly Dose 00:14:18 COVID-19 vaccine approvals; CDC leadership in turmoil; orforglipron weight loss trial results; Ixchiq license suspended by FDA; REMS updated for Filspari COVID-19 vaccine approvals; CDC leadership in turmoil; orforglipron weight loss trial results; Ixchiq license suspended by FDA; REMS updated for Filspari false full 245 1c1ea2eb-26b5-428e-8f18-a3839cfb94e0 MPR Weekly Dose Podcast #247 — AAP Release Pediatric Immunization Schedule; Blood Pressure MGMT Guideline; Wegovy Approved for Noncirrhotic MASH; New Fibromyalgia Tx; Investigational Sickle Cell Tx Fails to Meet Endpoint The American Academy of Pediatrics release their own immunization schedule; The American Heart Association update 2017 guidelines for the prevention of high blood pressure; weight loss drug gains indication to treat noncirrhotic MASH; FDA approve a new fibromyalgia treatment; investigational SCD Tx to meet trial endpoint.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Thu, 21 Aug 2025 19:38:57 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com The American Academy of Pediatrics release their own immunization schedule; The American Heart Association update 2017 guidelines for the prevention of high blood pressure; weight loss drug gains indication to treat noncirrhotic MASH; FDA approve a new fibromyalgia treatment; investigational SCD Tx to meet trial endpoint.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose Podcast #247 — AAP Release Pediatric Immunization Schedule; Blood Pressure MGMT Guideline; Wegovy Approved for Noncirrhotic MASH; New Fibromyalgia Tx; Investigational Sickle Cell Tx Fails to Meet Endpoint MPR Weekly Dose 00:18:11 The American Academy of Pediatrics release their own immunization schedule; The American Heart Association update 2017 guidelines for the prevention of high blood pressure; weight loss drug gains indication to treat noncirrhotic MASH; FDA approve a new fibromyalgia treatment; investigational SCD Tx to meet trial endpoint. The American Academy of Pediatrics release their own immunization schedule; The American Heart Association update 2017 guidelines for the prevention of high blood pressure; weight loss drug gains indication to treat noncirrhotic MASH; FDA approve a new fibromyalgia treatment; investigational SCD Tx to meet trial endpoint. false full 244 e1df02f4-b0e4-4bf9-be8b-1f74eed1c779 MPR Weekly Dose Podcast #246 — Device Cleared for Sleep Apnea; Skysona Safety Update; Non-Cystic Fibrosis Bronchiectasis Tx; Animal-Derived Thyroid Meds Safety Update; Synagis Discontinued Nerve stimulation device cleared for sleep apnea; Skysona safety update; new non-cystic fibrosis bronchiectasis treatment; FDA cracks down on animal-derived thyroid meds; RSV therapy to be discontinued.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 15 Aug 2025 15:05:30 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com Nerve stimulation device cleared for sleep apnea; Skysona safety update; new non-cystic fibrosis bronchiectasis treatment; FDA cracks down on animal-derived thyroid meds; RSV therapy to be discontinued.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose Podcast #246 — Device Cleared for Sleep Apnea; Skysona Safety Update; Non-Cystic Fibrosis Bronchiectasis Tx; Animal-Derived Thyroid Meds Safety Update; Synagis Discontinued MPR Weekly Dose 00:13:02 Nerve stimulation device cleared for sleep apnea; Skysona safety update; new non-cystic fibrosis bronchiectasis treatment; FDA cracks down on animal-derived thyroid meds; RSV therapy to be discontinued. Nerve stimulation device cleared for sleep apnea; Skysona safety update; new non-cystic fibrosis bronchiectasis treatment; FDA cracks down on animal-derived thyroid meds; RSV therapy to be discontinued. false full 243 20be5e4f-4051-445d-9282-00f5fc046001 MPR Weekly Dose Podcast #245 — Label Change for Opioids; Results From Weight-Loss Pill Trial; Ajovy Approved for Some Peds; Ixchiq Vaccine Restrictions Lifted; Modeyso Approved for Rare Brain Tumor Class-wide label change for opioids; positive results for oral GLP-1; migraine prevention therapy approved for children; FDA removes restriction on Ixchiq for older adults; Modeyso approved for rare brain tumor.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Thu, 7 Aug 2025 19:30:10 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com Class-wide label change for opioids; positive results for oral GLP-1; migraine prevention therapy approved for children; FDA removes restriction on Ixchiq for older adults; Modeyso approved for rare brain tumor.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose Podcast #245 — Label Change for Opioids; Results From Weight-Loss Pill Trial; Ajovy Approved for Some Peds; Ixchiq Vaccine Restrictions Lifted; Modeyso Approved for Rare Brain Tumor MPR Weekly Dose 00:13:23 Class-wide label change for opioids; positive results for oral GLP-1; migraine prevention therapy approved for children; FDA removes restriction on Ixchiq for older adults; Modeyso approved for rare brain tumor. Class-wide label change for opioids; positive results for oral GLP-1; migraine prevention therapy approved for children; FDA removes restriction on Ixchiq for older adults; Modeyso approved for rare brain tumor. false full 242 edef296f-d9e4-4668-a5ed-999a228fb1d9 MPR Weekly Dose Podcast #244 — Treatment Approved for Two Rare Kidney Diseases; Elevidys Can Resume Shipments for Ambulatory Patients; Mounjaro Shows Cardio Benefits; New Wearable Cardiac Monitor Cleared; Hair Regrowth With Upadacitinib Empaveli approved to treat two rare kidney diseases; Elevidys available again for ambulatory patients; Mounjaro shows benefit in cardiovascular disease; wearable cardiac monitor gets clearance; upadacitinib trial shows hair regrowth in individuals with alopecia areata.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 1 Aug 2025 13:16:14 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com Empaveli approved to treat two rare kidney diseases; Elevidys available again for ambulatory patients; Mounjaro shows benefit in cardiovascular disease; wearable cardiac monitor gets clearance; upadacitinib trial shows hair regrowth in individuals with alopecia areata.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose Podcast #244 — Treatment Approved for Two Rare Kidney Diseases; Elevidys Can Resume Shipments for Ambulatory Patients; Mounjaro Shows Cardio Benefits; New Wearable Cardiac Monitor Cleared; Hair Regrowth With Upadacitinib MPR Weekly Dose 00:16:08 Empaveli approved to treat two rare kidney diseases; Elevidys available again for ambulatory patients; Mounjaro shows benefit in cardiovascular disease; wearable cardiac monitor gets clearance; upadacitinib trial shows hair regrowth in individuals with alopecia areata. Empaveli approved to treat two rare kidney diseases; Elevidys available again for ambulatory patients; Mounjaro shows benefit in cardiovascular disease; wearable cardiac monitor gets clearance; upadacitinib trial shows hair regrowth in individuals with alopecia areata. false full 241 d3c3b869-29d4-4b9c-bda8-a21c63fc92f3 MPR Weekly Dose Podcast #243 — Sarepta Pauses Elevidys Shipments; Advisory Committee Votes Against PTSD Tx; Rapiblyk Now Available; Pill for Sleep Apnea; JUUL Cigs Authorized Elevidys shipments paused following third death; FDA committee votes against brexpiprazole combo for PTSD; Rapiblyk now available for SVT; sleep apnea pill looks promising; JUUL e-cigarettes gain marketing authorization.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 25 Jul 2025 13:20:21 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com Elevidys shipments paused following third death; FDA committee votes against brexpiprazole combo for PTSD; Rapiblyk now available for SVT; sleep apnea pill looks promising; JUUL e-cigarettes gain marketing authorization.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose Podcast #243 — Sarepta Pauses Elevidys Shipments; Advisory Committee Votes Against PTSD Tx; Rapiblyk Now Available; Pill for Sleep Apnea; JUUL Cigs Authorized MPR Weekly Dose 00:13:52 Elevidys shipments paused following third death; FDA committee votes against brexpiprazole combo for PTSD; Rapiblyk now available for SVT; sleep apnea pill looks promising; JUUL e-cigarettes gain marketing authorization. Elevidys shipments paused following third death; FDA committee votes against brexpiprazole combo for PTSD; Rapiblyk now available for SVT; sleep apnea pill looks promising; JUUL e-cigarettes gain marketing authorization. false full 240 b4e633ee-ab30-4c9f-9edb-6709440d4aa1 MPR Weekly Dose #242 — New indication for Kerendia; investigational Tx shows promise for hypertension; Novolog biosimilar; trial results for hormone-free contraceptive; new prefilled Shringrix syringe New indication for Kerendia; investigational therapy shows promise for hypertension; Novolog interchangeable biosimilar gets approval; trial results for hormone-free contraceptive; Shingrix now supplied in a prefilled syringe.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 18 Jul 2025 13:39:35 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com New indication for Kerendia; investigational therapy shows promise for hypertension; Novolog interchangeable biosimilar gets approval; trial results for hormone-free contraceptive; Shingrix now supplied in a prefilled syringe.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose #242 — New indication for Kerendia; investigational Tx shows promise for hypertension; Novolog biosimilar; trial results for hormone-free contraceptive; new prefilled Shringrix syringe MPR Weekly Dose 00:11:30 New indication for Kerendia; investigational therapy shows promise for hypertension; Novolog interchangeable biosimilar gets approval; trial results for hormone-free contraceptive; Shingrix now supplied in a prefilled syringe. New indication for Kerendia; investigational therapy shows promise for hypertension; Novolog interchangeable biosimilar gets approval; trial results for hormone-free contraceptive; Shingrix now supplied in a prefilled syringe. false full 239 94ff8988-d139-4f91-a411-0856e2488268 MPR Weekly Dose Podcast #241 — RFK Jr Sued Over Vaccine Policy Changes; Hereditary Angioedema Tx Approved; New OTC Blood Pressure Monitor; Kisunla Dosing Regime; REMS removed for ERA meds Lawsuit filed against RFK Jr over vaccine policy changes; oral on-demand treatment approved for HAE; OTC cuffless blood pressure monitor gets greenlit; dosing schedule update for Alzheimer treatment; REMS requirement removed for endothelin receptor antagonist meds.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 11 Jul 2025 16:42:43 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com Lawsuit filed against RFK Jr over vaccine policy changes; oral on-demand treatment approved for HAE; OTC cuffless blood pressure monitor gets greenlit; dosing schedule update for Alzheimer treatment; REMS requirement removed for endothelin receptor antagonist meds.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose Podcast #241 — RFK Jr Sued Over Vaccine Policy Changes; Hereditary Angioedema Tx Approved; New OTC Blood Pressure Monitor; Kisunla Dosing Regime; REMS removed for ERA meds MPR Weekly Dose 00:12:19 Lawsuit filed against RFK Jr over vaccine policy changes; oral on-demand treatment approved for HAE; OTC cuffless blood pressure monitor gets greenlit; dosing schedule update for Alzheimer treatment; REMS requirement removed for endothelin receptor antagonist meds. Lawsuit filed against RFK Jr over vaccine policy changes; oral on-demand treatment approved for HAE; OTC cuffless blood pressure monitor gets greenlit; dosing schedule update for Alzheimer treatment; REMS requirement removed for endothelin receptor antagonist meds. false full 238 7b563ba0-4d00-47ea-a1bb-007144f5afe7 MPR Weekly Dose Podcast #240 — Wristband to Improve Tremors; Weight Loss Risk With ADHD Meds; REMS Eliminated for CAR T-Cell Immunotherapies; Zegfrovy Approved; New CDC Advisory Committee Has First Meeting Wristband that provides relief for upper limb tremor is approved; FDA warns of clinically significant weight loss in younger kids taking ADHD meds; REMS removed for CAR T-cell immunotherapies; treatment approved for lung cancer patients with EGFR exon20 insertion mutations; and CDC committee recommends removing preservative from flu vaccines.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 4 Jul 2025 01:17:04 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com Wristband that provides relief for upper limb tremor is approved; FDA warns of clinically significant weight loss in younger kids taking ADHD meds; REMS removed for CAR T-cell immunotherapies; treatment approved for lung cancer patients with EGFR exon20 insertion mutations; and CDC committee recommends removing preservative from flu vaccines.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose Podcast #240 — Wristband to Improve Tremors; Weight Loss Risk With ADHD Meds; REMS Eliminated for CAR T-Cell Immunotherapies; Zegfrovy Approved; New CDC Advisory Committee Has First Meeting MPR Weekly Dose 00:14:08 Wristband that provides relief for upper limb tremor is approved; FDA warns of clinically significant weight loss in younger kids taking ADHD meds; REMS removed for CAR T-cell immunotherapies; treatment approved for lung cancer patients with EGFR exon20 insertion mutations; and CDC committee recommends removing preservative from flu vaccines. Wristband that provides relief for upper limb tremor is approved; FDA warns of clinically significant weight loss in younger kids taking ADHD meds; REMS removed for CAR T-cell immunotherapies; treatment approved for lung cancer patients with EGFR exon20 insertion mutations; and CDC committee recommends removing preservative from flu vaccines. false full 237 934a6ee0-5092-476d-90b8-3f967ee71367 MPR Weekly Dose Podcast #239 — Novo Nordisk Cut Ties With Hims & Hers; Updates to Label for Imaging Agent Vizamyl; Subcutaneous Autoinjector for Lupus; Psilocybin for Treatment-Resistant Depression; Sotatercept Phase 3 PAH Results Novo Nordisk end their partnership with Hims & Hers; update to Vizamyl labeling; autoinjector approved for pediatrics with lupus nephritis; psilocybin shows promise in treatment-resistant depression; sotatercept phase 3 trial results.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 27 Jun 2025 13:54:17 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com Novo Nordisk end their partnership with Hims & Hers; update to Vizamyl labeling; autoinjector approved for pediatrics with lupus nephritis; psilocybin shows promise in treatment-resistant depression; sotatercept phase 3 trial results.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose Podcast #239 — Novo Nordisk Cut Ties With Hims & Hers; Updates to Label for Imaging Agent Vizamyl; Subcutaneous Autoinjector for Lupus; Psilocybin for Treatment-Resistant Depression; Sotatercept Phase 3 PAH Results MPR Weekly Dose 00:13:12 Novo Nordisk end their partnership with Hims & Hers; update to Vizamyl labeling; autoinjector approved for pediatrics with lupus nephritis; psilocybin shows promise in treatment-resistant depression; sotatercept phase 3 trial results. Novo Nordisk end their partnership with Hims & Hers; update to Vizamyl labeling; autoinjector approved for pediatrics with lupus nephritis; psilocybin shows promise in treatment-resistant depression; sotatercept phase 3 trial results. false full 236 dfd19c88-7d2d-48ce-bf4b-20489cc712ad MPR Weekly Dose Podcast #238 — Nucala New Indication; FDA To Make COVID-19 Vaccines Harder to Obtain; Pruritus Reported With Allergy Med Discontinuation; Oral Antibiotic for cUTIs; Investigational Celiac Tx Fast Tracked Nucala gains new indication; the FDA are set to require placebo-controlled trials to evaluate COVID-19 vaccines; pruritus reported following discontinuation of antihistamines; oral carbapenem antibiotic looks promising for cUTIs; investigational celiac disease Tx gets Fast Tracked


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 30 May 2025 13:36:40 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com Nucala gains new indication; the FDA are set to require placebo-controlled trials to evaluate COVID-19 vaccines; pruritus reported following discontinuation of antihistamines; oral carbapenem antibiotic looks promising for cUTIs; investigational celiac disease Tx gets Fast Tracked


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose Podcast #238 — Nucala New Indication; FDA To Make COVID-19 Vaccines Harder to Obtain; Pruritus Reported With Allergy Med Discontinuation; Oral Antibiotic for cUTIs; Investigational Celiac Tx Fast Tracked MPR Weekly Dose 00:12:39 Nucala gains new indication; the FDA are set to require placebo-controlled trials to evaluate COVID-19 vaccines; pruritus reported following discontinuation of antihistamines; oral carbapenem antibiotic looks promising for cUTIs; investigational celiac disease Tx gets Fast Tracked Nucala gains new indication; the FDA are set to require placebo-controlled trials to evaluate COVID-19 vaccines; pruritus reported following discontinuation of antihistamines; oral carbapenem antibiotic looks promising for cUTIs; investigational celiac disease Tx gets Fast Tracked false full 235 12379974-fff3-480d-b867-5d4ebca19fa5 MPR Weekly Dose Podcast #237 — At-Home Cervical CA Screening; FDA Assess Removing Fluoride Products; Chikungunya Vaccination Pause; SC Inj. for Migraine Tx; Gene Therapy for Hunter Syndrome At-home cervical cancer screening device gains clearance; the FDA indicates it wants to remove pediatric fluoride products from the market; the chikungunya vaccine is put on-pause for some individuals; a subcutaneous autoinjector is approved to treat migraines; and the FDA will review a gene therapy for Hunter syndrome.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Thu, 15 May 2025 20:31:43 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com At-home cervical cancer screening device gains clearance; the FDA indicates it wants to remove pediatric fluoride products from the market; the chikungunya vaccine is put on-pause for some individuals; a subcutaneous autoinjector is approved to treat migraines; and the FDA will review a gene therapy for Hunter syndrome.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose Podcast #237 — At-Home Cervical CA Screening; FDA Assess Removing Fluoride Products; Chikungunya Vaccination Pause; SC Inj. for Migraine Tx; Gene Therapy for Hunter Syndrome MPR Weekly Dose 00:15:06 At-home cervical cancer screening device gains clearance; the FDA indicates it wants to remove pediatric fluoride products from the market; the chikungunya vaccine is put on-pause for some individuals; a subcutaneous autoinjector is approved to treat migraines; and the FDA will review a gene therapy for Hunter syndrome. At-home cervical cancer screening device gains clearance; the FDA indicates it wants to remove pediatric fluoride products from the market; the chikungunya vaccine is put on-pause for some individuals; a subcutaneous autoinjector is approved to treat migraines; and the FDA will review a gene therapy for Hunter syndrome. false full 234 58a5688e-4584-4721-84da-1df54449be13 MPR Daily Dose Podcast #236 — Needle-Free Epinephrine for Peds; Oral Semaglutide for Weight Mgmt; Wearable Defibrillator; Hypertension Tx Approved; Stelara Biosimilar A new epinephrine nasal spray dosage has been approved for pediatrics; FDA agree to review Semaglutide for weight management; A wearable defibrillator is cleared to prevent sudden cardiac arrest; a low dose formulation of chlorthalidone is approved to treat hypertension; and Selarsdi is now interchangeable with Stelara.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 9 May 2025 14:39:43 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com A new epinephrine nasal spray dosage has been approved for pediatrics; FDA agree to review Semaglutide for weight management; A wearable defibrillator is cleared to prevent sudden cardiac arrest; a low dose formulation of chlorthalidone is approved to treat hypertension; and Selarsdi is now interchangeable with Stelara.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Daily Dose Podcast #236 — Needle-Free Epinephrine for Peds; Oral Semaglutide for Weight Mgmt; Wearable Defibrillator; Hypertension Tx Approved; Stelara Biosimilar MPR Weekly Dose 00:11:27 A new epinephrine nasal spray dosage has been approved for pediatrics; FDA agree to review Semaglutide for weight management; A wearable defibrillator is cleared to prevent sudden cardiac arrest; a low dose formulation of chlorthalidone is approved to treat hypertension; and Selarsdi is now interchangeable with Stelara. A new epinephrine nasal spray dosage has been approved for pediatrics; FDA agree to review Semaglutide for weight management; A wearable defibrillator is cleared to prevent sudden cardiac arrest; a low dose formulation of chlorthalidone is approved to treat hypertension; and Selarsdi is now interchangeable with Stelara. false full 233 81e3012b-865f-466f-8d04-5d9c3a5fa25f MPR Weekly Dose Podcast #235 — Rinvoq Approval Expanded; Wegovy Telehealth Link-Up; Epidermolysis Bullosa Wound Healing Tx; Imaavy Approved for gMG; Nasal Powder to Treat Migraines Rinvoq approved for giant cell arteritis; telehealth companies collaborate with Novo Nordisk for Wegovy access; epidermolysis bullosa wound healing treatment approved; Imaavy approved for gMG; New nasal powder approved for migraine treatment.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 2 May 2025 14:00:31 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com Rinvoq approved for giant cell arteritis; telehealth companies collaborate with Novo Nordisk for Wegovy access; epidermolysis bullosa wound healing treatment approved; Imaavy approved for gMG; New nasal powder approved for migraine treatment.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose Podcast #235 — Rinvoq Approval Expanded; Wegovy Telehealth Link-Up; Epidermolysis Bullosa Wound Healing Tx; Imaavy Approved for gMG; Nasal Powder to Treat Migraines MPR Weekly Dose 00:15:05 Rinvoq approved for giant cell arteritis; telehealth companies collaborate with Novo Nordisk for Wegovy access; epidermolysis bullosa wound healing treatment approved; Imaavy approved for gMG; New nasal powder approved for migraine treatment. Rinvoq approved for giant cell arteritis; telehealth companies collaborate with Novo Nordisk for Wegovy access; epidermolysis bullosa wound healing treatment approved; Imaavy approved for gMG; New nasal powder approved for migraine treatment. false full 232 35b27c51-0710-4bf6-998f-6bd9eeb85552 MPR Weekly Dose Podcast #234 — Alert for Compounded Finasteride; Cytisinicline Improves Smoking Cessation; GERD Tx Shows Promise; ACIP Makes New Vaccine Recs The FDA issues alert regarding a compounded topical finasteride; plant-based alkaloid shows improvement for smoking cessations; potential new treatment option for GERD; and the CDC's Advisory Committee on Immunization Practices make new recommendations.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 25 Apr 2025 12:19:26 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com The FDA issues alert regarding a compounded topical finasteride; plant-based alkaloid shows improvement for smoking cessations; potential new treatment option for GERD; and the CDC's Advisory Committee on Immunization Practices make new recommendations.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose Podcast #234 — Alert for Compounded Finasteride; Cytisinicline Improves Smoking Cessation; GERD Tx Shows Promise; ACIP Makes New Vaccine Recs MPR Weekly Dose 00:15:20 The FDA issues alert regarding a compounded topical finasteride; plant-based alkaloid shows improvement for smoking cessations; potential new treatment option for GERD; and the CDC's Advisory Committee on Immunization Practices make new recommendations. The FDA issues alert regarding a compounded topical finasteride; plant-based alkaloid shows improvement for smoking cessations; potential new treatment option for GERD; and the CDC's Advisory Committee on Immunization Practices make new recommendations. false full 231 68ab5eb3-ad1b-4e9e-91a1-27a9f8fc4568 MPR Weekly Dose Podcast #233 — Pfizer ends development of weight loss drug; counterfeit Ozempic seized; daily pill demonstrates HbA1c reductions; mavacamten misses trial endpoint; smart belt to reduce fall injury Pfizer ends danuglipron clinical program for obesity; FDA warns about counterfeit Ozempic; daily pill shows promise in reducing HbA1c; mavacamten misses in nonobstructive HCM trial and the FDA clears smart belt device reduce fall injury.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 18 Apr 2025 12:34:39 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com Pfizer ends danuglipron clinical program for obesity; FDA warns about counterfeit Ozempic; daily pill shows promise in reducing HbA1c; mavacamten misses in nonobstructive HCM trial and the FDA clears smart belt device reduce fall injury.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose Podcast #233 — Pfizer ends development of weight loss drug; counterfeit Ozempic seized; daily pill demonstrates HbA1c reductions; mavacamten misses trial endpoint; smart belt to reduce fall injury MPR Weekly Dose 00:12:35 Pfizer ends danuglipron clinical program for obesity; FDA warns about counterfeit Ozempic; daily pill shows promise in reducing HbA1c; mavacamten misses in nonobstructive HCM trial and the FDA clears smart belt device reduce fall injury. Pfizer ends danuglipron clinical program for obesity; FDA warns about counterfeit Ozempic; daily pill shows promise in reducing HbA1c; mavacamten misses in nonobstructive HCM trial and the FDA clears smart belt device reduce fall injury. false full 230 44d201e0-584f-4fc4-bb3b-5f92028c9f64 MPR Weekly Dose Podcast #232 — Uplizna gains new approval; Vanrafia approved for proteinuria in IgAN; schizophrenia ER Tx now available; Imcivree shows promise in hypothalamic obesity; GLP-1RAs may reduce dementia risk Uplizna gains new indication; Vanrafia approved for proteinuria in IgAN; Erzofri now available for schizophrenia; setmelanotide shows promise in hypothalamic obesity; GLP-1RAs may reduce dementia risk.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 11 Apr 2025 13:48:00 +0000 editor@empr.com (Steve Duffy) https://www.empr.com Uplizna gains new indication; Vanrafia approved for proteinuria in IgAN; Erzofri now available for schizophrenia; setmelanotide shows promise in hypothalamic obesity; GLP-1RAs may reduce dementia risk.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose Podcast #232 — Uplizna gains new approval; Vanrafia approved for proteinuria in IgAN; schizophrenia ER Tx now available; Imcivree shows promise in hypothalamic obesity; GLP-1RAs may reduce dementia risk Steve Duffy 00:15:11 Uplizna gains new indication; Vanrafia approved for proteinuria in IgAN; Erzofri now available for schizophrenia; setmelanotide shows promise in hypothalamic obesity; GLP-1RAs may reduce dementia risk.   Uplizna gains new indication; Vanrafia approved for proteinuria in IgAN; Erzofri now available for schizophrenia; setmelanotide shows promise in hypothalamic obesity; GLP-1RAs may reduce dementia risk.   false full 232 99503ed9-649b-440a-bee6-19332030ea17 MPR Weekly Dose Podcast #231 — Treatment for hyperphagia in Prader-Willi Syndrome; Qfitlia Approved; Chlamydia Vaccine and OTC Test; Semaglutide Improves Walking; Imfinzi Approved for MIBC New treatments for Prader-Willi Syndrome and hemophilia; FDA fast tracks a chlamydia vaccine candidate; over-the-counter test cleared for identifying chlamydia, gonorrhea and trichomoniasis; semaglutide improves walking ability in patients with peripheral artery disease; and Imfinzi combo therapy approved for MIBC.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 4 Apr 2025 15:15:44 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com New treatments for Prader-Willi Syndrome and hemophilia; FDA fast tracks a chlamydia vaccine candidate; over-the-counter test cleared for identifying chlamydia, gonorrhea and trichomoniasis; semaglutide improves walking ability in patients with peripheral artery disease; and Imfinzi combo therapy approved for MIBC.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose Podcast #231 — Treatment for hyperphagia in Prader-Willi Syndrome; Qfitlia Approved; Chlamydia Vaccine and OTC Test; Semaglutide Improves Walking; Imfinzi Approved for MIBC MPR Weekly Dose 00:16:58 New treatments for Prader-Willi Syndrome and hemophilia; FDA fast tracks a chlamydia vaccine candidate; over-the-counter test cleared for identifying chlamydia, gonorrhea and trichomoniasis; semaglutide improves walking ability in patients with peripheral artery disease; and Imfinzi combo therapy approved for MIBC.     New treatments for Prader-Willi Syndrome and hemophilia; FDA fast tracks a chlamydia vaccine candidate; over-the-counter test cleared for identifying chlamydia, gonorrhea and trichomoniasis; semaglutide improves walking ability in patients with peripheral artery disease; and Imfinzi combo therapy approved for MIBC.     false full 228 8aa16693-45cc-4bed-a36b-2b42369ce372 MPR Weekly Dose Podcast #230 — New Antibiotic for uUTIs; Treatment Approved for Advanced Neuroendocrine Tumors; New Rosacea Tx Option; Tremfya Gains Crohn Disease Indication; Dept. of HHS Cuts 10,000 Jobs New antibiotic has been approved for uncomplicated UTIs; Cabometyx approved for advanced neuroendocrine tumors; new rosacea treatment option; Tremfya gains Crohn disease indication; Department of HHS cuts 10,000 jobs.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 28 Mar 2025 15:49:17 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com New antibiotic has been approved for uncomplicated UTIs; Cabometyx approved for advanced neuroendocrine tumors; new rosacea treatment option; Tremfya gains Crohn disease indication; Department of HHS cuts 10,000 jobs.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose Podcast #230 — New Antibiotic for uUTIs; Treatment Approved for Advanced Neuroendocrine Tumors; New Rosacea Tx Option; Tremfya Gains Crohn Disease Indication; Dept. of HHS Cuts 10,000 Jobs MPR Weekly Dose 00:15:14 New antibiotic has been approved for uncomplicated UTIs; Cabometyx approved for advanced neuroendocrine tumors; new rosacea treatment option; Tremfya gains Crohn disease indication; Department of HHS cuts 10,000 jobs.  New antibiotic has been approved for uncomplicated UTIs; Cabometyx approved for advanced neuroendocrine tumors; new rosacea treatment option; Tremfya gains Crohn disease indication; Department of HHS cuts 10,000 jobs.  false full 227 583d3a8c-95d9-447e-b81f-85f2e2c90f36 MPR Weekly Dose Podcast #229 — Flu Vaccine Recommendations; Patient Dies Following Gene Therapy; Chikungungya Vaccine; Zunveyl Available; REMS Removed for Tryvio Influenza vaccine recommendations made for upcoming season; a patient dies following Elevidys infusion; Chikungunya vaccine now available and recommended for those traveling to areas with an outbreak; novel Alzheimer disease treatment launches; risk evaluation and mitigation strategies removed for hypertension treatment.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 21 Mar 2025 13:23:37 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com Influenza vaccine recommendations made for upcoming season; a patient dies following Elevidys infusion; Chikungunya vaccine now available and recommended for those traveling to areas with an outbreak; novel Alzheimer disease treatment launches; risk evaluation and mitigation strategies removed for hypertension treatment.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose Podcast #229 — Flu Vaccine Recommendations; Patient Dies Following Gene Therapy; Chikungungya Vaccine; Zunveyl Available; REMS Removed for Tryvio MPR Weekly Dose 00:11:36 Influenza vaccine recommendations made for upcoming season; a patient dies following Elevidys infusion; Chikungunya vaccine now available and recommended for those traveling to areas with an outbreak; novel Alzheimer disease treatment launches; risk evaluation and mitigation strategies removed for hypertension treatment. Influenza vaccine recommendations made for upcoming season; a patient dies following Elevidys infusion; Chikungunya vaccine now available and recommended for those traveling to areas with an outbreak; novel Alzheimer disease treatment launches; risk evaluation and mitigation strategies removed for hypertension treatment. false full 226 c4f5fb13-3e6e-4a2a-a4be-9014d7521c51 MPR Weekly Dose Podcast #228 — Xolair biosimilar approved; Furoscix indication expanded; Novel implant for rare eye disease; Lorundrostat trial data; Elevated benzene in acne treatments First Xolair biosimilar approved, Wearable furosemide loop diuretic gains expanded indication; Implant approved for macular telangiectasia; Novel treatment shows promise in hypertension; And testing reveals high benzene levels in over-the-counter acne treatments.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 14 Mar 2025 16:56:58 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com First Xolair biosimilar approved, Wearable furosemide loop diuretic gains expanded indication; Implant approved for macular telangiectasia; Novel treatment shows promise in hypertension; And testing reveals high benzene levels in over-the-counter acne treatments.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose Podcast #228 — Xolair biosimilar approved; Furoscix indication expanded; Novel implant for rare eye disease; Lorundrostat trial data; Elevated benzene in acne treatments MPR Weekly Dose 00:13:20 First Xolair biosimilar approved, Wearable furosemide loop diuretic gains expanded indication; Implant approved for macular telangiectasia; Novel treatment shows promise in hypertension; And testing reveals high benzene levels in over-the-counter acne treatments. First Xolair biosimilar approved, Wearable furosemide loop diuretic gains expanded indication; Implant approved for macular telangiectasia; Novel treatment shows promise in hypertension; And testing reveals high benzene levels in over-the-counter acne treatments. false full 225 2e477b30-c30d-41af-b404-7fb5fdc8216e MPR Weekly Dose Podcast #227 — Labeling Changes for Testosterone Products; Food Allergy Treatments Compared; FDA Approves Stroke Tx; COVID-19, Flu Vaccine Effectiveness for Recent Season; Neffy 1mg Approved Labeling changes for testosterone products; food allergy treatments compared; FDA approves stroke Tx; COVID-19, flu vaccine effectiveness for recent season; Neffy 1mg approved


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Thu, 6 Mar 2025 22:32:07 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com Labeling changes for testosterone products; food allergy treatments compared; FDA approves stroke Tx; COVID-19, flu vaccine effectiveness for recent season; Neffy 1mg approved


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose Podcast #227 — Labeling Changes for Testosterone Products; Food Allergy Treatments Compared; FDA Approves Stroke Tx; COVID-19, Flu Vaccine Effectiveness for Recent Season; Neffy 1mg Approved MPR Weekly Dose 00:15:06 Labeling changes for testosterone products; food allergy treatments compared; FDA approves stroke Tx; COVID-19, flu vaccine effectiveness for recent season; Neffy 1mg approved Labeling changes for testosterone products; food allergy treatments compared; FDA approves stroke Tx; COVID-19, flu vaccine effectiveness for recent season; Neffy 1mg approved false full 224 d4fd302b-95e3-4b54-9c03-cffeaef3b468 MPR Weekly Dose Podcast #226 — REMS Removed for Schizophrenia Tx; New Copper Intrauterine Device; Wegovy, Ozempic Supply Update; Lumbar Disc Disease Tx Fast Tracked; Tourette Syndrome Shows Promise REMS requirement removed for schizophrenia treatment; new copper intrauterine device approved; Wegovy, Ozempic no longer in short supply; stem cell therapy for chronic lumbar disc disease fast tracked; ecopipam shows promise for Tourette syndrome.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 28 Feb 2025 14:05:26 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com REMS requirement removed for schizophrenia treatment; new copper intrauterine device approved; Wegovy, Ozempic no longer in short supply; stem cell therapy for chronic lumbar disc disease fast tracked; ecopipam shows promise for Tourette syndrome.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose Podcast #226 — REMS Removed for Schizophrenia Tx; New Copper Intrauterine Device; Wegovy, Ozempic Supply Update; Lumbar Disc Disease Tx Fast Tracked; Tourette Syndrome Shows Promise MPR Weekly Dose 00:11:36 REMS requirement removed for schizophrenia treatment; new copper intrauterine device approved; Wegovy, Ozempic no longer in short supply; stem cell therapy for chronic lumbar disc disease fast tracked; ecopipam shows promise for Tourette syndrome. REMS requirement removed for schizophrenia treatment; new copper intrauterine device approved; Wegovy, Ozempic no longer in short supply; stem cell therapy for chronic lumbar disc disease fast tracked; ecopipam shows promise for Tourette syndrome. false full 223 656c279c-dc0f-41f8-9642-67dc116144ad MPR Weekly Dose 225 — New Vaccine Approvals; Skin Prep Recalled; Insulin Biosimilar Approved; Twice-yearly lenacapavir to be reviewed New vaccines to protect against meningococcal disease and chikungunya virus; skin prep product recalled due to fungal contamination; rapid-acting insulin biosimilar approved; and twice-yearly lenacapavir gets FDA's priority review for HIV PrEP.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Thu, 20 Feb 2025 22:41:46 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com New vaccines to protect against meningococcal disease and chikungunya virus; skin prep product recalled due to fungal contamination; rapid-acting insulin biosimilar approved; and twice-yearly lenacapavir gets FDA's priority review for HIV PrEP.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose 225 — New Vaccine Approvals; Skin Prep Recalled; Insulin Biosimilar Approved; Twice-yearly lenacapavir to be reviewed MPR Weekly Dose 00:12:47 New vaccines to protect against meningococcal disease and chikungunya virus; skin prep product recalled due to fungal contamination; rapid-acting insulin biosimilar approved; and twice-yearly lenacapavir gets FDA's priority review for HIV PrEP. New vaccines to protect against meningococcal disease and chikungunya virus; skin prep product recalled due to fungal contamination; rapid-acting insulin biosimilar approved; and twice-yearly lenacapavir gets FDA's priority review for HIV PrEP. false full 222 2cd3dc6d-0aa6-4d5e-91fd-0f4313c02177 MPR Weekly Dose Podcast #224 — Strategy for High-Threshold Peanut Allergy; Emblaveo Approved for Complicated Infections; New Formulation of Evrysdi; FDA Fast Tracks Designations Investigational Agents for Alzheimer Disease and Cannabis Use Disorder. Study identifies potential treatment strategy for high-threshold peanut allergy; Emblaveo approved for complicated intra-abdominal infections; new tablet formulation of Evrysdi; FDA fast tracks investigational agents for Alzheimer disease and cannabis use disorder.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Thu, 13 Feb 2025 21:45:40 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com Study identifies potential treatment strategy for high-threshold peanut allergy; Emblaveo approved for complicated intra-abdominal infections; new tablet formulation of Evrysdi; FDA fast tracks investigational agents for Alzheimer disease and cannabis use disorder.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose Podcast #224 — Strategy for High-Threshold Peanut Allergy; Emblaveo Approved for Complicated Infections; New Formulation of Evrysdi; FDA Fast Tracks Designations Investigational Agents for Alzheimer Disease and Cannabis Use Disorder. MPR Weekly Dose 00:12:30 Study identifies potential treatment strategy for high-threshold peanut allergy; Emblaveo approved for complicated intra-abdominal infections; new tablet formulation of Evrysdi; FDA fast tracks investigational agents for Alzheimer disease and cannabis use disorder.   Study identifies potential treatment strategy for high-threshold peanut allergy; Emblaveo approved for complicated intra-abdominal infections; new tablet formulation of Evrysdi; FDA fast tracks investigational agents for Alzheimer disease and cannabis use disorder.   false full 221 267fb210-af48-41f7-acc8-55c038ed7ea6 MPR Weekly Dose 223 — Diabetes Devices Alert Warning; Continuous Apomorphine Device Approved for Parkinson Disease; Symbravo Approved; New Pain Tx; Propranolol May Cut Stroke Risk FDA say there are reports that diabetes patients are missing critical safety data from their smartphone devices; A wearable continuous apomorphine infusion device has been approved for Parkinson disease 'off' periods; New migraine and pain treatments get the green light; And a study suggest propranolol may cut stroke risk in certain patients.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 7 Feb 2025 15:23:55 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com FDA say there are reports that diabetes patients are missing critical safety data from their smartphone devices; A wearable continuous apomorphine infusion device has been approved for Parkinson disease 'off' periods; New migraine and pain treatments get the green light; And a study suggest propranolol may cut stroke risk in certain patients.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose 223 — Diabetes Devices Alert Warning; Continuous Apomorphine Device Approved for Parkinson Disease; Symbravo Approved; New Pain Tx; Propranolol May Cut Stroke Risk MPR Weekly Dose 00:15:21 FDA say there are reports that diabetes patients are missing critical safety data from their smartphone devices; A wearable continuous apomorphine infusion device has been approved for Parkinson disease 'off' periods; New migraine and pain treatments get the green light; And a study suggest propranolol may cut stroke risk in certain patients.   FDA say there are reports that diabetes patients are missing critical safety data from their smartphone devices; A wearable continuous apomorphine infusion device has been approved for Parkinson disease 'off' periods; New migraine and pain treatments get the green light; And a study suggest propranolol may cut stroke risk in certain patients.   false full 220 21c232d4-6a8a-4264-b043-714dc6c8626c MPR Weekly Dose 222 — Ozempic expanded approval; MS treatment gets Boxed Warning; Monotherapy approval for Spravato; Alzheimer Tx maintenance regimen; Enhertu new Breast CA indication Ozempic gains expanded approval; MS treatment gets Boxed Warning added to label; Monotherapy approval granted for treatment resistant depression Tx Spravato; Leqembi gains maintenance regimen; Enhertu gains new Breast CA indication.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Thu, 30 Jan 2025 21:02:19 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com Ozempic gains expanded approval; MS treatment gets Boxed Warning added to label; Monotherapy approval granted for treatment resistant depression Tx Spravato; Leqembi gains maintenance regimen; Enhertu gains new Breast CA indication.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose 222 — Ozempic expanded approval; MS treatment gets Boxed Warning; Monotherapy approval for Spravato; Alzheimer Tx maintenance regimen; Enhertu new Breast CA indication MPR Weekly Dose 00:13:49 Ozempic gains expanded approval; MS treatment gets Boxed Warning added to label; Monotherapy approval granted for treatment resistant depression Tx Spravato; Leqembi gains  maintenance regimen; Enhertu gains new Breast CA indication.   Ozempic gains expanded approval; MS treatment gets Boxed Warning added to label; Monotherapy approval granted for treatment resistant depression Tx Spravato; Leqembi gains  maintenance regimen; Enhertu gains new Breast CA indication.   false full 219 b837329c-a820-4456-9e3a-be79785d5767 MPR Weekly Dose Podcast #221 — OTC Phenylephrine Removal; Schizophrenia Drug Efficacy Data; FDA Vote on Sotagliflozin; IV Ibuprofen vs Ketorolac; Semaglutide Improves Liver Fibrosis The FDA has issued a proposal to remove a common decongestant in over the counter products; A follow-up study assesses the efficacy of a schizophrenia treatment; The FDA's Endocrinologic and Metabolic Drugs Advisory Committee panel takes vote on the potential of approving a new diabetes treatment; IV ibuprofen adverse reactions examined; And semaglutide found to improve liver fibrosis.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 8 Nov 2024 18:59:46 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com The FDA has issued a proposal to remove a common decongestant in over the counter products; A follow-up study assesses the efficacy of a schizophrenia treatment; The FDA's Endocrinologic and Metabolic Drugs Advisory Committee panel takes vote on the potential of approving a new diabetes treatment; IV ibuprofen adverse reactions examined; And semaglutide found to improve liver fibrosis.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose Podcast #221 — OTC Phenylephrine Removal; Schizophrenia Drug Efficacy Data; FDA Vote on Sotagliflozin; IV Ibuprofen vs Ketorolac; Semaglutide Improves Liver Fibrosis MPR Weekly Dose 00:13:15 The FDA has issued a proposal to remove a common decongestant in over the counter products; A follow-up study assesses the efficacy of a schizophrenia treatment; The FDA's Endocrinologic and Metabolic Drugs Advisory Committee panel takes vote on the potential of approving a new diabetes treatment; IV ibuprofen adverse reactions examined; And semaglutide found to improve liver fibrosis.   The FDA has issued a proposal to remove a common decongestant in over the counter products; A follow-up study assesses the efficacy of a schizophrenia treatment; The FDA's Endocrinologic and Metabolic Drugs Advisory Committee panel takes vote on the potential of approving a new diabetes treatment; IV ibuprofen adverse reactions examined; And semaglutide found to improve liver fibrosis.   false full 218 9ac1d891-53e4-44bf-9e87-b40ea58dda7d Illegal Online Pharmacies: An interview with Libby Baney, senior advisor to the Alliance for Safe Online Pharmacies Libby Baney, Senior Advisor to ASOP Global and a partner at Faegre Drinker Consulting, talks to MPR about the current state of online pharmacies and what is being done to protect patients.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Mon, 4 Nov 2024 15:18:13 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com Libby Baney, Senior Advisor to ASOP Global and a partner at Faegre Drinker Consulting, talks to MPR about the current state of online pharmacies and what is being done to protect patients.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Illegal Online Pharmacies: An interview with Libby Baney, senior advisor to the Alliance for Safe Online Pharmacies MPR Weekly Dose 00:25:07 Libby Baney, Senior Advisor to ASOP Global and a partner at Faegre Drinker Consulting, talks to MPR about the current state of online pharmacies and what is being done to protect patients.  Libby Baney, Senior Advisor to ASOP Global and a partner at Faegre Drinker Consulting, talks to MPR about the current state of online pharmacies and what is being done to protect patients.  false full 217 9115c395-7998-4ec8-b462-d4ef4e1c91f4 MPR Weekly Dose Podcast #219 — Hurricane Helene Impacts IV Supply; At-Home COVID/Flu Test; Fake Online Pharmacies; Depression Tx Fast Tracked; Cologuard Plus Cleared Supplies of a significant number of IV solutions have been impacted by Hurricane Helene; First at-home COVID-19/Flu over-the-counter antigen test gains market authorization; DOJ clamp down on fake online pharmacies; Investigational therapy Fast Tracked for treatment resistant depression; and Cologuard Plus gets cleared for colorectal cancer screening.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 11 Oct 2024 14:35:02 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com Supplies of a significant number of IV solutions have been impacted by Hurricane Helene; First at-home COVID-19/Flu over-the-counter antigen test gains market authorization; DOJ clamp down on fake online pharmacies; Investigational therapy Fast Tracked for treatment resistant depression; and Cologuard Plus gets cleared for colorectal cancer screening.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose Podcast #219 — Hurricane Helene Impacts IV Supply; At-Home COVID/Flu Test; Fake Online Pharmacies; Depression Tx Fast Tracked; Cologuard Plus Cleared MPR Weekly Dose 00:11:27 Supplies of a significant number of IV solutions have been impacted by Hurricane Helene; First at-home COVID-19/Flu over-the-counter antigen test gains market authorization; DOJ clamp down on fake online pharmacies; Investigational therapy Fast Tracked for treatment resistant depression; and Cologuard Plus gets cleared for colorectal cancer screening.  Supplies of a significant number of IV solutions have been impacted by Hurricane Helene; First at-home COVID-19/Flu over-the-counter antigen test gains market authorization; DOJ clamp down on fake online pharmacies; Investigational therapy Fast Tracked for treatment resistant depression; and Cologuard Plus gets cleared for colorectal cancer screening.  false full 216 8938a5e8-fb59-4c9b-a308-cb53e930eddc MPR Weekly Dose Podcast #218 — Novel Weight Management Tx; Complete Response Letter for Tradipitant; Apple's Sleep Apnea Feature Cleared; New Keytruda Indication; Ebglyss for Atopic Dermatitis The FDA clears capsule that creates sensation of fullness in the stomach; Complete Response Letter issued for gastroparesis treatment; Apple's sleep apnea notification feature gets clearance; Keytruda gains malignant pleural mesothelioma indication; Ebglyss approved for atopic dermatitis


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 20 Sep 2024 14:54:41 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com The FDA clears capsule that creates sensation of fullness in the stomach; Complete Response Letter issued for gastroparesis treatment; Apple's sleep apnea notification feature gets clearance; Keytruda gains malignant pleural mesothelioma indication; Ebglyss approved for atopic dermatitis


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose Podcast #218 — Novel Weight Management Tx; Complete Response Letter for Tradipitant; Apple's Sleep Apnea Feature Cleared; New Keytruda Indication; Ebglyss for Atopic Dermatitis MPR Weekly Dose 00:13:17 The FDA clears capsule that creates sensation of fullness in the stomach; Complete Response Letter issued for gastroparesis treatment; Apple's sleep apnea notification feature gets clearance; Keytruda gains malignant pleural mesothelioma indication; Ebglyss approved for atopic dermatitis The FDA clears capsule that creates sensation of fullness in the stomach; Complete Response Letter issued for gastroparesis treatment; Apple's sleep apnea notification feature gets clearance; Keytruda gains malignant pleural mesothelioma indication; Ebglyss approved for atopic dermatitis false full 215 a1b92061-de27-4874-b407-0299984cd000 MPR Weekly Dose Podcast #217 — Novel Ulcerative Colitis Tx; Once-Weekly Insulin Efsitora in T1D; Dupilumab for Urticaria; Ultra-Long Acting Biologic in Asthma; Results for Herpes Vaccine New drug approved to treat ulcerative colitis; Once-weekly insulin efsitora investigated in type 1 diabetes; Dupilumab shows efficacy for treating urticaria; A twice-yearly injection shows potential for treating severe asthma; and GSK calls an end to their development of a herpes vaccine.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 13 Sep 2024 14:51:30 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com New drug approved to treat ulcerative colitis; Once-weekly insulin efsitora investigated in type 1 diabetes; Dupilumab shows efficacy for treating urticaria; A twice-yearly injection shows potential for treating severe asthma; and GSK calls an end to their development of a herpes vaccine.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose Podcast #217 — Novel Ulcerative Colitis Tx; Once-Weekly Insulin Efsitora in T1D; Dupilumab for Urticaria; Ultra-Long Acting Biologic in Asthma; Results for Herpes Vaccine MPR Weekly Dose 00:12:20 New drug approved to treat ulcerative colitis; Once-weekly insulin efsitora investigated in type 1 diabetes; Dupilumab shows efficacy for treating urticaria; A twice-yearly injection shows potential for treating severe asthma; and GSK calls an end to their development of a herpes vaccine. New drug approved to treat ulcerative colitis; Once-weekly insulin efsitora investigated in type 1 diabetes; Dupilumab shows efficacy for treating urticaria; A twice-yearly injection shows potential for treating severe asthma; and GSK calls an end to their development of a herpes vaccine. false full 214 696ac48f-8554-4221-9dbb-25bede09ad6f MPR Weekly Dose Podcast #216 — Vaccine Guidance for Flu Season; Mpox Vaccine; Updated Novavax Vaccine Authorization; OTC Gel for ED; New Insertion Device for Paragard CDC Advisory Committee issue vaccine guidelines for flu season; Smallpox vaccine gains expanded indication; Updated Novavax COVID-19 vaccine; Over-the-counter gel for erectile dysfunction; New inserter system for placement of contraceptive intrauterine system.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 6 Sep 2024 14:20:30 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com CDC Advisory Committee issue vaccine guidelines for flu season; Smallpox vaccine gains expanded indication; Updated Novavax COVID-19 vaccine; Over-the-counter gel for erectile dysfunction; New inserter system for placement of contraceptive intrauterine system.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose Podcast #216 — Vaccine Guidance for Flu Season; Mpox Vaccine; Updated Novavax Vaccine Authorization; OTC Gel for ED; New Insertion Device for Paragard MPR Weekly Dose 00:12:45 CDC Advisory Committee issue vaccine guidelines for flu season; Smallpox vaccine gains expanded indication; Updated Novavax COVID-19 vaccine; Over-the-counter gel for erectile dysfunction; New inserter system for placement of contraceptive intrauterine system. CDC Advisory Committee issue vaccine guidelines for flu season; Smallpox vaccine gains expanded indication; Updated Novavax COVID-19 vaccine; Over-the-counter gel for erectile dysfunction; New inserter system for placement of contraceptive intrauterine system. false full 213 03fd2959-f7ea-4bdb-8a8e-318f450fb183 MPR Weekly Dose Podcast #215 — HIV Drug Discontinuation; Combo for EGFR-Mutated NSCLC; Update on Unapproved Potassium Phosphates in Peds; Otezla Indication Expanded; Tirzepatide Diabetes Risk Reduction Trial Genentech decide to remove Fuzeon from US market; Rybrevant and Lazcluze approved as first-line treatment for certain patients with EGFR-mutated advanced NSCLC; FDA warning regarding unapproved potassium phosphates; Otezla approval expanded to include treatment of pediatric patients; Results from tirzepatide diabetes risk reduction study.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 23 Aug 2024 15:15:10 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com Genentech decide to remove Fuzeon from US market; Rybrevant and Lazcluze approved as first-line treatment for certain patients with EGFR-mutated advanced NSCLC; FDA warning regarding unapproved potassium phosphates; Otezla approval expanded to include treatment of pediatric patients; Results from tirzepatide diabetes risk reduction study.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose Podcast #215 — HIV Drug Discontinuation; Combo for EGFR-Mutated NSCLC; Update on Unapproved Potassium Phosphates in Peds; Otezla Indication Expanded; Tirzepatide Diabetes Risk Reduction Trial MPR Weekly Dose 00:12:37 Genentech decide to remove Fuzeon from US market; Rybrevant and Lazcluze approved as first-line treatment for certain patients with EGFR-mutated advanced NSCLC; FDA warning regarding unapproved potassium phosphates; Otezla approval expanded to include treatment of pediatric patients; Results from tirzepatide diabetes risk reduction study. Genentech decide to remove Fuzeon from US market; Rybrevant and Lazcluze approved as first-line treatment for certain patients with EGFR-mutated advanced NSCLC; FDA warning regarding unapproved potassium phosphates; Otezla approval expanded to include treatment of pediatric patients; Results from tirzepatide diabetes risk reduction study. false full 212 016af8a5-b82d-45f4-98d1-9304c49227b5 MPR Weekly Dose Podcast #214 — Livdelzi Approved for PBC; Novel Prurigo Nodularis Tx; FDA Denies MDMA Therapy; Yorvipath Approved; Digital Therapy for MDD New Treatment for Primary Biliary Cholangitis; Nemluvio approved for prurigo nodularis; FDA Denies MDMA for PTSD; New hypoparathyroidism treatment; First digital therapeutic approved for depression.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 16 Aug 2024 14:34:54 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com New Treatment for Primary Biliary Cholangitis; Nemluvio approved for prurigo nodularis; FDA Denies MDMA for PTSD; New hypoparathyroidism treatment; First digital therapeutic approved for depression.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose Podcast #214 — Livdelzi Approved for PBC; Novel Prurigo Nodularis Tx; FDA Denies MDMA Therapy; Yorvipath Approved; Digital Therapy for MDD MPR Weekly Dose 00:14:18 New Treatment for Primary Biliary Cholangitis; Nemluvio approved for prurigo nodularis; FDA Denies MDMA for PTSD; New hypoparathyroidism treatment; First digital therapeutic approved for depression. New Treatment for Primary Biliary Cholangitis; Nemluvio approved for prurigo nodularis; FDA Denies MDMA for PTSD; New hypoparathyroidism treatment; First digital therapeutic approved for depression. false full 211 468bbe8b-a617-425c-9282-fb86ac69b3b5 MPR Weekly Dose Podcast #213 — Obesity Drug Shortage Update; Updated Contraceptive Recs; Synovial Sarcoma T-Cell Tx; Lymphir Approved; Fabhalta Gains a New Indication The FDA give an updated on the availability of obesity drugs; The CDC has issued an updated guideline on contraceptive use; The first T-cell gene therapy is approved for synovial sarcoma; Lymphir gains approval for relapsed or refractory cutaneous T-cell lymphoma; Fabhalta gains a new indication.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 9 Aug 2024 14:52:14 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com The FDA give an updated on the availability of obesity drugs; The CDC has issued an updated guideline on contraceptive use; The first T-cell gene therapy is approved for synovial sarcoma; Lymphir gains approval for relapsed or refractory cutaneous T-cell lymphoma; Fabhalta gains a new indication.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose Podcast #213 — Obesity Drug Shortage Update; Updated Contraceptive Recs; Synovial Sarcoma T-Cell Tx; Lymphir Approved; Fabhalta Gains a New Indication MPR Weekly Dose 00:17:43 The FDA give an updated on the availability of obesity drugs; The CDC has issued an updated guideline on contraceptive use; The first T-cell gene therapy is approved for synovial sarcoma; Lymphir gains approval for relapsed or refractory cutaneous T-cell lymphoma; Fabhalta gains a new indication. The FDA give an updated on the availability of obesity drugs; The CDC has issued an updated guideline on contraceptive use; The first T-cell gene therapy is approved for synovial sarcoma; Lymphir gains approval for relapsed or refractory cutaneous T-cell lymphoma; Fabhalta gains a new indication. false full 210 704f988f-3c24-4011-9ef1-549bae33bedc MPR Weekly Dose Podcast #212 — Compounded Semaglutide Errors; New Alzheimer Disease Tx; Test for Colorectal Cancer; Leqselvi Approved for Alopecia; Palforzia Expanded Approval FDA voice concerns over compounded semaglutide; New treatment approved for mild to moderate dementia of the Alzheimer type; Colorectal cancer screening test gets green light; Leqselvi approved for alopecia; And peanut allergy treatment gains expanded indication.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 2 Aug 2024 15:01:58 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com FDA voice concerns over compounded semaglutide; New treatment approved for mild to moderate dementia of the Alzheimer type; Colorectal cancer screening test gets green light; Leqselvi approved for alopecia; And peanut allergy treatment gains expanded indication.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose Podcast #212 — Compounded Semaglutide Errors; New Alzheimer Disease Tx; Test for Colorectal Cancer; Leqselvi Approved for Alopecia; Palforzia Expanded Approval MPR Weekly Dose 00:14:08 FDA voice concerns over compounded semaglutide; New treatment approved for mild to moderate dementia of the Alzheimer type; Colorectal cancer screening test gets green light; Leqselvi approved for alopecia; And peanut allergy treatment gains expanded indication. FDA voice concerns over compounded semaglutide; New treatment approved for mild to moderate dementia of the Alzheimer type; Colorectal cancer screening test gets green light; Leqselvi approved for alopecia; And peanut allergy treatment gains expanded indication. false full 209 b0f43848-8b07-4027-a647-500f10502fe0 MPR Weekly Dose Podcast #211 — Duvyzat Available; Device to Treat Nasal Congestion; Pediatric Tx to Delay Diabetes; Soliris Biosimilar; First Orally-Disintegrating Contraceptive Duchenne muscular dystrophy treatment now available; Noise therapy wearable for nasal congestion; Treatment for delaying diabetes gets Fast Tracked; Soliris biosimilar approved; And the first orally-disintegrating contraceptive.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 26 Jul 2024 15:02:50 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com Duchenne muscular dystrophy treatment now available; Noise therapy wearable for nasal congestion; Treatment for delaying diabetes gets Fast Tracked; Soliris biosimilar approved; And the first orally-disintegrating contraceptive.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose Podcast #211 — Duvyzat Available; Device to Treat Nasal Congestion; Pediatric Tx to Delay Diabetes; Soliris Biosimilar; First Orally-Disintegrating Contraceptive MPR Weekly Dose 00:12:15 Duchenne muscular dystrophy treatment now available; Noise therapy wearable for nasal congestion; Treatment for delaying diabetes gets Fast Tracked; Soliris biosimilar approved; And the first orally-disintegrating contraceptive. Duchenne muscular dystrophy treatment now available; Noise therapy wearable for nasal congestion; Treatment for delaying diabetes gets Fast Tracked; Soliris biosimilar approved; And the first orally-disintegrating contraceptive. false full 208 d49d9a00-a893-4226-bce2-2ed67e2ce299 MPR Weekly Dose Podcast #210 — Clonazepam ODT Recall; Parkinson Disease Tx Gets Fast Tracked; Pancreatic CA Vaccine; Voquenzna New Approval; Endari Generic Seizure medication recalled due to wrong strength on carton; Gene therapy gains Fast Track status for Parkinson disease; Dendritic cell vaccine being developed for pancreatic cancer; Generic version of sickle cell disease treatment Endari is made available


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 19 Jul 2024 14:39:25 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com Seizure medication recalled due to wrong strength on carton; Gene therapy gains Fast Track status for Parkinson disease; Dendritic cell vaccine being developed for pancreatic cancer; Generic version of sickle cell disease treatment Endari is made available


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose Podcast #210 — Clonazepam ODT Recall; Parkinson Disease Tx Gets Fast Tracked; Pancreatic CA Vaccine; Voquenzna New Approval; Endari Generic MPR Weekly Dose 00:14:10 Seizure medication recalled due to wrong strength on carton; Gene therapy gains Fast Track status for Parkinson disease; Dendritic cell vaccine being developed for pancreatic cancer; Generic version of sickle cell disease treatment Endari is made available Seizure medication recalled due to wrong strength on carton; Gene therapy gains Fast Track status for Parkinson disease; Dendritic cell vaccine being developed for pancreatic cancer; Generic version of sickle cell disease treatment Endari is made available false full 207 67fc3a1a-ffe2-4c30-a250-80a65c76a2d7 MPR Weekly Dose Podcast #209 — Atopic Dermatitis Topical; Wet AMD Implant Available Again; Neurostimulation Device for RA; FDA Denies Weekly Insulin; Smarthphone Therapy for Fibromyalgia New steroid-free topical for atopic dermatitis; A refillable ocular implant for the treatment of neovascular (wet) age-related macular degeneration returns following recall; A neuroimmune modulation device shows clinical benefit in adults with rheumatoid arthritis; FDA denies Novo Nordisk's once-weekly insulin icodec; And a smarthphone therapy shows benefit for patients with fibromyalgia.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 12 Jul 2024 14:58:19 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com New steroid-free topical for atopic dermatitis; A refillable ocular implant for the treatment of neovascular (wet) age-related macular degeneration returns following recall; A neuroimmune modulation device shows clinical benefit in adults with rheumatoid arthritis; FDA denies Novo Nordisk's once-weekly insulin icodec; And a smarthphone therapy shows benefit for patients with fibromyalgia.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose Podcast #209 — Atopic Dermatitis Topical; Wet AMD Implant Available Again; Neurostimulation Device for RA; FDA Denies Weekly Insulin; Smarthphone Therapy for Fibromyalgia MPR Weekly Dose 00:12:55 New steroid-free topical for atopic dermatitis; A refillable ocular implant for the treatment of  neovascular (wet) age-related macular degeneration returns following recall; A neuroimmune modulation device shows clinical benefit in adults with rheumatoid arthritis; FDA denies Novo Nordisk's once-weekly insulin icodec; And a smarthphone therapy shows benefit for patients with fibromyalgia. New steroid-free topical for atopic dermatitis; A refillable ocular implant for the treatment of  neovascular (wet) age-related macular degeneration returns following recall; A neuroimmune modulation device shows clinical benefit in adults with rheumatoid arthritis; FDA denies Novo Nordisk's once-weekly insulin icodec; And a smarthphone therapy shows benefit for patients with fibromyalgia. false full 206 1ffafe97-d0dd-4bd8-bbc6-41914cfd2ef0 MPR Weekly Dose Podcast #208 — Ohtuvayre Approved; Generic Victoza; DMD Gene Therapy Expanded; Treatment for Pediatric Narcolepsy; OTC Video Game for ADHD New maintenance treatment approved for COPD; Authorized generic version of Victoza launches; Duchenne muscular dystrophy treatment indication expanded; Narcolepsy treatment expanded for certain pediatric patients; FDA clears digital therapeutic for ADHD.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 28 Jun 2024 14:18:51 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com New maintenance treatment approved for COPD; Authorized generic version of Victoza launches; Duchenne muscular dystrophy treatment indication expanded; Narcolepsy treatment expanded for certain pediatric patients; FDA clears digital therapeutic for ADHD.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose Podcast #208 — Ohtuvayre Approved; Generic Victoza; DMD Gene Therapy Expanded; Treatment for Pediatric Narcolepsy; OTC Video Game for ADHD MPR Weekly Dose 00:12:20 New maintenance treatment approved for COPD; Authorized generic version of Victoza launches; Duchenne muscular dystrophy treatment indication expanded; Narcolepsy treatment expanded for certain pediatric patients; FDA clears digital therapeutic for ADHD.   New maintenance treatment approved for COPD; Authorized generic version of Victoza launches; Duchenne muscular dystrophy treatment indication expanded; Narcolepsy treatment expanded for certain pediatric patients; FDA clears digital therapeutic for ADHD.   false full 205 ace611ce-272f-47ce-bdae-b40a8ee8ce03 MPR Weekly Dose Podcast #207 — Skyrizi for UC; 21-Valent Pneumococcal Vaccine; Indictment May Affect ADHD Meds; Next-Gen COVID-19 Vaccine; Farxiga Approval Expanded Skyrizi has been approved for ulcerative colitis; New pneumococcal vaccine approved; An indictment may impact as much as 50,000 patients who need ADHD meds; Results announced for Moderna's next-gen COVID-19 vaccine; Farxiga approval expanded.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 21 Jun 2024 13:39:00 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com Skyrizi has been approved for ulcerative colitis; New pneumococcal vaccine approved; An indictment may impact as much as 50,000 patients who need ADHD meds; Results announced for Moderna's next-gen COVID-19 vaccine; Farxiga approval expanded.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose Podcast #207 — Skyrizi for UC; 21-Valent Pneumococcal Vaccine; Indictment May Affect ADHD Meds; Next-Gen COVID-19 Vaccine; Farxiga Approval Expanded MPR Weekly Dose 00:13:29 Skyrizi has been approved for ulcerative colitis; New pneumococcal vaccine approved; An indictment may impact as much as 50,000 patients who need ADHD meds; Results announced for Moderna's next-gen COVID-19 vaccine; Farxiga approval expanded. Skyrizi has been approved for ulcerative colitis; New pneumococcal vaccine approved; An indictment may impact as much as 50,000 patients who need ADHD meds; Results announced for Moderna's next-gen COVID-19 vaccine; Farxiga approval expanded. false full 204 006a5e24-7e9d-4d30-a324-31cc6bd3dd67 MPR Weekly Dose 206 — OTC Glucose Monitors; RSV Vaccine Approval Expanded; Juvenile Idiopathic Arthritis Tx; Emflaza Generic; New Primary Biliary Cholangitis Tx Two glucose monitoring systems have been cleared for over-the-counter sale; Arexvy gains approval for adults aged 50 to 59 years; Kevzara approved for active polyarticular juvenile idiopathic arthritis; Generic Duchenne muscular dystrophy drug is made available; and Iqirvo gets accelerated approval for primary biliary cholangitis.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 14 Jun 2024 14:39:45 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com Two glucose monitoring systems have been cleared for over-the-counter sale; Arexvy gains approval for adults aged 50 to 59 years; Kevzara approved for active polyarticular juvenile idiopathic arthritis; Generic Duchenne muscular dystrophy drug is made available; and Iqirvo gets accelerated approval for primary biliary cholangitis.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose 206 — OTC Glucose Monitors; RSV Vaccine Approval Expanded; Juvenile Idiopathic Arthritis Tx; Emflaza Generic; New Primary Biliary Cholangitis Tx MPR Weekly Dose 00:11:33 Two glucose monitoring systems have been cleared for over-the-counter sale; Arexvy gains approval for adults aged 50 to 59 years; Kevzara approved for active polyarticular juvenile idiopathic arthritis; Generic Duchenne muscular dystrophy drug is made available; and Iqirvo gets accelerated approval for primary biliary cholangitis. Two glucose monitoring systems have been cleared for over-the-counter sale; Arexvy gains approval for adults aged 50 to 59 years; Kevzara approved for active polyarticular juvenile idiopathic arthritis; Generic Duchenne muscular dystrophy drug is made available; and Iqirvo gets accelerated approval for primary biliary cholangitis. false full 203 aaa8f97c-4462-42c3-9009-42505643f4aa MPR Weekly Dose Podcast #205 — Entresto Generics; mRNA-Based RSV Vaccine; Doxycycline PEP for STI Prevention; FDA Vote on MDMA Therapy; Rinvoq Indication Expanded First generics of heart failure drug gain approval; mRNA vaccine approved for RSV; CDC make drug recommendation for STI prevention; Advisory Committee vote on MDMA for PTSD; Rinvoq approval expanded


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 7 Jun 2024 14:55:57 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com First generics of heart failure drug gain approval; mRNA vaccine approved for RSV; CDC make drug recommendation for STI prevention; Advisory Committee vote on MDMA for PTSD; Rinvoq approval expanded


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose Podcast #205 — Entresto Generics; mRNA-Based RSV Vaccine; Doxycycline PEP for STI Prevention; FDA Vote on MDMA Therapy; Rinvoq Indication Expanded MPR Weekly Dose 00:11:55 First generics of heart failure drug gain approval; mRNA vaccine approved for RSV; CDC make drug recommendation for STI prevention; Advisory Committee vote on MDMA for PTSD; Rinvoq approval expanded First generics of heart failure drug gain approval; mRNA vaccine approved for RSV; CDC make drug recommendation for STI prevention; Advisory Committee vote on MDMA for PTSD; Rinvoq approval expanded false full 202 49c1a25d-e94d-4169-8f1a-5f6023869178 MPR Weekly Dose 204 — Novel ADHD Extended-Release Tx; Soliris Biosimilar Approved; Depression, Insomnia Tx; FDA Vote on Colorectal CA Test; Mistrust in the FDA Extended-release ADHD treatment gains approval; An interchangeable biosimilar to Soliris is approved; Investigational treatment shows promise for improving depression and insomnia; The FDA vote on a blood-based colorectal cancer diagnostic; Survey reveals public attitudes towards the FDA.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 31 May 2024 14:37:33 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com Extended-release ADHD treatment gains approval; An interchangeable biosimilar to Soliris is approved; Investigational treatment shows promise for improving depression and insomnia; The FDA vote on a blood-based colorectal cancer diagnostic; Survey reveals public attitudes towards the FDA.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose 204 — Novel ADHD Extended-Release Tx; Soliris Biosimilar Approved; Depression, Insomnia Tx; FDA Vote on Colorectal CA Test; Mistrust in the FDA MPR Weekly Dose 00:11:48 Extended-release ADHD treatment gains approval; An interchangeable biosimilar to Soliris is approved; Investigational treatment shows promise for improving depression and insomnia; The FDA vote on a blood-based colorectal cancer diagnostic; Survey reveals public attitudes towards the FDA. Extended-release ADHD treatment gains approval; An interchangeable biosimilar to Soliris is approved; Investigational treatment shows promise for improving depression and insomnia; The FDA vote on a blood-based colorectal cancer diagnostic; Survey reveals public attitudes towards the FDA. false full 201 29cebe77-a51f-492b-96bb-cb0a1412211a MPR Weekly Dose Podcast 203 — Urinary Incontinence Device; Autoinjector Warning for MS Tx; COVID-19 Preexposure Prophylaxis; Elyea Biosimilars; Lung Cancer Treatment Approved Self-administered device cleared to treat stress urinary incontinence in women; Autoinjector warning for relapsing MS treatment; COVID-19 preexposure prophylaxis investigational treatment looks promising; Biosimilars for Eylea approved; Imdelltra approved for extensive stage small cell lung cancer with disease progression.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 24 May 2024 13:44:06 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com Self-administered device cleared to treat stress urinary incontinence in women; Autoinjector warning for relapsing MS treatment; COVID-19 preexposure prophylaxis investigational treatment looks promising; Biosimilars for Eylea approved; Imdelltra approved for extensive stage small cell lung cancer with disease progression.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose Podcast 203 — Urinary Incontinence Device; Autoinjector Warning for MS Tx; COVID-19 Preexposure Prophylaxis; Elyea Biosimilars; Lung Cancer Treatment Approved MPR Weekly Dose 00:14:18 Self-administered device cleared to treat stress urinary incontinence in women; Autoinjector warning for relapsing MS treatment; COVID-19 preexposure prophylaxis investigational treatment looks promising; Biosimilars for Eylea approved; Imdelltra approved for extensive stage small cell lung cancer with disease progression.   Self-administered device cleared to treat stress urinary incontinence in women; Autoinjector warning for relapsing MS treatment; COVID-19 preexposure prophylaxis investigational treatment looks promising; Biosimilars for Eylea approved; Imdelltra approved for extensive stage small cell lung cancer with disease progression.   false full 200 51a8fa65-0fe5-4355-b933-8e01725d621e MPR Weekly Dose 202 — Unreliable COVID-19 Tests; Insulin Pump App Update; Noninvasive Colorectal CA Test; Self-Collection HPV Screening Option; Drug Threats to the US Reliability of COVID-19 tests unreliable; Insulin pump app updated following battery issue; Noninvasive colorectal cancer test gets FDA approval; Self-collection HPV screening option; National Drug Threat Assessment highlights illicit drugs currently endangering the US.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 17 May 2024 15:27:14 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com Reliability of COVID-19 tests unreliable; Insulin pump app updated following battery issue; Noninvasive colorectal cancer test gets FDA approval; Self-collection HPV screening option; National Drug Threat Assessment highlights illicit drugs currently endangering the US.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose 202 — Unreliable COVID-19 Tests; Insulin Pump App Update; Noninvasive Colorectal CA Test; Self-Collection HPV Screening Option; Drug Threats to the US MPR Weekly Dose 00:11:08 Reliability of COVID-19 tests unreliable; Insulin pump app updated following battery issue; Noninvasive colorectal cancer test gets FDA approval; Self-collection HPV screening option; National Drug Threat Assessment highlights illicit drugs currently endangering the US.  Reliability of COVID-19 tests unreliable; Insulin pump app updated following battery issue; Noninvasive colorectal cancer test gets FDA approval; Self-collection HPV screening option; National Drug Threat Assessment highlights illicit drugs currently endangering the US.  false full 199 af176da1-6603-4bc9-9370-b06c91671b8c Drug Shortage Crisis: An interview with Dr. Michael Ganio Dr. Michael Ganio, ASHP's Director of Pharmacy Practice and Quality, joins me to discuss the current drug shortage crisis, which has reached new levels.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 10 May 2024 14:36:12 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com Dr. Michael Ganio, ASHP's Director of Pharmacy Practice and Quality, joins me to discuss the current drug shortage crisis, which has reached new levels.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Drug Shortage Crisis: An interview with Dr. Michael Ganio MPR Weekly Dose 00:13:53 Dr. Michael Ganio, ASHP's Director of Pharmacy Practice and Quality, joins me to discuss the current drug shortage crisis, which has reached new levels. Dr. Michael Ganio, ASHP's Director of Pharmacy Practice and Quality, joins me to discuss the current drug shortage crisis, which has reached new levels. false full 198 c13bcf30-7a52-44f5-ae8d-43d241cdf6de Psilocybin for Depression: An interview with Dr. Charles Raison Dr Charles Raison, the Director of Clinical Research at the Usona Institute and Professor in the Department of Psychiatry at the University of Wisconsin–Madison, joins me to discuss the potential of psilocybin as a therapy for major depressive disorder.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Tue, 30 Apr 2024 15:16:00 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com Dr Charles Raison, the Director of Clinical Research at the Usona Institute and Professor in the Department of Psychiatry at the University of Wisconsin–Madison, joins me to discuss the potential of psilocybin as a therapy for major depressive disorder.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Psilocybin for Depression: An interview with Dr. Charles Raison MPR Weekly Dose 00:28:52 Dr Charles Raison, the Director of Clinical Research at the Usona Institute and Professor in the Department of Psychiatry at the University of Wisconsin–Madison, joins me to discuss the potential of psilocybin as a therapy for major depressive disorder. Dr Charles Raison, the Director of Clinical Research at the Usona Institute and Professor in the Department of Psychiatry at the University of Wisconsin–Madison, joins me to discuss the potential of psilocybin as a therapy for major depressive disorder. false full 197 ed473e63-3d2b-488a-a232-71002cc5c62b MPR Weekly Dose 199 — Fasenra Expanded Approval; HIV Tx Approval Expanded; ALS Drug Discontinued; CRL for Apomorphine Device; At-Home Mpox Test Asthma treatment gains approval for severe cases in pediatrics; Dovato gains expanded indication; Decision taken to remove ALS drug from market; Complete Response Letter issued for apomorphine device; At-home Mpox test kit made available.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 12 Apr 2024 14:36:17 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com Asthma treatment gains approval for severe cases in pediatrics; Dovato gains expanded indication; Decision taken to remove ALS drug from market; Complete Response Letter issued for apomorphine device; At-home Mpox test kit made available.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose 199 — Fasenra Expanded Approval; HIV Tx Approval Expanded; ALS Drug Discontinued; CRL for Apomorphine Device; At-Home Mpox Test MPR Weekly Dose 00:11:24 Asthma treatment gains approval for severe cases in pediatrics; Dovato gains expanded indication; Decision taken to remove ALS drug from market; Complete Response Letter issued for apomorphine device; At-home Mpox test kit made available. Asthma treatment gains approval for severe cases in pediatrics; Dovato gains expanded indication; Decision taken to remove ALS drug from market; Complete Response Letter issued for apomorphine device; At-home Mpox test kit made available. false full 196 36a023be-f57d-47dc-b40c-ce06efe9e8dd MPR Weekly Dose 198 — Prescription App for MDD; Traumatic Brain Injury Blood Test; New Bloodstream Infection Antibiotic; Mpox Vaccine Availability; Left Ventricular Ejection Fraction Detection First prescription smartphone app approved for major depressive disorder; Novel blood test to detect TBI; Zevtera approved for bloodstream infections; Mpox vaccine is now commercially available; Algorithm cleared for LVEF dectection.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 5 Apr 2024 15:43:16 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com First prescription smartphone app approved for major depressive disorder; Novel blood test to detect TBI; Zevtera approved for bloodstream infections; Mpox vaccine is now commercially available; Algorithm cleared for LVEF dectection.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose 198 — Prescription App for MDD; Traumatic Brain Injury Blood Test; New Bloodstream Infection Antibiotic; Mpox Vaccine Availability; Left Ventricular Ejection Fraction Detection MPR Weekly Dose 00:11:39 First prescription smartphone app approved for major depressive disorder; Novel blood test to detect TBI; Zevtera approved for bloodstream infections; Mpox vaccine is now commercially available; Algorithm cleared for LVEF dectection.   First prescription smartphone app approved for major depressive disorder; Novel blood test to detect TBI; Zevtera approved for bloodstream infections; Mpox vaccine is now commercially available; Algorithm cleared for LVEF dectection.   false full 195 e242fda5-25a0-4bea-8b62-6284d5b8032c MPR Weekly Dose 197 — Pemgarda Emergency Use; Expansion of Nexletol, Nexlizet; DMD Drug Approval; First Molecular Malaria Blood Test; OTC Topical Analgesic Warning Preexposure prophylaxis approved for COVID-19; Nexletol and Nexlizet gain expanded approval; Novel Duchenne muscular dystrophy treatment; First blood test to screen for malaria in donors; Warning letter for OTC topical analgesic products.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 29 Mar 2024 15:44:47 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com Preexposure prophylaxis approved for COVID-19; Nexletol and Nexlizet gain expanded approval; Novel Duchenne muscular dystrophy treatment; First blood test to screen for malaria in donors; Warning letter for OTC topical analgesic products.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose 197 — Pemgarda Emergency Use; Expansion of Nexletol, Nexlizet; DMD Drug Approval; First Molecular Malaria Blood Test; OTC Topical Analgesic Warning MPR Weekly Dose 00:13:31 Preexposure prophylaxis approved for COVID-19; Nexletol and Nexlizet gain expanded approval; Novel Duchenne muscular dystrophy treatment; First blood test to screen for malaria in donors; Warning letter for OTC topical analgesic products.   Preexposure prophylaxis approved for COVID-19; Nexletol and Nexlizet gain expanded approval; Novel Duchenne muscular dystrophy treatment; First blood test to screen for malaria in donors; Warning letter for OTC topical analgesic products.   false full 194 cb148b81-57f5-4f22-88f7-085af694a516 MPR Weekly Dose 196 — Chronic Rhinosinusitis Nasal Spray; Novel hypertension Tx; Stem-Cell Treatment Approved for Rare Disease; Accelerated approval for NASH Tx; Automated Insulin Delivery System Nasal spray approved for chronic rhinosinusitis; Endothelin receptor antagonist gains approval to lower blood pressure in hypertension; One-time stem cell treatment approved for metachromatic leukodystrophy; NASH treatment gains accelerated approval; New automated insulin delivery system for type 1 diabetes.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 22 Mar 2024 14:04:04 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com Nasal spray approved for chronic rhinosinusitis; Endothelin receptor antagonist gains approval to lower blood pressure in hypertension; One-time stem cell treatment approved for metachromatic leukodystrophy; NASH treatment gains accelerated approval; New automated insulin delivery system for type 1 diabetes.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose 196 — Chronic Rhinosinusitis Nasal Spray; Novel hypertension Tx; Stem-Cell Treatment Approved for Rare Disease; Accelerated approval for NASH Tx; Automated Insulin Delivery System MPR Weekly Dose 00:14:09 Nasal spray approved for chronic rhinosinusitis; Endothelin receptor antagonist gains approval to lower blood pressure in hypertension; One-time stem cell treatment approved for metachromatic leukodystrophy; NASH treatment gains accelerated approval; New automated insulin delivery system for type 1 diabetes.   Nasal spray approved for chronic rhinosinusitis; Endothelin receptor antagonist gains approval to lower blood pressure in hypertension; One-time stem cell treatment approved for metachromatic leukodystrophy; NASH treatment gains accelerated approval; New automated insulin delivery system for type 1 diabetes.   false full 193 400c286d-8982-491b-9394-e9f33dbaa50c MPR Weekly Dose 195 — Weight Loss Tx Gains Cardiovascular Indication; Paxlovid Update; Psilocybin Granted Breakthrough Therapy; Decision Delay for Alzheimer Tx; Relyvrio Trial Results Weight loss treatment has approval expanded; Paxlovid with Emergency Use Authorized label must be disposed of; psychedelic gets Breakthrough therapy designation; Advisory Committee announce meeting to discuss Alzheimer treatment; ALS treatment trial results


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 15 Mar 2024 15:54:21 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com Weight loss treatment has approval expanded; Paxlovid with Emergency Use Authorized label must be disposed of; psychedelic gets Breakthrough therapy designation; Advisory Committee announce meeting to discuss Alzheimer treatment; ALS treatment trial results


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose 195 — Weight Loss Tx Gains Cardiovascular Indication; Paxlovid Update; Psilocybin Granted Breakthrough Therapy; Decision Delay for Alzheimer Tx; Relyvrio Trial Results MPR Weekly Dose 00:13:10 Weight loss treatment has approval expanded; Paxlovid with Emergency Use Authorized label must be disposed of; psychedelic gets Breakthrough therapy designation; Advisory Committee announce meeting to discuss Alzheimer treatment; ALS treatment trial results Weight loss treatment has approval expanded; Paxlovid with Emergency Use Authorized label must be disposed of; psychedelic gets Breakthrough therapy designation; Advisory Committee announce meeting to discuss Alzheimer treatment; ALS treatment trial results false full 192 0db3e398-23d3-4f67-aeea-34cd8b220a93 MPR Weekly Dose 194 — OTC Birth Control Pill; First OTC Continuous Glucose Monitor; Influenza Vaccine for 2024/2025 Season; Breakthrough Therapy for LSD; Biosimilars to Prolia and Xgeva Over-the-counter birth control pill to be available in the coming weeks; first over-the-counter continuous glucose monitor to be available starting this summer; the 2024-2025 US influenza season vaccine will be trivalent; LSD granted Breakthrough Therapy for treatment of generalized anxiety disorder; interchangeable biosimilars to Prolia and Xgeva approved.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 8 Mar 2024 16:00:53 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com Over-the-counter birth control pill to be available in the coming weeks; first over-the-counter continuous glucose monitor to be available starting this summer; the 2024-2025 US influenza season vaccine will be trivalent; LSD granted Breakthrough Therapy for treatment of generalized anxiety disorder; interchangeable biosimilars to Prolia and Xgeva approved.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose 194 — OTC Birth Control Pill; First OTC Continuous Glucose Monitor; Influenza Vaccine for 2024/2025 Season; Breakthrough Therapy for LSD; Biosimilars to Prolia and Xgeva MPR Weekly Dose 00:13:35 Over-the-counter birth control pill to be available in the coming weeks; first over-the-counter continuous glucose monitor to be available starting this summer; the 2024-2025 US influenza season vaccine will be trivalent; LSD granted Breakthrough Therapy for treatment of generalized anxiety disorder; interchangeable biosimilars to Prolia and Xgeva approved.  Over-the-counter birth control pill to be available in the coming weeks; first over-the-counter continuous glucose monitor to be available starting this summer; the 2024-2025 US influenza season vaccine will be trivalent; LSD granted Breakthrough Therapy for treatment of generalized anxiety disorder; interchangeable biosimilars to Prolia and Xgeva approved.  false full 191 54978b29-8d97-4095-a518-c792babe5cc7 MPR Weekly Dose 193 — Pepaxto Approval Withdrawn; Abrysvo Efficacy; Ixchiq Vaccine Recommendations; Novel Schizophrenia Tx Decision; UTI Tx Approval; Eye Ointment Recalled FDA withdraw multiple myeloma treatment after a confirmatory trial showed an increased risk of death; latest efficacy results for lower respiratory tract disease vaccine; CDC Chikungunya virus vaccine recommendations; Complete Response Letter issued to investigative schizophrenia treatment; new treatment for complicated UTIs including pyelonephritis; over-the-counter eye ointments recalled.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 1 Mar 2024 15:49:54 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com FDA withdraw multiple myeloma treatment after a confirmatory trial showed an increased risk of death; latest efficacy results for lower respiratory tract disease vaccine; CDC Chikungunya virus vaccine recommendations; Complete Response Letter issued to investigative schizophrenia treatment; new treatment for complicated UTIs including pyelonephritis; over-the-counter eye ointments recalled.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose 193 — Pepaxto Approval Withdrawn; Abrysvo Efficacy; Ixchiq Vaccine Recommendations; Novel Schizophrenia Tx Decision; UTI Tx Approval; Eye Ointment Recalled MPR Weekly Dose 00:17:00 FDA withdraw multiple myeloma treatment after a confirmatory trial showed an increased risk of death; latest efficacy results for lower respiratory tract disease vaccine; CDC Chikungunya virus vaccine recommendations; Complete Response Letter issued to investigative schizophrenia treatment; new treatment for complicated UTIs including pyelonephritis; over-the-counter eye ointments recalled.   FDA withdraw multiple myeloma treatment after a confirmatory trial showed an increased risk of death; latest efficacy results for lower respiratory tract disease vaccine; CDC Chikungunya virus vaccine recommendations; Complete Response Letter issued to investigative schizophrenia treatment; new treatment for complicated UTIs including pyelonephritis; over-the-counter eye ointments recalled.   false full 190 b8ed27ca-bdc4-4ed0-95df-0ba62e8f43a4 MPR Weekly Dose 192 — Xolair Approved for Multiple Food Allergies; Amtagvi Gets Approval; Vit D Supplement Recalled; Cannabidiol for Pericarditis; Smartwatch Warning First treatment approved to reduce allergic reactions in those with multiple food allergies; T-cell therapy given accelerated approval to treat unresectable or metastatic melanoma; Vit D supplement recalled due to superpotency; cannabidiol may help resolve the symptoms of pericarditis; FDA warn against certain wearables that claim to measure blood glucose.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 23 Feb 2024 15:38:33 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com First treatment approved to reduce allergic reactions in those with multiple food allergies; T-cell therapy given accelerated approval to treat unresectable or metastatic melanoma; Vit D supplement recalled due to superpotency; cannabidiol may help resolve the symptoms of pericarditis; FDA warn against certain wearables that claim to measure blood glucose.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose 192 — Xolair Approved for Multiple Food Allergies; Amtagvi Gets Approval; Vit D Supplement Recalled; Cannabidiol for Pericarditis; Smartwatch Warning MPR Weekly Dose 00:13:35 First treatment approved to reduce allergic reactions in those with multiple food allergies; T-cell therapy given accelerated approval to treat unresectable or metastatic melanoma; Vit D supplement recalled due to superpotency; cannabidiol may help resolve the symptoms of pericarditis; FDA warn against certain wearables that claim to measure blood glucose. First treatment approved to reduce allergic reactions in those with multiple food allergies; T-cell therapy given accelerated approval to treat unresectable or metastatic melanoma; Vit D supplement recalled due to superpotency; cannabidiol may help resolve the symptoms of pericarditis; FDA warn against certain wearables that claim to measure blood glucose. false full 189 de298da5-611e-422c-9301-125b5c9db773 MPR Weekly Dose 191 — First FDA-Approved Tx for Frostbite; New Eosinophilic Esophagitis Tx; Psychoactive Accepted for Review for PTSD; Novel Tx for Prurigo Nodularis; OTC Oximeter FDA approves first treatment for severe frostbite; Eohilia gains approval to treat eosinophilic esophagitis; MDMA accepted for Priority Review for PTSD; novel subcutaneous to be reviewed for prurigo nodularis, atopic dermatitis; OTC pulse oximeter device is cleared.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 16 Feb 2024 15:38:00 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com FDA approves first treatment for severe frostbite; Eohilia gains approval to treat eosinophilic esophagitis; MDMA accepted for Priority Review for PTSD; novel subcutaneous to be reviewed for prurigo nodularis, atopic dermatitis; OTC pulse oximeter device is cleared.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose 191 — First FDA-Approved Tx for Frostbite; New Eosinophilic Esophagitis Tx; Psychoactive Accepted for Review for PTSD; Novel Tx for Prurigo Nodularis; OTC Oximeter MPR Weekly Dose 00:14:06 FDA approves first treatment for severe frostbite; Eohilia gains approval to treat eosinophilic esophagitis; MDMA accepted for Priority Review for PTSD; novel subcutaneous to be reviewed for prurigo nodularis, atopic dermatitis; OTC pulse oximeter device is cleared. FDA approves first treatment for severe frostbite; Eohilia gains approval to treat eosinophilic esophagitis; MDMA accepted for Priority Review for PTSD; novel subcutaneous to be reviewed for prurigo nodularis, atopic dermatitis; OTC pulse oximeter device is cleared. false full 188 f5bf4c2e-0465-468b-a59c-8b46e94f9749 MPR Weekly Dose 190 — Nonopioid Pain Med; Dental Pain Management; Arexvy Review; Magrolimab Development Ended; Athlete's Foot Spray Recalled Combination intravenous formulation of acetaminophen and ibuprofen approved; recommendations from the ADA for dealing with acute dental pain; RSV vaccine under review for younger adult age group; Gilead call halt on investigational leukemia treatment hagrolimab; athlete foot spray recalled.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 9 Feb 2024 16:57:25 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com Combination intravenous formulation of acetaminophen and ibuprofen approved; recommendations from the ADA for dealing with acute dental pain; RSV vaccine under review for younger adult age group; Gilead call halt on investigational leukemia treatment hagrolimab; athlete foot spray recalled.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose 190 — Nonopioid Pain Med; Dental Pain Management; Arexvy Review; Magrolimab Development Ended; Athlete's Foot Spray Recalled MPR Weekly Dose 00:14:36 Combination intravenous formulation of acetaminophen and ibuprofen approved; recommendations from the ADA for dealing with acute dental pain; RSV vaccine under review for younger adult age group; Gilead call halt on investigational leukemia treatment hagrolimab; athlete foot spray recalled. Combination intravenous formulation of acetaminophen and ibuprofen approved; recommendations from the ADA for dealing with acute dental pain; RSV vaccine under review for younger adult age group; Gilead call halt on investigational leukemia treatment hagrolimab; athlete foot spray recalled. false full 187 e686fbef-3a72-4a44-acbd-5cd40e8c7a90 MPR Weekly Dose 189 — Alzheimer Drug Discontinued; New Acne Vulgaris Guidelines; Paxlovid Update; ADHD Drug Recall; Safety Alert for Copycat Eye Drops Biogen discontinue Alzheimer treatment; The American Academy of Dermatology issue new acne vulgaris management guidelines; Update for ongoing availability of Paxlovid; Narcolepsy/ADHD treatment recalled for containing wrong drug; FDA warn against copycat eye drop products


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 2 Feb 2024 15:39:42 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com Biogen discontinue Alzheimer treatment; The American Academy of Dermatology issue new acne vulgaris management guidelines; Update for ongoing availability of Paxlovid; Narcolepsy/ADHD treatment recalled for containing wrong drug; FDA warn against copycat eye drop products


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose 189 — Alzheimer Drug Discontinued; New Acne Vulgaris Guidelines; Paxlovid Update; ADHD Drug Recall; Safety Alert for Copycat Eye Drops MPR Weekly Dose 00:12:30 Biogen discontinue Alzheimer treatment; The American Academy of Dermatology issue new acne vulgaris management guidelines; Update for ongoing availability of Paxlovid; Narcolepsy/ADHD treatment recalled for containing wrong drug; FDA warn against copycat eye drop products Biogen discontinue Alzheimer treatment; The American Academy of Dermatology issue new acne vulgaris management guidelines; Update for ongoing availability of Paxlovid; Narcolepsy/ADHD treatment recalled for containing wrong drug; FDA warn against copycat eye drop products false full 186 87c74ab0-428a-43b7-8639-997da70eac65 MPR Weekly Dose 188 — Labeling Changes for T-Cell Immunotherapies; Novel Opioid Therapy; Boxed Warning for Prolia; At-Home Insemination Kit; Novel Rescue Inhaler T-cell malignancies prompt label changes for certain T-cell immunotherapies; Novel opioid provides in-built protection against overdose; Hypocalcemia risk with Prolia; At-Home semen insemination kit cleared; New asthma rescued medicine approved


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 26 Jan 2024 15:31:07 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com T-cell malignancies prompt label changes for certain T-cell immunotherapies; Novel opioid provides in-built protection against overdose; Hypocalcemia risk with Prolia; At-Home semen insemination kit cleared; New asthma rescued medicine approved


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose 188 — Labeling Changes for T-Cell Immunotherapies; Novel Opioid Therapy; Boxed Warning for Prolia; At-Home Insemination Kit; Novel Rescue Inhaler MPR Weekly Dose 00:12:56 T-cell malignancies prompt label changes for certain T-cell immunotherapies; Novel opioid provides in-built protection against overdose; Hypocalcemia risk with Prolia; At-Home semen insemination kit cleared; New asthma rescued medicine approved T-cell malignancies prompt label changes for certain T-cell immunotherapies; Novel opioid provides in-built protection against overdose; Hypocalcemia risk with Prolia; At-Home semen insemination kit cleared; New asthma rescued medicine approved false full 185 f706d5ce-0c2f-4651-bc45-7caaca0e431c MPR Weekly Dose 187 — Gene Therapy for TDT; HyQvia Approved for CIDP; Handheld Skin Assessing Device; Vertebral Strength Device for Low-Bone Mass; Narcan Shelf-Life Extended Gene therapy approved for beta thalassemia; treatment for preventing of chronic inflammatory demyelinating polyneuropathy relapse; device to aid dermatologist referrals; vertebral strength device for low-bone mass; Narcan shelf-life extension


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 19 Jan 2024 15:44:06 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com Gene therapy approved for beta thalassemia; treatment for preventing of chronic inflammatory demyelinating polyneuropathy relapse; device to aid dermatologist referrals; vertebral strength device for low-bone mass; Narcan shelf-life extension


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose 187 — Gene Therapy for TDT; HyQvia Approved for CIDP; Handheld Skin Assessing Device; Vertebral Strength Device for Low-Bone Mass; Narcan Shelf-Life Extended MPR Weekly Dose 00:13:31 Gene therapy approved for beta thalassemia; treatment for preventing of chronic inflammatory demyelinating polyneuropathy relapse; device to aid dermatologist referrals; vertebral strength device for low-bone mass; Narcan shelf-life extension Gene therapy approved for beta thalassemia; treatment for preventing of chronic inflammatory demyelinating polyneuropathy relapse; device to aid dermatologist referrals; vertebral strength device for low-bone mass; Narcan shelf-life extension false full 184 28887bcf-053f-4b5b-8ac9-0616d0244216 MPR Weekly Dose 186 — Diabetes Tx Suicidal Ideation Link Examined; Topical Molluscum Contagiosum Tx; Superpotent IV Bags Recalled; Syphilis Treatment Update; Menstrual Blood to Measure HbA1c Researchers examine link between diabetes, obesity treatments and suicidal ideation; topical treatment for molluscum contagiosum; IV bags recalled following discovery that they may contain twice as much of the labeled drug; update on the penicillin shortage; newly cleared test measures HbA1c from menstrual blood.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 12 Jan 2024 14:49:10 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com Researchers examine link between diabetes, obesity treatments and suicidal ideation; topical treatment for molluscum contagiosum; IV bags recalled following discovery that they may contain twice as much of the labeled drug; update on the penicillin shortage; newly cleared test measures HbA1c from menstrual blood.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose 186 — Diabetes Tx Suicidal Ideation Link Examined; Topical Molluscum Contagiosum Tx; Superpotent IV Bags Recalled; Syphilis Treatment Update; Menstrual Blood to Measure HbA1c MPR Weekly Dose 00:14:58 Researchers examine link between diabetes, obesity treatments and suicidal ideation; topical treatment for molluscum contagiosum; IV bags recalled following discovery that they may contain twice as much of the labeled drug; update on the penicillin shortage; newly cleared test measures HbA1c from menstrual blood. Researchers examine link between diabetes, obesity treatments and suicidal ideation; topical treatment for molluscum contagiosum; IV bags recalled following discovery that they may contain twice as much of the labeled drug; update on the penicillin shortage; newly cleared test measures HbA1c from menstrual blood. false full 183 4df3767c-e596-4399-8996-aa9c893ab71e MPR Weekly Dose 185 — Best Diets for 2024; Counterfeit Ozempic; Myasthenia Gravis Tx Approved; Herpes False Positive Test Results; Promethazine Hydrochloride Safety Concerns An expert panel rank the 30 best diets for 2024; Counterfeit Ozempic on the rise; Myasthenia gravis drug approved; Herpes tests may produce false positives; Safety concerns over IV promethazine hydrochloride.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 5 Jan 2024 15:47:15 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com An expert panel rank the 30 best diets for 2024; Counterfeit Ozempic on the rise; Myasthenia gravis drug approved; Herpes tests may produce false positives; Safety concerns over IV promethazine hydrochloride.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose 185 — Best Diets for 2024; Counterfeit Ozempic; Myasthenia Gravis Tx Approved; Herpes False Positive Test Results; Promethazine Hydrochloride Safety Concerns MPR Weekly Dose 00:12:27 An expert panel rank the 30 best diets for 2024; Counterfeit Ozempic on the rise; Myasthenia gravis drug approved; Herpes tests may produce false positives; Safety concerns over IV promethazine hydrochloride.  An expert panel rank the 30 best diets for 2024; Counterfeit Ozempic on the rise; Myasthenia gravis drug approved; Herpes tests may produce false positives; Safety concerns over IV promethazine hydrochloride.  false full 182 85896164-875d-416a-bd58-a4c271ac65dd MPR Weekly Dose 184 — Gel Approved for EB Wounds; 21-Valent Pneumococcal Vaccine; Prescription Game Therapy for ADHD; HIV-Protecting Vaginal Insert; Multiple Food Allergy Drug Topical gel approved to treat partial thickness wounds in epidermolysis bullosa; Priority Review given to 21-valent pneumococcal conjugate vaccine; sensory and motor stimuli video game for ADHD gains expanded age approval; on-demand HIV prevention for women; multiple food allergy drug


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Thu, 21 Dec 2023 22:32:00 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com Topical gel approved to treat partial thickness wounds in epidermolysis bullosa; Priority Review given to 21-valent pneumococcal conjugate vaccine; sensory and motor stimuli video game for ADHD gains expanded age approval; on-demand HIV prevention for women; multiple food allergy drug


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose 184 — Gel Approved for EB Wounds; 21-Valent Pneumococcal Vaccine; Prescription Game Therapy for ADHD; HIV-Protecting Vaginal Insert; Multiple Food Allergy Drug MPR Weekly Dose 00:16:23 Topical gel approved to treat partial thickness wounds in epidermolysis bullosa; Priority Review given to 21-valent pneumococcal conjugate vaccine; sensory and motor stimuli video game for ADHD gains expanded age approval; on-demand HIV prevention for women; multiple food allergy drug Topical gel approved to treat partial thickness wounds in epidermolysis bullosa; Priority Review given to 21-valent pneumococcal conjugate vaccine; sensory and motor stimuli video game for ADHD gains expanded age approval; on-demand HIV prevention for women; multiple food allergy drug false full 181 a60159b5-357c-4e38-9548-af81c0470c99 MPR Weekly Dose 183 — Updated Diabetes Guidelines; Novel Blood Collection Device; Postpartum Depression Tx; Male Birth Control Study; Approval Sought for Psychoactive Drug The ADA release their new guidance for the management of diabetes 2024; a new blood collection device obtains lab-quality samples using a the finger; novel treatment for postpartum depression becomes available; a study for a male birth control pill begins; and a Public Benefit Corporation seeks approval for an MDMA-assisted therapy.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 15 Dec 2023 16:36:05 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com The ADA release their new guidance for the management of diabetes 2024; a new blood collection device obtains lab-quality samples using a the finger; novel treatment for postpartum depression becomes available; a study for a male birth control pill begins; and a Public Benefit Corporation seeks approval for an MDMA-assisted therapy.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose 183 — Updated Diabetes Guidelines; Novel Blood Collection Device; Postpartum Depression Tx; Male Birth Control Study; Approval Sought for Psychoactive Drug MPR Weekly Dose 00:13:30 The ADA release their new guidance for the management of diabetes 2024; a new blood collection device obtains lab-quality samples using a the finger; novel treatment for postpartum depression becomes available; a study for a male birth control pill begins; and a Public Benefit Corporation seeks approval for an MDMA-assisted therapy.   The ADA release their new guidance for the management of diabetes 2024; a new blood collection device obtains lab-quality samples using a the finger; novel treatment for postpartum depression becomes available; a study for a male birth control pill begins; and a Public Benefit Corporation seeks approval for an MDMA-assisted therapy.   false full 180 e966250c-319b-4326-bf65-73d3408832cd MPR Weekly Dose Podcast #182 — Novel Weight Loss Tx; Safety Risks for Compounded Semaglutide; Fabhalta Approved for PNH; At-Home Insemination Kit; Sleep Apnea Device Cleared Novel weight loss treatment now available in pharmacies; Novo Nordisk warns about the risks of compounded semaglutide; treatment approved for paroxysmal nocturnal hemoglobinuria; over-the-counter insemination kit cleared by the FDA.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 8 Dec 2023 17:15:56 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com Novel weight loss treatment now available in pharmacies; Novo Nordisk warns about the risks of compounded semaglutide; treatment approved for paroxysmal nocturnal hemoglobinuria; over-the-counter insemination kit cleared by the FDA.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose Podcast #182 — Novel Weight Loss Tx; Safety Risks for Compounded Semaglutide; Fabhalta Approved for PNH; At-Home Insemination Kit; Sleep Apnea Device Cleared MPR Weekly Dose 00:14:57 Novel weight loss treatment now available in pharmacies; Novo Nordisk warns about the risks of compounded semaglutide; treatment approved for paroxysmal nocturnal hemoglobinuria; over-the-counter insemination kit cleared by the FDA.   Novel weight loss treatment now available in pharmacies; Novo Nordisk warns about the risks of compounded semaglutide; treatment approved for paroxysmal nocturnal hemoglobinuria; over-the-counter insemination kit cleared by the FDA.   false full 179 b65814d2-92b4-42de-9976-d966a65a5095 MPR Weekly Dose Podcast #181 — Serious Reactions to Seizure Treatments; Desmoid Tumor Tx; Secondary CAR T-Cell Malignancies; Immunosuppressive Recall; CPAP Machine Issues Safety alert issued for serious reactions to certain seizure drugs; Drug approved to treat a rare form of tumor; T-cell malignancies reported with cell immunotherapies; organ transplant rejection treatment recalled; CPAP machine associated with reports of burns and fires.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 1 Dec 2023 15:41:15 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com Safety alert issued for serious reactions to certain seizure drugs; Drug approved to treat a rare form of tumor; T-cell malignancies reported with cell immunotherapies; organ transplant rejection treatment recalled; CPAP machine associated with reports of burns and fires.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose Podcast #181 — Serious Reactions to Seizure Treatments; Desmoid Tumor Tx; Secondary CAR T-Cell Malignancies; Immunosuppressive Recall; CPAP Machine Issues MPR Weekly Dose 00:14:35 Safety alert issued for serious reactions to certain seizure drugs; Drug approved to treat a rare form of tumor; T-cell malignancies reported with cell immunotherapies; organ transplant rejection treatment recalled; CPAP machine associated with reports of burns and fires. Safety alert issued for serious reactions to certain seizure drugs; Drug approved to treat a rare form of tumor; T-cell malignancies reported with cell immunotherapies; organ transplant rejection treatment recalled; CPAP machine associated with reports of burns and fires. false full 178 a49f86da-2dbd-4395-9e3b-d50149299c97 MPR Weekly Dose Podcast #180 — Chikungunya Vaccine; Amazon FDA Warning; At-Home STD Test; Lymphoma Drug Withdrawn; Antimicrobial Catheter Lock Solution for CRBSI First chikungunya vaccine approved; FDA send warning letter to Amazon about ophthalmic products; at-home STD test cleared; Bayer withdraw lymphoma drug; and a combo treatment to reduce catheter-related bloodstream infections is approved.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 17 Nov 2023 14:16:50 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com First chikungunya vaccine approved; FDA send warning letter to Amazon about ophthalmic products; at-home STD test cleared; Bayer withdraw lymphoma drug; and a combo treatment to reduce catheter-related bloodstream infections is approved.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose Podcast #180 — Chikungunya Vaccine; Amazon FDA Warning; At-Home STD Test; Lymphoma Drug Withdrawn; Antimicrobial Catheter Lock Solution for CRBSI MPR Weekly Dose 00:13:56 First chikungunya vaccine approved; FDA send warning letter to Amazon about ophthalmic products; at-home STD test cleared; Bayer withdraw lymphoma drug; and a combo treatment to reduce catheter-related bloodstream infections is approved. First chikungunya vaccine approved; FDA send warning letter to Amazon about ophthalmic products; at-home STD test cleared; Bayer withdraw lymphoma drug; and a combo treatment to reduce catheter-related bloodstream infections is approved. false full 177 1a705467-5dbd-4d4e-be8d-3aea8c7e5fae MPR Weekly Dose Podcast #179 — Weight Management Tx; Levemir Discontinued; Renal Denervation System Approved; Gene Therapy Fasted Tracked; Hidden Drugs in Glucose Supplement New weight management approved; Novo Nordisk discontinue Levemir; adjunctive system for hypertension patients; frontotemporal dementia treatment given Fast Track designation; and the FDA advise against use of glucose supplement.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 10 Nov 2023 17:51:49 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com New weight management approved; Novo Nordisk discontinue Levemir; adjunctive system for hypertension patients; frontotemporal dementia treatment given Fast Track designation; and the FDA advise against use of glucose supplement.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose Podcast #179 — Weight Management Tx; Levemir Discontinued; Renal Denervation System Approved; Gene Therapy Fasted Tracked; Hidden Drugs in Glucose Supplement MPR Weekly Dose 00:12:43 New weight management approved; Novo Nordisk discontinue Levemir; adjunctive system for hypertension patients; frontotemporal dementia treatment given Fast Track designation; and the FDA advise against use of glucose supplement. New weight management approved; Novo Nordisk discontinue Levemir; adjunctive system for hypertension patients; frontotemporal dementia treatment given Fast Track designation; and the FDA advise against use of glucose supplement. false full 176 b958cbbb-862a-42fe-a537-1efbeafbeea0 MPR Weekly Dose Podcast #178 — FDA Flags Eye Drops; Ped Alert for COVID-19 Vaccine; Novel Heartburn Tx; Biosimilar to Stelara Approved; Anti-Fentanyl Monoclonal Antibody FDA urge immediate discontinuation for eye drop products; safety alert issued for the pediatric Moderna COVID-19 vaccine; novel heartburn medicine approved; Stelara biosimilar approved; and an antibody to prevent fentanyl overdose gets fast tracked.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 3 Nov 2023 14:45:05 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com FDA urge immediate discontinuation for eye drop products; safety alert issued for the pediatric Moderna COVID-19 vaccine; novel heartburn medicine approved; Stelara biosimilar approved; and an antibody to prevent fentanyl overdose gets fast tracked.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose Podcast #178 — FDA Flags Eye Drops; Ped Alert for COVID-19 Vaccine; Novel Heartburn Tx; Biosimilar to Stelara Approved; Anti-Fentanyl Monoclonal Antibody MPR Weekly Dose 00:11:52 FDA urge immediate discontinuation for eye drop products; safety alert issued for the pediatric Moderna COVID-19 vaccine; novel heartburn medicine approved; Stelara biosimilar approved; and an antibody to prevent fentanyl overdose gets fast tracked. FDA urge immediate discontinuation for eye drop products; safety alert issued for the pediatric Moderna COVID-19 vaccine; novel heartburn medicine approved; Stelara biosimilar approved; and an antibody to prevent fentanyl overdose gets fast tracked. false full 175 5601a4ee-3198-4858-954e-9f6bad292842 MPR Weekly Dose Podcast 177 — Penbraya Approved; COVID-19 Therapy Shelf-Life Extended; New Formulation for IBD Tx; Self-Admin FluMist; Nonopioid Combo for Postop Pain New pentavalent meningococcal vaccine approved; Gohibic's shelf-life extended by 6 months; maintenance treatment approved for adults with moderately to severely active ulcerative colitis or Crohn disease; self-administered option for FluMist Quadrivalent accepted for review; intravenous combo formulation of acetaminophen and ibuprofen approved for postoperative pain.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 27 Oct 2023 14:13:21 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com New pentavalent meningococcal vaccine approved; Gohibic's shelf-life extended by 6 months; maintenance treatment approved for adults with moderately to severely active ulcerative colitis or Crohn disease; self-administered option for FluMist Quadrivalent accepted for review; intravenous combo formulation of acetaminophen and ibuprofen approved for postoperative pain.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose Podcast 177 — Penbraya Approved; COVID-19 Therapy Shelf-Life Extended; New Formulation for IBD Tx; Self-Admin FluMist; Nonopioid Combo for Postop Pain MPR Weekly Dose 00:11:32 New pentavalent meningococcal vaccine approved; Gohibic's shelf-life extended by 6 months; maintenance treatment approved for adults with moderately to severely active ulcerative colitis or Crohn disease; self-administered option for FluMist Quadrivalent accepted for review; intravenous combo formulation of acetaminophen and ibuprofen approved for postoperative pain. New pentavalent meningococcal vaccine approved; Gohibic's shelf-life extended by 6 months; maintenance treatment approved for adults with moderately to severely active ulcerative colitis or Crohn disease; self-administered option for FluMist Quadrivalent accepted for review; intravenous combo formulation of acetaminophen and ibuprofen approved for postoperative pain. false full 174 4fcdfc94-8a0c-4760-ba02-03a2a7a53e79 MPR Weekly Dose 176 — Novel MDD Tx; Panel Votes Against ALS Therapy; Preservation-Free Iyuzeh; RSV Vaccine Recommended for During Pregnancy; Investigative Tx Shows Promise in FCS FDA approves a novel treatment for major depressive disorder; vote taken on stem cell therapy for ALS; preservation-free Iyuzeh now available; CDC recommends RSV vaccine for during pregnancy; investigational treatment shows promise in familial chylomicronemia syndrome.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 29 Sep 2023 12:50:40 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com FDA approves a novel treatment for major depressive disorder; vote taken on stem cell therapy for ALS; preservation-free Iyuzeh now available; CDC recommends RSV vaccine for during pregnancy; investigational treatment shows promise in familial chylomicronemia syndrome.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose 176 — Novel MDD Tx; Panel Votes Against ALS Therapy; Preservation-Free Iyuzeh; RSV Vaccine Recommended for During Pregnancy; Investigative Tx Shows Promise in FCS MPR Weekly Dose 00:13:41 FDA approves a novel treatment for major depressive disorder; vote taken on stem cell therapy for ALS; preservation-free Iyuzeh now available; CDC recommends RSV vaccine for during pregnancy; investigational treatment shows promise in familial chylomicronemia syndrome. FDA approves a novel treatment for major depressive disorder; vote taken on stem cell therapy for ALS; preservation-free Iyuzeh now available; CDC recommends RSV vaccine for during pregnancy; investigational treatment shows promise in familial chylomicronemia syndrome. false full 173 419f83e1-e44f-4c51-a6aa-4bdec16b14a3 MPR Weekly Dose 175 — Xacduro Now Available; Epinephrine Application Denied; Flu Vaccine Efficacy; New Dosing Regimen for Talicia; Change to Generic Tacrolimus Bacterial pneumonia treatment now available; FDA deny proposed anaphylaxis treatment; Results on flu vaccine efficacy; More flexible dosing for Talicia; Change in the therapeutic equivalence for organ rejection drug generic.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 22 Sep 2023 16:30:23 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com Bacterial pneumonia treatment now available; FDA deny proposed anaphylaxis treatment; Results on flu vaccine efficacy; More flexible dosing for Talicia; Change in the therapeutic equivalence for organ rejection drug generic.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose 175 — Xacduro Now Available; Epinephrine Application Denied; Flu Vaccine Efficacy; New Dosing Regimen for Talicia; Change to Generic Tacrolimus MPR Weekly Dose 00:13:05 Bacterial pneumonia treatment now available; FDA deny proposed anaphylaxis treatment; Results on flu vaccine efficacy; More flexible dosing for Talicia; Change in the therapeutic equivalence for organ rejection drug generic.  Bacterial pneumonia treatment now available; FDA deny proposed anaphylaxis treatment; Results on flu vaccine efficacy; More flexible dosing for Talicia; Change in the therapeutic equivalence for organ rejection drug generic.  false full 172 4432b91c-10a2-4faf-a1a3-6222a2f9df38 MPR Weekly Dose 174 — Updated COVID-19 Vaccines; Px Drop for Dry Eye Disease; Crohn Disease Tx Trial; Lotronex Update; FDA Cracks Down on Unapproved Eye Products The FDA and CDC greenlight updated COVID-19; prescription drug for dry eye disease now available; head-to-head study comparing Skyrizi to Stelara for Crohn disease; the REMS program has been updated for IBS treatment Lotronex; and the FDA cracks down on companies selling unnaproved eye products.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 15 Sep 2023 21:56:46 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com The FDA and CDC greenlight updated COVID-19; prescription drug for dry eye disease now available; head-to-head study comparing Skyrizi to Stelara for Crohn disease; the REMS program has been updated for IBS treatment Lotronex; and the FDA cracks down on companies selling unnaproved eye products.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose 174 — Updated COVID-19 Vaccines; Px Drop for Dry Eye Disease; Crohn Disease Tx Trial; Lotronex Update; FDA Cracks Down on Unapproved Eye Products MPR Weekly Dose 00:12:13 The FDA and CDC greenlight updated COVID-19; prescription drug for dry eye disease now available; head-to-head study comparing Skyrizi to Stelara for Crohn disease; the REMS program has been updated for IBS treatment Lotronex; and the FDA cracks down on companies selling unnaproved eye products. The FDA and CDC greenlight updated COVID-19; prescription drug for dry eye disease now available; head-to-head study comparing Skyrizi to Stelara for Crohn disease; the REMS program has been updated for IBS treatment Lotronex; and the FDA cracks down on companies selling unnaproved eye products. false full 171 6acf7aa8-de6a-440d-8450-42a3c0958813 MPR Weekly Dose Podcast #173 — Talking vaccines with Dr. Abdul-Mutakabbir With fall on the horizon, MPR sat down with Assistant Professor of Clinical Pharmacy at the University of California San Diego, Dr. Abdul-Mutakabbir. Our wide ranging talk covers the updated COVID-19, flu and RSV vaccines. We also discuss vaccine hesitancy, health equity and representation in medicine.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Wed, 6 Sep 2023 14:46:38 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com With fall on the horizon, MPR sat down with Assistant Professor of Clinical Pharmacy at the University of California San Diego, Dr. Abdul-Mutakabbir. Our wide ranging talk covers the updated COVID-19, flu and RSV vaccines. We also discuss vaccine hesitancy, health equity and representation in medicine.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose Podcast #173 — Talking vaccines with Dr. Abdul-Mutakabbir MPR Weekly Dose 00:30:17 With fall on the horizon, MPR sat down with Assistant Professor of Clinical Pharmacy at the University of California San Diego, Dr. Abdul-Mutakabbir. Our wide ranging talk covers the updated COVID-19, flu and RSV vaccines. We also discuss vaccine hesitancy, health equity and representation in medicine. With fall on the horizon, MPR sat down with Assistant Professor of Clinical Pharmacy at the University of California San Diego, Dr. Abdul-Mutakabbir. Our wide ranging talk covers the updated COVID-19, flu and RSV vaccines. We also discuss vaccine hesitancy, health equity and representation in medicine. false full 170 159d2a29-048f-45f6-9e00-f7a42bf6d692 MPR Weekly Dose 171 — Vaccine Guidance for Flu Season; PrEP Recommendation; Maternal RSV Vaccine; Latest on Updated COVID Vaccine; CHAPLE Disease Tx Approved New vaccine guidelines issued for the 2023-2024 flu season; USPSTF make recommendations on PrEP prescribing; maternal RSV vaccine; updated COVID vaccine shows strong immune response; new treatment approved for rare immune disease.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 25 Aug 2023 14:11:32 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com New vaccine guidelines issued for the 2023-2024 flu season; USPSTF make recommendations on PrEP prescribing; maternal RSV vaccine; updated COVID vaccine shows strong immune response; new treatment approved for rare immune disease.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose 171 — Vaccine Guidance for Flu Season; PrEP Recommendation; Maternal RSV Vaccine; Latest on Updated COVID Vaccine; CHAPLE Disease Tx Approved MPR Weekly Dose 00:18:15 New vaccine guidelines issued for the 2023-2024 flu season; USPSTF make recommendations on PrEP prescribing; maternal RSV vaccine; updated COVID vaccine shows strong immune response; new treatment approved for rare immune disease. New vaccine guidelines issued for the 2023-2024 flu season; USPSTF make recommendations on PrEP prescribing; maternal RSV vaccine; updated COVID vaccine shows strong immune response; new treatment approved for rare immune disease. false full 169 ca3ac1dd-41a1-4f5a-80bd-bb77870068b1 MPR Weekly Dose 170 — Warning Alert for Tests; Arexy Available for Older Adults; Sohonos and Hezato Kit Approved; Statement on GLP-1 Use Before Endoscopy FDA issue recommendations to avoid Company's tests; RSV vaccine now available for older adults; New treatments approved for fibrodysplasia ossificans progressiva and for those with metastatic uveal melanoma with unresectable hepatic metastases; and gastrointestinal associations issue a statement regarding GLP-1 use prior to upper gastrointestinal endoscopy.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 18 Aug 2023 13:59:48 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com FDA issue recommendations to avoid Company's tests; RSV vaccine now available for older adults; New treatments approved for fibrodysplasia ossificans progressiva and for those with metastatic uveal melanoma with unresectable hepatic metastases; and gastrointestinal associations issue a statement regarding GLP-1 use prior to upper gastrointestinal endoscopy.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose 170 — Warning Alert for Tests; Arexy Available for Older Adults; Sohonos and Hezato Kit Approved; Statement on GLP-1 Use Before Endoscopy MPR Weekly Dose 00:15:34 FDA issue recommendations to avoid Company's tests; RSV vaccine now available for older adults; New treatments approved for fibrodysplasia ossificans progressiva and for those with metastatic uveal melanoma with unresectable hepatic metastases; and gastrointestinal associations issue a statement regarding GLP-1 use prior to upper gastrointestinal endoscopy. FDA issue recommendations to avoid Company's tests; RSV vaccine now available for older adults; New treatments approved for fibrodysplasia ossificans progressiva and for those with metastatic uveal melanoma with unresectable hepatic metastases; and gastrointestinal associations issue a statement regarding GLP-1 use prior to upper gastrointestinal endoscopy. false full 168 967ad093-dc1d-47ef-93aa-435b7749903f MPR Weekly Dose 169 — New Postpartum Depression Tx; Generic Naloxone Spray; Weight Management Drug Shows Heart Benefits; CDC Recommends RSV Vaccine; SAD Tx Oral postpartum depression treatment approved; generic naloxone nasal spray now available; weight management drug shows promise in reducing major cardiovascular events; CDC recommends routine use of RSV vaccine; social anxiety disorder spray shows potential.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 11 Aug 2023 14:21:32 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com Oral postpartum depression treatment approved; generic naloxone nasal spray now available; weight management drug shows promise in reducing major cardiovascular events; CDC recommends routine use of RSV vaccine; social anxiety disorder spray shows potential.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose 169 — New Postpartum Depression Tx; Generic Naloxone Spray; Weight Management Drug Shows Heart Benefits; CDC Recommends RSV Vaccine; SAD Tx MPR Weekly Dose 00:14:09 Oral postpartum depression treatment approved; generic naloxone nasal spray now available; weight management drug shows promise in reducing major cardiovascular events; CDC recommends routine use of RSV vaccine; social anxiety disorder spray shows potential. Oral postpartum depression treatment approved; generic naloxone nasal spray now available; weight management drug shows promise in reducing major cardiovascular events; CDC recommends routine use of RSV vaccine; social anxiety disorder spray shows potential. false full 167 eaab5122-1ba6-47c8-942b-1ecedd14d18c MPR Weekly Dose 168 — Prescription stimulant shortage; Electronic transfer of controlled substances; Oral contraceptive recall; Ebola vaccine; OTC opioid overdose approval Drug agencies issue letter addressing the prescription stimulant shortage; electronic transfer of controlled substances given green light; oral contraceptives recalled; expanded indication for Ebola vaccine; and a new over-the-counter opioid overdose treatment.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 4 Aug 2023 13:18:47 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com Drug agencies issue letter addressing the prescription stimulant shortage; electronic transfer of controlled substances given green light; oral contraceptives recalled; expanded indication for Ebola vaccine; and a new over-the-counter opioid overdose treatment.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose 168 — Prescription stimulant shortage; Electronic transfer of controlled substances; Oral contraceptive recall; Ebola vaccine; OTC opioid overdose approval MPR Weekly Dose 00:11:57 Drug agencies issue letter addressing the prescription stimulant shortage; electronic transfer of controlled substances given green light; oral contraceptives recalled; expanded indication for Ebola vaccine; and a new over-the-counter opioid overdose treatment. Drug agencies issue letter addressing the prescription stimulant shortage; electronic transfer of controlled substances given green light; oral contraceptives recalled; expanded indication for Ebola vaccine; and a new over-the-counter opioid overdose treatment. false full 166 20b7be80-24d8-4776-a195-7e37bfd1064f MPR Weekly Dose 167 — Molluscum contagiosum Tx approved; Xdemvy and Balfaxar approved; Weight loss drug in short supply; Cervical pessary assessed for reducing preterm birth Single-use application to treat the molluscum contagiosum approved; Xdermvy has gotten the green light to treat demodex blepharitis; warfarin reversal treatment for use in urgent surgery; weight loss drug in short supply through 2023; cervical pessary assessed for reducing preterm birth.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 28 Jul 2023 13:38:05 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com Single-use application to treat the molluscum contagiosum approved; Xdermvy has gotten the green light to treat demodex blepharitis; warfarin reversal treatment for use in urgent surgery; weight loss drug in short supply through 2023; cervical pessary assessed for reducing preterm birth.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose 167 — Molluscum contagiosum Tx approved; Xdemvy and Balfaxar approved; Weight loss drug in short supply; Cervical pessary assessed for reducing preterm birth MPR Weekly Dose 00:12:53 Single-use application to treat the molluscum contagiosum approved; Xdermvy has gotten the green light to treat demodex blepharitis; warfarin reversal treatment for use in urgent surgery; weight loss drug in short supply through 2023; cervical pessary assessed for reducing preterm birth. Single-use application to treat the molluscum contagiosum approved; Xdermvy has gotten the green light to treat demodex blepharitis; warfarin reversal treatment for use in urgent surgery; weight loss drug in short supply through 2023; cervical pessary assessed for reducing preterm birth. false full 165 4b44508f-d301-47f2-8230-1a667be2b53e MPR Weekly Dose 166 — Potential Alzheimer drug may slow disease; RSV Tx for neonates, toddlers; Veklury and Brenzavvy approvals expanded; Blood test false negatives Study supports the benefit of potential new Alzheimer drug; RSV treatment approved for neonates and infants; Veklury approval expanded; a blood test used to diagnose life-threatening heart muscle injuries has been recalled; Brenzavvy available for adults.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 21 Jul 2023 13:21:21 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com Study supports the benefit of potential new Alzheimer drug; RSV treatment approved for neonates and infants; Veklury approval expanded; a blood test used to diagnose life-threatening heart muscle injuries has been recalled; Brenzavvy available for adults.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose 166 — Potential Alzheimer drug may slow disease; RSV Tx for neonates, toddlers; Veklury and Brenzavvy approvals expanded; Blood test false negatives MPR Weekly Dose 00:15:06 Study supports the benefit of potential new Alzheimer drug; RSV treatment approved for neonates and infants; Veklury approval expanded; a blood test used to diagnose life-threatening heart muscle injuries has been recalled; Brenzavvy available for adults. Study supports the benefit of potential new Alzheimer drug; RSV treatment approved for neonates and infants; Veklury approval expanded; a blood test used to diagnose life-threatening heart muscle injuries has been recalled; Brenzavvy available for adults. false full 164 14232624-6d05-48a9-9a15-4fdbbdeadb2f MPR Weekly Dose 165 — OTC Birth Control Pill; Heart Tx Gains Expanded Approval; Gavreto Indication Withdrawn; Albuterol Inhaler Recall; Paclitaxel-Coated Device Analysis First over-the-counter birth control pill; expanded approval for Leqvio; Gavreto has an indication withdrawn; batches of Albuterol inhalers recalled; results from analysis of paclitaxel-coated devices.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 14 Jul 2023 14:08:19 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com First over-the-counter birth control pill; expanded approval for Leqvio; Gavreto has an indication withdrawn; batches of Albuterol inhalers recalled; results from analysis of paclitaxel-coated devices.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose 165 — OTC Birth Control Pill; Heart Tx Gains Expanded Approval; Gavreto Indication Withdrawn; Albuterol Inhaler Recall; Paclitaxel-Coated Device Analysis MPR Weekly Dose 00:11:14 First over-the-counter birth control pill; expanded approval for Leqvio; Gavreto has an indication withdrawn; batches of Albuterol inhalers recalled; results from analysis of paclitaxel-coated devices. First over-the-counter birth control pill; expanded approval for Leqvio; Gavreto has an indication withdrawn; batches of Albuterol inhalers recalled; results from analysis of paclitaxel-coated devices. false full 163 45446d1e-147c-40b7-b7af-6dd71862f162 MPR Weekly Dose 164 — Approvals for Alopecia, Generalized Myasthenia Gravis, and Type 1 Diabetes; Colonoscopy Prep; FDA Deny Application for Pre-Cirrhotic Fibrosis Tx New approvals for alopecia, generalized myasthenia gravis and type 1 diabetes; New colonoscopy prep option; And FDA denies application for pre-chirrotic fibrosis due to NASH.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 30 Jun 2023 13:59:48 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com New approvals for alopecia, generalized myasthenia gravis and type 1 diabetes; New colonoscopy prep option; And FDA denies application for pre-chirrotic fibrosis due to NASH.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose 164 — Approvals for Alopecia, Generalized Myasthenia Gravis, and Type 1 Diabetes; Colonoscopy Prep; FDA Deny Application for Pre-Cirrhotic Fibrosis Tx MPR Weekly Dose 00:13:02 New approvals for alopecia, generalized myasthenia gravis and type 1 diabetes; New colonoscopy prep option; And FDA denies application for pre-chirrotic fibrosis due to NASH. New approvals for alopecia, generalized myasthenia gravis and type 1 diabetes; New colonoscopy prep option; And FDA denies application for pre-chirrotic fibrosis due to NASH. false full 162 50b5abdb-aa2d-40b1-9226-099824490c58 MPR Weekly Dose 163 — COVID-19 Vaccine Authorization Revoked; Injectafer Approved; Lumryz Single Dose for Narcolepsy; Vowst for C. Difficile; Approval for CMV Disease Prevention FDA revoke Emergency Use Authorization for a COVID-19 vaccine; New approval for treatment of iron deficiency in patients with heart failure; Lumryz now available for excessive daytime sleepiness; Vowst approved for C. difficile infection; Prevymis approved for prophylaxis of CMV disease in adult kidney transplant recipients.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Thu, 8 Jun 2023 22:20:37 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com FDA revoke Emergency Use Authorization for a COVID-19 vaccine; New approval for treatment of iron deficiency in patients with heart failure; Lumryz now available for excessive daytime sleepiness; Vowst approved for C. difficile infection; Prevymis approved for prophylaxis of CMV disease in adult kidney transplant recipients.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose 163 — COVID-19 Vaccine Authorization Revoked; Injectafer Approved; Lumryz Single Dose for Narcolepsy; Vowst for C. Difficile; Approval for CMV Disease Prevention MPR Weekly Dose 00:13:23 FDA revoke Emergency Use Authorization for a COVID-19 vaccine; New approval for treatment of iron deficiency in patients with heart failure; Lumryz now available for excessive daytime sleepiness; Vowst approved for C. difficile infection; Prevymis approved for prophylaxis of CMV disease in adult kidney transplant recipients. FDA revoke Emergency Use Authorization for a COVID-19 vaccine; New approval for treatment of iron deficiency in patients with heart failure; Lumryz now available for excessive daytime sleepiness; Vowst approved for C. difficile infection; Prevymis approved for prophylaxis of CMV disease in adult kidney transplant recipients. false full 161 bc9dff8e-476f-43e7-a3c8-1e01e719b962 MPR Weekly Dose 162 — LRTD Vaccine; Novel Heart Failure Tx; Compounded Semaglutide Concerns; Opioid Use Disorder Tx; Positive Results for Motion Sickness Tx New vaccine for lower respiratory tract disease; A new treatment for heart failure; Concerns over some compounded semaglutide; New opioid use disorder treatment; Motion sickness Tx shows promise.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 2 Jun 2023 14:36:50 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com New vaccine for lower respiratory tract disease; A new treatment for heart failure; Concerns over some compounded semaglutide; New opioid use disorder treatment; Motion sickness Tx shows promise.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose 162 — LRTD Vaccine; Novel Heart Failure Tx; Compounded Semaglutide Concerns; Opioid Use Disorder Tx; Positive Results for Motion Sickness Tx MPR Weekly Dose 00:12:48 New vaccine for lower respiratory tract disease; A new treatment for heart failure; Concerns over some compounded semaglutide; New opioid use disorder treatment; Motion sickness Tx shows promise.   New vaccine for lower respiratory tract disease; A new treatment for heart failure; Concerns over some compounded semaglutide; New opioid use disorder treatment; Motion sickness Tx shows promise.   false full 160 e38efab7-1770-4888-8311-61c198af1544 MPR Weekly Dose 161 — First Oral Antiviral Approved for COVID-19; First Topical Tx for Epidermolysis Bullosa; Xacduro and Opvee Approved; Cough Suppressant Recall First oral antiviral approved for COVID-19; First topical treatment approved for epidermolysis bullosa; Xacduro gets green like for bacterial pneumonia; New nasal spray for opioid overdoses; Child cough suppressant recalled.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 26 May 2023 14:16:38 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com First oral antiviral approved for COVID-19; First topical treatment approved for epidermolysis bullosa; Xacduro gets green like for bacterial pneumonia; New nasal spray for opioid overdoses; Child cough suppressant recalled.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose 161 — First Oral Antiviral Approved for COVID-19; First Topical Tx for Epidermolysis Bullosa; Xacduro and Opvee Approved; Cough Suppressant Recall MPR Weekly Dose 00:15:34 First oral antiviral approved for COVID-19; First topical treatment approved for epidermolysis bullosa; Xacduro gets green like for bacterial pneumonia; New nasal spray for opioid overdoses; Child cough suppressant recalled. First oral antiviral approved for COVID-19; First topical treatment approved for epidermolysis bullosa; Xacduro gets green like for bacterial pneumonia; New nasal spray for opioid overdoses; Child cough suppressant recalled. false full 159 fc1e09d1-1616-4d61-88ec-175efb88c78d MPR Weekly Dose 160 — Labeling Update for Prescription Stimulants; Veozah Approved for Vasomotor Symptoms; FDA Vote on DMD Therapy; Fungal Meningitis Cases in US; Child's Smart Thermometer Recalled FDA requires label updates for the entire class of prescription stimulants; Novel treatment approved for menopause symptoms; FDA Committee takes votes on potentially accelerated approval of Duchenne muscular dystrophy gene therapy; Fungal meningitis outbreak in US; Wearable child thermometer recalled.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 19 May 2023 16:48:35 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com FDA requires label updates for the entire class of prescription stimulants; Novel treatment approved for menopause symptoms; FDA Committee takes votes on potentially accelerated approval of Duchenne muscular dystrophy gene therapy; Fungal meningitis outbreak in US; Wearable child thermometer recalled.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose 160 — Labeling Update for Prescription Stimulants; Veozah Approved for Vasomotor Symptoms; FDA Vote on DMD Therapy; Fungal Meningitis Cases in US; Child's Smart Thermometer Recalled MPR Weekly Dose 00:11:55 FDA requires label updates for the entire class of prescription stimulants; Novel treatment approved for menopause symptoms; FDA Committee takes votes on potentially accelerated approval of Duchenne muscular dystrophy gene therapy; Fungal meningitis outbreak in US; Wearable child thermometer recalled. FDA requires label updates for the entire class of prescription stimulants; Novel treatment approved for menopause symptoms; FDA Committee takes votes on potentially accelerated approval of Duchenne muscular dystrophy gene therapy; Fungal meningitis outbreak in US; Wearable child thermometer recalled. false full 158 36882397-63d4-42a0-9665-341c7a15374e MPR Weekly Dose 159 — OTC Birth Control Pill Switch; First Tx for Agitation Associated With Dementia; Fabry Disease Treatment; Farxiga Approval Expanded; Contaminated COVID-19 Tests Panel votes unanimously in favour of over-the-counter change for contraceptive pill; First pharmacological therapy for agitation associated with dementia due to Alzheimer disease; Elfabrio approved for the treatment of Fabry disease; Farxiga approval expanded; Bacterial contamination concerns for certain COVID-19 at-home tests.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 12 May 2023 15:07:22 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com Panel votes unanimously in favour of over-the-counter change for contraceptive pill; First pharmacological therapy for agitation associated with dementia due to Alzheimer disease; Elfabrio approved for the treatment of Fabry disease; Farxiga approval expanded; Bacterial contamination concerns for certain COVID-19 at-home tests.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose 159 — OTC Birth Control Pill Switch; First Tx for Agitation Associated With Dementia; Fabry Disease Treatment; Farxiga Approval Expanded; Contaminated COVID-19 Tests MPR Weekly Dose 00:13:11 Panel votes unanimously in favour of over-the-counter change for contraceptive pill; First pharmacological therapy for agitation associated with dementia due to Alzheimer disease; Elfabrio approved for the treatment of Fabry disease; Farxiga approval expanded; Bacterial contamination concerns for certain COVID-19 at-home tests. Panel votes unanimously in favour of over-the-counter change for contraceptive pill; First pharmacological therapy for agitation associated with dementia due to Alzheimer disease; Elfabrio approved for the treatment of Fabry disease; Farxiga approval expanded; Bacterial contamination concerns for certain COVID-19 at-home tests. false full 157 63aa346e-05d7-49b3-aad6-72a289aba7ba MPR Weekly Dose 158 — Early Alzheimer Treatment; First RSV Vaccine; Narcolepsy Tx; Toilet Seat That Monitors Health; FDA Ammonia Warning Investigational treatment for early Alzheimer disease shows promise; First vaccine for the prevention of lower respiratory tract disease caused by RSV; Nightly granules approved for narcolepsy; Latest health tech advance in toilets; And the FDA warns of energy boosting over-the-counter inhalants.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 5 May 2023 14:51:25 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com Investigational treatment for early Alzheimer disease shows promise; First vaccine for the prevention of lower respiratory tract disease caused by RSV; Nightly granules approved for narcolepsy; Latest health tech advance in toilets; And the FDA warns of energy boosting over-the-counter inhalants.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose 158 — Early Alzheimer Treatment; First RSV Vaccine; Narcolepsy Tx; Toilet Seat That Monitors Health; FDA Ammonia Warning MPR Weekly Dose 00:12:01 Investigational treatment for early Alzheimer disease shows promise; First vaccine for the prevention of lower respiratory tract disease caused by RSV; Nightly granules approved for narcolepsy; Latest health tech advance in toilets; And the FDA warns of energy boosting over-the-counter inhalants. Investigational treatment for early Alzheimer disease shows promise; First vaccine for the prevention of lower respiratory tract disease caused by RSV; Nightly granules approved for narcolepsy; Latest health tech advance in toilets; And the FDA warns of energy boosting over-the-counter inhalants. false full 156 412e2534-7d9a-441b-9ae8-83539f0c0ad6 MPR Weekly Dose 157 — Akorn Pharmaceutical Recalls; First Oral Fecal Microbiota Tx; ALS Treatment Approved; Basal-Only Insulin Delivery for T2D; Eyedrop Safety Alert Large recall of drugs due to company shutdown; First orally administered fecal microbiota treatment given green light; Treatment approved for certain ALS patients; Type 2 diabetes insulin delivery system; FDA issue safety alert concerning eyedrops.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 28 Apr 2023 14:24:22 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com Large recall of drugs due to company shutdown; First orally administered fecal microbiota treatment given green light; Treatment approved for certain ALS patients; Type 2 diabetes insulin delivery system; FDA issue safety alert concerning eyedrops.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose 157 — Akorn Pharmaceutical Recalls; First Oral Fecal Microbiota Tx; ALS Treatment Approved; Basal-Only Insulin Delivery for T2D; Eyedrop Safety Alert MPR Weekly Dose 00:10:56 Large recall of drugs due to company shutdown; First orally administered fecal microbiota treatment given green light; Treatment approved for certain ALS patients; Type 2 diabetes insulin delivery system; FDA issue safety alert concerning eyedrops. Large recall of drugs due to company shutdown; First orally administered fecal microbiota treatment given green light; Treatment approved for certain ALS patients; Type 2 diabetes insulin delivery system; FDA issue safety alert concerning eyedrops. false full 155 feb79368-57d4-41d7-a858-f24f182c9626 MPR Weekly Dose 156 — Bivalent COVID-19 Vaccines; Vote on Agitation With Alzheimer Dementia Tx; Descheduled Drug; Migraine Tx Expansion; Restless Legs Syndrome Device Updates to COVID-19 vaccines; FDA panel votse on potential treatment for agitation with Alzheimer dementia; DEA deschedule drug; Migraine treatment indication expanded; A new device is cleared to aid in restless legs syndrome.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 21 Apr 2023 15:25:14 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com Updates to COVID-19 vaccines; FDA panel votse on potential treatment for agitation with Alzheimer dementia; DEA deschedule drug; Migraine treatment indication expanded; A new device is cleared to aid in restless legs syndrome.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose 156 — Bivalent COVID-19 Vaccines; Vote on Agitation With Alzheimer Dementia Tx; Descheduled Drug; Migraine Tx Expansion; Restless Legs Syndrome Device MPR Weekly Dose 00:11:38 Updates to COVID-19 vaccines; FDA panel votse on potential treatment for agitation with Alzheimer dementia; DEA deschedule drug; Migraine treatment indication expanded; A new device is cleared to aid in restless legs syndrome. Updates to COVID-19 vaccines; FDA panel votse on potential treatment for agitation with Alzheimer dementia; DEA deschedule drug; Migraine treatment indication expanded; A new device is cleared to aid in restless legs syndrome. false full 154 d0977536-064f-4d9c-b25f-bdf1fcb76460 MPR Weekly Dose 155 — Knee Shock Absorber; Opioid Label Updates; Imbruvica Indications Withdrawn; Patch for Excessive Sweating; Polyclonal Tx for Flu Implantable device approved for those with knee osteoarthritis; Prescribing Information labeling updated for opioids; Imbruvica indications withdrawn; Patch to combat excessive underarm sweating given green light; Novel treatment Fast Tracked for Type A and B influenza.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 14 Apr 2023 15:12:52 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com Implantable device approved for those with knee osteoarthritis; Prescribing Information labeling updated for opioids; Imbruvica indications withdrawn; Patch to combat excessive underarm sweating given green light; Novel treatment Fast Tracked for Type A and B influenza.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose 155 — Knee Shock Absorber; Opioid Label Updates; Imbruvica Indications Withdrawn; Patch for Excessive Sweating; Polyclonal Tx for Flu MPR Weekly Dose 00:12:59 Implantable device approved for those with knee osteoarthritis; Prescribing Information labeling updated for opioids; Imbruvica indications withdrawn; Patch to combat excessive underarm sweating given green light; Novel treatment Fast Tracked for Type A and B influenza. Implantable device approved for those with knee osteoarthritis; Prescribing Information labeling updated for opioids; Imbruvica indications withdrawn; Patch to combat excessive underarm sweating given green light; Novel treatment Fast Tracked for Type A and B influenza. false full 153 4ef7d489-f8b6-4d9d-81ff-089bab61cd61 MPR Weekly Dose 154 — Novel COVID-19 Tx Granted EUA; Makena Withdrawn; Infant Supine Sleep System; Padcev Plus Keytruda Approved; Opioid Mail-Back Envelopes, Respiratory Depression Detection Device Treatment granted Emergency Use Authorization for hospitalized COVID-19 patients; Preterm-birth prevention treatment withdrawn from market; Sleep device for infants gets green light for marketing; New Padcev plus Keytruda indication; Mail-back system for unused opioids; Opioid overdose prevention device approved


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 7 Apr 2023 14:20:47 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com Treatment granted Emergency Use Authorization for hospitalized COVID-19 patients; Preterm-birth prevention treatment withdrawn from market; Sleep device for infants gets green light for marketing; New Padcev plus Keytruda indication; Mail-back system for unused opioids; Opioid overdose prevention device approved


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose 154 — Novel COVID-19 Tx Granted EUA; Makena Withdrawn; Infant Supine Sleep System; Padcev Plus Keytruda Approved; Opioid Mail-Back Envelopes, Respiratory Depression Detection Device MPR Weekly Dose 00:15:11 Treatment granted Emergency Use Authorization for hospitalized COVID-19 patients; Preterm-birth prevention treatment withdrawn from market; Sleep device for infants gets green light for marketing; New Padcev plus Keytruda indication; Mail-back system for unused opioids; Opioid overdose prevention device approved Treatment granted Emergency Use Authorization for hospitalized COVID-19 patients; Preterm-birth prevention treatment withdrawn from market; Sleep device for infants gets green light for marketing; New Padcev plus Keytruda indication; Mail-back system for unused opioids; Opioid overdose prevention device approved false full 152 979cc202-d53c-41ce-96b8-bccf45ea001c MPR Weekly Dose 153 — Diabetes Drugs Discontinued; Trial Results for Schizophrenia Tx; Intranasal Spray Assessed for SAD; High-concentration Humira biosimilar; Inspire Therapy Indication Expanded Two diabetes drugs permanently discontinued; Consistent reduction in schizophrenia symptoms with an investigational Tx; Positive results for investigational Social Anxiety Disorder therapy; High-concentration Humira biosimilar approved; Sleep apnea treatment expanded for pediatrics with Down syndrome


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 24 Mar 2023 13:51:22 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com Two diabetes drugs permanently discontinued; Consistent reduction in schizophrenia symptoms with an investigational Tx; Positive results for investigational Social Anxiety Disorder therapy; High-concentration Humira biosimilar approved; Sleep apnea treatment expanded for pediatrics with Down syndrome


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose 153 — Diabetes Drugs Discontinued; Trial Results for Schizophrenia Tx; Intranasal Spray Assessed for SAD; High-concentration Humira biosimilar; Inspire Therapy Indication Expanded MPR Weekly Dose 00:11:24 Two diabetes drugs permanently discontinued; Consistent reduction in schizophrenia symptoms with an investigational Tx; Positive results for investigational Social Anxiety Disorder therapy; High-concentration Humira biosimilar approved; Sleep apnea treatment expanded for pediatrics with Down syndrome Two diabetes drugs permanently discontinued; Consistent reduction in schizophrenia symptoms with an investigational Tx; Positive results for investigational Social Anxiety Disorder therapy; High-concentration Humira biosimilar approved; Sleep apnea treatment expanded for pediatrics with Down syndrome false full 151 43e5b17d-370b-4080-b9b9-9bed020d7c27 MPR Weekly Dose 152 — Booster Dose Authorized for Under 5s; Rapid STI Test; Rett Syndrome and Migraine Tx Approved; Panel Takes Vote for Polivy Combo COVID-19 Booster dose authorized for those aged 6 months through 4 years; Rapid STI point-of-care test for women is cleared; Rett syndrome and migraine Tx Approved; and The Oncology Drugs Advisory Committee takes a vote on a drug combination treatment for diffuse large b-cell lymphoma.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 17 Mar 2023 14:56:54 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com COVID-19 Booster dose authorized for those aged 6 months through 4 years; Rapid STI point-of-care test for women is cleared; Rett syndrome and migraine Tx Approved; and The Oncology Drugs Advisory Committee takes a vote on a drug combination treatment for diffuse large b-cell lymphoma.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose 152 — Booster Dose Authorized for Under 5s; Rapid STI Test; Rett Syndrome and Migraine Tx Approved; Panel Takes Vote for Polivy Combo MPR Weekly Dose 00:12:25 COVID-19 Booster dose authorized for those aged 6 months through 4 years; Rapid STI point-of-care test for women is cleared; Rett syndrome and migraine Tx Approved; and The Oncology Drugs Advisory Committee takes a vote on a drug combination treatment for diffuse large b-cell lymphoma.   COVID-19 Booster dose authorized for those aged 6 months through 4 years; Rapid STI point-of-care test for women is cleared; Rett syndrome and migraine Tx Approved; and The Oncology Drugs Advisory Committee takes a vote on a drug combination treatment for diffuse large b-cell lymphoma.   false full 150 0d108cce-4430-4709-a458-14ef4fedfab0 MPR Weekly Dose 151 — Liver Injury Decline Tied to FDA Rule; Alzheimer Disease Tx Update; Bempedoic Acid in MACE; Blood Test Cleared for TBI Assessment; Mammography Regulatory Update. Limits on acetaminophen levels in combination opioid products linked to declines in liver injuries; Investigational Alzheimer disease drug fails to show efficacy; Bempedoic acid assessed for reducing major adverse cardiovascular events; Commercial blood test for suspected TBIs; Mammography regulations updated.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 10 Mar 2023 15:46:55 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com Limits on acetaminophen levels in combination opioid products linked to declines in liver injuries; Investigational Alzheimer disease drug fails to show efficacy; Bempedoic acid assessed for reducing major adverse cardiovascular events; Commercial blood test for suspected TBIs; Mammography regulations updated.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose 151 — Liver Injury Decline Tied to FDA Rule; Alzheimer Disease Tx Update; Bempedoic Acid in MACE; Blood Test Cleared for TBI Assessment; Mammography Regulatory Update. MPR Weekly Dose 00:12:57 Limits on acetaminophen levels in combination opioid products linked to declines in liver injuries; Investigational Alzheimer disease drug fails to show efficacy; Bempedoic acid assessed for reducing major adverse cardiovascular events; Commercial blood test for suspected TBIs; Mammography regulations updated. Limits on acetaminophen levels in combination opioid products linked to declines in liver injuries; Investigational Alzheimer disease drug fails to show efficacy; Bempedoic acid assessed for reducing major adverse cardiovascular events; Commercial blood test for suspected TBIs; Mammography regulations updated. false full 149 cf2641d2-e0bf-42d1-a484-83d6bd431c98 MPR Weekly Dose 150 — Kevzara, Skyclarys Approved; At-Home Combo COVID and Flu Test; Drug-Resistant Shigellosis on Rise; FDA Restrictions on Xylazine-Containing Products Kevzara approved for polymyalgia rheumatica; Skyclarys approved for Friedreich ataxia; Emergency authorization granted to at-home COVID-19, flu test; Drug-resistant bacteria virus spiking in the US; FDA clamps down on unlawful xylazine imports.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 3 Mar 2023 15:15:17 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com Kevzara approved for polymyalgia rheumatica; Skyclarys approved for Friedreich ataxia; Emergency authorization granted to at-home COVID-19, flu test; Drug-resistant bacteria virus spiking in the US; FDA clamps down on unlawful xylazine imports.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose 150 — Kevzara, Skyclarys Approved; At-Home Combo COVID and Flu Test; Drug-Resistant Shigellosis on Rise; FDA Restrictions on Xylazine-Containing Products MPR Weekly Dose 00:13:43 Kevzara approved for polymyalgia rheumatica; Skyclarys approved for Friedreich ataxia; Emergency authorization granted to at-home COVID-19, flu test; Drug-resistant bacteria virus spiking in the US; FDA clamps down on unlawful xylazine imports. Kevzara approved for polymyalgia rheumatica; Skyclarys approved for Friedreich ataxia; Emergency authorization granted to at-home COVID-19, flu test; Drug-resistant bacteria virus spiking in the US; FDA clamps down on unlawful xylazine imports. false full 148 e2468b38-20b1-4e51-9e4d-68e7ac1e19a7 MPR Weekly Dose 149 — Post-Exposure Molnupiravir Study; Filspari Approved; Treatment for Geographic Atrophy Secondary to AMD Approved; Personalized Melanoma Vaccine; RSV Maternal Vaccine Results from postexposure prophylaxis study of molnupiravir; Treatment approved to reduce proteinuria in adults with primary immunoglobulin A nephropathy; Intravitreal injection approved for geographic atrophy secondary to AMD; Potential vaccines for melanoma and pregnant individuals to help protect from RSV complications in infants.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 24 Feb 2023 14:48:04 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com Results from postexposure prophylaxis study of molnupiravir; Treatment approved to reduce proteinuria in adults with primary immunoglobulin A nephropathy; Intravitreal injection approved for geographic atrophy secondary to AMD; Potential vaccines for melanoma and pregnant individuals to help protect from RSV complications in infants.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose 149 — Post-Exposure Molnupiravir Study; Filspari Approved; Treatment for Geographic Atrophy Secondary to AMD Approved; Personalized Melanoma Vaccine; RSV Maternal Vaccine MPR Weekly Dose 00:14:21 Results from postexposure prophylaxis study of molnupiravir; Treatment approved to reduce proteinuria in adults with primary immunoglobulin A nephropathy; Intravitreal injection approved for geographic atrophy secondary to AMD; Potential vaccines for melanoma and pregnant individuals to help protect from RSV complications in infants.   Results from postexposure prophylaxis study of molnupiravir; Treatment approved to reduce proteinuria in adults with primary immunoglobulin A nephropathy; Intravitreal injection approved for geographic atrophy secondary to AMD; Potential vaccines for melanoma and pregnant individuals to help protect from RSV complications in infants.   false full 147 7dbf1977-78b3-4061-922f-cfe42edfe5f0 MPR Weekly Dose 148 — OTC Narcan; Fecal Microbiota Available; Azithromycin for Postpartum Sepsis; Cibinqo Expanded Approval; Delgocitinib for Hand Eczema FDA Committee take vote on possible OTC Narcan; Rebyota available to prevent CDI recurrence; Risk of maternal sepsis lowered with azithromycin; Cinbinqo indication expanded; Topical treatment shows promise for hand eczema


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 17 Feb 2023 15:06:11 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com FDA Committee take vote on possible OTC Narcan; Rebyota available to prevent CDI recurrence; Risk of maternal sepsis lowered with azithromycin; Cinbinqo indication expanded; Topical treatment shows promise for hand eczema


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose 148 — OTC Narcan; Fecal Microbiota Available; Azithromycin for Postpartum Sepsis; Cibinqo Expanded Approval; Delgocitinib for Hand Eczema MPR Weekly Dose 00:12:09 FDA Committee take vote on possible OTC Narcan; Rebyota available to prevent CDI recurrence; Risk of maternal sepsis lowered with azithromycin; Cinbinqo indication expanded; Topical treatment shows promise for hand eczema FDA Committee take vote on possible OTC Narcan; Rebyota available to prevent CDI recurrence; Risk of maternal sepsis lowered with azithromycin; Cinbinqo indication expanded; Topical treatment shows promise for hand eczema false full 146 fc33c96a-b08f-48a1-94d1-91bb36424989 MPR Weekly Dose 147 — Adlyxin Availability; Zuranolone Priority Review; Recall of Hypothyroidism Treatment; Weight Loss Supplement Warning; First ROP Treatment Type 2 diabetes treatment discontinued; Depression, postpartum treatment gets Priority Review; Hypothyroid treatment recalled; FDA warns about weight loss supplement; First retinopathy of prematurity treatment for preterm infants approved.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 10 Feb 2023 13:58:25 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com Type 2 diabetes treatment discontinued; Depression, postpartum treatment gets Priority Review; Hypothyroid treatment recalled; FDA warns about weight loss supplement; First retinopathy of prematurity treatment for preterm infants approved.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose 147 — Adlyxin Availability; Zuranolone Priority Review; Recall of Hypothyroidism Treatment; Weight Loss Supplement Warning; First ROP Treatment MPR Weekly Dose 00:09:00 Type 2 diabetes treatment discontinued; Depression, postpartum treatment gets Priority Review; Hypothyroid treatment recalled; FDA warns about weight loss supplement; First retinopathy of prematurity treatment for preterm infants approved. Type 2 diabetes treatment discontinued; Depression, postpartum treatment gets Priority Review; Hypothyroid treatment recalled; FDA warns about weight loss supplement; First retinopathy of prematurity treatment for preterm infants approved. false full 145 50f7c25e-f82e-4ca2-81ba-d44e52fe4a19 MPR Weekly Dose 146 — Paxlovid, Lagevrio EUA Revised; Beta Blockers and Violence; Jesduvroq Approved; Artificial Tears Product Recall; FDA Halt Use of COVID Therapy The FDA make major revisions to COVID-19 antiretrovirals; Large study finds possible new indication for beta blockers; Jesduvroq approved; Artificial tears product recalled; Evusheld emergency use authorization halted.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 3 Feb 2023 18:32:01 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com The FDA make major revisions to COVID-19 antiretrovirals; Large study finds possible new indication for beta blockers; Jesduvroq approved; Artificial tears product recalled; Evusheld emergency use authorization halted.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose 146 — Paxlovid, Lagevrio EUA Revised; Beta Blockers and Violence; Jesduvroq Approved; Artificial Tears Product Recall; FDA Halt Use of COVID Therapy MPR Weekly Dose 00:11:54 The FDA make major revisions to COVID-19 antiretrovirals; Large study finds possible new indication for beta blockers; Jesduvroq approved; Artificial tears product recalled; Evusheld emergency use authorization halted. The FDA make major revisions to COVID-19 antiretrovirals; Large study finds possible new indication for beta blockers; Jesduvroq approved; Artificial tears product recalled; Evusheld emergency use authorization halted. false full 144 da920aad-ce26-4e01-b33b-6785d78c5b3f MPR Weekly Dose 145 — COVID-19 Vaccine Investigation; HIV Vaccine Lacks Efficacy; Sepsis Diagnostic Test; RSV-Associated Disease Vaccine; Combo Tx Reduces CA Recurrence Pfizer-BioNTech bivalent vaccine under investigation; Trial evaluating HIV prevention vaccine discontinued; Early detection sepsis test cleared; Trial results for RSV-associated disease vaccine; Combo Tx for HCC recurrence shows promise


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 20 Jan 2023 15:04:11 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com Pfizer-BioNTech bivalent vaccine under investigation; Trial evaluating HIV prevention vaccine discontinued; Early detection sepsis test cleared; Trial results for RSV-associated disease vaccine; Combo Tx for HCC recurrence shows promise


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose 145 — COVID-19 Vaccine Investigation; HIV Vaccine Lacks Efficacy; Sepsis Diagnostic Test; RSV-Associated Disease Vaccine; Combo Tx Reduces CA Recurrence MPR Weekly Dose 00:13:07 Pfizer-BioNTech bivalent vaccine under investigation; Trial evaluating HIV prevention vaccine discontinued; Early detection sepsis test cleared; Trial results for RSV-associated disease vaccine; Combo Tx for HCC recurrence shows promise Pfizer-BioNTech bivalent vaccine under investigation; Trial evaluating HIV prevention vaccine discontinued; Early detection sepsis test cleared; Trial results for RSV-associated disease vaccine; Combo Tx for HCC recurrence shows promise false full 143 2bd24630-c76f-460e-8d9e-b330d7164223 MPR Weekly Dose 144 — New Alzheimer disease Tx; Asthma rescue therapy; NERD Tx shows promise; Leukemia drug to be withdrawn; Adacel approved for during pregnancy FDA grant accelerated approval to Alzheimer disease treatment; New fixed-dose asthma treatment; NERD therapy looks promising; Leukemia drug to be withdrawn; Pertussis prevention treatment approved for use during pregnancy


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 13 Jan 2023 15:28:04 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com FDA grant accelerated approval to Alzheimer disease treatment; New fixed-dose asthma treatment; NERD therapy looks promising; Leukemia drug to be withdrawn; Pertussis prevention treatment approved for use during pregnancy


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose 144 — New Alzheimer disease Tx; Asthma rescue therapy; NERD Tx shows promise; Leukemia drug to be withdrawn; Adacel approved for during pregnancy MPR Weekly Dose 00:11:59 FDA grant accelerated approval to Alzheimer disease treatment; New fixed-dose asthma treatment; NERD therapy looks promising; Leukemia drug to be withdrawn; Pertussis prevention treatment approved for use during pregnancy FDA grant accelerated approval to Alzheimer disease treatment; New fixed-dose asthma treatment; NERD therapy looks promising; Leukemia drug to be withdrawn; Pertussis prevention treatment approved for use during pregnancy false full 142 1fe73f8b-e678-4152-b0c5-ca9b8e1cda8f MPR Weekly Dose 143 — Pharmacists can dispense abortion pill; MDMA trial meets endpoints; HIV meds to be discontinued; Obesity Tx approved for children; 2023 best diets rankings Risk evaluation and mitigation strategy updated for abortion pill, mifepristone; Potential PTSD therapy shows positive results; A host of HIV meds are to be discontinued in the next year; Weight-loss treatment gains expanded approval in pediatrics; Experts rank their best diets for a variety of categories.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 6 Jan 2023 15:41:05 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com Risk evaluation and mitigation strategy updated for abortion pill, mifepristone; Potential PTSD therapy shows positive results; A host of HIV meds are to be discontinued in the next year; Weight-loss treatment gains expanded approval in pediatrics; Experts rank their best diets for a variety of categories.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose 143 — Pharmacists can dispense abortion pill; MDMA trial meets endpoints; HIV meds to be discontinued; Obesity Tx approved for children; 2023 best diets rankings MPR Weekly Dose 00:13:22 Risk evaluation and mitigation strategy updated for abortion pill, mifepristone; Potential PTSD therapy shows positive results; A host of HIV meds are to be discontinued in the next year; Weight-loss treatment gains expanded approval in pediatrics; Experts rank their best diets for a variety of categories.  Risk evaluation and mitigation strategy updated for abortion pill, mifepristone; Potential PTSD therapy shows positive results; A host of HIV meds are to be discontinued in the next year; Weight-loss treatment gains expanded approval in pediatrics; Experts rank their best diets for a variety of categories.  false full 141 f2812740-260d-4ef8-adea-f255cf8b4f78 MPR Weekly Dose 142 — Interview with US News managing health editor, Gretel Schueller In this week's episode we interviewed Gretel Schueller, managing editor of health at US news, to discuss the results from this year's Best Diet rankings and the methodology used to compile the list.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Tue, 3 Jan 2023 17:55:14 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com In this week's episode we interviewed Gretel Schueller, managing editor of health at US news, to discuss the results from this year's Best Diet rankings and the methodology used to compile the list.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose 142 — Interview with US News managing health editor, Gretel Schueller MPR Weekly Dose 00:20:01 In this week's episode we interviewed Gretel Schueller, managing editor of health at US news, to discuss the results from this year's Best Diet rankings and the methodology used to compile the list. In this week's episode we interviewed Gretel Schueller, managing editor of health at US news, to discuss the results from this year's Best Diet rankings and the methodology used to compile the list. false full 140 bca9031b-53e9-45cd-bc65-504fc0ec82b9 MPR Weekly Dose 141 — Guidance for Influenza Treatment; Panel Vote on Omecamtiv Mecarbil; Tecentriq Approval; Flu and COVID Combo Vax; Certain COVD Tests Recalled Interim guidance for influenza treatment with limited oseltamivir; FDA panel vote on omecamtiv mecarbil; Tecentriq gains new indication; Potential combo COVID-19 and influenza vaccine; Detect COVID-19 tests recalled.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 16 Dec 2022 15:01:50 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com Interim guidance for influenza treatment with limited oseltamivir; FDA panel vote on omecamtiv mecarbil; Tecentriq gains new indication; Potential combo COVID-19 and influenza vaccine; Detect COVID-19 tests recalled.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose 141 — Guidance for Influenza Treatment; Panel Vote on Omecamtiv Mecarbil; Tecentriq Approval; Flu and COVID Combo Vax; Certain COVD Tests Recalled MPR Weekly Dose 00:11:54 Interim guidance for influenza treatment with limited oseltamivir; FDA panel vote on omecamtiv mecarbil; Tecentriq gains new indication; Potential combo COVID-19 and influenza vaccine; Detect COVID-19 tests recalled. Interim guidance for influenza treatment with limited oseltamivir; FDA panel vote on omecamtiv mecarbil; Tecentriq gains new indication; Potential combo COVID-19 and influenza vaccine; Detect COVID-19 tests recalled. false full 139 73ffc053-39ec-4a8f-ab78-214c3a25f6a6 MPR Weekly Dose 140 — COVID-19 Vaccines; Narcan for OTC; Diabetes Tx in Peds; Major Depressive Disorder Therapy Fast Tracked; Tecentriq Indication Withdrawn New authorization for COVID-19 vaccines in certain children; Narcan nasal spray to be reviewed for OTC status; Empagliflozin assessed in children with diabetes; a major depressive disorder therapy gains fast track status; and Tecentriq has an indication withdrawn.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 9 Dec 2022 18:59:39 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com New authorization for COVID-19 vaccines in certain children; Narcan nasal spray to be reviewed for OTC status; Empagliflozin assessed in children with diabetes; a major depressive disorder therapy gains fast track status; and Tecentriq has an indication withdrawn.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose 140 — COVID-19 Vaccines; Narcan for OTC; Diabetes Tx in Peds; Major Depressive Disorder Therapy Fast Tracked; Tecentriq Indication Withdrawn MPR Weekly Dose 00:11:55 New authorization for COVID-19 vaccines in certain children; Narcan nasal spray to be reviewed for OTC status; Empagliflozin assessed in children with diabetes; a major depressive disorder therapy gains fast track status; and Tecentriq has an indication withdrawn.  New authorization for COVID-19 vaccines in certain children; Narcan nasal spray to be reviewed for OTC status; Empagliflozin assessed in children with diabetes; a major depressive disorder therapy gains fast track status; and Tecentriq has an indication withdrawn.  false full 138 8e3d038c-7381-409f-af15-ce97aae13214 MPR Weekly Dose 139 — FDA Pulls COVID-19 Treatment; Amoxicillin Guidance; Fecal Microbiota Treatment Approved; Alzheimer Agitation Tx; Priority Review for DMD Therapy FDA pull bebtelovimab; compounding guidance issued in light of the amoxicillin shortage; the first fecal microbiota treatment is approved; a treatment for Alzheimer disease agitation shows promise; and a gene therapy for duchenne muscular dystrophy is accepted for Priority Review.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 2 Dec 2022 16:52:27 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com FDA pull bebtelovimab; compounding guidance issued in light of the amoxicillin shortage; the first fecal microbiota treatment is approved; a treatment for Alzheimer disease agitation shows promise; and a gene therapy for duchenne muscular dystrophy is accepted for Priority Review.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose 139 — FDA Pulls COVID-19 Treatment; Amoxicillin Guidance; Fecal Microbiota Treatment Approved; Alzheimer Agitation Tx; Priority Review for DMD Therapy MPR Weekly Dose 00:11:35 FDA pull bebtelovimab; compounding guidance issued in light of the amoxicillin shortage; the first fecal microbiota treatment is approved; a treatment for Alzheimer disease agitation shows promise; and a gene therapy for duchenne muscular dystrophy is accepted for Priority Review. FDA pull bebtelovimab; compounding guidance issued in light of the amoxicillin shortage; the first fecal microbiota treatment is approved; a treatment for Alzheimer disease agitation shows promise; and a gene therapy for duchenne muscular dystrophy is accepted for Priority Review. false full 137 ed49f395-ed78-482d-9fd5-462252909c0c MP R Weekly Dose 138 — Elahere Gets Accelerated Approval; Zejula Use Restricted; Update for IUD System; Interchangeable Insulin Products; Panel Votes on Tenapanor Newly approved gynecologic cancer treatment; Zejula has it's use restricted; intrauterine system use extended; a second insulin product is approved as a biosimilar to Lantus; and an FDA Advisory Committee take a vote on tenapanor.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 18 Nov 2022 19:32:15 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com Newly approved gynecologic cancer treatment; Zejula has it's use restricted; intrauterine system use extended; a second insulin product is approved as a biosimilar to Lantus; and an FDA Advisory Committee take a vote on tenapanor.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MP R Weekly Dose 138 — Elahere Gets Accelerated Approval; Zejula Use Restricted; Update for IUD System; Interchangeable Insulin Products; Panel Votes on Tenapanor MPR Weekly Dose 00:13:38 Newly approved gynecologic cancer treatment; Zejula has it's use restricted; intrauterine system use extended; a second insulin product is approved as a biosimilar to Lantus; and an FDA Advisory Committee take a vote on tenapanor. Newly approved gynecologic cancer treatment; Zejula has it's use restricted; intrauterine system use extended; a second insulin product is approved as a biosimilar to Lantus; and an FDA Advisory Committee take a vote on tenapanor. false full 136 070e8749-2877-4c22-8ca7-3815f2074be2 MPR Weekly Dose 137 — USPSTF Hormone Recommendations; Semaglutide in Obese Teens; Maternal RSV Vaccine Candidate; Antipsychotic REMS Update; Omburtamab Panel Vote USPSTF recommendations on estrogen and progesterone; semaglutide assessed in obese teenagers; efficacy and safety data released for maternal RSV vaccine; updates to clozapine REMS; FDA panel vote on investigational CNS/leptomeningeal metastasis treatment.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 4 Nov 2022 16:25:43 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com USPSTF recommendations on estrogen and progesterone; semaglutide assessed in obese teenagers; efficacy and safety data released for maternal RSV vaccine; updates to clozapine REMS; FDA panel vote on investigational CNS/leptomeningeal metastasis treatment.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose 137 — USPSTF Hormone Recommendations; Semaglutide in Obese Teens; Maternal RSV Vaccine Candidate; Antipsychotic REMS Update; Omburtamab Panel Vote MPR Weekly Dose 00:15:09 USPSTF recommendations on estrogen and progesterone; semaglutide assessed in obese teenagers; efficacy and safety data released for maternal RSV vaccine; updates to clozapine REMS; FDA panel vote on investigational CNS/leptomeningeal metastasis treatment. USPSTF recommendations on estrogen and progesterone; semaglutide assessed in obese teenagers; efficacy and safety data released for maternal RSV vaccine; updates to clozapine REMS; FDA panel vote on investigational CNS/leptomeningeal metastasis treatment. false full 135 d42e1b56-1961-435d-bd89-11e79c9633e3 MPR Weekly Dose 136 — Approvals in Multiple Myeloma, Axial Spondyloarthritis, and Hepatocellular Carcinoma; FDA Panel Vote; Oral Suspension of Tadalafil Approvals for relapsed or refractory multiple myeloma, non-radiographic axial spondyloarthritis, and unresectable hepatocellular carcinoma; advisory committee takes vote on potential treatment for anemia of chronic kidney disease; and an oral formulation of pulmonary arterial hypertension treatment.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 28 Oct 2022 16:48:27 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com Approvals for relapsed or refractory multiple myeloma, non-radiographic axial spondyloarthritis, and unresectable hepatocellular carcinoma; advisory committee takes vote on potential treatment for anemia of chronic kidney disease; and an oral formulation of pulmonary arterial hypertension treatment.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose 136 — Approvals in Multiple Myeloma, Axial Spondyloarthritis, and Hepatocellular Carcinoma; FDA Panel Vote; Oral Suspension of Tadalafil MPR Weekly Dose 00:13:13 Approvals for relapsed or refractory multiple myeloma, non-radiographic axial spondyloarthritis, and unresectable hepatocellular carcinoma; advisory committee takes vote on potential treatment for anemia of chronic kidney disease; and an oral formulation of pulmonary arterial hypertension treatment. Approvals for relapsed or refractory multiple myeloma, non-radiographic axial spondyloarthritis, and unresectable hepatocellular carcinoma; advisory committee takes vote on potential treatment for anemia of chronic kidney disease; and an oral formulation of pulmonary arterial hypertension treatment. false full 134 3ef5bddc-adbd-4dc0-818e-502cded3f88e MPR Weekly Dose 135 — Makena Panel Vote; Apixaban vs Rivaroxaban; Monkeypox Ocular Complications; Novavax COVID-19 Booster; Sparsentan, Tofersen Reviews Extended FDA Panel votes on the potential removal from the market of Makena; results from an apixaban trial of patients with atrial fibrillation and valvular heart disease; reports of serious ocular complications with monkeypox infection; the novavax vaccine becomes the latest authorized COVID-19 booster; and treatments for nephropathy and ALS have their review period extended.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 21 Oct 2022 14:18:23 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com FDA Panel votes on the potential removal from the market of Makena; results from an apixaban trial of patients with atrial fibrillation and valvular heart disease; reports of serious ocular complications with monkeypox infection; the novavax vaccine becomes the latest authorized COVID-19 booster; and treatments for nephropathy and ALS have their review period extended.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose 135 — Makena Panel Vote; Apixaban vs Rivaroxaban; Monkeypox Ocular Complications; Novavax COVID-19 Booster; Sparsentan, Tofersen Reviews Extended MPR Weekly Dose 00:16:28 FDA Panel votes on the potential removal from the market of Makena; results from an apixaban trial of patients with atrial fibrillation and valvular heart disease; reports of serious ocular complications with monkeypox infection; the novavax vaccine becomes the latest authorized COVID-19 booster; and treatments for nephropathy and ALS have their review period extended. FDA Panel votes on the potential removal from the market of Makena; results from an apixaban trial of patients with atrial fibrillation and valvular heart disease; reports of serious ocular complications with monkeypox infection; the novavax vaccine becomes the latest authorized COVID-19 booster; and treatments for nephropathy and ALS have their review period extended. false full 133 9627dec5-fa50-4ce2-bff1-411bd932241e MPR Weekly Dose 134 — Vaccine Boosters Authorized; Wearable Furosemide System Approved; Molnupiravir Data; Pertussis Vaccine; FDA Apomorphine Device Update Bivalent COVID-19 booster vaccines for children; wearable device to help treat fluid overload in adults with chronic heart failure; real-world data insights into molnupiravir efficacy; vaccine for the third trimester of pregnancy to prevent pertussis; and an FDA update on apomorphine infusion in Parkinson disease.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 14 Oct 2022 15:27:37 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com Bivalent COVID-19 booster vaccines for children; wearable device to help treat fluid overload in adults with chronic heart failure; real-world data insights into molnupiravir efficacy; vaccine for the third trimester of pregnancy to prevent pertussis; and an FDA update on apomorphine infusion in Parkinson disease.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose 134 — Vaccine Boosters Authorized; Wearable Furosemide System Approved; Molnupiravir Data; Pertussis Vaccine; FDA Apomorphine Device Update MPR Weekly Dose 00:16:37 Bivalent COVID-19 booster vaccines for children; wearable device to help treat fluid overload in adults with chronic heart failure; real-world data insights into molnupiravir efficacy; vaccine for the third trimester of pregnancy to prevent pertussis; and an FDA update on apomorphine infusion in Parkinson disease.  Bivalent COVID-19 booster vaccines for children; wearable device to help treat fluid overload in adults with chronic heart failure; real-world data insights into molnupiravir efficacy; vaccine for the third trimester of pregnancy to prevent pertussis; and an FDA update on apomorphine infusion in Parkinson disease.  false full 132 1e588138-54c0-4e6e-a52f-e84d0839bf9b MPR Weekly Dose 133 — ALS Treatment Approval; Evusheld Update; At-Home Epilepsy Diagnosis; Clopidogrel, Atenolol Recall; Laser Therapy for Fibromyalgia ALS treatment news; Evusheld fact sheet update; an at-home epilepsy diagnostic aid gets cleared; drug recalls; and a laser therapy for fibromyalgia.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 7 Oct 2022 15:38:15 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com ALS treatment news; Evusheld fact sheet update; an at-home epilepsy diagnostic aid gets cleared; drug recalls; and a laser therapy for fibromyalgia.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose 133 — ALS Treatment Approval; Evusheld Update; At-Home Epilepsy Diagnosis; Clopidogrel, Atenolol Recall; Laser Therapy for Fibromyalgia MPR Weekly Dose 00:11:48 ALS treatment news; Evusheld fact sheet update; an at-home epilepsy diagnostic aid gets cleared; drug recalls; and a laser therapy for fibromyalgia. ALS treatment news; Evusheld fact sheet update; an at-home epilepsy diagnostic aid gets cleared; drug recalls; and a laser therapy for fibromyalgia. false full 131 002e7d1c-0e57-4551-9614-1f8ab738822d MPR Weekly Dose 132 — Social Media Warning; Cisplatin-Associated Ototoxicity Tx; New Cerebral Adrenoleukodystrophy Tx; MRI Contrast Agent; Generic Tazorac This week we go over warnings about a new social media challenge; treatment approvals in cisplatin-associated ototoxicity, cerebral adrenoleukodystrophy, MRI contrast agents and a generic version of tazorac.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 23 Sep 2022 13:29:34 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com This week we go over warnings about a new social media challenge; treatment approvals in cisplatin-associated ototoxicity, cerebral adrenoleukodystrophy, MRI contrast agents and a generic version of tazorac.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose 132 — Social Media Warning; Cisplatin-Associated Ototoxicity Tx; New Cerebral Adrenoleukodystrophy Tx; MRI Contrast Agent; Generic Tazorac MPR Weekly Dose 00:13:38 This week we go over warnings about a new social media challenge; treatment approvals in cisplatin-associated ototoxicity, cerebral adrenoleukodystrophy, MRI contrast agents and a generic version of tazorac.  This week we go over warnings about a new social media challenge; treatment approvals in cisplatin-associated ototoxicity, cerebral adrenoleukodystrophy, MRI contrast agents and a generic version of tazorac.  false full 130 4fdd6b87-0f4c-4874-9606-634f6da6d06a MPR Weekly Dose 131 — Approvals in Plaque Psoriasis, Hepatorenal Syndrome and Neutropenia; Priority Review for Rett Syndrome Therapy; Multivitamins Assessed in Cognition Approvals in psoriasis, hepatorenal syndrome, and neutropenia; novel therapy gains Priority Review for Rett Syndrome; and the effects of multivitamin supplementation assessed on cognitive function.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 16 Sep 2022 16:16:19 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com Approvals in psoriasis, hepatorenal syndrome, and neutropenia; novel therapy gains Priority Review for Rett Syndrome; and the effects of multivitamin supplementation assessed on cognitive function.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose 131 — Approvals in Plaque Psoriasis, Hepatorenal Syndrome and Neutropenia; Priority Review for Rett Syndrome Therapy; Multivitamins Assessed in Cognition MPR Weekly Dose 00:13:16 Approvals in psoriasis, hepatorenal syndrome, and neutropenia; novel therapy gains Priority Review for Rett Syndrome; and the effects of multivitamin supplementation assessed on cognitive function.   Approvals in psoriasis, hepatorenal syndrome, and neutropenia; novel therapy gains Priority Review for Rett Syndrome; and the effects of multivitamin supplementation assessed on cognitive function.   false full 129 4f5f80d7-6344-44eb-a89c-348258838f31 MPR Weekly Dose 130 — FDA Vote on ALS Treatment; CPAP, BiPAP Recall; CRISPR Therapy for Hereditary Angioedema; Imfinzi Approved for Biliary Tract Cancer; Spevigo Approved Hello listener and welcome to episode 130 of the MPR Weekly Dose Podcast. This week we have news of the FDA's vote on an ALS treatment; CPAP and BiPAP device recalls; Orphan Drug designation for a novel CRISPR therapy; Imfinzi gains new approval; and Spevigo is approved for pustular psoriasis flares.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 9 Sep 2022 15:57:54 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com Hello listener and welcome to episode 130 of the MPR Weekly Dose Podcast. This week we have news of the FDA's vote on an ALS treatment; CPAP and BiPAP device recalls; Orphan Drug designation for a novel CRISPR therapy; Imfinzi gains new approval; and Spevigo is approved for pustular psoriasis flares.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose 130 — FDA Vote on ALS Treatment; CPAP, BiPAP Recall; CRISPR Therapy for Hereditary Angioedema; Imfinzi Approved for Biliary Tract Cancer; Spevigo Approved MPR Weekly Dose 00:13:39 Hello listener and welcome to episode 130 of the MPR Weekly Dose Podcast. This week we have news of the FDA's vote on an ALS treatment; CPAP and BiPAP device recalls; Orphan Drug designation for a novel CRISPR therapy; Imfinzi gains new approval; and Spevigo is approved for pustular psoriasis flares. Hello listener and welcome to episode 130 of the MPR Weekly Dose Podcast. This week we have news of the FDA's vote on an ALS treatment; CPAP and BiPAP device recalls; Orphan Drug designation for a novel CRISPR therapy; Imfinzi gains new approval; and Spevigo is approved for pustular psoriasis flares. false full 128 42abc885-d091-4953-a434-0051ca04a86a MPR Weekly Dose 129 — Omicron-Adapted Booster Dose; Influenza Season Guidance; Nirmatrelvir Efficacy; DEA Warn Over "Rainbow Fentanyl"; Chronic Idiopathic Constipation Tx Omicron-adapted COVID-19 booster vaccines; guidance for the 2022-23 influenza season; efficacy of COVID-19 antiviral; 'rainbow fentanly' targeting youth; and a device to treat chronic idiopathic constipation.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Thu, 1 Sep 2022 20:36:49 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com Omicron-adapted COVID-19 booster vaccines; guidance for the 2022-23 influenza season; efficacy of COVID-19 antiviral; 'rainbow fentanly' targeting youth; and a device to treat chronic idiopathic constipation.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose 129 — Omicron-Adapted Booster Dose; Influenza Season Guidance; Nirmatrelvir Efficacy; DEA Warn Over "Rainbow Fentanyl"; Chronic Idiopathic Constipation Tx MPR Weekly Dose 00:15:16 Omicron-adapted COVID-19 booster vaccines; guidance for the 2022-23 influenza season; efficacy of COVID-19 antiviral; 'rainbow fentanly' targeting youth; and a device to treat chronic idiopathic constipation.  Omicron-adapted COVID-19 booster vaccines; guidance for the 2022-23 influenza season; efficacy of COVID-19 antiviral; 'rainbow fentanly' targeting youth; and a device to treat chronic idiopathic constipation.  false full 127 0822b14e-345c-400c-99da-36b2aca6d80a MPR Weekly Dose 128 — USPSTF Statin Recommendations; At-Home Visual Test; Novel MDD Treatment; Novavax Authorized in Adolescents; FDA Fecal Microbiota Transplant Alert USPSTF recommendations on the use of statins for primary prevention of cardiovascular disease; At-home visual acuity test; A new treatment for major depressive disorder; Novavax COVID-19 vaccine approved for adolescents; And there is an alert regarding the potential risk of transmission of monkey virus through fecal microbiota transplantation.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 26 Aug 2022 13:33:29 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com USPSTF recommendations on the use of statins for primary prevention of cardiovascular disease; At-home visual acuity test; A new treatment for major depressive disorder; Novavax COVID-19 vaccine approved for adolescents; And there is an alert regarding the potential risk of transmission of monkey virus through fecal microbiota transplantation.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose 128 — USPSTF Statin Recommendations; At-Home Visual Test; Novel MDD Treatment; Novavax Authorized in Adolescents; FDA Fecal Microbiota Transplant Alert MPR Weekly Dose 00:14:00 USPSTF recommendations on the use of statins for primary prevention of cardiovascular disease; At-home visual acuity test; A new treatment for major depressive disorder; Novavax COVID-19 vaccine approved for adolescents; And there is an alert regarding the potential risk of transmission of monkey virus through fecal microbiota transplantation. USPSTF recommendations on the use of statins for primary prevention of cardiovascular disease; At-home visual acuity test; A new treatment for major depressive disorder; Novavax COVID-19 vaccine approved for adolescents; And there is an alert regarding the potential risk of transmission of monkey virus through fecal microbiota transplantation. false full 126 35ffef2d-346e-4070-b2fa-67c8011e1c44 MPR Weekly Dose 127 — Novavax Booster; OTC Hearing Aids; Combo Prostate Cancer Tx; First Gene Therapy for Beta-Thalassemia; Repeat At-Home COVID-19 Testing Needed Novavax vaccine booster update; over-the-counter hearing aids; priority review for a castration-resistant prostate cancer combination treatment; a first gene therapy approved for beta-thalassemia; FDA urges repeat at home COVID-19 testing to reduce risk of missing infection.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 19 Aug 2022 14:24:51 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com Novavax vaccine booster update; over-the-counter hearing aids; priority review for a castration-resistant prostate cancer combination treatment; a first gene therapy approved for beta-thalassemia; FDA urges repeat at home COVID-19 testing to reduce risk of missing infection.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose 127 — Novavax Booster; OTC Hearing Aids; Combo Prostate Cancer Tx; First Gene Therapy for Beta-Thalassemia; Repeat At-Home COVID-19 Testing Needed MPR Weekly Dose 00:14:49 Novavax vaccine booster update; over-the-counter hearing aids; priority review for a castration-resistant prostate cancer combination treatment; a first gene therapy approved for beta-thalassemia; FDA urges repeat at home COVID-19 testing to reduce risk of missing infection. Novavax vaccine booster update; over-the-counter hearing aids; priority review for a castration-resistant prostate cancer combination treatment; a first gene therapy approved for beta-thalassemia; FDA urges repeat at home COVID-19 testing to reduce risk of missing infection. false full 125 65ab8e96-32e9-48a7-a590-73ce20d89e3c MPR Weekly Dose 126 — Change to Monkeypox Vaccine Supply; Myfembree Indication Expanded; Amazon Among Companies to Receive FDA Warning; Impurity in Diabetes Tx New authorization for intradermal administration of monkeypox vaccine; a new approval for endometriosis pain; Amazon is among the companies to receive an FDA Warning Letter for selling unapproved drugs; a diabetes drug is found to contain a possible carcinogen; and a new scale that measures peripheral impedance and pulse rate.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Thu, 11 Aug 2022 21:56:38 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com New authorization for intradermal administration of monkeypox vaccine; a new approval for endometriosis pain; Amazon is among the companies to receive an FDA Warning Letter for selling unapproved drugs; a diabetes drug is found to contain a possible carcinogen; and a new scale that measures peripheral impedance and pulse rate.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose 126 — Change to Monkeypox Vaccine Supply; Myfembree Indication Expanded; Amazon Among Companies to Receive FDA Warning; Impurity in Diabetes Tx MPR Weekly Dose 00:10:51 New authorization for intradermal administration of monkeypox vaccine; a new approval for endometriosis pain; Amazon is among the companies to receive an FDA Warning Letter for selling unapproved drugs; a diabetes drug is found to contain a possible carcinogen; and a new scale that measures peripheral impedance and pulse rate.   New authorization for intradermal administration of monkeypox vaccine; a new approval for endometriosis pain; Amazon is among the companies to receive an FDA Warning Letter for selling unapproved drugs; a diabetes drug is found to contain a possible carcinogen; and a new scale that measures peripheral impedance and pulse rate.   false full 124 97ca7281-77c2-409f-be50-96fa6e45a347 MPR Weekly Dose 125 — Device Cleared to Treat C-Section Pain; Plaque Psoriasis Cream; Contrast Agent Shortage Addressed; Lucentis Biosimilar Approved; OTC Laxative Recall Expanded A neurostimulation device has been cleared for post-C-section pain; a new plaque psoriasis treatment; the FDA address the contrast agent shortage; Lucentis biosimilar treatment is approved; and the recall for an over-the-counter laxative is expanded.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 5 Aug 2022 13:49:21 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com A neurostimulation device has been cleared for post-C-section pain; a new plaque psoriasis treatment; the FDA address the contrast agent shortage; Lucentis biosimilar treatment is approved; and the recall for an over-the-counter laxative is expanded.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose 125 — Device Cleared to Treat C-Section Pain; Plaque Psoriasis Cream; Contrast Agent Shortage Addressed; Lucentis Biosimilar Approved; OTC Laxative Recall Expanded MPR Weekly Dose 00:11:02 A neurostimulation device has been cleared for post-C-section pain; a new plaque psoriasis treatment; the FDA address the contrast agent shortage; Lucentis biosimilar treatment is approved; and the recall for an over-the-counter laxative is expanded. A neurostimulation device has been cleared for post-C-section pain; a new plaque psoriasis treatment; the FDA address the contrast agent shortage; Lucentis biosimilar treatment is approved; and the recall for an over-the-counter laxative is expanded. false full 123 aa47a716-8507-4713-8f6e-758f5e5952d5 MPR Weekly Dose 124 — Novavax Vaccine Gains EUA; Comirnaty Adolescent Approval; OTC Switch for Contraceptive; Nasal Spray Available OTC; Dupilumab for Pediatric EoE Novavax Emergency Use authorization; the Pfizer-BioNTech vaccine gets approval in adolescents; submission for oral contraceptive to be switched to over the counter; Astepro nasal spray gets over-the-counter approval; and Dupixent shows benefits in pediatric patients with eosinophilic esophagitis.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 15 Jul 2022 15:22:26 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com Novavax Emergency Use authorization; the Pfizer-BioNTech vaccine gets approval in adolescents; submission for oral contraceptive to be switched to over the counter; Astepro nasal spray gets over-the-counter approval; and Dupixent shows benefits in pediatric patients with eosinophilic esophagitis.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose 124 — Novavax Vaccine Gains EUA; Comirnaty Adolescent Approval; OTC Switch for Contraceptive; Nasal Spray Available OTC; Dupilumab for Pediatric EoE MPR Weekly Dose 00:13:35 Novavax Emergency Use authorization; the Pfizer-BioNTech vaccine gets approval in adolescents; submission for oral contraceptive to be switched to over the counter; Astepro nasal spray gets over-the-counter approval; and Dupixent shows benefits in pediatric patients with eosinophilic esophagitis. Novavax Emergency Use authorization; the Pfizer-BioNTech vaccine gets approval in adolescents; submission for oral contraceptive to be switched to over the counter; Astepro nasal spray gets over-the-counter approval; and Dupixent shows benefits in pediatric patients with eosinophilic esophagitis. false full 122 d2859993-391b-4097-b2d7-a70af6ec10f2 MPR Weekly Dose MPR 123 — Paxlovid Prescribing; Evusheld Dosing Updates; New Abuse-Deterrent Opioid; Lecanemab Priority Review; Morphine Tablet Recall Pharmacists now allowed to prescribe Paxlovid; new dosing recommendations for Evusheld; abuse-deterrent opioid analgesic; priority review for early alzheimer disease treatment; morphine tablets recalled.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Thu, 7 Jul 2022 20:23:57 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com Pharmacists now allowed to prescribe Paxlovid; new dosing recommendations for Evusheld; abuse-deterrent opioid analgesic; priority review for early alzheimer disease treatment; morphine tablets recalled.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose MPR 123 — Paxlovid Prescribing; Evusheld Dosing Updates; New Abuse-Deterrent Opioid; Lecanemab Priority Review; Morphine Tablet Recall MPR Weekly Dose 00:13:13 Pharmacists now allowed to prescribe Paxlovid; new dosing recommendations for Evusheld; abuse-deterrent opioid analgesic; priority review for early alzheimer disease treatment; morphine tablets recalled. Pharmacists now allowed to prescribe Paxlovid; new dosing recommendations for Evusheld; abuse-deterrent opioid analgesic; priority review for early alzheimer disease treatment; morphine tablets recalled. false full 121 b5d75c1a-5571-4d4c-877f-7bfbd4e0ae43 MPR Weekly Dose MPR 122 — Nasal Spray for Allergic Rhinitis; Qsymia Approval Expanded; Monkeypox Vaccine; Antibodies Shelf Life Extended; FDA Ban JUUL Products New nasal spray for allergic rhinitis; weight management drug indication is expanded to include teens; monkeypox vaccine access; COVID-19 antibody shelf-life extension; JUUL banned in the US.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 1 Jul 2022 13:58:12 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com New nasal spray for allergic rhinitis; weight management drug indication is expanded to include teens; monkeypox vaccine access; COVID-19 antibody shelf-life extension; JUUL banned in the US.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose MPR 122 — Nasal Spray for Allergic Rhinitis; Qsymia Approval Expanded; Monkeypox Vaccine; Antibodies Shelf Life Extended; FDA Ban JUUL Products MPR Weekly Dose 00:12:28 New nasal spray for allergic rhinitis; weight management drug indication is expanded to include teens; monkeypox vaccine access; COVID-19 antibody shelf-life extension; JUUL banned in the US. New nasal spray for allergic rhinitis; weight management drug indication is expanded to include teens; monkeypox vaccine access; COVID-19 antibody shelf-life extension; JUUL banned in the US. false full 120 81b15a5f-8b40-40ae-b3ec-6a16c792c9a2 MPR Weekly Dose MPR 121 — New Treatment for Crohn Disease; USPSTF Recommendations on Vitamins for CVD, CA Prevention; Panel Vote on Alzheimer Tx; Phexxi Analysis; Vaxneuvance Approved for Pediatrics Skyrizi gains new approval; the USPSTF make recommendations on multivitamin use to prevent CVD and cancer; an FDA Panel vote on pimavanserin efficacy for treating hallucinations associated with Alzheimer disease psychosis; Phexxi analysed in over 1000 patients; and Vaxneuvance approved for some pediatrics.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 24 Jun 2022 13:21:55 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com Skyrizi gains new approval; the USPSTF make recommendations on multivitamin use to prevent CVD and cancer; an FDA Panel vote on pimavanserin efficacy for treating hallucinations associated with Alzheimer disease psychosis; Phexxi analysed in over 1000 patients; and Vaxneuvance approved for some pediatrics.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose MPR 121 — New Treatment for Crohn Disease; USPSTF Recommendations on Vitamins for CVD, CA Prevention; Panel Vote on Alzheimer Tx; Phexxi Analysis; Vaxneuvance Approved for Pediatrics MPR Weekly Dose 00:13:50 Skyrizi gains new approval; the USPSTF make recommendations on multivitamin use to prevent CVD and cancer; an FDA Panel vote on pimavanserin efficacy for treating hallucinations associated with Alzheimer disease psychosis; Phexxi analysed in over 1000 patients; and Vaxneuvance approved for some pediatrics. Skyrizi gains new approval; the USPSTF make recommendations on multivitamin use to prevent CVD and cancer; an FDA Panel vote on pimavanserin efficacy for treating hallucinations associated with Alzheimer disease psychosis; Phexxi analysed in over 1000 patients; and Vaxneuvance approved for some pediatrics. false full 119 e5805eb3-debc-4ffe-a53e-682fcd35849c MPR Weekly Dose MPR 120 — Child COVID Vaccine Vote; Alopecia Tx Approved; Paxlovid in Standard Risk Patients; Autism Diagnostic Aid; Polyneuropathy hATTR Amyloidosis FDA panel vote on COVID vaccines for young children; new drug approved to treat alopecia; paxlovid tested in standard risk individuals; a device to aid autism diagnosis; and a new approval for polyneuropathy hATTR.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 17 Jun 2022 13:45:50 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com FDA panel vote on COVID vaccines for young children; new drug approved to treat alopecia; paxlovid tested in standard risk individuals; a device to aid autism diagnosis; and a new approval for polyneuropathy hATTR.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose MPR 120 — Child COVID Vaccine Vote; Alopecia Tx Approved; Paxlovid in Standard Risk Patients; Autism Diagnostic Aid; Polyneuropathy hATTR Amyloidosis MPR Weekly Dose 00:16:14 FDA panel vote on COVID vaccines for young children; new drug approved to treat alopecia; paxlovid tested in standard risk individuals; a device to aid autism diagnosis; and a new approval for polyneuropathy hATTR. FDA panel vote on COVID vaccines for young children; new drug approved to treat alopecia; paxlovid tested in standard risk individuals; a device to aid autism diagnosis; and a new approval for polyneuropathy hATTR. false full 118 ef733bda-ad6c-426d-bcb7-91dd1ca52863 MPR Weekly Dose MPR 119 — FDA Panel Votes on Novavax; MMR Vaccination; Dupixent Approval Expanded; Investigative COVID-19 Treatments The FDA Advisory Committee vote on Novavax; new option for MMR vaccination; Dupixent approval expanded; and we take a look at the latest data on COVID-19 treatments.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 10 Jun 2022 15:02:12 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com The FDA Advisory Committee vote on Novavax; new option for MMR vaccination; Dupixent approval expanded; and we take a look at the latest data on COVID-19 treatments.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose MPR 119 — FDA Panel Votes on Novavax; MMR Vaccination; Dupixent Approval Expanded; Investigative COVID-19 Treatments MPR Weekly Dose 00:15:35 The FDA Advisory Committee vote on Novavax; new option for MMR vaccination; Dupixent approval expanded; and we take a look at the latest data on COVID-19 treatments. The FDA Advisory Committee vote on Novavax; new option for MMR vaccination; Dupixent approval expanded; and we take a look at the latest data on COVID-19 treatments. false full 117 eefa6718-e100-4800-bc14-7d6c9cc698b4 MPR Weekly Dose 118 — Ukoniq Approval Withdrawn; Rescue Inhaler to Be Reviewed; Dupilumab Priority Review; Kymriah Update; Novel Postpartum Depression Tx Shows Promise Ukoniq, a treatment just approved last year, has been withdrawn; We rundown a host of drug pipeline news in asthma, dermatology and oncology; and there's positive results for a novel postpartum depression treatment.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 3 Jun 2022 15:41:27 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com Ukoniq, a treatment just approved last year, has been withdrawn; We rundown a host of drug pipeline news in asthma, dermatology and oncology; and there's positive results for a novel postpartum depression treatment.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose 118 — Ukoniq Approval Withdrawn; Rescue Inhaler to Be Reviewed; Dupilumab Priority Review; Kymriah Update; Novel Postpartum Depression Tx Shows Promise MPR Weekly Dose 00:11:14 Ukoniq, a treatment just approved last year, has been withdrawn; We rundown a host of drug pipeline news in asthma, dermatology and oncology; and there's positive results for a novel postpartum depression treatment. Ukoniq, a treatment just approved last year, has been withdrawn; We rundown a host of drug pipeline news in asthma, dermatology and oncology; and there's positive results for a novel postpartum depression treatment. false full 116 3d6bf6b5-db1a-4408-addf-26777f627e68 MPR Weekly Dose 117 — Guidance on Paxlovid Tx; Dupixent Approval; Plaque Psoriasis Cream Approved; COVID-19 Vaccine Response in Under 5s; CDC Monkeypox Alert The latest guidance for Paxlovid treatment following rebound reports; Dupixent gets a new approval; A new treatment is approved for plaque psoriasis; Update on the efficacy of a COVID-19 vaccine in those aged under 5; And the latest on Monkeypox.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 27 May 2022 15:10:46 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com The latest guidance for Paxlovid treatment following rebound reports; Dupixent gets a new approval; A new treatment is approved for plaque psoriasis; Update on the efficacy of a COVID-19 vaccine in those aged under 5; And the latest on Monkeypox.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose 117 — Guidance on Paxlovid Tx; Dupixent Approval; Plaque Psoriasis Cream Approved; COVID-19 Vaccine Response in Under 5s; CDC Monkeypox Alert MPR Weekly Dose 00:12:09 The latest guidance for Paxlovid treatment following rebound reports; Dupixent gets a new approval; A new treatment is approved for plaque psoriasis; Update on the efficacy of a COVID-19 vaccine in those aged under 5; And the latest on Monkeypox. The latest guidance for Paxlovid treatment following rebound reports; Dupixent gets a new approval; A new treatment is approved for plaque psoriasis; Update on the efficacy of a COVID-19 vaccine in those aged under 5; And the latest on Monkeypox. false full 115 8d46df49-2a63-46ee-bdd6-810f1b034c87 MPR Weekly Dose 116 — First-in-Class T2D Treatment; FDA Decline Fluvoxamine; Booster Doses for Children; COVID-19, Influenza, and RSV Test; Wearable Furosemide Delivery System The FDA decide to decline COVID-19 treatment; Booster doses authorized for children; A direct to consumer test to detect COVID-19, influenza, and RSV; And a wearable furosemide delivery system accepted for review.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 20 May 2022 18:12:22 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com The FDA decide to decline COVID-19 treatment; Booster doses authorized for children; A direct to consumer test to detect COVID-19, influenza, and RSV; And a wearable furosemide delivery system accepted for review.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose 116 — First-in-Class T2D Treatment; FDA Decline Fluvoxamine; Booster Doses for Children; COVID-19, Influenza, and RSV Test; Wearable Furosemide Delivery System MPR Weekly Dose 00:12:13 The FDA decide to decline COVID-19 treatment; Booster doses authorized for children; A direct to consumer test to detect COVID-19, influenza, and RSV; And a wearable furosemide delivery system accepted for review. The FDA decide to decline COVID-19 treatment; Booster doses authorized for children; A direct to consumer test to detect COVID-19, influenza, and RSV; And a wearable furosemide delivery system accepted for review. false full 114 79e998be-3ece-45bc-aff8-55fedcd6d097 MPR Weekly Dose 115 — Janus Kinase Inhibitor Approved for COVID-19; Varenicline Supply; Janssen Vaccine Limits Set; Test Safety Alert; Potential Hemodialysis Chemical Exposure Treatment approved for hospitalized COVID-19 patients; Update on Varenicline supply; Limits have been set for the Janssen COVID-19 vaccine; Safety alert issued for a COVID-19 test; And certain hemodialysis machines may carry the potential for chemical exposure.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Thu, 12 May 2022 17:41:50 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com Treatment approved for hospitalized COVID-19 patients; Update on Varenicline supply; Limits have been set for the Janssen COVID-19 vaccine; Safety alert issued for a COVID-19 test; And certain hemodialysis machines may carry the potential for chemical exposure.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose 115 — Janus Kinase Inhibitor Approved for COVID-19; Varenicline Supply; Janssen Vaccine Limits Set; Test Safety Alert; Potential Hemodialysis Chemical Exposure MPR Weekly Dose 00:11:40 Treatment approved for hospitalized COVID-19 patients; Update on Varenicline supply; Limits have been set for the Janssen COVID-19 vaccine; Safety alert issued for a COVID-19 test; And certain hemodialysis machines may carry the potential for chemical exposure. Treatment approved for hospitalized COVID-19 patients; Update on Varenicline supply; Limits have been set for the Janssen COVID-19 vaccine; Safety alert issued for a COVID-19 test; And certain hemodialysis machines may carry the potential for chemical exposure. false full 113 60fd98ae-e72c-448f-8f28-06f1f563ae79 MPR Weekly Dose 114 - USPSTF Aspirin Recommendations; COVID-19 treatment expansion; Accupril Recall; Counterfeit HIV Meds; White House Plan to Tackle Overdose Epidemic This week: USPSTF recommendations on aspirin use to prevent cardiovascular disease; Veklury indication expanded; Accupril Lots recalled; Legal action on counterfeit HIV medication; And the White House releases plan to tackle the overdose epidemic.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 29 Apr 2022 13:33:25 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com This week: USPSTF recommendations on aspirin use to prevent cardiovascular disease; Veklury indication expanded; Accupril Lots recalled; Legal action on counterfeit HIV medication; And the White House releases plan to tackle the overdose epidemic.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose 114 - USPSTF Aspirin Recommendations; COVID-19 treatment expansion; Accupril Recall; Counterfeit HIV Meds; White House Plan to Tackle Overdose Epidemic MPR Weekly Dose 00:13:10 This week: USPSTF recommendations on aspirin use to prevent cardiovascular disease; Veklury indication expanded; Accupril Lots recalled; Legal action on counterfeit HIV medication; And the White House releases plan to tackle the overdose epidemic. This week: USPSTF recommendations on aspirin use to prevent cardiovascular disease; Veklury indication expanded; Accupril Lots recalled; Legal action on counterfeit HIV medication; And the White House releases plan to tackle the overdose epidemic. false full 112 7dae7c97-ffe2-4fe0-bf4f-7e720cef06ef MPR Weekly Dose 113 - Sabizabulin Trial Stopped; Booster Request for Peds; Diversity in Clinical Trials; Myopericarditis Risks Compared for Vaccines; Approval Effect on the Unvaccinated This week: the halting of the sabizabulin trial in COVID-19; Emergency Use Authorization to be requested for booster dose in 5 to 11 year olds; Diversity in Clinical Trials; Myopericarditis risk compared for COVID-19 vaccines vs other vaccines; And survey results of unvaccinated attitudes following FDA approval.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 15 Apr 2022 15:28:24 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com This week: the halting of the sabizabulin trial in COVID-19; Emergency Use Authorization to be requested for booster dose in 5 to 11 year olds; Diversity in Clinical Trials; Myopericarditis risk compared for COVID-19 vaccines vs other vaccines; And survey results of unvaccinated attitudes following FDA approval.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose 113 - Sabizabulin Trial Stopped; Booster Request for Peds; Diversity in Clinical Trials; Myopericarditis Risks Compared for Vaccines; Approval Effect on the Unvaccinated MPR Weekly Dose 00:13:00 This week: the halting of the sabizabulin trial in COVID-19; Emergency Use Authorization to be requested for booster dose in 5 to 11 year olds; Diversity in Clinical Trials; Myopericarditis risk compared for COVID-19 vaccines vs other vaccines; And survey results of unvaccinated attitudes following FDA approval. This week: the halting of the sabizabulin trial in COVID-19; Emergency Use Authorization to be requested for booster dose in 5 to 11 year olds; Diversity in Clinical Trials; Myopericarditis risk compared for COVID-19 vaccines vs other vaccines; And survey results of unvaccinated attitudes following FDA approval. false full 111 b3b10107-ec37-46aa-83bb-4edb6ae805ef MPR Weekly Dose 112 - Second COVID-19 Booster Dose Authorized; Sotrovimab Use Limited; Oral COVID-19 Tx; PreHevbrio Hep B Vaccination; Thyroid Dysfunction Alert Following ICM A second booster dose for some COVID-19 vaccines is authorized; Sotrovimab has its use limited due to the BA.2 Omicron subvariant; An investigational oral antiviral gains Fast Track designation; PreHevbrio hepatitis B vaccine now available; And the FDA update a safety communication regard the risk of thyroid dysfunction in infants following the use of contrast media containing iodine.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 1 Apr 2022 14:54:46 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com A second booster dose for some COVID-19 vaccines is authorized; Sotrovimab has its use limited due to the BA.2 Omicron subvariant; An investigational oral antiviral gains Fast Track designation; PreHevbrio hepatitis B vaccine now available; And the FDA update a safety communication regard the risk of thyroid dysfunction in infants following the use of contrast media containing iodine.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose 112 - Second COVID-19 Booster Dose Authorized; Sotrovimab Use Limited; Oral COVID-19 Tx; PreHevbrio Hep B Vaccination; Thyroid Dysfunction Alert Following ICM MPR Weekly Dose 00:11:42 A second booster dose for some COVID-19 vaccines is authorized; Sotrovimab has its use limited due to the BA.2 Omicron subvariant; An investigational oral antiviral gains Fast Track designation; PreHevbrio hepatitis B vaccine now available; And the FDA update a safety communication regard the risk of thyroid dysfunction in infants following the use of contrast media containing iodine. A second booster dose for some COVID-19 vaccines is authorized; Sotrovimab has its use limited due to the BA.2 Omicron subvariant; An investigational oral antiviral gains Fast Track designation; PreHevbrio hepatitis B vaccine now available; And the FDA update a safety communication regard the risk of thyroid dysfunction in infants following the use of contrast media containing iodine. false full 110 5d727bd8-6079-4041-9117-018bb1b0bb6e MPR Weekly Dose 111 - Allergy Spray OTC Switch; Syringe Malfunction Prompts Recall; Sciatica Pain Tx Update; FDA Alert for COVID-19 Tests; Resubmitted Teplizumab Application Accepted Allergy treatment gets over-the-counter approval; Anaphylaxis treatment recalled; Phase 3 trial results for investigational sciatica treatment; FDA alert regarding at-home COVID tests; And the resubmitted Biologics License Application for teplizumab for type 1 diabetes is accepted.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 25 Mar 2022 14:23:45 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com Allergy treatment gets over-the-counter approval; Anaphylaxis treatment recalled; Phase 3 trial results for investigational sciatica treatment; FDA alert regarding at-home COVID tests; And the resubmitted Biologics License Application for teplizumab for type 1 diabetes is accepted.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose 111 - Allergy Spray OTC Switch; Syringe Malfunction Prompts Recall; Sciatica Pain Tx Update; FDA Alert for COVID-19 Tests; Resubmitted Teplizumab Application Accepted MPR Weekly Dose 00:10:55 Allergy treatment gets over-the-counter approval; Anaphylaxis treatment recalled; Phase 3 trial results for investigational sciatica treatment; FDA alert regarding at-home COVID tests; And the resubmitted Biologics License Application for teplizumab for type 1 diabetes is accepted.  Allergy treatment gets over-the-counter approval; Anaphylaxis treatment recalled; Phase 3 trial results for investigational sciatica treatment; FDA alert regarding at-home COVID tests; And the resubmitted Biologics License Application for teplizumab for type 1 diabetes is accepted.  false full 109 174b7cd7-e023-4553-8a99-b8287d346ca0 MPR Weekly Dose #110: Interview With Dr Tobias Janowitz In this week's special episode of The Weekly Dose Podcast we interview Dr Tobias Janowitz, a medical oncologist, assistant professor at the Cold Spring Harbor Laboratories and adjunct professor at the Feinstein Institutes. Dr Janowitz was part of a team that recently conducted a phase 2 clinical trial assessing high doses of famotidine in adults with COVID-19. The trial was conducted completely remotely and the findings were published in Gut. As well as discussing their findings, Dr Janowitz talks about the process of conducting a fully-remote trial and the greater possibilities this may hold for future clinical research.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 18 Mar 2022 18:02:09 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com In this week's special episode of The Weekly Dose Podcast we interview Dr Tobias Janowitz, a medical oncologist, assistant professor at the Cold Spring Harbor Laboratories and adjunct professor at the Feinstein Institutes. Dr Janowitz was part of a team that recently conducted a phase 2 clinical trial assessing high doses of famotidine in adults with COVID-19. The trial was conducted completely remotely and the findings were published in Gut. As well as discussing their findings, Dr Janowitz talks about the process of conducting a fully-remote trial and the greater possibilities this may hold for future clinical research.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose #110: Interview With Dr Tobias Janowitz MPR Weekly Dose 00:20:06 In this week's special episode of The Weekly Dose Podcast we interview Dr Tobias Janowitz, a medical oncologist, assistant professor at the Cold Spring Harbor Laboratories and adjunct professor at the Feinstein Institutes. Dr Janowitz was part of a team that recently conducted a phase 2 clinical trial assessing high doses of famotidine in adults with COVID-19. The trial was conducted completely remotely and the findings were published in Gut. As well as discussing their findings, Dr Janowitz talks about the process of conducting a fully-remote trial and the greater possibilities this may hold for future clinical research. In this week's special episode of The Weekly Dose Podcast we interview Dr Tobias Janowitz, a medical oncologist, assistant professor at the Cold Spring Harbor Laboratories and adjunct professor at the Feinstein Institutes. Dr Janowitz was part of a team that recently conducted a phase 2 clinical trial assessing high doses of famotidine in adults with COVID-19. The trial was conducted completely remotely and the findings were published in Gut. As well as discussing their findings, Dr Janowitz talks about the process of conducting a fully-remote trial and the greater possibilities this may hold for future clinical research. false full 108 455b4ec9-f6e0-4b4d-87dd-4c50d93fcbc0 MPR Weekly Dose 109 - Purdue Overdose Treatment Approved; ACIP Immunization Schedules; FDA Provide List of COVID-19 Tests; Urticaria Trial Stopped; First Condom for Anal Intercourse. A new injection is approved for opioid overdose; The Advisory Committee on Immunization Practices releases vaccine schedules; The FDA provides a list of approved COVID-19 tests; A trial of an investigational spontaneous urticaria treatment is stopped; And the first condom is authorized for anal intercourse.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 25 Feb 2022 14:27:54 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com A new injection is approved for opioid overdose; The Advisory Committee on Immunization Practices releases vaccine schedules; The FDA provides a list of approved COVID-19 tests; A trial of an investigational spontaneous urticaria treatment is stopped; And the first condom is authorized for anal intercourse.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose 109 - Purdue Overdose Treatment Approved; ACIP Immunization Schedules; FDA Provide List of COVID-19 Tests; Urticaria Trial Stopped; First Condom for Anal Intercourse. MPR Weekly Dose 00:13:19 A new injection is approved for opioid overdose; The Advisory Committee on Immunization Practices releases vaccine schedules; The FDA provides a list of approved COVID-19 tests; A trial of an investigational spontaneous urticaria treatment is stopped; And the first condom is authorized for anal intercourse. A new injection is approved for opioid overdose; The Advisory Committee on Immunization Practices releases vaccine schedules; The FDA provides a list of approved COVID-19 tests; A trial of an investigational spontaneous urticaria treatment is stopped; And the first condom is authorized for anal intercourse. false full 107 d936bc32-9693-46c2-81f9-d0d4f44f08f4 MPR Weekly Dose 108 - OTC Treatment Shows Benefit in COVID-19; Emergency Use Granted to Antibody; Parkinson Disease Tx Available; Veklury Study Results; Safety Concern for Ketamine This week in COVID related news, a heartburn medication shows benefit in patients; Bebtelovimab is authroized; Veklury is shown to retain antiviral activity against variants. Away from COVID, a functionally scored carbidopa/levodopa tablet is now available for Parkinson disease, and the FDA issue a ketamine compounding warning.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 18 Feb 2022 16:39:06 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com This week in COVID related news, a heartburn medication shows benefit in patients; Bebtelovimab is authroized; Veklury is shown to retain antiviral activity against variants. Away from COVID, a functionally scored carbidopa/levodopa tablet is now available for Parkinson disease, and the FDA issue a ketamine compounding warning.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose 108 - OTC Treatment Shows Benefit in COVID-19; Emergency Use Granted to Antibody; Parkinson Disease Tx Available; Veklury Study Results; Safety Concern for Ketamine MPR Weekly Dose 00:14:38 This week in COVID related news, a heartburn medication shows benefit in patients; Bebtelovimab is authroized; Veklury is shown to retain antiviral activity against variants. Away from COVID, a functionally scored carbidopa/levodopa tablet is now available for Parkinson disease, and the FDA issue a ketamine compounding warning. This week in COVID related news, a heartburn medication shows benefit in patients; Bebtelovimab is authroized; Veklury is shown to retain antiviral activity against variants. Away from COVID, a functionally scored carbidopa/levodopa tablet is now available for Parkinson disease, and the FDA issue a ketamine compounding warning. false full 106 8e0c478e-a2e9-4675-9884-fcfb4709bd0e MPR Weekly Dose 107 - Millions of Molnupiravir Courses Delivered; Guidance on Nonopioid Analgesic Development; Enteral Feeding Tube Warning; Enjaymo Approved; Mecarbil Under Review for HFrEF This week: news of millions of courses of a COVID-19 oral antiviral being provided to the US government for distribution throughout the country; There's a draft guidance for novel nonopioid analgesics; Possible strangulation warning for enteral feeding tubes; A new treatment has been approved for cold agglutinin disease; And a treatment is under review for HFrEF.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 11 Feb 2022 14:53:02 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com This week: news of millions of courses of a COVID-19 oral antiviral being provided to the US government for distribution throughout the country; There's a draft guidance for novel nonopioid analgesics; Possible strangulation warning for enteral feeding tubes; A new treatment has been approved for cold agglutinin disease; And a treatment is under review for HFrEF.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose 107 - Millions of Molnupiravir Courses Delivered; Guidance on Nonopioid Analgesic Development; Enteral Feeding Tube Warning; Enjaymo Approved; Mecarbil Under Review for HFrEF MPR Weekly Dose 00:10:51 This week: news of millions of courses of a COVID-19 oral antiviral being provided to the US government for distribution throughout the country; There's a draft guidance for novel nonopioid analgesics; Possible strangulation warning for enteral feeding tubes; A new treatment has been approved for cold agglutinin disease; And a treatment is under review for HFrEF. This week: news of millions of courses of a COVID-19 oral antiviral being provided to the US government for distribution throughout the country; There's a draft guidance for novel nonopioid analgesics; Possible strangulation warning for enteral feeding tubes; A new treatment has been approved for cold agglutinin disease; And a treatment is under review for HFrEF. false full 105 00f915f6-e8bd-4d1f-b777-a5185a679e6f MPR Weekly Dose 106 - FDA Approves COVID-19 Vaccine; EUA Submission for Kids Under 5; COVID Tests Recalled; Vupanorsen Development Ends; Cabenuva Approval Expanded This week: The approval of a second COVID-19 vaccine; Pfizer and BioNTech submit for Emergency use of their vaccine for children under 5; Pfizer have also stopped development on a potential drug treatment to reduce cardiovascular risk and severe hypertriglyceridemia; And new dosing options for a HIV drug.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Thu, 3 Feb 2022 22:47:57 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com This week: The approval of a second COVID-19 vaccine; Pfizer and BioNTech submit for Emergency use of their vaccine for children under 5; Pfizer have also stopped development on a potential drug treatment to reduce cardiovascular risk and severe hypertriglyceridemia; And new dosing options for a HIV drug.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose 106 - FDA Approves COVID-19 Vaccine; EUA Submission for Kids Under 5; COVID Tests Recalled; Vupanorsen Development Ends; Cabenuva Approval Expanded MPR Weekly Dose 00:13:29 This week: The approval of a second COVID-19 vaccine; Pfizer and BioNTech submit for Emergency use of their vaccine for children under 5; Pfizer have also stopped development on a potential drug treatment to reduce cardiovascular risk and severe hypertriglyceridemia; And new dosing options for a HIV drug. This week: The approval of a second COVID-19 vaccine; Pfizer and BioNTech submit for Emergency use of their vaccine for children under 5; Pfizer have also stopped development on a potential drug treatment to reduce cardiovascular risk and severe hypertriglyceridemia; And new dosing options for a HIV drug. false full 104 6d89f16d-2159-457f-93a2-f08f61745cb9 MPR Weekly Dose 105 - Antibody Therapies Restricted; Veklury Greenlit for Outpatients; Parsaclisib Indication Withdrawn; Pepaxto Withdrawal Reconsidered; Kimmtrak Approved Use of monoclonal antibodies restricted due to Omicron; Veklury given the go-ahead as an outpatient treatment; New data produces a reconsideration for Pepaxto withdrawal; And there's a new treatment approval for unresectable or metastatic uveal melanoma.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 28 Jan 2022 00:34:48 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com Use of monoclonal antibodies restricted due to Omicron; Veklury given the go-ahead as an outpatient treatment; New data produces a reconsideration for Pepaxto withdrawal; And there's a new treatment approval for unresectable or metastatic uveal melanoma.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose 105 - Antibody Therapies Restricted; Veklury Greenlit for Outpatients; Parsaclisib Indication Withdrawn; Pepaxto Withdrawal Reconsidered; Kimmtrak Approved MPR Weekly Dose 00:11:22 Use of monoclonal antibodies restricted due to Omicron; Veklury given the go-ahead as an outpatient treatment; New data produces a reconsideration for Pepaxto withdrawal; And there's a new treatment approval for unresectable or metastatic uveal melanoma. Use of monoclonal antibodies restricted due to Omicron; Veklury given the go-ahead as an outpatient treatment; New data produces a reconsideration for Pepaxto withdrawal; And there's a new treatment approval for unresectable or metastatic uveal melanoma. false full 103 bf9d6257-223e-4505-ae8c-3e3fbc5b8090 MPR Weekly Dose 104 - Two New Atopic Dermatitis Therapies; Counterfeit HIV; Indications Withdrawn for Zydelig; CDC Pediatric Influenza Vaccine Study Results; COVID Test Warning This week we have news of two new approval for atopic dermatitis; Warnings around counterfeit HIV treatments; Zydelig indications withdrawn; CDC pediatric influenza vaccine study results; And an FDA warning against a particular brand of COVID-19 antibody tests.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Thu, 20 Jan 2022 22:11:26 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com This week we have news of two new approval for atopic dermatitis; Warnings around counterfeit HIV treatments; Zydelig indications withdrawn; CDC pediatric influenza vaccine study results; And an FDA warning against a particular brand of COVID-19 antibody tests.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose 104 - Two New Atopic Dermatitis Therapies; Counterfeit HIV; Indications Withdrawn for Zydelig; CDC Pediatric Influenza Vaccine Study Results; COVID Test Warning MPR Weekly Dose 00:12:32 This week we have news of two new approval for atopic dermatitis; Warnings around counterfeit HIV treatments; Zydelig indications withdrawn; CDC pediatric influenza vaccine study results; And an FDA warning against a particular brand of COVID-19 antibody tests. This week we have news of two new approval for atopic dermatitis; Warnings around counterfeit HIV treatments; Zydelig indications withdrawn; CDC pediatric influenza vaccine study results; And an FDA warning against a particular brand of COVID-19 antibody tests. false full 102 75e77d6b-62ec-48a8-89b1-699c5d74e3a3 MPR Weekly Dose 103 - Novel treatment for insomnia; Magnesium health claim; Dental decay and transmucosal med; Vaccine and menstrual cycle findings; Best diets for 2022 This week: Novel insomnia treatment; The FDA comment on magnesium hypertension claim; Transmucosal buprenorphine linked to dental decay; Researchers assess changes in menstrual cycle in relation to COVID vaccines; And experts have their say on the best diets for 2022.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Thu, 13 Jan 2022 21:17:09 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com This week: Novel insomnia treatment; The FDA comment on magnesium hypertension claim; Transmucosal buprenorphine linked to dental decay; Researchers assess changes in menstrual cycle in relation to COVID vaccines; And experts have their say on the best diets for 2022.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose 103 - Novel treatment for insomnia; Magnesium health claim; Dental decay and transmucosal med; Vaccine and menstrual cycle findings; Best diets for 2022 MPR Weekly Dose 00:12:17 This week: Novel insomnia treatment; The FDA comment on magnesium hypertension claim; Transmucosal buprenorphine linked to dental decay; Researchers assess changes in menstrual cycle in relation to COVID vaccines; And experts have their say on the best diets for 2022. This week: Novel insomnia treatment; The FDA comment on magnesium hypertension claim; Transmucosal buprenorphine linked to dental decay; Researchers assess changes in menstrual cycle in relation to COVID vaccines; And experts have their say on the best diets for 2022. false full 101 e6e143c3-ca53-4aef-b455-5bc1a036bffc MPR Weekly Dose 102 - COVID-19 vaccine contraindication; Final results for COVID-19 antiviral; Entadfi approved; CAR T-cell REMS change; New approval for psoriatic arthritis Contraindication added to Janssen COVID-19 vaccine; Pfizer announce final results for their COVID-19 oral antiviral; A new treatment for benign prostatic hyperplasia; REMS change for CAR T-cell therapy, and Rinvoq gains approval for active psoriatic arthritis.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 17 Dec 2021 14:41:45 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com Contraindication added to Janssen COVID-19 vaccine; Pfizer announce final results for their COVID-19 oral antiviral; A new treatment for benign prostatic hyperplasia; REMS change for CAR T-cell therapy, and Rinvoq gains approval for active psoriatic arthritis.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose 102 - COVID-19 vaccine contraindication; Final results for COVID-19 antiviral; Entadfi approved; CAR T-cell REMS change; New approval for psoriatic arthritis MPR Weekly Dose 00:14:20 Contraindication added to Janssen COVID-19 vaccine; Pfizer announce final results for their COVID-19 oral antiviral; A new treatment for benign prostatic hyperplasia; REMS change for CAR T-cell therapy, and Rinvoq gains approval for active psoriatic arthritis.  Contraindication added to Janssen COVID-19 vaccine; Pfizer announce final results for their COVID-19 oral antiviral; A new treatment for benign prostatic hyperplasia; REMS change for CAR T-cell therapy, and Rinvoq gains approval for active psoriatic arthritis.  false full 100 2a3f212b-efb4-41c5-bcb1-94d49c056b4a MPR Weekly Dose 101 - COVID-19: Pre-exposure prophylaxis approved; Omicron vaccine protection; Antibody authorized for kids; Heterolous boosting assessed; Veklury recall This week we bring you up to speed on a lot of COVID-related news, despite the emergence of Omicron, there is positive news; Evusheld has become the first pre-exposure prophylaxis for COVID-19; Data shows that the Pfizer-BioNTech booster dose offers protection against Omicron; Monoclonal antibody therapy is authorized for kids; Heterologous boosting may be more beneficial than homogeneous; and important info about some Veklury lots being recalled.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 10 Dec 2021 16:09:54 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com This week we bring you up to speed on a lot of COVID-related news, despite the emergence of Omicron, there is positive news; Evusheld has become the first pre-exposure prophylaxis for COVID-19; Data shows that the Pfizer-BioNTech booster dose offers protection against Omicron; Monoclonal antibody therapy is authorized for kids; Heterologous boosting may be more beneficial than homogeneous; and important info about some Veklury lots being recalled.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose 101 - COVID-19: Pre-exposure prophylaxis approved; Omicron vaccine protection; Antibody authorized for kids; Heterolous boosting assessed; Veklury recall MPR Weekly Dose 00:13:27 This week we bring you up to speed on a lot of COVID-related news, despite the emergence of Omicron, there is positive news; Evusheld has become the first pre-exposure prophylaxis for COVID-19; Data shows that the Pfizer-BioNTech booster dose offers protection against Omicron; Monoclonal antibody therapy is authorized for kids; Heterologous boosting may be more beneficial than homogeneous; and important info about some Veklury lots being recalled. This week we bring you up to speed on a lot of COVID-related news, despite the emergence of Omicron, there is positive news; Evusheld has become the first pre-exposure prophylaxis for COVID-19; Data shows that the Pfizer-BioNTech booster dose offers protection against Omicron; Monoclonal antibody therapy is authorized for kids; Heterologous boosting may be more beneficial than homogeneous; and important info about some Veklury lots being recalled. false full 99 c841723d-ffff-4700-8767-0fdd8cd9df17 MPR Weekly Dose 100 - Paxlovid EUA submission; Drugs linked to orthostatic hypotension; Besremi approved; Pill for remote endoscopy; Largest psilocybin trial to date We made it to 100! This week Pfizer seeks Emergency Use Authorization for their COVID oral antiviral; A meta-analysis found commonly prescribed drugs were linked to orthostatic hypotension; A novel treatment is approved for polycythemia vera; A new program has been cleared to allow individuals to carry out remote endoscopy procedures; And the largest to date psilocybin trial shows promise in treatment-resistant depression.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 19 Nov 2021 14:26:15 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com We made it to 100! This week Pfizer seeks Emergency Use Authorization for their COVID oral antiviral; A meta-analysis found commonly prescribed drugs were linked to orthostatic hypotension; A novel treatment is approved for polycythemia vera; A new program has been cleared to allow individuals to carry out remote endoscopy procedures; And the largest to date psilocybin trial shows promise in treatment-resistant depression.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose 100 - Paxlovid EUA submission; Drugs linked to orthostatic hypotension; Besremi approved; Pill for remote endoscopy; Largest psilocybin trial to date MPR Weekly Dose 00:13:22 We made it to 100! This week Pfizer seeks Emergency Use Authorization for their COVID oral antiviral; A meta-analysis found commonly prescribed drugs were linked to orthostatic hypotension; A novel treatment is approved for polycythemia vera; A new program has been cleared to allow individuals to carry out remote endoscopy procedures; And the largest to date psilocybin trial shows promise in treatment-resistant depression.  We made it to 100! This week Pfizer seeks Emergency Use Authorization for their COVID oral antiviral; A meta-analysis found commonly prescribed drugs were linked to orthostatic hypotension; A novel treatment is approved for polycythemia vera; A new program has been cleared to allow individuals to carry out remote endoscopy procedures; And the largest to date psilocybin trial shows promise in treatment-resistant depression.  false full 98 833d5b6b-1b94-4bed-9b7e-1db0c84b021f MPR Weekly Dose 99 - Oral COVID-19 candidate reduces risk of death; aromatherapy sprays recalled; Presbyopia Tx; Naloxone alternative; Migraine drug head-to-head study This week there's positive news for the COVID-19 oral antiviral candidate, Paxlovid; The CDC expands a recall for aromatherapy sprays connected to fatal cases of a rare tropical disease; The first eye drop to treat presbyopia is approved; An alternative to naloxone gets fast tracked; And a study compares the migraine treatments erenumab and topiramate.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 12 Nov 2021 15:56:51 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com This week there's positive news for the COVID-19 oral antiviral candidate, Paxlovid; The CDC expands a recall for aromatherapy sprays connected to fatal cases of a rare tropical disease; The first eye drop to treat presbyopia is approved; An alternative to naloxone gets fast tracked; And a study compares the migraine treatments erenumab and topiramate.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose 99 - Oral COVID-19 candidate reduces risk of death; aromatherapy sprays recalled; Presbyopia Tx; Naloxone alternative; Migraine drug head-to-head study MPR Weekly Dose 00:11:42 This week there's positive news for the COVID-19 oral antiviral candidate, Paxlovid; The CDC expands a recall for aromatherapy sprays connected to fatal cases of a rare tropical disease; The first eye drop to treat presbyopia is approved; An alternative to naloxone gets fast tracked; And a study compares the migraine treatments erenumab and topiramate.  This week there's positive news for the COVID-19 oral antiviral candidate, Paxlovid; The CDC expands a recall for aromatherapy sprays connected to fatal cases of a rare tropical disease; The first eye drop to treat presbyopia is approved; An alternative to naloxone gets fast tracked; And a study compares the migraine treatments erenumab and topiramate.  false full 97 72dc2caa-01a1-45ba-901a-a024044850b1 MPR Weekly Dose 98 - FDA Committee Vote on Vaccines for Children; Booster Efficacy Results; Shingrix Recommendations; Novel Treatment for Macular Edema; Pepaxto Withdrawn The FDA votes on whether the Pfizer-BioNTech vaccine should be authorized in 5 to 11 year olds; The Moderna vaccine elicits strong antibody responses in pediatrics; Trial results shed light on booster dose efficacy; Shingrix is recommended for immunocompromised patients; A novel treatment is approved for macular edema associated with uveitis; And Pepaxto is withdrawn following new findings.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 29 Oct 2021 14:01:04 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com The FDA votes on whether the Pfizer-BioNTech vaccine should be authorized in 5 to 11 year olds; The Moderna vaccine elicits strong antibody responses in pediatrics; Trial results shed light on booster dose efficacy; Shingrix is recommended for immunocompromised patients; A novel treatment is approved for macular edema associated with uveitis; And Pepaxto is withdrawn following new findings.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose 98 - FDA Committee Vote on Vaccines for Children; Booster Efficacy Results; Shingrix Recommendations; Novel Treatment for Macular Edema; Pepaxto Withdrawn MPR Weekly Dose 00:14:29 The FDA votes on whether the Pfizer-BioNTech vaccine should be authorized in 5 to 11 year olds; The Moderna vaccine elicits strong antibody responses in pediatrics; Trial results shed light on booster dose efficacy; Shingrix is recommended for immunocompromised patients; A novel treatment is approved for macular edema associated with uveitis; And Pepaxto is withdrawn following new findings. The FDA votes on whether the Pfizer-BioNTech vaccine should be authorized in 5 to 11 year olds; The Moderna vaccine elicits strong antibody responses in pediatrics; Trial results shed light on booster dose efficacy; Shingrix is recommended for immunocompromised patients; A novel treatment is approved for macular edema associated with uveitis; And Pepaxto is withdrawn following new findings. false full 96 445b1c1a-4e62-4b51-835d-6feaf707fe62 MPR Weekly Dose 97 - 'Mix and Match' Boosters Authorized; Biosimilar to Humira; Nasal Spray for Dry Eye Disease; Novel Pain Treatment; Opioid Overdose Treatment This week: big news announced in COVID-19, with the FDA stating that mixing and matching of vaccines for the booster dose is authorized. The first interchangeable biosimilar to Humira is approved. Also there's approvals for dry eye disease, pain management and opioid overdoses.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 22 Oct 2021 13:30:49 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com This week: big news announced in COVID-19, with the FDA stating that mixing and matching of vaccines for the booster dose is authorized. The first interchangeable biosimilar to Humira is approved. Also there's approvals for dry eye disease, pain management and opioid overdoses.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose 97 - 'Mix and Match' Boosters Authorized; Biosimilar to Humira; Nasal Spray for Dry Eye Disease; Novel Pain Treatment; Opioid Overdose Treatment MPR Weekly Dose 00:12:10 This week: big news announced in COVID-19, with the FDA stating that mixing and matching of vaccines for the booster dose is authorized. The first interchangeable biosimilar to Humira is approved. Also there's approvals for dry eye disease, pain management and opioid overdoses.  This week: big news announced in COVID-19, with the FDA stating that mixing and matching of vaccines for the booster dose is authorized. The first interchangeable biosimilar to Humira is approved. Also there's approvals for dry eye disease, pain management and opioid overdoses.  false full 95 341adee6-d3ea-46c5-bfd6-10f35457f88b MPR Weekly Dose 96 - Updated Aspirin Recommendations; Needle-Free Warning; Isotretinoin REMS program; Pediatric Athymia Tx; EU Request for Molnupiravir; Advisory Panel Votes on Moderna Booster Shot This week the USPSTF update aspirin recommendations for those 60 years and older; The FDA take a stance on needle-free devices for injecting dermal fillers; REMS requirements are updated for isotretinoin products; A new treatment approved for pediatric congenital athymia; An emergency use request submitted for an oral antiviral COVID treatment; And the FDA advisory panel vote on boosters for the Moderna vaccine.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 15 Oct 2021 13:37:06 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com This week the USPSTF update aspirin recommendations for those 60 years and older; The FDA take a stance on needle-free devices for injecting dermal fillers; REMS requirements are updated for isotretinoin products; A new treatment approved for pediatric congenital athymia; An emergency use request submitted for an oral antiviral COVID treatment; And the FDA advisory panel vote on boosters for the Moderna vaccine.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose 96 - Updated Aspirin Recommendations; Needle-Free Warning; Isotretinoin REMS program; Pediatric Athymia Tx; EU Request for Molnupiravir; Advisory Panel Votes on Moderna Booster Shot MPR Weekly Dose 00:13:17 This week the USPSTF update aspirin recommendations for those 60 years and older; The FDA take a stance on needle-free devices for injecting dermal fillers; REMS requirements are updated for isotretinoin products; A new treatment approved for pediatric congenital athymia; An emergency use request submitted for an oral antiviral COVID treatment; And the FDA advisory panel vote on boosters for the Moderna vaccine. This week the USPSTF update aspirin recommendations for those 60 years and older; The FDA take a stance on needle-free devices for injecting dermal fillers; REMS requirements are updated for isotretinoin products; A new treatment approved for pediatric congenital athymia; An emergency use request submitted for an oral antiviral COVID treatment; And the FDA advisory panel vote on boosters for the Moderna vaccine. false full 94 f99d4dc6-4719-491a-831a-0d548f354e30 MPR Weekly Dose 95 - Interview with Dr Preeti Malani, Chief Health Officer and Professor of Medicine in the Division of Infectious Diseases at the University of Michigan Dr Preeti Malani, Chief Health Officer at UM, joined us to talk about the current state of the COVID-19 pandemic, including vaccine hesitancy, mandates, boosters and how the future may unfold.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Thu, 7 Oct 2021 14:52:26 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com Dr Preeti Malani, Chief Health Officer at UM, joined us to talk about the current state of the COVID-19 pandemic, including vaccine hesitancy, mandates, boosters and how the future may unfold.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose 95 - Interview with Dr Preeti Malani, Chief Health Officer and Professor of Medicine in the Division of Infectious Diseases at the University of Michigan MPR Weekly Dose 00:23:03 Dr Preeti Malani, Chief Health Officer at UM, joined us to talk about the current state of the COVID-19 pandemic, including vaccine hesitancy, mandates, boosters and how the future may unfold. Dr Preeti Malani, Chief Health Officer at UM, joined us to talk about the current state of the COVID-19 pandemic, including vaccine hesitancy, mandates, boosters and how the future may unfold. false full 93 7c6bccee-b781-4140-98a1-6d0af702e953 MPR Weekly Dose 94 - COVID Vaccine Booster Doses; Pediatric Vaccine Trial; Parental Vaccine Hesitancy; Remdesivir and Hospitalization Risk; Atopic Dermatitis Treatment The Pfizer-BioNTech vaccine gets Emergency Use Authorization for booster dose in certain individuals; A smaller dose appears safe and effective in children; Janssen share booster data for their vaccine; A survey sheds light on parents' thoughts on child COVID vaccination; Remdesivir efficacy data in COVID-19 patients, And Opzelura is approved for atopic dermatitis.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 24 Sep 2021 17:08:48 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com The Pfizer-BioNTech vaccine gets Emergency Use Authorization for booster dose in certain individuals; A smaller dose appears safe and effective in children; Janssen share booster data for their vaccine; A survey sheds light on parents' thoughts on child COVID vaccination; Remdesivir efficacy data in COVID-19 patients, And Opzelura is approved for atopic dermatitis.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose 94 - COVID Vaccine Booster Doses; Pediatric Vaccine Trial; Parental Vaccine Hesitancy; Remdesivir and Hospitalization Risk; Atopic Dermatitis Treatment MPR Weekly Dose 00:13:42 The Pfizer-BioNTech vaccine gets Emergency Use Authorization for booster dose in certain individuals; A smaller dose appears safe and effective in children; Janssen share booster data for their vaccine; A survey sheds light on parents' thoughts on child COVID vaccination; Remdesivir efficacy data in COVID-19 patients, And Opzelura is approved for atopic dermatitis. The Pfizer-BioNTech vaccine gets Emergency Use Authorization for booster dose in certain individuals; A smaller dose appears safe and effective in children; Janssen share booster data for their vaccine; A survey sheds light on parents' thoughts on child COVID vaccination; Remdesivir efficacy data in COVID-19 patients, And Opzelura is approved for atopic dermatitis. false full 92 eefa93fc-96c6-4ecc-9f75-6ad32c45017f MPR Weekly Dose 93 - Mandatory Opioid Prescriber Education; Rise in Delta-8 THC Products; Brukinsa and Exkivity Approved; Warning Letters for Supplement Companies This week the FDA weigh up mandatory education for opioid prescribers; There's an increase in the sale of strong psychoactive THC products; Brukinsa and Exkivity gain approvals for lymphoma and NSCLC, respectively; And a number of supplement companies received FDA warning letters.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 17 Sep 2021 16:30:16 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com This week the FDA weigh up mandatory education for opioid prescribers; There's an increase in the sale of strong psychoactive THC products; Brukinsa and Exkivity gain approvals for lymphoma and NSCLC, respectively; And a number of supplement companies received FDA warning letters.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose 93 - Mandatory Opioid Prescriber Education; Rise in Delta-8 THC Products; Brukinsa and Exkivity Approved; Warning Letters for Supplement Companies MPR Weekly Dose 00:13:10 This week the FDA weigh up mandatory education for opioid prescribers; There's an increase in the sale of strong psychoactive THC products; Brukinsa and Exkivity gain approvals for lymphoma and NSCLC, respectively; And a number of supplement companies received FDA warning letters.  This week the FDA weigh up mandatory education for opioid prescribers; There's an increase in the sale of strong psychoactive THC products; Brukinsa and Exkivity gain approvals for lymphoma and NSCLC, respectively; And a number of supplement companies received FDA warning letters.  false full 91 e60e44ce-4eae-4fda-bf59-46051888d8db MPR Weekly Dose 92 - AAP Vaccination Guidance; Moderna Booster; JAK Inhibitor Warnings; New Migraine Treatment Nasal Spray; Hold Placed on Phenylketonuria This week we have news on pediatric influenza vaccine guidance; Moderna submit data for their COVID-19 booster dose; There's new FDA warnings for some JAK inhibitors; Trudhesa nasal spray is approved; And the FDA places a clinical hold on a gene therapy for phenylketonuria.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 10 Sep 2021 13:01:34 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com This week we have news on pediatric influenza vaccine guidance; Moderna submit data for their COVID-19 booster dose; There's new FDA warnings for some JAK inhibitors; Trudhesa nasal spray is approved; And the FDA places a clinical hold on a gene therapy for phenylketonuria.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose 92 - AAP Vaccination Guidance; Moderna Booster; JAK Inhibitor Warnings; New Migraine Treatment Nasal Spray; Hold Placed on Phenylketonuria MPR Weekly Dose 00:11:05 This week we have news on pediatric influenza vaccine guidance; Moderna submit data for their COVID-19 booster dose; There's new FDA warnings for some JAK inhibitors; Trudhesa nasal spray is approved; And the FDA places a clinical hold on a gene therapy for phenylketonuria. This week we have news on pediatric influenza vaccine guidance; Moderna submit data for their COVID-19 booster dose; There's new FDA warnings for some JAK inhibitors; Trudhesa nasal spray is approved; And the FDA places a clinical hold on a gene therapy for phenylketonuria. false full 90 e3e9632b-49b2-4662-9082-361dc2fc202f MPR Weekly Dose 91 - First Full COVID-19 Vaccine Approval; Pfizer Submit for Third Dose; AAP Advises on Off-Label Vaccinations; COVID Antibody Tx; Moderna BLA Submission The first COVID-19 vaccine is fully approved by the FDA, we'll go into all that that entails and also news regarding booster doses, off-label recommendations, promising antibody treatments and a BLA submission from Moderna for their vaccine.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Thu, 26 Aug 2021 18:12:05 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com The first COVID-19 vaccine is fully approved by the FDA, we'll go into all that that entails and also news regarding booster doses, off-label recommendations, promising antibody treatments and a BLA submission from Moderna for their vaccine.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose 91 - First Full COVID-19 Vaccine Approval; Pfizer Submit for Third Dose; AAP Advises on Off-Label Vaccinations; COVID Antibody Tx; Moderna BLA Submission MPR Weekly Dose 00:11:29 The first COVID-19 vaccine is fully approved by the FDA, we'll go into all that that entails and also news regarding booster doses, off-label recommendations, promising antibody treatments and a BLA submission from Moderna for their vaccine. The first COVID-19 vaccine is fully approved by the FDA, we'll go into all that that entails and also news regarding booster doses, off-label recommendations, promising antibody treatments and a BLA submission from Moderna for their vaccine. false full 89 ea86bc92-f556-4d24-b96a-6c498d8dd87f MPR Weekly Dose 90 - COVID-19 Vaccine Booster Dose; Vaccine for Tick-Borne Encephalitis; Jardiance Approval; FDA Wristband Warning; Jemperli Accelerated Approval This week we have significant news on the status of a third COVID-19 vaccine booster dose, as well as news for an encephalitis vaccine, another jardiance indication, an FDA warning concerning patient wristbands, and Jemperli gets accelerated approval.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Thu, 19 Aug 2021 20:16:02 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com This week we have significant news on the status of a third COVID-19 vaccine booster dose, as well as news for an encephalitis vaccine, another jardiance indication, an FDA warning concerning patient wristbands, and Jemperli gets accelerated approval.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose 90 - COVID-19 Vaccine Booster Dose; Vaccine for Tick-Borne Encephalitis; Jardiance Approval; FDA Wristband Warning; Jemperli Accelerated Approval MPR Weekly Dose 00:11:04 This week we have significant news on the status of a third COVID-19 vaccine booster dose, as well as news for an encephalitis vaccine, another jardiance indication, an FDA warning concerning patient wristbands, and Jemperli gets accelerated approval.  This week we have significant news on the status of a third COVID-19 vaccine booster dose, as well as news for an encephalitis vaccine, another jardiance indication, an FDA warning concerning patient wristbands, and Jemperli gets accelerated approval.  false full 88 814be0fb-4b2d-4bf9-9ed3-da4ededda1af MPR Weekly Dose 89 - COVID Vaccine Booster Dose; Vaccines Recommended in Pregnancy; Post-Vaccine Myocarditis Study; Moderna Efficacy at 6 Months; Pompe Disease Tx; FDA Denies Roxadustat Big news on the COVID-19 vaccine booster dose. The CDC issues new recommendations on vaccines. What protection the Moderna vaccine offers after 6 months. A treatment approved for Pompe disease. And the FDA denies an application for a new roxadustat indication.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 13 Aug 2021 15:52:41 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com Big news on the COVID-19 vaccine booster dose. The CDC issues new recommendations on vaccines. What protection the Moderna vaccine offers after 6 months. A treatment approved for Pompe disease. And the FDA denies an application for a new roxadustat indication.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose 89 - COVID Vaccine Booster Dose; Vaccines Recommended in Pregnancy; Post-Vaccine Myocarditis Study; Moderna Efficacy at 6 Months; Pompe Disease Tx; FDA Denies Roxadustat MPR Weekly Dose 00:11:18 Big news on the COVID-19 vaccine booster dose. The CDC issues new recommendations on vaccines. What protection the Moderna vaccine offers after 6 months. A treatment approved for Pompe disease. And the FDA denies an application for a new roxadustat indication. Big news on the COVID-19 vaccine booster dose. The CDC issues new recommendations on vaccines. What protection the Moderna vaccine offers after 6 months. A treatment approved for Pompe disease. And the FDA denies an application for a new roxadustat indication. false full 87 e8a64705-ff4a-4a93-ae8d-6650fa58f07c MPR Weekly Dose 88 - Postexposure Tx for COVID-19; Novel lupus treatment; Higher dose naloxone; Clozapine REMS changes; Istodax indication withdrawn The FDA authorizes a postexposure prophylaxis for COVID-19; a new treatment is okay'd for lupus; a higher dose naloxone nasal spray became available; the risk evaluation and mitigation program for Clozapine has had important changes, and finally, Istodax has had an indication withdrawn.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 6 Aug 2021 13:54:14 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com The FDA authorizes a postexposure prophylaxis for COVID-19; a new treatment is okay'd for lupus; a higher dose naloxone nasal spray became available; the risk evaluation and mitigation program for Clozapine has had important changes, and finally, Istodax has had an indication withdrawn.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose 88 - Postexposure Tx for COVID-19; Novel lupus treatment; Higher dose naloxone; Clozapine REMS changes; Istodax indication withdrawn MPR Weekly Dose 00:09:59 The FDA authorizes a postexposure prophylaxis for COVID-19; a new treatment is okay'd for lupus; a higher dose naloxone nasal spray became available; the risk evaluation and mitigation program for Clozapine has had important changes, and finally, Istodax has had an indication withdrawn.  The FDA authorizes a postexposure prophylaxis for COVID-19; a new treatment is okay'd for lupus; a higher dose naloxone nasal spray became available; the risk evaluation and mitigation program for Clozapine has had important changes, and finally, Istodax has had an indication withdrawn.  false full 86 55879efe-2eda-4525-a990-76ac9ee81f11 MPR Weekly Dose 87 - Statin contraindication change; Vaccine for streptococcus pneumoniae; Plaque psoriasis cream; Therapy fast tracked for Parkinson disease; Bylvay approved This week we have news of the FDA requesting a change to statin prescribing labels, a new vaccine for streptococcus pneumoniae, a new plaque psoriasis cream, a stem cell therapy gets fast tracked as a possible Parkinson disease treatment, and there's a new treatment approved for Progressive Familial Intrahepatic Cholestasis (PFIC).


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 23 Jul 2021 18:01:56 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com This week we have news of the FDA requesting a change to statin prescribing labels, a new vaccine for streptococcus pneumoniae, a new plaque psoriasis cream, a stem cell therapy gets fast tracked as a possible Parkinson disease treatment, and there's a new treatment approved for Progressive Familial Intrahepatic Cholestasis (PFIC).


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose 87 - Statin contraindication change; Vaccine for streptococcus pneumoniae; Plaque psoriasis cream; Therapy fast tracked for Parkinson disease; Bylvay approved MPR Weekly Dose 00:11:16 This week we have news of the FDA requesting a change to statin prescribing labels, a new vaccine for streptococcus pneumoniae, a new plaque psoriasis cream, a stem cell therapy gets fast tracked as a possible Parkinson disease treatment, and there's a new treatment approved for Progressive Familial Intrahepatic Cholestasis (PFIC). This week we have news of the FDA requesting a change to statin prescribing labels, a new vaccine for streptococcus pneumoniae, a new plaque psoriasis cream, a stem cell therapy gets fast tracked as a possible Parkinson disease treatment, and there's a new treatment approved for Progressive Familial Intrahepatic Cholestasis (PFIC). false full 85 aaf24c04-eed7-4430-af3d-f40c215e65d3 MPR Weekly Dose Podcast Episode 86 This week on the pod we speak about a fact sheet update for the Janssen COVID vaccine. Pfizer and BioNTech are working on a booster version of their vaccine. A supplement is found to contain a prescription ingredient. There's a new treatment for patients with diabetic kidney disease. And two popular sunscreen brands are recalled due to the presence of benzene.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 16 Jul 2021 15:33:11 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com This week on the pod we speak about a fact sheet update for the Janssen COVID vaccine. Pfizer and BioNTech are working on a booster version of their vaccine. A supplement is found to contain a prescription ingredient. There's a new treatment for patients with diabetic kidney disease. And two popular sunscreen brands are recalled due to the presence of benzene.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose Podcast Episode 86 MPR Weekly Dose 00:08:54 This week on the pod we speak about a fact sheet update for the Janssen COVID vaccine. Pfizer and BioNTech are working on a booster version of their vaccine. A supplement is found to contain a prescription ingredient. There's a new treatment for patients with diabetic kidney disease. And two popular sunscreen brands are recalled due to the presence of benzene. This week on the pod we speak about a fact sheet update for the Janssen COVID vaccine. Pfizer and BioNTech are working on a booster version of their vaccine. A supplement is found to contain a prescription ingredient. There's a new treatment for patients with diabetic kidney disease. And two popular sunscreen brands are recalled due to the presence of benzene. false full 84 a2174754-61b8-41a3-be62-7b55211ea42c MPR Weekly Dose 85 - Chantix recalled; Kimyrsa for ABSSSI; Aduhelm label update; Blood lead test recall; Keytruda changes This week Pfizer recalled their smoking cessation therapy Chantix. A treatment for acute bacterial skin and skin structure infections becomes available. Aduhelm, the newly approved Alzheimer Disease treatment, has its label updated. A blood lead level test is recalled, and there's updates to the cancer drug Keytruda.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 9 Jul 2021 13:58:43 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com This week Pfizer recalled their smoking cessation therapy Chantix. A treatment for acute bacterial skin and skin structure infections becomes available. Aduhelm, the newly approved Alzheimer Disease treatment, has its label updated. A blood lead level test is recalled, and there's updates to the cancer drug Keytruda.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose 85 - Chantix recalled; Kimyrsa for ABSSSI; Aduhelm label update; Blood lead test recall; Keytruda changes MPR Weekly Dose 00:09:31 This week Pfizer recalled their smoking cessation therapy Chantix. A treatment for acute bacterial skin and skin structure infections becomes available. Aduhelm, the newly approved Alzheimer Disease treatment, has its label updated. A blood lead level test is recalled, and there's updates to the cancer drug Keytruda. This week Pfizer recalled their smoking cessation therapy Chantix. A treatment for acute bacterial skin and skin structure infections becomes available. Aduhelm, the newly approved Alzheimer Disease treatment, has its label updated. A blood lead level test is recalled, and there's updates to the cancer drug Keytruda. false full 83 a8b47bed-c253-4aff-88da-ad69b9c7b279 MPR Weekly Dose 84 - Emergency Use for COVID-19 treatment; Fact sheet update for vaccines; Rylaze approved; Expanded approval for Solosec; NDA submitted for HIV-1 treatment The FDA grants Emergency Use to Actemra to treat hospitalized COVID patients. Revisions are been made to the fact sheets for the Moderna and Pfizer BioNTech COVID vaccines to include information related to the risk of myocarditis and pericarditis. A new treatment is approved for some cancer patients allergic to E. coli-Derived asparaginase products. Solosec gets an expanded indication and a new drug application for a HIV-1 treatment has been submitted.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 2 Jul 2021 12:34:43 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com The FDA grants Emergency Use to Actemra to treat hospitalized COVID patients. Revisions are been made to the fact sheets for the Moderna and Pfizer BioNTech COVID vaccines to include information related to the risk of myocarditis and pericarditis. A new treatment is approved for some cancer patients allergic to E. coli-Derived asparaginase products. Solosec gets an expanded indication and a new drug application for a HIV-1 treatment has been submitted.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose 84 - Emergency Use for COVID-19 treatment; Fact sheet update for vaccines; Rylaze approved; Expanded approval for Solosec; NDA submitted for HIV-1 treatment MPR Weekly Dose 00:12:29 The FDA grants Emergency Use to Actemra to treat hospitalized COVID patients. Revisions are been made to the fact sheets for the Moderna and Pfizer BioNTech COVID vaccines to include information related to the risk of myocarditis and pericarditis. A new treatment is approved for some cancer patients allergic to E. coli-Derived asparaginase products. Solosec gets an expanded indication and a new drug application for a HIV-1 treatment has been submitted.  The FDA grants Emergency Use to Actemra to treat hospitalized COVID patients. Revisions are been made to the fact sheets for the Moderna and Pfizer BioNTech COVID vaccines to include information related to the risk of myocarditis and pericarditis. A new treatment is approved for some cancer patients allergic to E. coli-Derived asparaginase products. Solosec gets an expanded indication and a new drug application for a HIV-1 treatment has been submitted.  false full 82 a87cfebd-c185-4e5d-906c-6dd8f9543103 MPR Weekly Dose 83 - Rx-to-OTC for allergy spray; Novel contraceptive; Pediatric VTE Tx; Veklury real world efficacy data; Wearable thermometer This week the FDA approved a first-in-class switch for an antihistamine nasal spray, a new oral contraceptive, and Pradaxa was approved to prevent venous thromboembolism in pediatric patients. Meanwhile, real-world data on the efficacy of the COVID-`9 treatment remdesivir has been published.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Thu, 24 Jun 2021 21:21:08 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com This week the FDA approved a first-in-class switch for an antihistamine nasal spray, a new oral contraceptive, and Pradaxa was approved to prevent venous thromboembolism in pediatric patients. Meanwhile, real-world data on the efficacy of the COVID-`9 treatment remdesivir has been published.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose 83 - Rx-to-OTC for allergy spray; Novel contraceptive; Pediatric VTE Tx; Veklury real world efficacy data; Wearable thermometer MPR Weekly Dose 00:10:40 This week the FDA approved a first-in-class switch for an antihistamine nasal spray, a new oral contraceptive, and Pradaxa was approved to prevent venous thromboembolism in pediatric patients. Meanwhile, real-world data on the efficacy of the COVID-`9 treatment remdesivir has been published.  This week the FDA approved a first-in-class switch for an antihistamine nasal spray, a new oral contraceptive, and Pradaxa was approved to prevent venous thromboembolism in pediatric patients. Meanwhile, real-world data on the efficacy of the COVID-`9 treatment remdesivir has been published.  false full 81 0bd71207-c838-4973-b31e-84398175ce57 MPR Weekly Dose 82 - A regenerative skin therapy; Novavax vaccine shows promise; Mastocytosis treatment; Potential new depression treatment; And an FDA warning for hand sanitizers. This week the FDA approved a regenerative skin tissue therapy and a treatment for advanced mastocytosis, while Novavax's vaccine for COVID and a novel treatment for MDD show promise. Also the FDA issue warning concerning hand sanitizers.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Thu, 17 Jun 2021 22:47:07 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com This week the FDA approved a regenerative skin tissue therapy and a treatment for advanced mastocytosis, while Novavax's vaccine for COVID and a novel treatment for MDD show promise. Also the FDA issue warning concerning hand sanitizers.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose 82 - A regenerative skin therapy; Novavax vaccine shows promise; Mastocytosis treatment; Potential new depression treatment; And an FDA warning for hand sanitizers. MPR Weekly Dose 00:08:11 This week the FDA approved a regenerative skin tissue therapy and a treatment for advanced mastocytosis, while Novavax's vaccine for COVID and a novel treatment for MDD show promise. Also the FDA issue warning concerning hand sanitizers. This week the FDA approved a regenerative skin tissue therapy and a treatment for advanced mastocytosis, while Novavax's vaccine for COVID and a novel treatment for MDD show promise. Also the FDA issue warning concerning hand sanitizers. false full 80 c63d0417-9820-4828-8178-acd024cbebf1 MPR Weekly Dose 81 - A first therapy to target underlying process of Alzheimer disease; Moderna requests EUA; And a list of new approvals in a variety of therapeutic categories This week it's the big one: aducanumab - a treatment for alzheimer disease - got FDA approval. We'll go into that, plus a semaglutide treatment for obesity, a first treatment for Plasminogen Deficiency Type 1, and Moderna have sent a request for an EUA to extend the use of their COVID-19 vaccine to those aged over 12.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 11 Jun 2021 21:51:29 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com This week it's the big one: aducanumab - a treatment for alzheimer disease - got FDA approval. We'll go into that, plus a semaglutide treatment for obesity, a first treatment for Plasminogen Deficiency Type 1, and Moderna have sent a request for an EUA to extend the use of their COVID-19 vaccine to those aged over 12.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose 81 - A first therapy to target underlying process of Alzheimer disease; Moderna requests EUA; And a list of new approvals in a variety of therapeutic categories MPR Weekly Dose 00:14:02 This week it's the big one: aducanumab - a treatment for alzheimer disease - got FDA approval. We'll go into that, plus a semaglutide treatment for obesity, a first treatment for Plasminogen Deficiency Type 1, and Moderna have sent a request for an EUA to extend the use of their COVID-19 vaccine to those aged over 12. This week it's the big one: aducanumab - a treatment for alzheimer disease - got FDA approval. We'll go into that, plus a semaglutide treatment for obesity, a first treatment for Plasminogen Deficiency Type 1, and Moderna have sent a request for an EUA to extend the use of their COVID-19 vaccine to those aged over 12. false full 79 e1135501-175a-46b7-97e8-68ddd301806e MPR Weekly Dose 80 - Migraine prevention treatment; Pediatric combo vaccine; Schizophrenia, Bipolar I approval; AI-based Autism diagnostic On this week's show we have news of migraine prevention treatment, a hexavalent vaccine is approved for pediatrics, there's also an approval for schizophrenia and bipolar I disorder, lumakras gets fast tracked and there's a new diagnostic aid for Autism, and it is artificial intelligence.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 4 Jun 2021 19:10:49 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com On this week's show we have news of migraine prevention treatment, a hexavalent vaccine is approved for pediatrics, there's also an approval for schizophrenia and bipolar I disorder, lumakras gets fast tracked and there's a new diagnostic aid for Autism, and it is artificial intelligence.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose 80 - Migraine prevention treatment; Pediatric combo vaccine; Schizophrenia, Bipolar I approval; AI-based Autism diagnostic MPR Weekly Dose 00:10:29 On this week's show we have news of migraine prevention treatment, a hexavalent vaccine is approved for pediatrics, there's also an approval for schizophrenia and bipolar I disorder, lumakras gets fast tracked and there's a new diagnostic aid for Autism, and it is artificial intelligence. On this week's show we have news of migraine prevention treatment, a hexavalent vaccine is approved for pediatrics, there's also an approval for schizophrenia and bipolar I disorder, lumakras gets fast tracked and there's a new diagnostic aid for Autism, and it is artificial intelligence. false full 78 b3ecb758-d58a-470a-bda3-40d82eb8b033 MPR Weekly Dose 79 - COVID-19: vaccine storage, efficacy updates; Gene therapy Fast Tracked; Vitiligo cream trial results; Aspirin dosage compared in ASCVD This week we have news of a change to the storage of the Pfizer-BioNTech vaccine; A gene therapy gets Fast Track status by the FDA; Vitiligo cream shows promise in clinical trials; And outcomes in atherosclerotic cardiovascular disease are compared for different aspirin dosages.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 21 May 2021 13:12:49 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com This week we have news of a change to the storage of the Pfizer-BioNTech vaccine; A gene therapy gets Fast Track status by the FDA; Vitiligo cream shows promise in clinical trials; And outcomes in atherosclerotic cardiovascular disease are compared for different aspirin dosages.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose 79 - COVID-19: vaccine storage, efficacy updates; Gene therapy Fast Tracked; Vitiligo cream trial results; Aspirin dosage compared in ASCVD MPR Weekly Dose 00:09:17 This week we have news of a change to the storage of the Pfizer-BioNTech vaccine; A gene therapy gets Fast Track status by the FDA; Vitiligo cream shows promise in clinical trials; And outcomes in atherosclerotic cardiovascular disease are compared for different aspirin dosages. This week we have news of a change to the storage of the Pfizer-BioNTech vaccine; A gene therapy gets Fast Track status by the FDA; Vitiligo cream shows promise in clinical trials; And outcomes in atherosclerotic cardiovascular disease are compared for different aspirin dosages. false full 77 30d5c699-6fbc-4aa2-bf19-2f9998acf3fe MPR Weekly Dose 78 - Vaccine authorized for adolescents; Postoperative pain Tx approval; Insulin products recalled; Treatment Fast Tracked for facioscapulohumeral muscular dystrophy This week we have news of a COVID-19 vaccine authorization expanded for adolescents; A new postoperative pain treatment; There's a new insulin smart pen devices; Insulin products are recalled; And the FDA grants fast track status to a potential treatment for the rare disease, FSHD.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 14 May 2021 14:21:57 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com This week we have news of a COVID-19 vaccine authorization expanded for adolescents; A new postoperative pain treatment; There's a new insulin smart pen devices; Insulin products are recalled; And the FDA grants fast track status to a potential treatment for the rare disease, FSHD.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose 78 - Vaccine authorized for adolescents; Postoperative pain Tx approval; Insulin products recalled; Treatment Fast Tracked for facioscapulohumeral muscular dystrophy MPR Weekly Dose 00:13:25 This week we have news of a COVID-19 vaccine authorization expanded for adolescents; A new postoperative pain treatment; There's a new insulin smart pen devices; Insulin products are recalled; And the FDA grants fast track status to a potential treatment for the rare disease, FSHD. This week we have news of a COVID-19 vaccine authorization expanded for adolescents; A new postoperative pain treatment; There's a new insulin smart pen devices; Insulin products are recalled; And the FDA grants fast track status to a potential treatment for the rare disease, FSHD. false full 76 565841eb-8d29-4d1a-a116-2127dc9158b0 MPR Weekly Dose 77 - Updated mask guidance; Janssen vaccine resumption; Steroid therapy in COVID-19; Novel MDD gains Priority Review; Scabies treatment; Stroke rehabilitation device New guidelines on mask use; J&J vaccine update; Novel major depressive disorder treatment gains Priority Review; A scabies topical suspension; And a device to help stroke rehabilitation.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 30 Apr 2021 13:42:53 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com New guidelines on mask use; J&J vaccine update; Novel major depressive disorder treatment gains Priority Review; A scabies topical suspension; And a device to help stroke rehabilitation.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose 77 - Updated mask guidance; Janssen vaccine resumption; Steroid therapy in COVID-19; Novel MDD gains Priority Review; Scabies treatment; Stroke rehabilitation device MPR Weekly Dose 00:10:06 New guidelines on mask use; J&J vaccine update; Novel major depressive disorder treatment gains Priority Review; A scabies topical suspension; And a device to help stroke rehabilitation.  New guidelines on mask use; J&J vaccine update; Novel major depressive disorder treatment gains Priority Review; A scabies topical suspension; And a device to help stroke rehabilitation.  false full 75 494a9f0d-ed41-4b65-9715-fdc2bee20ec1 MPR Weekly Dose 76 - Bamlanivimab emergency use changes; Janssen vaccine facilities; Molnupiravir trial halted; New contraceptive approved; Ragweed pollen allergy treatment The FDA revoke Emergency Use Authorization for bamlanivimab; Issues identified at a Janssen manufacturing facility; Merck halts trials for investigational COVID-19 therapy; A new contraceptive is approved; And Ragwitek has approval expanded.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 23 Apr 2021 13:56:56 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com The FDA revoke Emergency Use Authorization for bamlanivimab; Issues identified at a Janssen manufacturing facility; Merck halts trials for investigational COVID-19 therapy; A new contraceptive is approved; And Ragwitek has approval expanded.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose 76 - Bamlanivimab emergency use changes; Janssen vaccine facilities; Molnupiravir trial halted; New contraceptive approved; Ragweed pollen allergy treatment MPR Weekly Dose 00:13:19 The FDA revoke Emergency Use Authorization for bamlanivimab; Issues identified at a Janssen manufacturing facility; Merck halts trials for investigational COVID-19 therapy; A new contraceptive is approved; And Ragwitek has approval expanded. The FDA revoke Emergency Use Authorization for bamlanivimab; Issues identified at a Janssen manufacturing facility; Merck halts trials for investigational COVID-19 therapy; A new contraceptive is approved; And Ragwitek has approval expanded. false full 74 763a7c6d-a27f-426f-9727-cc1db6717052 MPR Weekly Dose 75 - Janssen vaccine on pause; Antibody therapy guidance; Remote mifepristone dispensing; Xolair self-administration; And a new AI colonoscopy system The latest status on the Janssen vaccine; Updated guidance from the National Institutes of Health on COVID-19 antibody treatments; The FDA changes in-person mifepristone dispensing; Xolair prefilled syringe approved for self-administration in select patients; And the AI world comes to colonoscopies.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 16 Apr 2021 14:26:42 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com The latest status on the Janssen vaccine; Updated guidance from the National Institutes of Health on COVID-19 antibody treatments; The FDA changes in-person mifepristone dispensing; Xolair prefilled syringe approved for self-administration in select patients; And the AI world comes to colonoscopies.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose 75 - Janssen vaccine on pause; Antibody therapy guidance; Remote mifepristone dispensing; Xolair self-administration; And a new AI colonoscopy system MPR Weekly Dose 00:11:14 The latest status on the Janssen vaccine; Updated guidance from the National Institutes of Health on COVID-19 antibody treatments; The FDA changes in-person mifepristone dispensing; Xolair prefilled syringe approved for self-administration in select patients; And the AI world comes to colonoscopies.  The latest status on the Janssen vaccine; Updated guidance from the National Institutes of Health on COVID-19 antibody treatments; The FDA changes in-person mifepristone dispensing; Xolair prefilled syringe approved for self-administration in select patients; And the AI world comes to colonoscopies.  false full 73 bd97272c-b4ad-4951-a9e7-317eda41807d MPR Weekly Dose 74 - Updated travel guidance; Six month vaccine efficacy data; Increased Moderna doses per vial; New ADHD treatment; And a safety communication for lamotrigine Back to regular programming this week with a summary of the top news, which includes updated travel guidance; Six month efficacy data for the Moderna and Pfizer-BioNTech vaccines; Vial doses increased for Moderna; A new ADHD drug is approved; And the FDA has issued a safety communication regarding the potential increased risk of arrhythmias in patients taking lamotrigine.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 9 Apr 2021 15:54:23 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com Back to regular programming this week with a summary of the top news, which includes updated travel guidance; Six month efficacy data for the Moderna and Pfizer-BioNTech vaccines; Vial doses increased for Moderna; A new ADHD drug is approved; And the FDA has issued a safety communication regarding the potential increased risk of arrhythmias in patients taking lamotrigine.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose 74 - Updated travel guidance; Six month vaccine efficacy data; Increased Moderna doses per vial; New ADHD treatment; And a safety communication for lamotrigine MPR Weekly Dose 00:11:02 Back to regular programming this week with a summary of the top news, which includes updated travel guidance; Six month efficacy data for the Moderna and Pfizer-BioNTech vaccines; Vial doses increased for Moderna; A new ADHD drug is approved; And the FDA has issued a safety communication regarding the potential increased risk of arrhythmias in patients taking lamotrigine. Back to regular programming this week with a summary of the top news, which includes updated travel guidance; Six month efficacy data for the Moderna and Pfizer-BioNTech vaccines; Vial doses increased for Moderna; A new ADHD drug is approved; And the FDA has issued a safety communication regarding the potential increased risk of arrhythmias in patients taking lamotrigine. false full 72 a4f07db5-25bc-4182-80cf-f8487d105e74 MPR Weekly Dose #73: Interview with Dr Joshua Barocas

With three FDA authorized vaccines being administered throughout the US, but new variants growing in number, we are at a crucial moment in the COVID-19 pandemic.

To get a better understanding of how the future months could unfold, MPR sat down with Dr Joshua Barocas, an assistant professor of medicine at the Boston University School of Medicine and also an Infectious Diseases physician at Boston Medical Center.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Tue, 30 Mar 2021 20:36:08 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com

With three FDA authorized vaccines being administered throughout the US, but new variants growing in number, we are at a crucial moment in the COVID-19 pandemic.

To get a better understanding of how the future months could unfold, MPR sat down with Dr Joshua Barocas, an assistant professor of medicine at the Boston University School of Medicine and also an Infectious Diseases physician at Boston Medical Center.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose #73: Interview with Dr Joshua Barocas MPR Weekly Dose 00:23:52 With three FDA authorized vaccines being administered throughout the US, but new variants growing in number, we are at a crucial moment in the COVID-19 pandemic.  To get a better understanding of how the future months could unfold, MPR sat down with Dr Joshua Barocas, an assistant professor of medicine at the Boston University School of Medicine and also an Infectious Diseases physician at Boston Medical Center.  With three FDA authorized vaccines being administered throughout the US, but new variants growing in number, we are at a crucial moment in the COVID-19 pandemic.  To get a better understanding of how the future months could unfold, MPR sat down with Dr Joshua Barocas, an assistant professor of medicine at the Boston University School of Medicine and also an Infectious Diseases physician at Boston Medical Center.  false full 71 46b71e44-9b29-477a-a6d5-3163072e5e3b MPR Weekly Dose 72 - Real world vaccine effectiveness; Two-dose completion data; Moderana pediatric trial; Results from tocilizumab plus remdesivir trial; Kimyrsa approved. This week we have new study data on the real-world effectiveness of the Pfizer-BioNTech vaccine; The number of Americans who are completing both vaccine doses; A vaccine trial that has started in children; And an approval in acute bacterial skin and skin structure infections.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Thu, 18 Mar 2021 20:22:07 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com This week we have new study data on the real-world effectiveness of the Pfizer-BioNTech vaccine; The number of Americans who are completing both vaccine doses; A vaccine trial that has started in children; And an approval in acute bacterial skin and skin structure infections.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose 72 - Real world vaccine effectiveness; Two-dose completion data; Moderana pediatric trial; Results from tocilizumab plus remdesivir trial; Kimyrsa approved. MPR Weekly Dose 00:10:25 This week we have new study data on the real-world effectiveness of the Pfizer-BioNTech vaccine; The number of Americans who are completing both vaccine doses; A vaccine trial that has started in children; And an approval in acute bacterial skin and skin structure infections.  This week we have new study data on the real-world effectiveness of the Pfizer-BioNTech vaccine; The number of Americans who are completing both vaccine doses; A vaccine trial that has started in children; And an approval in acute bacterial skin and skin structure infections.  false full 70 c7387a08-47be-4efb-822f-9409fb412d62 MPR Weekly Dose 71 - Guidance for those fully vaccinated; A first in COVID-19 testing; Povidone Iodine and Bamlanivimab-Etesevimab examined; Delayed local vaccine reactions This week it's all COVID related news; There's new CDC guidance for those who are vaccinated; A first over the counter test that doesn't require a prescription; Nasopharyngeal povidone iodine and the combo of Bamlanivimab-Etesevimab is assessed; And there's reports of vaccine local reactions.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 12 Mar 2021 16:05:30 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com This week it's all COVID related news; There's new CDC guidance for those who are vaccinated; A first over the counter test that doesn't require a prescription; Nasopharyngeal povidone iodine and the combo of Bamlanivimab-Etesevimab is assessed; And there's reports of vaccine local reactions.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose 71 - Guidance for those fully vaccinated; A first in COVID-19 testing; Povidone Iodine and Bamlanivimab-Etesevimab examined; Delayed local vaccine reactions MPR Weekly Dose 00:10:50 This week it's all COVID related news; There's new CDC guidance for those who are vaccinated; A first over the counter test that doesn't require a prescription; Nasopharyngeal povidone iodine and the combo of Bamlanivimab-Etesevimab is assessed; And there's reports of vaccine local reactions. This week it's all COVID related news; There's new CDC guidance for those who are vaccinated; A first over the counter test that doesn't require a prescription; Nasopharyngeal povidone iodine and the combo of Bamlanivimab-Etesevimab is assessed; And there's reports of vaccine local reactions. false full 69 bb24d7f4-90ec-451d-90ff-045f60ab869d MPR Weekly Dose 70 - Keytruda indication withdrawn; Janssen's single-shot vaccine gains EUA; Ivermectin assessed for mild COVID-19; FDA clears wearables This week we have news of an indication for the cancer treatment, Keytruda, being withdrawn; Janssen's single dose vaccine gains Emergency Authorization; There's findings on the effectiveness of Ivermectin as a therapy for mild COVID-19; And devices to treat migraine and prevention of sub-concussive head impacts are authorized for marketing.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 5 Mar 2021 19:32:59 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com This week we have news of an indication for the cancer treatment, Keytruda, being withdrawn; Janssen's single dose vaccine gains Emergency Authorization; There's findings on the effectiveness of Ivermectin as a therapy for mild COVID-19; And devices to treat migraine and prevention of sub-concussive head impacts are authorized for marketing.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose 70 - Keytruda indication withdrawn; Janssen's single-shot vaccine gains EUA; Ivermectin assessed for mild COVID-19; FDA clears wearables MPR Weekly Dose 00:11:47 This week we have news of an indication for the cancer treatment, Keytruda, being withdrawn; Janssen's single dose vaccine gains Emergency Authorization; There's findings on the effectiveness of Ivermectin as a therapy for mild COVID-19; And devices to treat migraine and prevention of sub-concussive head impacts are authorized for marketing. This week we have news of an indication for the cancer treatment, Keytruda, being withdrawn; Janssen's single dose vaccine gains Emergency Authorization; There's findings on the effectiveness of Ivermectin as a therapy for mild COVID-19; And devices to treat migraine and prevention of sub-concussive head impacts are authorized for marketing. false full 68 6fd04760-5c0c-4f21-97fd-ac9922d1bf00 MPR Weekly Dose #69 - False and misleading pharma promo; Novel LDL-C therapy; Heart failure Tx expanded; Migraine device okay'd for teens. An FDA warning over pharma company's promo material; Entresto's approval is expanded, There's approvals in homozygous familial hypercholesterolemia and chronic inflammatory demyelinating polyneuropathy; And a migraine device for OK'd for teens.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Thu, 18 Feb 2021 22:32:12 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com An FDA warning over pharma company's promo material; Entresto's approval is expanded, There's approvals in homozygous familial hypercholesterolemia and chronic inflammatory demyelinating polyneuropathy; And a migraine device for OK'd for teens.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose #69 - False and misleading pharma promo; Novel LDL-C therapy; Heart failure Tx expanded; Migraine device okay'd for teens. MPR Weekly Dose 00:11:46 An FDA warning over pharma company's promo material; Entresto's approval is expanded, There's approvals in homozygous familial hypercholesterolemia and chronic inflammatory demyelinating polyneuropathy; And a migraine device for OK'd for teens. An FDA warning over pharma company's promo material; Entresto's approval is expanded, There's approvals in homozygous familial hypercholesterolemia and chronic inflammatory demyelinating polyneuropathy; And a migraine device for OK'd for teens. false full 67 86099725-e8ac-418a-93df-0d0e2127e62f MPR Weekly Dose #68 - Remdesivir compounding; Emergency Use Authorizations; Sleep apnea device; New Botox approval This week's stories include a caution about remdesivir; New and updated Emergency Use Authorizations; And new approvals in sleep apnea and for Botox.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 12 Feb 2021 14:39:06 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com This week's stories include a caution about remdesivir; New and updated Emergency Use Authorizations; And new approvals in sleep apnea and for Botox.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose #68 - Remdesivir compounding; Emergency Use Authorizations; Sleep apnea device; New Botox approval MPR Weekly Dose 00:11:11 This week's stories include a caution about remdesivir; New and updated Emergency Use Authorizations; And new approvals in sleep apnea and for Botox. This week's stories include a caution about remdesivir; New and updated Emergency Use Authorizations; And new approvals in sleep apnea and for Botox. false full 66 c88f6b80-3ae7-419d-82f3-8bb180a7236c MPR Weekly Dose #67 - Efficacy data for AstraZeneca, J&J and Novovax vaccines; Approvals in analgesia and influenza. This week we take a look at the remaining prospective COVID vaccines, that includes AstraZeneca, J&J and Novovax; There's also drug approvals for analgesia and influenza.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 5 Feb 2021 15:09:37 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com This week we take a look at the remaining prospective COVID vaccines, that includes AstraZeneca, J&J and Novovax; There's also drug approvals for analgesia and influenza.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose #67 - Efficacy data for AstraZeneca, J&J and Novovax vaccines; Approvals in analgesia and influenza. MPR Weekly Dose 00:11:58 This week we take a look at the remaining prospective COVID vaccines, that includes AstraZeneca, J&J and Novovax; There's also drug approvals for analgesia and influenza. This week we take a look at the remaining prospective COVID vaccines, that includes AstraZeneca, J&J and Novovax; There's also drug approvals for analgesia and influenza. false full 65 51f13f3c-fc22-4a33-880c-1fe3b7ee5e7b MPR Weekly Dose 66 - The Moderna vaccine's efficacy against new variants; Merck ends development of new vaccines; Antiviral treatment combos show promise; New lupus nephritis treatment On this week's pod: The Moderna vaccine and what we know about its effectiveness against emerging variants; Merck ends it's development of two vaccines; Two separate treatment combos show promise in reducing hospitalizations and preventing COVID, respectivel; And the FDA approve a new treatment for lupus nephritis.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Thu, 28 Jan 2021 21:50:57 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com On this week's pod: The Moderna vaccine and what we know about its effectiveness against emerging variants; Merck ends it's development of two vaccines; Two separate treatment combos show promise in reducing hospitalizations and preventing COVID, respectivel; And the FDA approve a new treatment for lupus nephritis.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose 66 - The Moderna vaccine's efficacy against new variants; Merck ends development of new vaccines; Antiviral treatment combos show promise; New lupus nephritis treatment MPR Weekly Dose 00:12:21 On this week's pod: The Moderna vaccine and what we know about its effectiveness against emerging variants; Merck ends it's development of two vaccines; Two separate treatment combos show promise in reducing hospitalizations and preventing COVID, respectivel; And the FDA approve a new treatment for lupus nephritis.  On this week's pod: The Moderna vaccine and what we know about its effectiveness against emerging variants; Merck ends it's development of two vaccines; Two separate treatment combos show promise in reducing hospitalizations and preventing COVID, respectivel; And the FDA approve a new treatment for lupus nephritis.  false full 64 286c25a8-97cc-4127-a568-5e5cfc9cca30 MPR Weekly Dose #65 - Johnson & Johnson's vaccine candidate; Blood donations during pandemic; New Tx for heart failure with reduced ejection fraction; A potential Alzheimer drug; Changes to vinca alkaloid labeling On this week's MPR pod we take a look at the current status of Johnson & Johnson's COVID-19 vaccine candidate; Considerations in assessing blood donors during the pandemic; A newly approved drug to treat heart failure; Promising results for a potential Alzheimer treatment; And changes declared for vinca alkaloid labeling.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 22 Jan 2021 14:45:10 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com On this week's MPR pod we take a look at the current status of Johnson & Johnson's COVID-19 vaccine candidate; Considerations in assessing blood donors during the pandemic; A newly approved drug to treat heart failure; Promising results for a potential Alzheimer treatment; And changes declared for vinca alkaloid labeling.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose #65 - Johnson & Johnson's vaccine candidate; Blood donations during pandemic; New Tx for heart failure with reduced ejection fraction; A potential Alzheimer drug; Changes to vinca alkaloid labeling MPR Weekly Dose 00:10:38 On this week's MPR pod we take a look at the current status of Johnson & Johnson's COVID-19 vaccine candidate; Considerations in assessing blood donors during the pandemic; A newly approved drug to treat heart failure; Promising results for a potential Alzheimer treatment; And changes declared for vinca alkaloid labeling. On this week's MPR pod we take a look at the current status of Johnson & Johnson's COVID-19 vaccine candidate; Considerations in assessing blood donors during the pandemic; A newly approved drug to treat heart failure; Promising results for a potential Alzheimer treatment; And changes declared for vinca alkaloid labeling. false full 63 becfd726-f0f6-48f2-93a7-300ec82189e8 MPR Weekly Dose #64 - Pfizer-BioNTech vaccine efficacy against new variant; Ravulizumab trial halted; Rapid concussion test; Novel chronic kidney disease Tx; NSAID recalled This week we have news of the neutralizing response of the Pfizer-BioNTech vaccine to the new COVID-19 variant; A trial investigated ravulizumab in adults with severe COVID is halted; A rapid blood test for concussions gets the all clear; A novel treatment for chronic kidney disease in patients with type 2 diabetes; and the drug manufacturer Fresenius Kabi announces a voluntary recall of one lot of an NSAID treatment.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 15 Jan 2021 23:03:38 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com This week we have news of the neutralizing response of the Pfizer-BioNTech vaccine to the new COVID-19 variant; A trial investigated ravulizumab in adults with severe COVID is halted; A rapid blood test for concussions gets the all clear; A novel treatment for chronic kidney disease in patients with type 2 diabetes; and the drug manufacturer Fresenius Kabi announces a voluntary recall of one lot of an NSAID treatment.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose #64 - Pfizer-BioNTech vaccine efficacy against new variant; Ravulizumab trial halted; Rapid concussion test; Novel chronic kidney disease Tx; NSAID recalled MPR Weekly Dose 00:09:43 This week we have news of the neutralizing response of the Pfizer-BioNTech vaccine to the new COVID-19 variant; A trial investigated ravulizumab in adults with severe COVID is halted; A rapid blood test for concussions gets the all clear; A novel treatment for chronic kidney disease in patients with type 2 diabetes; and the drug manufacturer Fresenius Kabi announces a voluntary recall of one lot of an NSAID treatment. This week we have news of the neutralizing response of the Pfizer-BioNTech vaccine to the new COVID-19 variant; A trial investigated ravulizumab in adults with severe COVID is halted; A rapid blood test for concussions gets the all clear; A novel treatment for chronic kidney disease in patients with type 2 diabetes; and the drug manufacturer Fresenius Kabi announces a voluntary recall of one lot of an NSAID treatment. false full 62 7a4aebdd-dd7f-4cc2-8966-bae81e3240f1 MPR weekly dose #63 - COVID-19 vaccine admin scheduling and production updates; A diagnostic test that is giving false negative results; Bristol Myers Squibb withdraws an indication for Opdivo; And experts vote on the best diets for 2021. On the first MPR pod of 2021 we cover the latest COVID-19 news including admin. scheduling and production news; A diagnostics test that is giving false negative results; Bristol Myers Squibb withdraw an indication for Opdivo; And experts vote on the best diets for 2021.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 8 Jan 2021 16:41:56 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com On the first MPR pod of 2021 we cover the latest COVID-19 news including admin. scheduling and production news; A diagnostics test that is giving false negative results; Bristol Myers Squibb withdraw an indication for Opdivo; And experts vote on the best diets for 2021.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR weekly dose #63 - COVID-19 vaccine admin scheduling and production updates; A diagnostic test that is giving false negative results; Bristol Myers Squibb withdraws an indication for Opdivo; And experts vote on the best diets for 2021. MPR Weekly Dose 00:08:41 On the first MPR pod of 2021 we cover the latest COVID-19 news including admin. scheduling and production news; A diagnostics test that is giving false negative results; Bristol Myers Squibb withdraw an indication for Opdivo; And experts vote on the best diets for 2021. On the first MPR pod of 2021 we cover the latest COVID-19 news including admin. scheduling and production news; A diagnostics test that is giving false negative results; Bristol Myers Squibb withdraw an indication for Opdivo; And experts vote on the best diets for 2021. false full 61 d049ca8b-5aa5-42b2-8f60-5a781b3cac71 MPR Weekly Dose #62 - Major vaccine developments; FDA authorizes rapid at-home COVID test; New findings for glucosamine supplementation; And a novel budesonide oral suspension gets Priority Review Its been a long year, but the monumental efforts to achieve a COVID-19 vaccine are bearing some fruits, we about that, and also a fully at home diagnostic COVID test, as well as new findings related to glucosamine supplements and a novel treatment for eosinophilic esophagitis.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 18 Dec 2020 16:10:48 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com Its been a long year, but the monumental efforts to achieve a COVID-19 vaccine are bearing some fruits, we about that, and also a fully at home diagnostic COVID test, as well as new findings related to glucosamine supplements and a novel treatment for eosinophilic esophagitis.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose #62 - Major vaccine developments; FDA authorizes rapid at-home COVID test; New findings for glucosamine supplementation; And a novel budesonide oral suspension gets Priority Review MPR Weekly Dose 00:09:14 Its been a long year, but the monumental efforts to achieve a COVID-19 vaccine are bearing some fruits, we about that, and also a fully at home diagnostic COVID test, as well as new findings related to glucosamine supplements and a novel treatment for eosinophilic esophagitis. Its been a long year, but the monumental efforts to achieve a COVID-19 vaccine are bearing some fruits, we about that, and also a fully at home diagnostic COVID test, as well as new findings related to glucosamine supplements and a novel treatment for eosinophilic esophagitis. false full 60 081e31b8-214f-483d-a757-0dcfca9264e2 MPR Weekly Dose #61 - Sitagliptin findings in pediatrics; Obesity treatment gains expanded approval; The FDA issue a CRL; And a new transdermal contraceptive This week we cover new findings for the diabetes drug sitagliptin in pediatrics; An obesity treatment has approval expanded; The FDA issue a Complete Response Letter for an outpatient alternative treatment; And news of availability for a transdermal contraceptive patch.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 11 Dec 2020 14:56:38 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com This week we cover new findings for the diabetes drug sitagliptin in pediatrics; An obesity treatment has approval expanded; The FDA issue a Complete Response Letter for an outpatient alternative treatment; And news of availability for a transdermal contraceptive patch.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose #61 - Sitagliptin findings in pediatrics; Obesity treatment gains expanded approval; The FDA issue a CRL; And a new transdermal contraceptive MPR Weekly Dose 00:09:29 This week we cover new findings for the diabetes drug sitagliptin in pediatrics; An obesity treatment has approval expanded; The FDA issue a Complete Response Letter for an outpatient alternative treatment; And news of availability for a transdermal contraceptive patch. This week we cover new findings for the diabetes drug sitagliptin in pediatrics; An obesity treatment has approval expanded; The FDA issue a Complete Response Letter for an outpatient alternative treatment; And news of availability for a transdermal contraceptive patch. false full 59 d7b37c51-10bf-4279-bea3-01e7e1783ebc MPR Weekly Dose #60 - The FDA stand by remdesivir; Who should get the vaccine first? Xolair and Hetlioz gain expanded approvals; And a novel neuroblastoma treatment This week we cover a back and forth between the FDA and the WHO over remdesivir efficacy; Recommendations for who should get a COVID vaccine first; Xolair and Hetlioz have approval expansions; And a novel neuroblastoma treatment gets accelerated approval. Moreover, there's movie trivia!


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 4 Dec 2020 14:30:09 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com This week we cover a back and forth between the FDA and the WHO over remdesivir efficacy; Recommendations for who should get a COVID vaccine first; Xolair and Hetlioz have approval expansions; And a novel neuroblastoma treatment gets accelerated approval. Moreover, there's movie trivia!


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose #60 - The FDA stand by remdesivir; Who should get the vaccine first? Xolair and Hetlioz gain expanded approvals; And a novel neuroblastoma treatment MPR Weekly Dose 00:09:39 This week we cover a back and forth between the FDA and the WHO over remdesivir efficacy; Recommendations for who should get a COVID vaccine first; Xolair and Hetlioz have approval expansions; And a novel neuroblastoma treatment gets accelerated approval. Moreover, there's movie trivia! This week we cover a back and forth between the FDA and the WHO over remdesivir efficacy; Recommendations for who should get a COVID vaccine first; Xolair and Hetlioz have approval expansions; And a novel neuroblastoma treatment gets accelerated approval. Moreover, there's movie trivia! false full 58 b1ae0007-df89-4aa4-ae2e-a312e88a8040 MPR Weekly Dose #59 - The latest on vaccine news from Moderna, and BioNTech and Pfizer as they release more trial data; A at-home diagnostic test; Keytruda gains expanded approval; and more The latest on vaccine news from Moderna, and BioNTech and Pfizer as they release more trial data; A at-home diagnostic test is approved; Keytruda gains expanded approval; and all the rest of the drug news from this past week.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 20 Nov 2020 14:35:00 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com The latest on vaccine news from Moderna, and BioNTech and Pfizer as they release more trial data; A at-home diagnostic test is approved; Keytruda gains expanded approval; and all the rest of the drug news from this past week.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose #59 - The latest on vaccine news from Moderna, and BioNTech and Pfizer as they release more trial data; A at-home diagnostic test; Keytruda gains expanded approval; and more MPR Weekly Dose 00:11:38 The latest on vaccine news from Moderna, and BioNTech and Pfizer as they release more trial data; A at-home diagnostic test is approved; Keytruda gains expanded approval; and all the rest of the drug news from this past week. The latest on vaccine news from Moderna, and BioNTech and Pfizer as they release more trial data; A at-home diagnostic test is approved; Keytruda gains expanded approval; and all the rest of the drug news from this past week. false full 57 9b62692d-7124-4d0c-9634-ebbee1370bd4 MPR Weekly Dose #58 - Major developments in COVID vaccine and antibody treatments; Also an FDA Advisory Committee vote on what would be the first Alzheimer drug in decades. Major developments in COVID-19 vaccine and antibody treatments: Are we close to having a vaccine gain Emergency Use Authorization? The antibody bamlanivimab is given Emergency Use Authorization; An NIH study concluded that hydroxychloroquine has no clinical benefit; And unrelated to COVID, but still big news, the Advisory Committee have voted on what would-be the first Alzheimer disease treatment in decades.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 13 Nov 2020 13:53:55 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com Major developments in COVID-19 vaccine and antibody treatments: Are we close to having a vaccine gain Emergency Use Authorization? The antibody bamlanivimab is given Emergency Use Authorization; An NIH study concluded that hydroxychloroquine has no clinical benefit; And unrelated to COVID, but still big news, the Advisory Committee have voted on what would-be the first Alzheimer disease treatment in decades.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose #58 - Major developments in COVID vaccine and antibody treatments; Also an FDA Advisory Committee vote on what would be the first Alzheimer drug in decades. MPR Weekly Dose 00:12:10 Major developments in COVID-19 vaccine and antibody treatments: Are we close to having a vaccine gain Emergency Use Authorization? The antibody bamlanivimab is given Emergency Use Authorization; An NIH study concluded that hydroxychloroquine has no clinical benefit; And unrelated to COVID, but still big news, the Advisory Committee have voted on what would-be the first Alzheimer disease treatment in decades. Major developments in COVID-19 vaccine and antibody treatments: Are we close to having a vaccine gain Emergency Use Authorization? The antibody bamlanivimab is given Emergency Use Authorization; An NIH study concluded that hydroxychloroquine has no clinical benefit; And unrelated to COVID, but still big news, the Advisory Committee have voted on what would-be the first Alzheimer disease treatment in decades. false full 56 00915c38-6cef-4044-91f0-562b68eed2be MPR Weekly Dose #57 - NDA in diabetes; Post-op implant pain Tx; DEA schedules new opioid; FDA lists 200+ drugs; Rifaximin and other drugs in the pipeline news This week we cover a new treatment submission to the FDA for the prevention of diabetes; The launch of a bupivacaine implant to treat post op pain; The DEA schedules a newly approved opioid; The FDA classifies over 200 drugs as essential and wants manufacturers to ramp up production; And more news on drugs that are in the pipeline.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 6 Nov 2020 15:56:59 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com This week we cover a new treatment submission to the FDA for the prevention of diabetes; The launch of a bupivacaine implant to treat post op pain; The DEA schedules a newly approved opioid; The FDA classifies over 200 drugs as essential and wants manufacturers to ramp up production; And more news on drugs that are in the pipeline.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose #57 - NDA in diabetes; Post-op implant pain Tx; DEA schedules new opioid; FDA lists 200+ drugs; Rifaximin and other drugs in the pipeline news MPR Weekly Dose 00:09:21 This week we cover a new treatment submission to the FDA for the prevention of diabetes; The launch of a bupivacaine implant to treat post op pain; The DEA schedules a newly approved opioid; The FDA classifies over 200 drugs as essential and wants manufacturers to ramp up production; And more news on drugs that are in the pipeline. This week we cover a new treatment submission to the FDA for the prevention of diabetes; The launch of a bupivacaine implant to treat post op pain; The DEA schedules a newly approved opioid; The FDA classifies over 200 drugs as essential and wants manufacturers to ramp up production; And more news on drugs that are in the pipeline. false full 55 764cb5f2-dfa9-4922-87ac-5bf3243bc2a2 MPR Weekly Dose Episode #56 - Antibody responses; Convalescent plasma; Nasal spray for diabetic gastroparesis; Colorectal cancer screening recommendations; New dry eye treatment; And movie trivia! This week: The study that identified factors associated with strong antibody responses to COVID; How convalescent plasmas benefits may be limited; A nasal spray to treat diabetic gastroparesis; Recommendations for colorectal cancer screening; And a new treatment approved for dry eye disease.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 30 Oct 2020 21:43:53 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com This week: The study that identified factors associated with strong antibody responses to COVID; How convalescent plasmas benefits may be limited; A nasal spray to treat diabetic gastroparesis; Recommendations for colorectal cancer screening; And a new treatment approved for dry eye disease.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose Episode #56 - Antibody responses; Convalescent plasma; Nasal spray for diabetic gastroparesis; Colorectal cancer screening recommendations; New dry eye treatment; And movie trivia! MPR Weekly Dose 00:06:55 This week: The study that identified factors associated with strong antibody responses to COVID; How convalescent plasmas benefits may be limited; A nasal spray to treat diabetic gastroparesis; Recommendations for colorectal cancer screening; And a new treatment approved for dry eye disease.   This week: The study that identified factors associated with strong antibody responses to COVID; How convalescent plasmas benefits may be limited; A nasal spray to treat diabetic gastroparesis; Recommendations for colorectal cancer screening; And a new treatment approved for dry eye disease.   false full 54 581a18b5-7eff-4b47-9746-b0c98b115ba8 MPR Weekly Dose Podcast Episode 55 This week on the pod: Results from the survey assessing willingness to receive a COVID vaccine; Dr. Fauci shares that he is 'cautiously optimistic' a vaccine could arrive before year's end; A short course of treatment for tuberculosis shows promise; Phase 3 results for a novel pneumococcal vaccine; The FDA rejects a patch intended to treat migraines; And the breaking news that remdesivir (Veklury) has gained FDA approval.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 23 Oct 2020 14:28:49 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com This week on the pod: Results from the survey assessing willingness to receive a COVID vaccine; Dr. Fauci shares that he is 'cautiously optimistic' a vaccine could arrive before year's end; A short course of treatment for tuberculosis shows promise; Phase 3 results for a novel pneumococcal vaccine; The FDA rejects a patch intended to treat migraines; And the breaking news that remdesivir (Veklury) has gained FDA approval.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose Podcast Episode 55 MPR Weekly Dose 00:11:10 This week on the pod: Results from the survey assessing willingness to receive a COVID vaccine; Dr. Fauci shares that he is 'cautiously optimistic' a vaccine could arrive before year's end; A short course of treatment for tuberculosis shows promise; Phase 3 results for a novel pneumococcal vaccine; The FDA rejects a patch intended to treat migraines; And the breaking news that remdesivir (Veklury) has gained FDA approval. This week on the pod: Results from the survey assessing willingness to receive a COVID vaccine; Dr. Fauci shares that he is 'cautiously optimistic' a vaccine could arrive before year's end; A short course of treatment for tuberculosis shows promise; Phase 3 results for a novel pneumococcal vaccine; The FDA rejects a patch intended to treat migraines; And the breaking news that remdesivir (Veklury) has gained FDA approval. false full 53 3d723d79-669b-40c7-9e51-16795b43d428 Weekly Dose #54 - Vaccine trial halted; Hyperimmune trial begins; IV tramadol rejected; FDA votes on schizophrenia, bipolar Tx; And a first in Ebola treatment This week: News of another vaccine trial being put on hold; A trial assessing hyperimmue globulin beings; An NDA for IV tramadol is rejected; FDA Committees vote on novel schizophrenia and bipolar I disorder therapy; And a first approval for Ebola.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 16 Oct 2020 14:10:19 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com This week: News of another vaccine trial being put on hold; A trial assessing hyperimmue globulin beings; An NDA for IV tramadol is rejected; FDA Committees vote on novel schizophrenia and bipolar I disorder therapy; And a first approval for Ebola.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Weekly Dose #54 - Vaccine trial halted; Hyperimmune trial begins; IV tramadol rejected; FDA votes on schizophrenia, bipolar Tx; And a first in Ebola treatment MPR Weekly Dose 00:09:57 This week: News of another vaccine trial being put on hold; A trial assessing hyperimmue globulin beings; An NDA for IV tramadol is rejected; FDA Committees vote on novel schizophrenia and bipolar I disorder therapy; And a first approval for Ebola.  This week: News of another vaccine trial being put on hold; A trial assessing hyperimmue globulin beings; An NDA for IV tramadol is rejected; FDA Committees vote on novel schizophrenia and bipolar I disorder therapy; And a first approval for Ebola.  false full 52 a43f31e8-a991-432c-ad1e-b7b3050eda5d Weekly Dose #53 - Encouraging news on antibody therapies; EUA guidelines for potential vaccines; Remdesivir distribution; The HIV drug that failed to have an impact; And the preterm birth treatment the FDA want withdrawn from the market. This week on the pod; the latest COVID news, including encouraging news on antibody therapies; Updated on Emergency Use Authorization guidelines for vaccines; Remdesivir distribution; A HIV drug fails to have an impact; And why the FDA want a preterm birth treatment withdrawn from the market.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 9 Oct 2020 13:36:23 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com This week on the pod; the latest COVID news, including encouraging news on antibody therapies; Updated on Emergency Use Authorization guidelines for vaccines; Remdesivir distribution; A HIV drug fails to have an impact; And why the FDA want a preterm birth treatment withdrawn from the market.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Weekly Dose #53 - Encouraging news on antibody therapies; EUA guidelines for potential vaccines; Remdesivir distribution; The HIV drug that failed to have an impact; And the preterm birth treatment the FDA want withdrawn from the market. MPR Weekly Dose 00:10:01 This week on the pod; the latest COVID news, including encouraging news on antibody therapies; Updated on Emergency Use Authorization guidelines for vaccines; Remdesivir distribution; A HIV drug fails to have an impact; And why the FDA want a preterm birth treatment withdrawn from the market. This week on the pod; the latest COVID news, including encouraging news on antibody therapies; Updated on Emergency Use Authorization guidelines for vaccines; Remdesivir distribution; A HIV drug fails to have an impact; And why the FDA want a preterm birth treatment withdrawn from the market. false full 51 6d19a64a-1966-4711-b830-257538410c2b Weekly Dose #52 – New Moderna vaccine results; Boxed Warning for benzodiazepines; Point-of-care COVID-19 antibody test; Diphenhydramine overdoses linked to TikTok 'Challenge'; And FDA grants Nucala new approval. New Moderna vaccine results; Boxed Warning for benzodiazepines; Point-of-care COVID-19 antibody test; Diphenhydramine overdoses linked to TikTok 'Challenge'; And FDA grants Nucala new approval. Also we look at this week's developments in drugs in the pipeline.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 2 Oct 2020 14:16:13 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com New Moderna vaccine results; Boxed Warning for benzodiazepines; Point-of-care COVID-19 antibody test; Diphenhydramine overdoses linked to TikTok 'Challenge'; And FDA grants Nucala new approval. Also we look at this week's developments in drugs in the pipeline.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Weekly Dose #52 – New Moderna vaccine results; Boxed Warning for benzodiazepines; Point-of-care COVID-19 antibody test; Diphenhydramine overdoses linked to TikTok 'Challenge'; And FDA grants Nucala new approval. MPR Weekly Dose 00:10:47 New Moderna vaccine results; Boxed Warning for benzodiazepines; Point-of-care COVID-19 antibody test; Diphenhydramine overdoses linked to TikTok 'Challenge'; And FDA grants Nucala new approval. Also we look at this week's developments in drugs in the pipeline. New Moderna vaccine results; Boxed Warning for benzodiazepines; Point-of-care COVID-19 antibody test; Diphenhydramine overdoses linked to TikTok 'Challenge'; And FDA grants Nucala new approval. Also we look at this week's developments in drugs in the pipeline. false full 50 5c60e598-3d16-4a1f-9459-831963de568c MPR Weekly Dose Podcast Episode 51 This week we cover AstraZeneca and the swift decision to restart their COVID-19 vaccine candidate trial; Pfizer and BioNTech want to expand enrollment for their candidate vaccine trial; There's the janus kinase inhibitor that could help reduce recovery time; An investigative antiviral may ease strain on hospitalizations; Aortic aneurysm, dissection assessed with fluoroquinolones; and a retrospective study compared cardiac events with azithromycin and amoxicillin use.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 18 Sep 2020 14:04:16 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com This week we cover AstraZeneca and the swift decision to restart their COVID-19 vaccine candidate trial; Pfizer and BioNTech want to expand enrollment for their candidate vaccine trial; There's the janus kinase inhibitor that could help reduce recovery time; An investigative antiviral may ease strain on hospitalizations; Aortic aneurysm, dissection assessed with fluoroquinolones; and a retrospective study compared cardiac events with azithromycin and amoxicillin use.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose Podcast Episode 51 MPR Weekly Dose 00:09:39 This week we cover AstraZeneca and the swift decision to restart their COVID-19 vaccine candidate trial; Pfizer and BioNTech want to expand enrollment for their candidate vaccine trial; There's the janus kinase inhibitor that could help reduce recovery time; An investigative antiviral may ease strain on hospitalizations; Aortic aneurysm, dissection assessed with fluoroquinolones; and a retrospective study compared cardiac events with azithromycin and amoxicillin use. This week we cover AstraZeneca and the swift decision to restart their COVID-19 vaccine candidate trial; Pfizer and BioNTech want to expand enrollment for their candidate vaccine trial; There's the janus kinase inhibitor that could help reduce recovery time; An investigative antiviral may ease strain on hospitalizations; Aortic aneurysm, dissection assessed with fluoroquinolones; and a retrospective study compared cardiac events with azithromycin and amoxicillin use. false full 49 312fbb68-df91-4a80-bcd8-360f936a000b Weekly Dose #50 - Pause on vaccine trial; Benefits for steroid therapy in COVID patients; Higher doses of diabetes treatment okay'd; First non-hormonal contraceptive; FDA issue SCS warning We cover AstraZeneca's decision to pause their COVID-19 vaccine trial; New studies indicate benefits for steroid therapy in COVID patients; Higher doses of diabetes treatment gain approval; The first non-hormonal contraceptive is launched; The FDA issues a letter regarding spinal cord stimulators; And we wrap up the latest news on drugs in the pipeline.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 11 Sep 2020 13:57:53 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com We cover AstraZeneca's decision to pause their COVID-19 vaccine trial; New studies indicate benefits for steroid therapy in COVID patients; Higher doses of diabetes treatment gain approval; The first non-hormonal contraceptive is launched; The FDA issues a letter regarding spinal cord stimulators; And we wrap up the latest news on drugs in the pipeline.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Weekly Dose #50 - Pause on vaccine trial; Benefits for steroid therapy in COVID patients; Higher doses of diabetes treatment okay'd; First non-hormonal contraceptive; FDA issue SCS warning MPR Weekly Dose 00:11:23 We cover AstraZeneca's decision to pause their COVID-19 vaccine trial; New studies indicate benefits for steroid therapy in COVID patients; Higher doses of diabetes treatment gain approval; The first non-hormonal contraceptive is launched; The FDA issues a letter regarding spinal cord stimulators; And we  wrap up the latest news on drugs in the pipeline. We cover AstraZeneca's decision to pause their COVID-19 vaccine trial; New studies indicate benefits for steroid therapy in COVID patients; Higher doses of diabetes treatment gain approval; The first non-hormonal contraceptive is launched; The FDA issues a letter regarding spinal cord stimulators; And we  wrap up the latest news on drugs in the pipeline. false full 48 5a1ee91e-458d-4d7b-be20-f43cf7a5f4e7 Weekly Dose #49 - ACIP vaccine guidelines; Convalescent plasma; 15 minute test; Plant warning; Intrauterine device; Hydrochlorothiazide The ACIP release guidelines for the 2020-2021 vaccination recommendations; In COVID, there's developments in convalescent plasma authorization; A 15 minute test; And ethnobotanist's give a stark warning concerning a plant that some are touting as a cure; In other news an intrauterine device gains expanded approval; Label update for hydrochlorothiazide.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 28 Aug 2020 14:07:53 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com The ACIP release guidelines for the 2020-2021 vaccination recommendations; In COVID, there's developments in convalescent plasma authorization; A 15 minute test; And ethnobotanist's give a stark warning concerning a plant that some are touting as a cure; In other news an intrauterine device gains expanded approval; Label update for hydrochlorothiazide.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Weekly Dose #49 - ACIP vaccine guidelines; Convalescent plasma; 15 minute test; Plant warning; Intrauterine device; Hydrochlorothiazide MPR Weekly Dose 00:08:42 The ACIP release guidelines for the 2020-2021 vaccination recommendations; In COVID, there's developments in convalescent plasma authorization; A 15 minute test; And ethnobotanist's give a stark warning concerning a plant that some are touting as a cure; In other news an intrauterine device gains expanded approval; Label update for hydrochlorothiazide. The ACIP release guidelines for the 2020-2021 vaccination recommendations; In COVID, there's developments in convalescent plasma authorization; A 15 minute test; And ethnobotanist's give a stark warning concerning a plant that some are touting as a cure; In other news an intrauterine device gains expanded approval; Label update for hydrochlorothiazide. false full 47 8ebdc86a-8918-4f59-a05b-731aec63d3a3 Pneumonia Associated COVID-19; Inaccurate Tests; Neck Gaiters; Drug Applications Halted; Narcan Update Treatment shows promise for patients who had pneumonia associated with COVID-19; A COVID-19 test that may have given inaccurate results; Neck gaiters as face masks may actually spread the virus; Drug applications are halted by the FDA; And Narcan has it's shelf life extended. Also, we recap drug pipeline news from the past week.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 21 Aug 2020 14:41:45 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com Treatment shows promise for patients who had pneumonia associated with COVID-19; A COVID-19 test that may have given inaccurate results; Neck gaiters as face masks may actually spread the virus; Drug applications are halted by the FDA; And Narcan has it's shelf life extended. Also, we recap drug pipeline news from the past week.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Pneumonia Associated COVID-19; Inaccurate Tests; Neck Gaiters; Drug Applications Halted; Narcan Update MPR Weekly Dose 00:07:36 Treatment shows promise for patients who had pneumonia associated with COVID-19; A COVID-19 test that may have given inaccurate results; Neck gaiters as face masks may actually spread the virus; Drug applications are halted by the FDA; And Narcan has it's shelf life extended. Also, we recap drug pipeline news from the past week. Treatment shows promise for patients who had pneumonia associated with COVID-19; A COVID-19 test that may have given inaccurate results; Neck gaiters as face masks may actually spread the virus; Drug applications are halted by the FDA; And Narcan has it's shelf life extended. Also, we recap drug pipeline news from the past week. false full 46 1615f852-eef2-492a-8f17-fd3369393cbf Weekly Dose #47: Remdesiver news; New opioid, SMA treatments; Sublingual epinephrine; Alzheimer treatment Remdesivir is submitted; New opioid approved by FDA; A new Spinal Muscular Atrophy treatment; A sublingual epinephrine treatment; and the latest on Biogen's investigational Alzheimer disease treatment.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 14 Aug 2020 14:29:48 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com Remdesivir is submitted; New opioid approved by FDA; A new Spinal Muscular Atrophy treatment; A sublingual epinephrine treatment; and the latest on Biogen's investigational Alzheimer disease treatment.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Weekly Dose #47: Remdesiver news; New opioid, SMA treatments; Sublingual epinephrine; Alzheimer treatment MPR Weekly Dose 00:09:07 Remdesivir is submitted; New opioid approved by FDA; A new Spinal Muscular Atrophy treatment;  A sublingual epinephrine treatment; and the latest on Biogen's investigational Alzheimer disease treatment. Remdesivir is submitted; New opioid approved by FDA; A new Spinal Muscular Atrophy treatment;  A sublingual epinephrine treatment; and the latest on Biogen's investigational Alzheimer disease treatment. false full 45 e30911fe-6289-4465-8574-e3f18434e0f9 COVID Vaccine Developments; Long-Term Facility Study; Cannabidiol; New Depression Treatment; Peanut Allergy Rejection This week there's more COVID vaccine developments; A first-of-its-kind trial assessing a drug for preventing COVID in long term care facilities; A cannabidiol treatment gains another indication; Depression treatment gains indication for major depressive disorders with acute suicidal ideation or behavior; And the FDA requests more information for their review of the peanut allergy treatment, Viaskin.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 7 Aug 2020 14:01:15 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com This week there's more COVID vaccine developments; A first-of-its-kind trial assessing a drug for preventing COVID in long term care facilities; A cannabidiol treatment gains another indication; Depression treatment gains indication for major depressive disorders with acute suicidal ideation or behavior; And the FDA requests more information for their review of the peanut allergy treatment, Viaskin.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> COVID Vaccine Developments; Long-Term Facility Study; Cannabidiol; New Depression Treatment; Peanut Allergy Rejection MPR Weekly Dose 00:08:26 This week there's more COVID vaccine developments; A first-of-its-kind trial assessing a drug for preventing COVID in long term care facilities; A cannabidiol treatment gains another indication; Depression treatment gains indication for major depressive disorders with acute suicidal ideation or behavior; And the FDA requests more information for their review of the peanut allergy treatment, Viaskin. This week there's more COVID vaccine developments; A first-of-its-kind trial assessing a drug for preventing COVID in long term care facilities; A cannabidiol treatment gains another indication; Depression treatment gains indication for major depressive disorders with acute suicidal ideation or behavior; And the FDA requests more information for their review of the peanut allergy treatment, Viaskin. false full 44 4fd5cade-35db-4bbf-8ea7-ebf0d0641920 MPR Weekly Dose Podcast Episode 45 It's been an important week with big developments in potential COVID-19 vaccines; News on how steroid therapy may help some COVID patients; There's results from the Actemra trial in COVID pneumonia patients; News that sputum samples may be just as effective as nasopharyngeal samples for detecting sars-cov-2; And researchers have linked vaccination to reduced risks of Alzheimer disease.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 31 Jul 2020 15:11:26 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com It's been an important week with big developments in potential COVID-19 vaccines; News on how steroid therapy may help some COVID patients; There's results from the Actemra trial in COVID pneumonia patients; News that sputum samples may be just as effective as nasopharyngeal samples for detecting sars-cov-2; And researchers have linked vaccination to reduced risks of Alzheimer disease.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose Podcast Episode 45 MPR Weekly Dose 00:10:21 It's been an important week with big developments in potential COVID-19 vaccines; News on how steroid therapy may help some COVID patients; There's results from the Actemra trial in COVID pneumonia patients; News that sputum samples may be just as effective as nasopharyngeal samples for detecting sars-cov-2; And  researchers have linked vaccination to reduced risks of Alzheimer disease. It's been an important week with big developments in potential COVID-19 vaccines; News on how steroid therapy may help some COVID patients; There's results from the Actemra trial in COVID pneumonia patients; News that sputum samples may be just as effective as nasopharyngeal samples for detecting sars-cov-2; And  researchers have linked vaccination to reduced risks of Alzheimer disease. false full 43 bb2d9b63-8da7-46e4-bca4-0ddc734a8cf1 MPR Weekly Dose Podcast Episode 44 This week: The government makes a $1.95 billion deal for a COVID-19 vaccine; Promising data from the Oxford vaccine trial; The CDC retakes control of COVID-19 data; Novel calcineurin inhibitor for lupus nephritis gets priority review; And there's new treatment for narcolepsy.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 24 Jul 2020 13:44:06 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com This week: The government makes a $1.95 billion deal for a COVID-19 vaccine; Promising data from the Oxford vaccine trial; The CDC retakes control of COVID-19 data; Novel calcineurin inhibitor for lupus nephritis gets priority review; And there's new treatment for narcolepsy.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose Podcast Episode 44 MPR Weekly Dose 00:07:27 This week: The government makes a $1.95 billion deal for a COVID-19 vaccine; Promising data from the Oxford vaccine trial; The CDC retakes control of COVID-19 data; Novel calcineurin inhibitor for lupus nephritis gets priority review; And there's new treatment for narcolepsy. This week: The government makes a $1.95 billion deal for a COVID-19 vaccine; Promising data from the Oxford vaccine trial; The CDC retakes control of COVID-19 data; Novel calcineurin inhibitor for lupus nephritis gets priority review; And there's new treatment for narcolepsy. false full 42 a9accb27-6c44-4edb-a582-957de01dd7df MPR Weekly Dose Podcast Episode 43 This week; Significant moves in COVID-19 vaccine development; Research finds a link between PPI use and increased risk of COVID-19; We look at remdesivir's efficacy in severe COVID-19 cases; And several Company's recall their metformin extended release tablets.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 17 Jul 2020 14:24:44 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com This week; Significant moves in COVID-19 vaccine development; Research finds a link between PPI use and increased risk of COVID-19; We look at remdesivir's efficacy in severe COVID-19 cases; And several Company's recall their metformin extended release tablets.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose Podcast Episode 43 MPR Weekly Dose 00:07:48 This week; Significant moves in COVID-19 vaccine development; Research finds a link between PPI use and increased risk of COVID-19; We look at remdesivir's efficacy in severe COVID-19 cases; And several Company's recall their metformin extended release tablets. This week; Significant moves in COVID-19 vaccine development; Research finds a link between PPI use and increased risk of COVID-19; We look at remdesivir's efficacy in severe COVID-19 cases; And several Company's recall their metformin extended release tablets. false full 41 a4a56626-0786-4d22-aebe-6c98a4cab9b4 MPR Weekly Dose Podcast Episode 42 The discontinuation of a trial investigating a potential COVID-19 treatment; A safety alert for toxic hand sanitizers; Vaccine guidance in the time of the pandemic; And new treatments in HIV and myelodysplastic syndromes.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Thu, 9 Jul 2020 21:12:56 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com The discontinuation of a trial investigating a potential COVID-19 treatment; A safety alert for toxic hand sanitizers; Vaccine guidance in the time of the pandemic; And new treatments in HIV and myelodysplastic syndromes.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose Podcast Episode 42 MPR Weekly Dose 00:07:35 The discontinuation of a trial investigating a potential COVID-19 treatment; A safety alert for toxic hand sanitizers; Vaccine guidance in the time of the pandemic; And new treatments in HIV and myelodysplastic syndromes. The discontinuation of a trial investigating a potential COVID-19 treatment; A safety alert for toxic hand sanitizers; Vaccine guidance in the time of the pandemic; And new treatments in HIV and myelodysplastic syndromes. false full 40 e19f4edb-fec6-4ce4-8db7-49aa060970a4 MPR Weekly Dose Podcast Episode 41 This week on the Pod: The FDA issues guidance for COVID-19 vaccine development; Accuracy in COVID-19 antibody testing; How statins may improve outcomes for hospitalized COVID-19 patients; and in non-COVID-related news there's a new drug approvals in breast cancer and Dravet syndome.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Thu, 2 Jul 2020 14:03:47 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com This week on the Pod: The FDA issues guidance for COVID-19 vaccine development; Accuracy in COVID-19 antibody testing; How statins may improve outcomes for hospitalized COVID-19 patients; and in non-COVID-related news there's a new drug approvals in breast cancer and Dravet syndome.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose Podcast Episode 41 MPR Weekly Dose 00:10:44 This week on the Pod: The FDA issues guidance for COVID-19 vaccine development; Accuracy in COVID-19 antibody testing; How statins may improve outcomes for hospitalized COVID-19 patients; and in non-COVID-related news there's a new drug approvals in breast cancer and Dravet syndome. This week on the Pod: The FDA issues guidance for COVID-19 vaccine development; Accuracy in COVID-19 antibody testing; How statins may improve outcomes for hospitalized COVID-19 patients; and in non-COVID-related news there's a new drug approvals in breast cancer and Dravet syndome. false full 39 7fe66aef-c08f-4673-92d6-de59b393644c MPR Weekly Dose Podcast Episode 40 This week on the Pod: Over-the-counter med recalls; a nasal spray approved for diabetic gastroparesis; reports of an uptick in penicillin-, ciprofloxacin-resistant meningococci; and in pandemic-related news, a possible inhaled version of remdesivir, and colchicine as a potential treatment.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 26 Jun 2020 14:35:19 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com This week on the Pod: Over-the-counter med recalls; a nasal spray approved for diabetic gastroparesis; reports of an uptick in penicillin-, ciprofloxacin-resistant meningococci; and in pandemic-related news, a possible inhaled version of remdesivir, and colchicine as a potential treatment.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose Podcast Episode 40 MPR Weekly Dose 00:08:34 This week on the Pod: Over-the-counter med recalls; a nasal spray approved for diabetic gastroparesis; reports of an uptick in penicillin-, ciprofloxacin-resistant meningococci; and in pandemic-related news, a possible inhaled version of remdesivir, and colchicine as a potential treatment.  This week on the Pod: Over-the-counter med recalls; a nasal spray approved for diabetic gastroparesis; reports of an uptick in penicillin-, ciprofloxacin-resistant meningococci; and in pandemic-related news, a possible inhaled version of remdesivir, and colchicine as a potential treatment.  false full 38 90286678-2f94-44b9-9fdd-fe6fa1a3f5d4 MPR Weekly Dose Podcast Episode 39 This week we cover the latest in the rapidly shifting perception of chloroquine and hydroxychloroquine; The polio vaccine as a potential protector against COVID-19; A new approval for Gardasil 9; And the American Gastroenterological Association draw up new guidelines for probiotic use as a treatment in gastrointestinal disorders.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 19 Jun 2020 13:08:33 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com This week we cover the latest in the rapidly shifting perception of chloroquine and hydroxychloroquine; The polio vaccine as a potential protector against COVID-19; A new approval for Gardasil 9; And the American Gastroenterological Association draw up new guidelines for probiotic use as a treatment in gastrointestinal disorders.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose Podcast Episode 39 MPR Weekly Dose 00:07:41 This week we cover the latest in the rapidly shifting perception of chloroquine and hydroxychloroquine; The polio vaccine as a potential protector against COVID-19; A new approval for Gardasil 9; And the American Gastroenterological Association draw up new guidelines for probiotic use as a treatment in gastrointestinal disorders. This week we cover the latest in the rapidly shifting perception of chloroquine and hydroxychloroquine; The polio vaccine as a potential protector against COVID-19; A new approval for Gardasil 9; And the American Gastroenterological Association draw up new guidelines for probiotic use as a treatment in gastrointestinal disorders. false full 37 82ab1d11-584c-4beb-a581-06a0d42dbd5e MPR Weekly Dose Podcast Episode 38 This week on the pod we cover the latest COVID19 news, including antibody tests and their accuracy; A study aiming to examine treatments in children; The potential benefit of Acalabrutinib in severe cases; The WHO's Technical Lead on COVID-19 having to backpedal a statement on transmission; And many states lodge record high numbers of infections.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 12 Jun 2020 13:00:18 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com This week on the pod we cover the latest COVID19 news, including antibody tests and their accuracy; A study aiming to examine treatments in children; The potential benefit of Acalabrutinib in severe cases; The WHO's Technical Lead on COVID-19 having to backpedal a statement on transmission; And many states lodge record high numbers of infections.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose Podcast Episode 38 MPR Weekly Dose 00:08:53 This week on the pod we cover the latest COVID19 news, including  antibody tests and their accuracy; A study aiming to examine treatments in children; The potential benefit of Acalabrutinib in severe cases; The WHO's Technical Lead on COVID-19 having to backpedal a statement on transmission; And many states lodge record high numbers of infections. This week on the pod we cover the latest COVID19 news, including  antibody tests and their accuracy; A study aiming to examine treatments in children; The potential benefit of Acalabrutinib in severe cases; The WHO's Technical Lead on COVID-19 having to backpedal a statement on transmission; And many states lodge record high numbers of infections. false full 36 e0d2dc22-74b3-4cef-a36f-81947724f064 MPR Weekly Dose Podcast Episode 37 This week on the pod we look at results from a COVID-19 prevention trial of hydroxychloroquine; A vaccine arrival date prediction by Dr Fauci; A FDA notification regarding vial caps; A look into prescription patterns during COVID-19; And an antibody treatment trial begins.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 5 Jun 2020 13:20:24 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com This week on the pod we look at results from a COVID-19 prevention trial of hydroxychloroquine; A vaccine arrival date prediction by Dr Fauci; A FDA notification regarding vial caps; A look into prescription patterns during COVID-19; And an antibody treatment trial begins.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose Podcast Episode 37 MPR Weekly Dose 00:10:10 This week on the pod we look at results from a COVID-19 prevention trial of hydroxychloroquine; A vaccine arrival date prediction by Dr Fauci; A FDA notification regarding vial caps; A look into prescription patterns during COVID-19; And an antibody treatment trial begins.  This week on the pod we look at results from a COVID-19 prevention trial of hydroxychloroquine; A vaccine arrival date prediction by Dr Fauci; A FDA notification regarding vial caps; A look into prescription patterns during COVID-19; And an antibody treatment trial begins.  false full 35 7d4ade03-bbda-4881-95d0-116405b4b7d9 MPR Weekly Dose Podcast Episode 36 Today's pod covers important news regarding hydroxychloroquine; The efficacy of dietary supplements as a means to manage or prevent COVID-19; The first non-hormonal contraceptive gel approved by the FDA; And an expanded approval for dupilumab.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 29 May 2020 12:54:38 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com Today's pod covers important news regarding hydroxychloroquine; The efficacy of dietary supplements as a means to manage or prevent COVID-19; The first non-hormonal contraceptive gel approved by the FDA; And an expanded approval for dupilumab.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose Podcast Episode 36 MPR Weekly Dose 00:08:56 Today's pod covers important news regarding hydroxychloroquine; The efficacy of dietary supplements as a means to manage or prevent COVID-19; The first non-hormonal contraceptive gel approved by the FDA; And an expanded approval for dupilumab. Today's pod covers important news regarding hydroxychloroquine; The efficacy of dietary supplements as a means to manage or prevent COVID-19; The first non-hormonal contraceptive gel approved by the FDA; And an expanded approval for dupilumab. false full 34 5b9f1747-6455-40f8-ae79-9e3157f167a7 MPR Weekly Dose Podcast Episode 35 This week we cover the latest COVID-19 developments including: reports of false negatives with Abbott's diagnostic test; the immune globulin therapy linked to recovery in multisystem inflammatory syndrome in children, related to COVID-19; and the clinical trials set to be initiated for an umbilical cord stem cell therapy and a high dose IV immune globulin therapy.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 22 May 2020 12:56:19 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com This week we cover the latest COVID-19 developments including: reports of false negatives with Abbott's diagnostic test; the immune globulin therapy linked to recovery in multisystem inflammatory syndrome in children, related to COVID-19; and the clinical trials set to be initiated for an umbilical cord stem cell therapy and a high dose IV immune globulin therapy.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose Podcast Episode 35 MPR Weekly Dose 00:08:32 This week we cover the latest COVID-19 developments including: reports of false negatives with Abbott's diagnostic test; the immune globulin therapy linked to recovery in multisystem inflammatory syndrome in children, related to COVID-19; and the clinical trials set to be initiated for an umbilical cord stem cell therapy and a high dose IV immune globulin therapy. This week we cover the latest COVID-19 developments including: reports of false negatives with Abbott's diagnostic test; the immune globulin therapy linked to recovery in multisystem inflammatory syndrome in children, related to COVID-19; and the clinical trials set to be initiated for an umbilical cord stem cell therapy and a high dose IV immune globulin therapy. false full 33 360c684a-7d21-42e7-9d00-393d2bd3ba6e MPR Weekly Dose Podcast Episode 34 This week we cover the latest COVID-19 developments including a triple antiviral therapy that looks promising, Emergency Use Authorizations granted to diagnostics and critical meds, Moderna's investigational vaccine gets Fast Tracked, and the National Institute of Health's remdesivir plus baricitinib trial.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Thu, 14 May 2020 21:39:07 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com This week we cover the latest COVID-19 developments including a triple antiviral therapy that looks promising, Emergency Use Authorizations granted to diagnostics and critical meds, Moderna's investigational vaccine gets Fast Tracked, and the National Institute of Health's remdesivir plus baricitinib trial.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose Podcast Episode 34 MPR Weekly Dose 00:09:34 This week we cover the latest COVID-19 developments including a triple antiviral therapy that looks promising, Emergency Use Authorizations granted to diagnostics and critical meds, Moderna's investigational vaccine gets Fast Tracked, and the National Institute of Health's remdesivir plus baricitinib trial. This week we cover the latest COVID-19 developments including a triple antiviral therapy that looks promising, Emergency Use Authorizations granted to diagnostics and critical meds, Moderna's investigational vaccine gets Fast Tracked, and the National Institute of Health's remdesivir plus baricitinib trial. false full 32 b92987b7-9b49-4e93-88f9-f429352750d2 MPR Weekly Dose Podcast Episode 33 This week we cover the the risk of antihypertensive med use during the pandemic; The Emergency Use Authorization for remdesivir in hospitalized patients with suspected or confirmed COVID-19; The addition of a Boxed Warning to Montelukast; A new Farxiga indication; And a novel treatment for acute migraines.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Thu, 7 May 2020 22:09:52 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com This week we cover the the risk of antihypertensive med use during the pandemic; The Emergency Use Authorization for remdesivir in hospitalized patients with suspected or confirmed COVID-19; The addition of a Boxed Warning to Montelukast; A new Farxiga indication; And a novel treatment for acute migraines.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose Podcast Episode 33 MPR Weekly Dose 00:08:22 This week we cover the the risk of antihypertensive med use during the pandemic; The Emergency Use Authorization for remdesivir in hospitalized patients with suspected or confirmed COVID-19; The addition of a Boxed Warning to Montelukast; A new Farxiga indication; And a novel treatment for acute migraines. This week we cover the the risk of antihypertensive med use during the pandemic; The Emergency Use Authorization for remdesivir in hospitalized patients with suspected or confirmed COVID-19; The addition of a Boxed Warning to Montelukast; A new Farxiga indication; And a novel treatment for acute migraines. false full 31 f5c5fbb1-1e65-4727-b07f-9943e91e3de5 MPR Weekly Dose Podcast Episode 32 There has been a lot of recent developments in possible COVID-19 treatments. I'll go over the latest status with remdesivir, hydroxychloroquine, sarilumab, and remestemcel-L, and also the treatment guidelines for COVID-19 issued by the National Institute of Health.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Thu, 30 Apr 2020 22:10:03 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com There has been a lot of recent developments in possible COVID-19 treatments. I'll go over the latest status with remdesivir, hydroxychloroquine, sarilumab, and remestemcel-L, and also the treatment guidelines for COVID-19 issued by the National Institute of Health.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose Podcast Episode 32 MPR Weekly Dose 00:09:19 There has been a lot of recent developments in possible COVID-19 treatments. I'll go over the latest status with remdesivir, hydroxychloroquine, sarilumab, and remestemcel-L, and also the treatment guidelines for COVID-19 issued by the National Institute of Health.  There has been a lot of recent developments in possible COVID-19 treatments. I'll go over the latest status with remdesivir, hydroxychloroquine, sarilumab, and remestemcel-L, and also the treatment guidelines for COVID-19 issued by the National Institute of Health.  false full 30 10008a26-692a-4369-a39b-2f9446e1994a MPR Weekly Dose Podcast Episode 31 On today's podcast we run through the top COVID-19 stories including a steep rise in poison control calls; the authorization of an at-home testing kit; The hydroxychloroquine trial that's beginning soon; The trial evaluating ruxolitinib for COVID-19 associated cytokine storms; and the lab failures which have led to ineffective COVID-19 tests being sent from the CDC to nearly all of the 100 state and local public health labs.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Thu, 23 Apr 2020 21:47:43 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com On today's podcast we run through the top COVID-19 stories including a steep rise in poison control calls; the authorization of an at-home testing kit; The hydroxychloroquine trial that's beginning soon; The trial evaluating ruxolitinib for COVID-19 associated cytokine storms; and the lab failures which have led to ineffective COVID-19 tests being sent from the CDC to nearly all of the 100 state and local public health labs.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose Podcast Episode 31 MPR Weekly Dose 00:07:46 On today's podcast we run through the top COVID-19 stories including a steep rise in poison control calls; the authorization of an at-home testing kit; The hydroxychloroquine trial that's beginning soon; The trial evaluating ruxolitinib for COVID-19 associated cytokine storms; and the lab failures which have led to ineffective COVID-19 tests being sent from the CDC to nearly all of the 100 state and local public health labs. On today's podcast we run through the top COVID-19 stories including a steep rise in poison control calls; the authorization of an at-home testing kit; The hydroxychloroquine trial that's beginning soon; The trial evaluating ruxolitinib for COVID-19 associated cytokine storms; and the lab failures which have led to ineffective COVID-19 tests being sent from the CDC to nearly all of the 100 state and local public health labs. false full 29 7419f30c-6385-46e2-bc33-a4f03def6836 MPR Weekly Dose Podcast Episode 30 We run through the latest COVID-19 news including results from a remdesivir trial; The blood purification system OK'd for patients in the ICU; A chloroquine trial halted early due to deaths; The saliva test that detects COVID19; And a bleaching agent product that is claiming to prevent COVID-19.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 17 Apr 2020 17:07:10 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com We run through the latest COVID-19 news including results from a remdesivir trial; The blood purification system OK'd for patients in the ICU; A chloroquine trial halted early due to deaths; The saliva test that detects COVID19; And a bleaching agent product that is claiming to prevent COVID-19.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose Podcast Episode 30 MPR Weekly Dose 00:06:57 We run through the latest COVID-19 news including results from a remdesivir trial; The blood purification system OK'd for patients in the ICU; A chloroquine trial halted early due to deaths; The saliva test that detects COVID19; And a bleaching agent product that is claiming to prevent COVID-19. We run through the latest COVID-19 news including results from a remdesivir trial; The blood purification system OK'd for patients in the ICU; A chloroquine trial halted early due to deaths; The saliva test that detects COVID19; And a bleaching agent product that is claiming to prevent COVID-19. false full 28 f43841de-41d2-4588-a17c-17415b955160 MPR Weekly Dose Podcast Episode 29 This week we run through the latest COVID-19 news including the shortage of critical meds, The CDC U-turn on face mask recommendations, Remdesivir trial enrollment, testing for COVID-19 antibodies, and new guidance from the FDA on blood donations aimed at helping maintain the supply.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Thu, 9 Apr 2020 21:06:41 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com This week we run through the latest COVID-19 news including the shortage of critical meds, The CDC U-turn on face mask recommendations, Remdesivir trial enrollment, testing for COVID-19 antibodies, and new guidance from the FDA on blood donations aimed at helping maintain the supply.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose Podcast Episode 29 MPR Weekly Dose 00:08:29 This week we run through the latest COVID-19 news including the shortage of critical meds, The CDC U-turn on face mask recommendations, Remdesivir trial enrollment, testing for COVID-19 antibodies, and new guidance from the FDA on blood donations aimed at helping maintain the supply.  This week we run through the latest COVID-19 news including the shortage of critical meds, The CDC U-turn on face mask recommendations, Remdesivir trial enrollment, testing for COVID-19 antibodies, and new guidance from the FDA on blood donations aimed at helping maintain the supply.  false full 27 e4931b7d-1a61-4cde-a8b2-bda85169ed83 MPR Weekly Dose Podcast Episode 28 This episodes covers the latest COVID-19 news including drug shortages, a new point-of-care diagnostic tool, the role of vitamin C, misuse of non-pharmacological chloroquine, and also some big news about a popular heartburn drug.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 3 Apr 2020 14:54:48 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com This episodes covers the latest COVID-19 news including drug shortages, a new point-of-care diagnostic tool, the role of vitamin C, misuse of non-pharmacological chloroquine, and also some big news about a popular heartburn drug.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose Podcast Episode 28 MPR Weekly Dose 00:06:37 This episodes covers the latest COVID-19 news including drug shortages, a new point-of-care diagnostic tool, the role of vitamin C, misuse of non-pharmacological chloroquine, and also some big news about a popular heartburn drug. This episodes covers the latest COVID-19 news including drug shortages, a new point-of-care diagnostic tool, the role of vitamin C, misuse of non-pharmacological chloroquine, and also some big news about a popular heartburn drug. false full 28 69677405-9128-48e8-9139-19ed0aed14bf MPR Weekly Dose Podcast Episode 27 This week we talk about the latest on COVID-19, including the virus in relation to NSAID use; the pandemics knock on effect on drug shortages; a safety alert for fecal microbiota transplants; and potential flaws in EpiPen devices.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 27 Mar 2020 16:30:00 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com This week we talk about the latest on COVID-19, including the virus in relation to NSAID use; the pandemics knock on effect on drug shortages; a safety alert for fecal microbiota transplants; and potential flaws in EpiPen devices.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose Podcast Episode 27 MPR Weekly Dose 00:07:12 This week we talk about the latest on COVID-19, including the virus in relation to NSAID use; the pandemics knock on effect on drug shortages; a safety alert for fecal microbiota transplants; and potential flaws in EpiPen devices. This week we talk about the latest on COVID-19, including the virus in relation to NSAID use; the pandemics knock on effect on drug shortages; a safety alert for fecal microbiota transplants; and potential flaws in EpiPen devices. false full 25 tag:soundcloud,2010:tracks/779745256 MPR Weekly Dose Podcast Episode 26 This week we talk about a phase 1 vaccine trial for COVID-19 underway in Seattle; Concerns over COVID-19 and ACE inhibitor, ARB use; Safety labeling changes for SGLT2 inhibitors; A biosimilar to Herceptin; And new graphic warnings for cigarette packages.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 20 Mar 2020 17:28:57 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com This week we talk about a phase 1 vaccine trial for COVID-19 underway in Seattle; Concerns over COVID-19 and ACE inhibitor, ARB use; Safety labeling changes for SGLT2 inhibitors; A biosimilar to Herceptin; And new graphic warnings for cigarette packages.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose Podcast Episode 26 MPR Weekly Dose 00:05:18 This week we talk about a phase 1 vaccine trial for COVID-19 underway in Seattle; Concerns over COVID-19 and ACE inhibitor, ARB use; Safety labeling changes for SGLT2 inhibitors; A biosimilar to Herceptin; And new graphic warnings for cigarette packages. This week we talk about a phase 1 vaccine trial for COVID-19 underway in Seattle; Concerns over COVID-19 and ACE inhibitor, ARB use; Safety labeling changes for SGLT2 inhibitors; A biosimilar to Herceptin; And new graphic warnings for cigarette packages. false full 24 tag:soundcloud,2010:tracks/775159018 MPR Weekly Dose Podcast Episode 25 Today we talk about the latest COVID-19 news; New approvals for chronic fibrosing interstitial lung diseases and Cushing disease; and stronger safety warnings for montelukast.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Thu, 12 Mar 2020 21:15:51 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com Today we talk about the latest COVID-19 news; New approvals for chronic fibrosing interstitial lung diseases and Cushing disease; and stronger safety warnings for montelukast.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose Podcast Episode 25 MPR Weekly Dose 00:07:06 Today we talk about the latest COVID-19 news; New approvals for chronic fibrosing interstitial lung diseases and Cushing disease; and stronger safety warnings for montelukast. Today we talk about the latest COVID-19 news; New approvals for chronic fibrosing interstitial lung diseases and Cushing disease; and stronger safety warnings for montelukast. false full 23 tag:soundcloud,2010:tracks/771397303 MPR Weekly Dose Podcast Episode 24 Today we talk about the ban on certain electrical stimulation devices, the latest COVID-19 news, a first generic of Daraprim, a New Drug Application for a potential microneedle migraine treatment patch, and a first over-the-counter combination of ibuprofen and acetaminophen: Advil Dual Action.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Thu, 5 Mar 2020 21:29:24 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com Today we talk about the ban on certain electrical stimulation devices, the latest COVID-19 news, a first generic of Daraprim, a New Drug Application for a potential microneedle migraine treatment patch, and a first over-the-counter combination of ibuprofen and acetaminophen: Advil Dual Action.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose Podcast Episode 24 MPR Weekly Dose 00:05:43 Today we talk about the ban on certain electrical stimulation devices, the latest COVID-19 news, a first generic of Daraprim, a New Drug Application for a potential microneedle migraine treatment patch, and a first over-the-counter combination of ibuprofen and acetaminophen: Advil Dual Action. Today we talk about the ban on certain electrical stimulation devices, the latest COVID-19 news, a first generic of Daraprim, a New Drug Application for a potential microneedle migraine treatment patch, and a first over-the-counter combination of ibuprofen and acetaminophen: Advil Dual Action. false full 22 tag:soundcloud,2010:tracks/767650783 MPR Weekly Dose Podcast Episode 23 This week on the pod we cover a first-in-class cholesterol lowering therapy; a new indication for Trulicity; Macrolide prescriptions in the first trimester and their relation to fetal malformations; a new fragile X diagnostic test; and a migraine prevention IV treatment.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Thu, 27 Feb 2020 21:58:16 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com This week on the pod we cover a first-in-class cholesterol lowering therapy; a new indication for Trulicity; Macrolide prescriptions in the first trimester and their relation to fetal malformations; a new fragile X diagnostic test; and a migraine prevention IV treatment.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose Podcast Episode 23 MPR Weekly Dose 00:06:11 This week on the pod we cover a first-in-class cholesterol lowering therapy; a new indication for Trulicity; Macrolide prescriptions in the first trimester and their relation to fetal malformations; a new fragile X diagnostic test; and a migraine prevention IV treatment. This week on the pod we cover a first-in-class cholesterol lowering therapy; a new indication for Trulicity; Macrolide prescriptions in the first trimester and their relation to fetal malformations; a new fragile X diagnostic test; and a migraine prevention IV treatment. false full 21 tag:soundcloud,2010:tracks/763967695 MPR Weekly Dose Podcast Episode 22 This week on the pod we cover the withdrawal of Belviq, the weight-loss drug, from the market; the over-the-counter approval of diclofenac gel and olopatadine eye drops; a new contraceptive transdermal patch; a possible vaccine for ricintoxin; and new research finds that hundreds of sellers are using Craigslist to sell prescribing medications.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Thu, 20 Feb 2020 21:12:20 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com This week on the pod we cover the withdrawal of Belviq, the weight-loss drug, from the market; the over-the-counter approval of diclofenac gel and olopatadine eye drops; a new contraceptive transdermal patch; a possible vaccine for ricintoxin; and new research finds that hundreds of sellers are using Craigslist to sell prescribing medications.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose Podcast Episode 22 MPR Weekly Dose 00:06:43 This week on the pod we cover the withdrawal of Belviq, the weight-loss drug, from the market; the over-the-counter approval of diclofenac gel and olopatadine eye drops; a new contraceptive transdermal patch; a possible vaccine for ricintoxin; and new research finds that hundreds of sellers are using Craigslist to sell prescribing medications. This week on the pod we cover the withdrawal of Belviq, the weight-loss drug, from the market; the over-the-counter approval of diclofenac gel and olopatadine eye drops; a new contraceptive transdermal patch; a possible vaccine for ricintoxin; and new research finds that hundreds of sellers are using Craigslist to sell prescribing medications. false full 20 tag:soundcloud,2010:tracks/760212712 MPR Weekly Dose Podcast Episode 21 This week on the pod we cover an insulin pump recall; Pharmacies running out of supplies in light of Covid-19 fears; Investigational Alzheimer disease treatments not meeting trial end points; A new cardiac ultrasound device; and a new oral testosterone replacement therapy.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Thu, 13 Feb 2020 21:49:42 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com This week on the pod we cover an insulin pump recall; Pharmacies running out of supplies in light of Covid-19 fears; Investigational Alzheimer disease treatments not meeting trial end points; A new cardiac ultrasound device; and a new oral testosterone replacement therapy.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose Podcast Episode 21 MPR Weekly Dose 00:05:57 This week on the pod we cover an insulin pump recall; Pharmacies running out of supplies in light of Covid-19 fears; Investigational Alzheimer disease treatments not meeting trial end points; A new cardiac ultrasound device; and a new oral testosterone replacement therapy. This week on the pod we cover an insulin pump recall; Pharmacies running out of supplies in light of Covid-19 fears; Investigational Alzheimer disease treatments not meeting trial end points; A new cardiac ultrasound device; and a new oral testosterone replacement therapy. false full 19 tag:soundcloud,2010:tracks/756293620 MPR Weekly Dose Podcast Episode 20 This week on the Pod we cover the approval of the first oral therapy for peanut allergy; The 2020 immunization schedule; The latest on the coronavirus, including the CDC's shipment of test kits; The withdrawal of an antibiotic; and results from the FDA investigation into possible impurities in metformin.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Thu, 6 Feb 2020 21:14:22 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com This week on the Pod we cover the approval of the first oral therapy for peanut allergy; The 2020 immunization schedule; The latest on the coronavirus, including the CDC's shipment of test kits; The withdrawal of an antibiotic; and results from the FDA investigation into possible impurities in metformin.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose Podcast Episode 20 MPR Weekly Dose 00:06:00 This week on the Pod we cover the approval of the first oral therapy for peanut allergy; The 2020 immunization schedule; The latest on the coronavirus, including the CDC's shipment of test kits; The withdrawal of an antibiotic; and results from the FDA investigation into possible impurities in metformin. This week on the Pod we cover the approval of the first oral therapy for peanut allergy; The 2020 immunization schedule; The latest on the coronavirus, including the CDC's shipment of test kits; The withdrawal of an antibiotic; and results from the FDA investigation into possible impurities in metformin. false full 18 tag:soundcloud,2010:tracks/752357188 MPR Weekly Dose Podcast Episode 19 This week we discuss the latest news surrounding the novel coronavirus, including the WHO's decision to declare the virus a global emergency; A new triple combo therapy in type 2 diabetes; Updated Tdap vaccination recommendations; An FDA warning regarding serious clozapine side effects; And news of possible cybersecurity vulnerabilities with certain patient monitoring devices.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Thu, 30 Jan 2020 21:26:18 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com This week we discuss the latest news surrounding the novel coronavirus, including the WHO's decision to declare the virus a global emergency; A new triple combo therapy in type 2 diabetes; Updated Tdap vaccination recommendations; An FDA warning regarding serious clozapine side effects; And news of possible cybersecurity vulnerabilities with certain patient monitoring devices.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose Podcast Episode 19 MPR Weekly Dose 00:06:25 This week we discuss the latest news surrounding the novel coronavirus, including the WHO's decision to declare the virus a global emergency; A new triple combo therapy in type 2 diabetes; Updated Tdap vaccination recommendations; An FDA warning regarding serious clozapine side effects; And news of possible cybersecurity vulnerabilities with certain patient monitoring devices. This week we discuss the latest news surrounding the novel coronavirus, including the WHO's decision to declare the virus a global emergency; A new triple combo therapy in type 2 diabetes; Updated Tdap vaccination recommendations; An FDA warning regarding serious clozapine side effects; And news of possible cybersecurity vulnerabilities with certain patient monitoring devices. false full 17 tag:soundcloud,2010:tracks/748775626 MPR Weekly Dose Podcast Episode 18 This week we cover the CDC coronavirus health advisory; A possible oral influenza vaccine; A new treatment to reduce the risk of MACE; An FDA Committee vote; And the first approved treatment for thyroid eye disease.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 24 Jan 2020 15:25:16 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com This week we cover the CDC coronavirus health advisory; A possible oral influenza vaccine; A new treatment to reduce the risk of MACE; An FDA Committee vote; And the first approved treatment for thyroid eye disease.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose Podcast Episode 18 MPR Weekly Dose 00:05:48 This week we cover the CDC coronavirus health advisory; A possible oral influenza vaccine; A new treatment to reduce the risk of MACE; An FDA Committee vote; And the first approved treatment for thyroid eye disease. This week we cover the CDC coronavirus health advisory; A possible oral influenza vaccine; A new treatment to reduce the risk of MACE; An FDA Committee vote; And the first approved treatment for thyroid eye disease. false full 16 tag:soundcloud,2010:tracks/744592795 MPR Weekly Dose Podcast Episode 17 This week we cover the approval of a cocaine nasal solution; 23andMe's entry into the drug development; The recall of an epilepsy and bipolar treatment; A new nasal spray for seizure patients; And the weight loss drug that may be linked to cancer.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Thu, 16 Jan 2020 21:18:43 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com This week we cover the approval of a cocaine nasal solution; 23andMe's entry into the drug development; The recall of an epilepsy and bipolar treatment; A new nasal spray for seizure patients; And the weight loss drug that may be linked to cancer.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose Podcast Episode 17 MPR Weekly Dose 00:05:48 This week we cover the approval of a cocaine nasal solution; 23andMe's entry into the drug development; The recall of an epilepsy and bipolar treatment; A new nasal spray for seizure patients; And the weight loss drug that may be linked to cancer. This week we cover the approval of a cocaine nasal solution; 23andMe's entry into the drug development; The recall of an epilepsy and bipolar treatment; A new nasal spray for seizure patients; And the weight loss drug that may be linked to cancer. false full 15 tag:soundcloud,2010:tracks/741464380 MPR Weekly Dose Podcast Episode 16 In our first episode of 2020 we cover new management guidelines in osteoarthritis; Recommendations for the use of testosterone therapy; The best diets for 2020; Two drug recalls; And a new drug approved for the treatment of migraines.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 10 Jan 2020 19:51:57 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com In our first episode of 2020 we cover new management guidelines in osteoarthritis; Recommendations for the use of testosterone therapy; The best diets for 2020; Two drug recalls; And a new drug approved for the treatment of migraines.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose Podcast Episode 16 MPR Weekly Dose 00:05:25 In our first episode of 2020 we cover new management guidelines in osteoarthritis; Recommendations for the use of testosterone therapy; The best diets for 2020; Two drug recalls; And a new drug approved for the treatment of migraines. In our first episode of 2020 we cover new management guidelines in osteoarthritis; Recommendations for the use of testosterone therapy; The best diets for 2020; Two drug recalls; And a new drug approved for the treatment of migraines. false full 14 tag:soundcloud,2010:tracks/723330457 MPR Weekly Dose Podcast Episode 15 Back from our Thanksgiving break, this week we talk about the new approval for sickle cell disease; the re-introduction of a product that was taken off the market in the 60's; The first ready-to-use phenylephrine injection; A new ultrasound enhancing agent; And an approval for arthritis.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Thu, 5 Dec 2019 21:26:03 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com Back from our Thanksgiving break, this week we talk about the new approval for sickle cell disease; the re-introduction of a product that was taken off the market in the 60's; The first ready-to-use phenylephrine injection; A new ultrasound enhancing agent; And an approval for arthritis.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose Podcast Episode 15 MPR Weekly Dose 00:05:24 Back from our Thanksgiving break, this week we talk about the new approval for sickle cell disease; the re-introduction of a product that was taken off the market in the 60's; The first ready-to-use phenylephrine injection; A new ultrasound enhancing agent; And an approval for arthritis. Back from our Thanksgiving break, this week we talk about the new approval for sickle cell disease; the re-introduction of a product that was taken off the market in the 60's; The first ready-to-use phenylephrine injection; A new ultrasound enhancing agent; And an approval for arthritis. false full 13 tag:soundcloud,2010:tracks/717075277 MPR Weekly Dose Podcast: Episode 14 MPR Weekly Dose Podcast: Episode 14 by MPR Weekly Dose


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 22 Nov 2019 21:39:13 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com MPR Weekly Dose Podcast: Episode 14 by MPR Weekly Dose


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose Podcast: Episode 14 MPR Weekly Dose 00:06:36 MPR Weekly Dose Podcast: Episode 14 by MPR Weekly Dose MPR Weekly Dose Podcast: Episode 14 by MPR Weekly Dose false full 12 tag:soundcloud,2010:tracks/712934182 MPR Weekly Dose Podcast Episode 13 This week on the Weekly Dose we talk about the first lung transplant due to vaping-related illness; A new approval for patients with beta thalassemia; Opioids in osteoarthritis; A new, free test to help diagnose COPD; and news of a potential new therapy for hypercholesterolemia.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Thu, 14 Nov 2019 21:42:31 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com This week on the Weekly Dose we talk about the first lung transplant due to vaping-related illness; A new approval for patients with beta thalassemia; Opioids in osteoarthritis; A new, free test to help diagnose COPD; and news of a potential new therapy for hypercholesterolemia.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose Podcast Episode 13 MPR Weekly Dose 00:06:10 This week on the Weekly Dose we talk about the first lung transplant due to vaping-related illness; A new approval for patients with beta thalassemia; Opioids in osteoarthritis; A new, free test to help diagnose COPD; and news of a potential new therapy for hypercholesterolemia. This week on the Weekly Dose we talk about the first lung transplant due to vaping-related illness; A new approval for patients with beta thalassemia; Opioids in osteoarthritis; A new, free test to help diagnose COPD; and news of a potential new therapy for hypercholesterolemia. false full 11 tag:soundcloud,2010:tracks/709939207 MPR Weekly Dose Podcast Episode 12 This week we talk about NDMA findings in ranitidine products; Approval of a new flu vaccine; The return of an antiarrhythmic agent; A new treatment for H. pylori infection; and the risk of biotin interference in test results which could lead to missed diagnoses.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 8 Nov 2019 20:25:10 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com This week we talk about NDMA findings in ranitidine products; Approval of a new flu vaccine; The return of an antiarrhythmic agent; A new treatment for H. pylori infection; and the risk of biotin interference in test results which could lead to missed diagnoses.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose Podcast Episode 12 MPR Weekly Dose 00:05:38 This week we talk about NDMA findings in ranitidine products; Approval of a new flu vaccine; The return of an antiarrhythmic agent; A new treatment for H. pylori infection; and the risk of biotin interference in test results which could lead to missed diagnoses. This week we talk about NDMA findings in ranitidine products; Approval of a new flu vaccine; The return of an antiarrhythmic agent; A new treatment for H. pylori infection; and the risk of biotin interference in test results which could lead to missed diagnoses. false full 10 tag:soundcloud,2010:tracks/706503679 MPR Weekly Dose Podcast: Episode 11 This week we talk about the recall of an anti-anxiety med; Possible withdrawal of Makena; New MS treatment approved; IUD approved for up to six years; and time of day when meds taken could affect CVD risk.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 1 Nov 2019 18:02:39 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com This week we talk about the recall of an anti-anxiety med; Possible withdrawal of Makena; New MS treatment approved; IUD approved for up to six years; and time of day when meds taken could affect CVD risk.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose Podcast: Episode 11 MPR Weekly Dose 00:05:46 This week we talk about the recall of an anti-anxiety med; Possible withdrawal of Makena; New MS treatment approved; IUD approved for up to six years; and time of day when meds taken could affect CVD risk. This week we talk about the recall of an anti-anxiety med; Possible withdrawal of Makena; New MS treatment approved; IUD approved for up to six years; and time of day when meds taken could affect CVD risk. false full 9 tag:soundcloud,2010:tracks/701235613 MPR Weekly Dose Podcast Episode 10 This week we talk about the resurrection of Biogen's novel Alzheimer treatment; A "landmark" approval in cystic fibrosis; Expanded indication for Farxiga; The first topical minocycline formulation for acne vulgaris; and the Johnson's baby powder recall.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Thu, 24 Oct 2019 20:16:10 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com This week we talk about the resurrection of Biogen's novel Alzheimer treatment; A "landmark" approval in cystic fibrosis; Expanded indication for Farxiga; The first topical minocycline formulation for acne vulgaris; and the Johnson's baby powder recall.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose Podcast Episode 10 MPR Weekly Dose 00:07:17 This week we talk about the resurrection of Biogen's novel Alzheimer treatment; A "landmark" approval in cystic fibrosis; Expanded indication for Farxiga; The first topical minocycline formulation for acne vulgaris; and the Johnson's baby powder recall. This week we talk about the resurrection of Biogen's novel Alzheimer treatment; A "landmark" approval in cystic fibrosis; Expanded indication for Farxiga; The first topical minocycline formulation for acne vulgaris; and the Johnson's baby powder recall. false full 8 tag:soundcloud,2010:tracks/697913353 MPR Weekly Dose Podcast Episode 9 This week we talk about new treatment approvals for acute migraine, dry eye disease and schizophrenia; a new indication for Xarelto; and the Centers for Disease Control and Prevention issue an interim guidance for physicians regarding electronic cigarette, or vaping, product use-associated lung injury, or 'EVALI'.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Thu, 17 Oct 2019 20:20:23 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com This week we talk about new treatment approvals for acute migraine, dry eye disease and schizophrenia; a new indication for Xarelto; and the Centers for Disease Control and Prevention issue an interim guidance for physicians regarding electronic cigarette, or vaping, product use-associated lung injury, or 'EVALI'.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose Podcast Episode 9 MPR Weekly Dose 00:06:08 This week we talk about new treatment approvals for acute migraine, dry eye disease and schizophrenia; a new indication for Xarelto; and the Centers for Disease Control and Prevention issue an interim guidance for physicians regarding electronic cigarette, or vaping, product use-associated lung injury, or 'EVALI'. This week we talk about new treatment approvals for acute migraine, dry eye disease and schizophrenia; a new indication for Xarelto; and the Centers for Disease Control and Prevention issue an interim guidance for physicians regarding electronic cigarette, or vaping, product use-associated lung injury, or 'EVALI'. false full 7 tag:soundcloud,2010:tracks/694252864 MPR Weekly Dose Podcast Episode 8 This week we talk about the FDA highlighting THC in the recent spate of vaping-related illnesses; Descovy's expanded approval; A new cream for acne; A treatment for the rare condition possibly behind the creation of vampire myths; and a new drug approval for the treatment of wet age-related macular degeneration.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 11 Oct 2019 14:14:15 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com This week we talk about the FDA highlighting THC in the recent spate of vaping-related illnesses; Descovy's expanded approval; A new cream for acne; A treatment for the rare condition possibly behind the creation of vampire myths; and a new drug approval for the treatment of wet age-related macular degeneration.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose Podcast Episode 8 MPR Weekly Dose 00:05:53 This week we talk about the FDA highlighting THC in the recent spate of vaping-related illnesses; Descovy's expanded approval; A new cream for acne; A treatment for the rare condition possibly behind the creation of vampire myths; and a new drug approval for the treatment of wet age-related macular degeneration. This week we talk about the FDA highlighting THC in the recent spate of vaping-related illnesses; Descovy's expanded approval; A new cream for acne; A treatment for the rare condition possibly behind the creation of vampire myths; and a new drug approval for the treatment of wet age-related macular degeneration. false full 6 tag:soundcloud,2010:tracks/690981352 MPR Weekly Dose Podcast: Episode 7 This week: New Invokana approval; More ranitidine recalls lead CVS to suspend all sales; FDA has identifies 11 serious cybersecurity vulnerabilities that could affect medical devices and hospital networks; Entresto indication expanded; and COPD investigate treatment is rejected.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 4 Oct 2019 14:43:10 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com This week: New Invokana approval; More ranitidine recalls lead CVS to suspend all sales; FDA has identifies 11 serious cybersecurity vulnerabilities that could affect medical devices and hospital networks; Entresto indication expanded; and COPD investigate treatment is rejected.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose Podcast: Episode 7 MPR Weekly Dose 00:08:05 This week: New Invokana approval; More ranitidine recalls lead CVS to suspend all sales; FDA has identifies 11 serious cybersecurity vulnerabilities that could affect medical devices and hospital networks; Entresto indication expanded; and COPD investigate treatment is rejected. This week: New Invokana approval; More ranitidine recalls lead CVS to suspend all sales; FDA has identifies 11 serious cybersecurity vulnerabilities that could affect medical devices and hospital networks; Entresto indication expanded; and COPD investigate treatment is rejected. false full 5 tag:soundcloud,2010:tracks/687288559 MPR Weekly Dose Podcast: Episode 6 This week: A new tablet treatment for type 2 diabetes; Pancreatitis treatment gains Orphan Drug status; New approval for smallpox, monkeypox; An investigational treatment for Guillain-Barré Syndrome; and big changes at e-cigarette maker, Juul.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Thu, 26 Sep 2019 20:20:57 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com This week: A new tablet treatment for type 2 diabetes; Pancreatitis treatment gains Orphan Drug status; New approval for smallpox, monkeypox; An investigational treatment for Guillain-Barré Syndrome; and big changes at e-cigarette maker, Juul.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose Podcast: Episode 6 MPR Weekly Dose 00:06:37 This week: A new tablet treatment for type 2 diabetes; Pancreatitis treatment gains Orphan Drug status; New approval for smallpox, monkeypox; An investigational treatment for Guillain-Barré Syndrome; and big changes at e-cigarette maker, Juul. This week: A new tablet treatment for type 2 diabetes; Pancreatitis treatment gains Orphan Drug status; New approval for smallpox, monkeypox; An investigational treatment for Guillain-Barré Syndrome; and big changes at e-cigarette maker, Juul. false full 4 tag:soundcloud,2010:tracks/684012809 MPR Weekly Dose Podcast: Episode 5 This week: FDA votes on possible peanut allergy treatment; New risks ID'd with some breast cancer drugs; a topical solution for common warts edges nearer; Nitrosamine impurity identified in acid suppressant; And news of another e-cigarette related fatality.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 20 Sep 2019 14:35:27 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com This week: FDA votes on possible peanut allergy treatment; New risks ID'd with some breast cancer drugs; a topical solution for common warts edges nearer; Nitrosamine impurity identified in acid suppressant; And news of another e-cigarette related fatality.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose Podcast: Episode 5 MPR Weekly Dose 00:06:24 This week: FDA votes on possible peanut allergy treatment; New risks ID'd with some breast cancer drugs; a topical solution for common warts edges nearer; Nitrosamine impurity identified in acid suppressant; And news of another e-cigarette related fatality. This week: FDA votes on possible peanut allergy treatment; New risks ID'd with some breast cancer drugs; a topical solution for common warts edges nearer; Nitrosamine impurity identified in acid suppressant; And news of another e-cigarette related fatality. false full 3 tag:soundcloud,2010:tracks/673390640 MPR Weekly Dose Podcast: Episode 3 This week: New adjunct treatment for Parkinson disease; Pain med associated with hypoglycemia; New approval for active ankylosing spondylitis; Fast track designation for possible kidney disease therapy; and a possible treatment for degenerative disc disease.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 30 Aug 2019 19:10:47 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com This week: New adjunct treatment for Parkinson disease; Pain med associated with hypoglycemia; New approval for active ankylosing spondylitis; Fast track designation for possible kidney disease therapy; and a possible treatment for degenerative disc disease.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose Podcast: Episode 3 MPR Weekly Dose 00:06:13 This week: New adjunct treatment for Parkinson disease; Pain med associated with hypoglycemia; New approval for active ankylosing spondylitis; Fast track designation for possible kidney disease therapy; and a possible treatment for degenerative disc disease. This week: New adjunct treatment for Parkinson disease; Pain med associated with hypoglycemia; New approval for active ankylosing spondylitis; Fast track designation for possible kidney disease therapy; and a possible treatment for degenerative disc disease. false full 2 tag:soundcloud,2010:tracks/669952451 MPR Weekly Dose Podcast: Episode 2 This week: New draft guidelines for Lyme Disease management; First-in-class antibiotic to treat community-acquired bacterial pneumonia; Duchenne muscular dystrophy drug denied; Approval for a rheumatoid arthritis treatment; and the FDA make a decision on Hetlioz for jet lag disorder.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 23 Aug 2019 17:35:05 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com This week: New draft guidelines for Lyme Disease management; First-in-class antibiotic to treat community-acquired bacterial pneumonia; Duchenne muscular dystrophy drug denied; Approval for a rheumatoid arthritis treatment; and the FDA make a decision on Hetlioz for jet lag disorder.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose Podcast: Episode 2 MPR Weekly Dose 00:05:58 This week: New draft guidelines for Lyme Disease management; First-in-class antibiotic to treat community-acquired bacterial pneumonia; Duchenne muscular dystrophy drug denied; Approval for a rheumatoid arthritis treatment; and the FDA make a decision on Hetlioz for jet lag disorder. This week: New draft guidelines for Lyme Disease management; First-in-class antibiotic to treat community-acquired bacterial pneumonia; Duchenne muscular dystrophy drug denied; Approval for a rheumatoid arthritis treatment; and the FDA make a decision on Hetlioz for jet lag disorder. false full 1 tag:soundcloud,2010:tracks/668130920 MPR Weekly Dose Podcast: Episode 1 This week the team discuss the 'Cure All' treatments that contain bleach, news concerning a Parkinson disease treatment, a new approval for a tuberculosis treatment, differences between the US and Canada in prescription drug use, and a new point-of-care, sexually transmitted infection test.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Mon, 19 Aug 2019 18:20:58 +0000 editor@empr.com (MPR Weekly Dose) https://www.empr.com This week the team discuss the 'Cure All' treatments that contain bleach, news concerning a Parkinson disease treatment, a new approval for a tuberculosis treatment, differences between the US and Canada in prescription drug use, and a new point-of-care, sexually transmitted infection test.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> MPR Weekly Dose Podcast: Episode 1 MPR Weekly Dose 00:07:34 This week the team discuss the 'Cure All' treatments that contain bleach, news concerning a Parkinson disease treatment, a new approval for a tuberculosis treatment, differences between the US and Canada in prescription drug use, and a new point-of-care, sexually transmitted infection test. This week the team discuss the 'Cure All' treatments that contain bleach, news concerning a Parkinson disease treatment, a new approval for a tuberculosis treatment, differences between the US and Canada in prescription drug use, and a new point-of-care, sexually transmitted infection test. false full 0